{"PMC7478592": [["IntroductionThe novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019 from Wuhan, China, has rapidly spread throughout the world, causing more than 6 million cases and 400,000 deaths globally as of June 2020.", [["coronavirus", "DISEASE", 22, 33], ["acute respiratory syndrome coronavirus", "DISEASE", 41, 79], ["deaths", "DISEASE", 227, 233], ["coronavirus severe acute respiratory syndrome coronavirus 2", "ORGANISM", 22, 81], ["SARS-CoV-2", "ORGANISM", 83, 93], ["coronavirus", "SPECIES", 22, 33], ["coronavirus severe acute respiratory syndrome coronavirus", "SPECIES", 22, 79], ["SARS-CoV-2", "SPECIES", 83, 93], ["The novel coronavirus severe acute respiratory syndrome coronavirus", "PROBLEM", 12, 79], ["coronavirus", "OBSERVATION_MODIFIER", 22, 33], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory syndrome", "OBSERVATION", 47, 67]]], ["Coronavirus disease 2019 (COVID-19) morbidity and mortality has been overwhelmingly concentrated in elderly individuals and those with preexisting comorbidities [1].", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["morbidity", "PROBLEM", 36, 45], ["preexisting comorbidities", "PROBLEM", 135, 160]]], ["In older individuals, immunosenescence and dysregulated antiviral responses due to viral chronic low-grade age-related inflammation may play an important role [2], as has been proposed for influenza [3].", [["inflammation", "DISEASE", 119, 131], ["influenza", "DISEASE", 189, 198], ["immunosenescence", "PROBLEM", 22, 38], ["dysregulated antiviral responses", "PROBLEM", 43, 75], ["viral chronic low-grade age", "PROBLEM", 83, 110], ["related inflammation", "PROBLEM", 111, 131], ["influenza", "PROBLEM", 189, 198], ["inflammation", "OBSERVATION", 119, 131]]], ["Males are known to be generally more susceptible to infectious disease than females [4], and severe acute respiratory syndrome coronavirus (SARS-CoV)-infected male mice had increased infiltration of inflammatory macrophages into their lungs, leading to a deleterious inflammatory response [5].", [["inflammatory macrophages", "ANATOMY", 199, 223], ["lungs", "ANATOMY", 235, 240], ["infectious disease", "DISEASE", 52, 70], ["acute respiratory syndrome coronavirus", "DISEASE", 100, 138], ["SARS-CoV)-infected", "DISEASE", 140, 158], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 93, 138], ["SARS-CoV", "ORGANISM", 140, 148], ["mice", "ORGANISM", 164, 168], ["macrophages", "CELL", 212, 223], ["lungs", "ORGAN", 235, 240], ["inflammatory macrophages", "CELL_TYPE", 199, 223], ["mice", "SPECIES", 164, 168], ["severe acute respiratory syndrome coronavirus", "SPECIES", 93, 138], ["SARS-CoV", "SPECIES", 140, 148], ["mice", "SPECIES", 164, 168], ["infectious disease", "PROBLEM", 52, 70], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 93, 138], ["increased infiltration of inflammatory macrophages into their lungs", "PROBLEM", 173, 240], ["a deleterious inflammatory response", "PROBLEM", 253, 288], ["infectious", "OBSERVATION", 52, 62], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome coronavirus", "OBSERVATION", 106, 138], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["infiltration", "OBSERVATION", 183, 195], ["inflammatory macrophages", "OBSERVATION", 199, 223], ["lungs", "ANATOMY", 235, 240], ["deleterious", "OBSERVATION_MODIFIER", 255, 266], ["inflammatory", "OBSERVATION", 267, 279]]], ["Accordingly, systemic inflammatory markers such as neutrophil-to-lymphocyte ratio and C-reactive protein were elevated in men who died of SARS-CoV-2 [6].", [["neutrophil", "ANATOMY", 51, 61], ["lymphocyte", "ANATOMY", 65, 75], ["SARS", "DISEASE", 138, 142], ["neutrophil", "CELL", 51, 61], ["lymphocyte", "CELL", 65, 75], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 86, 104], ["men", "ORGANISM", 122, 125], ["systemic inflammatory markers", "PROTEIN", 13, 42], ["neutrophil", "CELL_TYPE", 51, 61], ["C-reactive protein", "PROTEIN", 86, 104], ["men", "SPECIES", 122, 125], ["systemic inflammatory markers", "TEST", 13, 42], ["neutrophil", "TEST", 51, 61], ["lymphocyte ratio", "TEST", 65, 81], ["C-reactive protein", "PROBLEM", 86, 104], ["SARS", "PROBLEM", 138, 142], ["systemic", "OBSERVATION_MODIFIER", 13, 21], ["inflammatory", "OBSERVATION", 22, 34], ["reactive protein", "OBSERVATION", 88, 104]]], ["However, the mechanisms behind increased mortality among older adults and males with COVID-19 remain speculative.IntroductionEntry of SARS-CoV-2 into host cells depends on binding to the receptor angiotensin-converting enzyme 2 (ACE2) [7], expressed at a high level in the nasal epithelium [8], then further induced upon exposure to interferon [9], suggesting a mechanism by which SARS-CoV-2 exploits host antiviral responses.", [["cells", "ANATOMY", 155, 160], ["nasal epithelium", "ANATOMY", 273, 289], ["SARS", "DISEASE", 134, 138], ["angiotensin", "CHEMICAL", 196, 207], ["SARS", "DISEASE", 381, 385], ["COVID-19", "CHEMICAL", 85, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["host cells", "CELL", 150, 160], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 196, 227], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["nasal epithelium", "TISSUE", 273, 289], ["SARS-CoV-2", "ORGANISM", 381, 391], ["host cells", "CELL_TYPE", 150, 160], ["receptor angiotensin-converting enzyme 2", "PROTEIN", 187, 227], ["ACE2", "PROTEIN", 229, 233], ["interferon", "PROTEIN", 333, 343], ["increased mortality", "PROBLEM", 31, 50], ["COVID", "TEST", 85, 90], ["SARS", "PROBLEM", 134, 138], ["the receptor angiotensin", "TEST", 183, 207], ["interferon", "TREATMENT", 333, 343], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["mortality", "OBSERVATION_MODIFIER", 41, 50], ["nasal epithelium", "ANATOMY", 273, 289]]], ["SARS-CoV antagonizes initial viral detection and interferon responses by an as-yet unknown mechanism [10,11].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["interferon", "PROTEIN", 49, 59], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["viral detection", "TEST", 29, 44], ["interferon responses", "TREATMENT", 49, 69]]], ["SARS-CoV-2 may employ similar mechanisms, as infections of bronchial epithelial cells at low multiplicity of infection (MOI) do not result in extensive transcription of interferon-stimulated genes (ISGs) at 24 hours post infection [12].", [["bronchial epithelial cells", "ANATOMY", 59, 85], ["SARS", "DISEASE", 0, 4], ["infections", "DISEASE", 45, 55], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 221, 230], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["bronchial epithelial cells", "CELL", 59, 85], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 169, 196], ["bronchial epithelial cells", "CELL_TYPE", 59, 85], ["interferon-stimulated genes", "DNA", 169, 196], ["ISGs", "DNA", 198, 202], ["bronchial epithelial cells", "PROBLEM", 59, 85], ["infection", "PROBLEM", 109, 118], ["interferon-stimulated genes", "TREATMENT", 169, 196], ["infection", "PROBLEM", 221, 230], ["bronchial", "ANATOMY", 59, 68], ["epithelial cells", "OBSERVATION", 69, 85], ["low multiplicity", "OBSERVATION_MODIFIER", 89, 105], ["infection", "OBSERVATION", 109, 118]]], ["An important consequence of these observations is that SARS-CoV-2 viral load and transmissibility peaks at the time of symptom onset [13,14].", [["SARS-CoV-2", "ORGANISM", 55, 65], ["these observations", "TEST", 28, 46], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["viral load", "TEST", 66, 76], ["transmissibility peaks", "PROBLEM", 81, 103]]], ["The temporal relationship between viral load and host gene expression has not been fully explored.IntroductionIn the United States, diagnostic testing is generally performed on nasopharyngeal (NP) swabs, from which SARS-CoV-2 RNA can be recovered.", [["nasopharyngeal", "ANATOMY", 177, 191], ["swabs", "ANATOMY", 197, 202], ["SARS", "DISEASE", 215, 219], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 177, 191], ["CoV-2", "ORGANISM", 220, 225], ["SARS-CoV-2 RNA", "RNA", 215, 229], ["viral load and host gene expression", "PROBLEM", 34, 69], ["diagnostic testing", "TEST", 132, 150], ["nasopharyngeal (NP) swabs", "TREATMENT", 177, 202], ["CoV", "TEST", 220, 223], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["viral load", "OBSERVATION", 34, 44], ["host gene expression", "OBSERVATION", 49, 69]]], ["Shotgun RNA sequencing of this material allows for simultaneous recovery of viral genomes for transmission tracking as well as understanding of in situ host response [15].", [["viral genomes", "DNA", 76, 89], ["Shotgun RNA", "TREATMENT", 0, 11], ["viral genomes", "TREATMENT", 76, 89], ["viral genomes", "OBSERVATION", 76, 89]]], ["Since the first detection of SARS-CoV-2 in the US in Washington State, the University of Washington Virology Laboratory has performed shotgun RNA sequencing to recover more than 1,500 viral genomes as of August 16, 2020, to understand the evolution and molecular epidemiology of the virus [16,17].", [["SARS-CoV-2", "ORGANISM", 29, 39], ["1,500 viral genomes", "DNA", 178, 197], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["the virus", "PROBLEM", 279, 288]]], ["Here, we examine host-specific gene expression differences by SARS-CoV-2 infection status, host age, sex, and viral load in NP swabs from 430 SARS-CoV-2-infected individuals and 54 negative controls.SARS-CoV-2 infection induces an antiviral, interferon-mediated host response ::: ResultsWe first characterized the genes most differentially expressed (DE) in the nasopharynx as a result of SARS-CoV-2 infection (n = 430 positive, 54 negative).", [["nasopharynx", "ANATOMY", 362, 373], ["infection", "DISEASE", 73, 82], ["SARS-CoV-2-infected", "DISEASE", 142, 161], ["SARS", "DISEASE", 199, 203], ["infection", "DISEASE", 210, 219], ["SARS-CoV-2 infection", "DISEASE", 389, 409], ["SARS-CoV-2", "ORGANISM", 62, 72], ["SARS-CoV-2", "ORGANISM", 142, 152], ["individuals", "ORGANISM", 162, 173], ["SARS-CoV-2", "ORGANISM", 199, 209], ["interferon", "GENE_OR_GENE_PRODUCT", 242, 252], ["nasopharynx", "ORGAN", 362, 373], ["SARS-CoV-2", "ORGANISM", 389, 399], ["interferon", "PROTEIN", 242, 252], ["CoV-2", "SPECIES", 147, 152], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV-2", "SPECIES", 142, 152], ["SARS-CoV-2", "SPECIES", 199, 209], ["SARS-CoV", "SPECIES", 389, 397], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70], ["viral load", "TEST", 110, 120], ["NP swabs", "TEST", 124, 132], ["SARS", "TEST", 142, 146], ["CoV", "TEST", 147, 150], ["SARS", "PROBLEM", 199, 203], ["infection", "PROBLEM", 210, 219], ["an antiviral", "TREATMENT", 228, 240], ["SARS", "PROBLEM", 389, 393], ["CoV", "TEST", 394, 397], ["2 infection", "PROBLEM", 398, 409], ["nasopharynx", "ANATOMY", 362, 373], ["SARS", "OBSERVATION", 389, 393]]], ["After correcting for batch effects, we found 83 DE genes (padj < 0.1 and absolute log2 fold change > 1) between SARS-CoV-2 positive and negative samples, comprising 41 up-regulated genes and 42 down-regulated genes (S1 Table).", [["samples", "ANATOMY", 145, 152], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["samples", "CANCER", 145, 152], ["DE genes", "DNA", 48, 56], ["41 up-regulated genes", "DNA", 165, 186], ["42 down-regulated genes", "DNA", 191, 214], ["S1 Table", "DNA", 216, 224], ["SARS-CoV", "SPECIES", 112, 120], ["batch effects", "PROBLEM", 21, 34], ["padj", "TEST", 58, 62], ["absolute log2 fold change", "PROBLEM", 73, 98], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120], ["samples", "TEST", 145, 152]]], ["Clustering of samples by the 50 most significant DE genes reveals multiple gene expression clusters among SARS-CoV-2 positive samples, while most negative samples cluster together (Fig 1A).", [["samples", "ANATOMY", 14, 21], ["samples", "ANATOMY", 126, 133], ["samples", "ANATOMY", 155, 162], ["samples", "CANCER", 14, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["DE genes", "DNA", 49, 57], ["SARS-CoV", "SPECIES", 106, 114], ["Clustering of samples", "TEST", 0, 21], ["multiple gene expression clusters", "PROBLEM", 66, 99], ["CoV", "TEST", 111, 114], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["gene expression", "OBSERVATION", 75, 90], ["clusters", "OBSERVATION_MODIFIER", 91, 99]]], ["Consistent with results from Butler and colleagues [20], SARS-CoV-2 infection induces an interferon-driven antiviral response in the nasopharynx, up-regulating transcripts encoding viral sensors (IFIT1, DDX58), chemokines that attract effector T cells and natural killer (NK) cells (CXCL9, 10, 11), and direct inhibitors of viral replication and function (MX2, RSAD2, HERC5), highlighted in Fig 1A and 1B.SARS-CoV-2 infection induces an antiviral, interferon-mediated host response ::: ResultsTo interrogate the global regulatory and signaling programs induced by SARS-CoV-2 infection, we employed Gene Set Enrichment Analysis (GSEA) [21,22] of the 50 Hallmark Gene Sets of the Molecular Signatures Database [23].", [["nasopharynx", "ANATOMY", 133, 144], ["effector T cells", "ANATOMY", 235, 251], ["natural killer (NK) cells", "ANATOMY", 256, 281], ["infection", "DISEASE", 68, 77], ["SARS", "DISEASE", 405, 409], ["infection", "DISEASE", 416, 425], ["SARS-CoV-2", "ORGANISM", 57, 67], ["interferon", "GENE_OR_GENE_PRODUCT", 89, 99], ["nasopharynx", "ORGAN", 133, 144], ["IFIT1", "GENE_OR_GENE_PRODUCT", 196, 201], ["DDX58", "GENE_OR_GENE_PRODUCT", 203, 208], ["T cells", "CELL", 244, 251], ["natural killer (NK) cells", "CELL", 256, 281], ["CXCL9", "GENE_OR_GENE_PRODUCT", 283, 288], ["MX2", "GENE_OR_GENE_PRODUCT", 356, 359], ["RSAD2", "GENE_OR_GENE_PRODUCT", 361, 366], ["HERC5", "GENE_OR_GENE_PRODUCT", 368, 373], ["1B", "GENE_OR_GENE_PRODUCT", 402, 404], ["SARS-CoV-2", "ORGANISM", 405, 415], ["interferon", "GENE_OR_GENE_PRODUCT", 448, 458], ["SARS-CoV-2", "ORGANISM", 564, 574], ["interferon", "PROTEIN", 89, 99], ["viral sensors", "PROTEIN", 181, 194], ["IFIT1", "PROTEIN", 196, 201], ["DDX58", "PROTEIN", 203, 208], ["chemokines", "PROTEIN", 211, 221], ["effector T cells", "CELL_TYPE", 235, 251], ["natural killer (NK) cells", "CELL_TYPE", 256, 281], ["CXCL9", "PROTEIN", 283, 288], ["MX2", "PROTEIN", 356, 359], ["RSAD2", "PROTEIN", 361, 366], ["HERC5", "PROTEIN", 368, 373], ["interferon", "PROTEIN", 448, 458], ["SARS-CoV", "SPECIES", 57, 65], ["SARS-CoV-2", "SPECIES", 405, 415], ["SARS-CoV", "SPECIES", 564, 572], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["2 infection", "PROBLEM", 66, 77], ["an interferon", "TREATMENT", 86, 99], ["antiviral response in the nasopharynx", "PROBLEM", 107, 144], ["chemokines", "PROBLEM", 211, 221], ["CXCL9", "TEST", 283, 288], ["direct inhibitors", "TREATMENT", 303, 320], ["viral replication", "PROBLEM", 324, 341], ["MX2", "TEST", 356, 359], ["RSAD2", "TEST", 361, 366], ["HERC5", "TEST", 368, 373], ["SARS", "PROBLEM", 405, 409], ["infection", "PROBLEM", 416, 425], ["an antiviral", "TREATMENT", 434, 446], ["SARS", "PROBLEM", 564, 568], ["CoV-2 infection", "PROBLEM", 569, 584], ["nasopharynx", "ANATOMY", 133, 144], ["viral replication", "OBSERVATION", 324, 341]]], ["Sets with a significant (false discovery rate [FDR] < 0.05) positive enrichment score included Interferon Alpha, Interferon Gamma, and Inflammatory Responses (Fig 1C, S1A Fig).", [["Interferon Alpha", "GENE_OR_GENE_PRODUCT", 95, 111], ["Interferon Gamma", "GENE_OR_GENE_PRODUCT", 113, 129], ["Interferon Alpha", "PROTEIN", 95, 111], ["Interferon Gamma", "PROTEIN", 113, 129], ["positive enrichment score", "PROBLEM", 60, 85], ["Interferon Alpha", "TREATMENT", 95, 111], ["Interferon Gamma", "TREATMENT", 113, 129], ["Inflammatory Responses", "TEST", 135, 157], ["Interferon Gamma", "OBSERVATION", 113, 129], ["Inflammatory", "OBSERVATION_MODIFIER", 135, 147]]], ["Interestingly, we also found several metabolic pathways negatively enriched, including both Oxidative Phosphorylation and Glycolysis, suggesting a global reduction in production of proteins related to cellular energy production (Fig 1C, S1B Fig).", [["cellular", "ANATOMY", 201, 209], ["cellular", "CELL", 201, 209], ["several metabolic pathways", "PROBLEM", 29, 55], ["Glycolysis", "TEST", 122, 132], ["a global reduction in production of proteins", "PROBLEM", 145, 189], ["cellular energy production", "PROBLEM", 201, 227], ["metabolic pathways", "OBSERVATION", 37, 55], ["Oxidative Phosphorylation", "OBSERVATION", 92, 117], ["global", "OBSERVATION_MODIFIER", 147, 153], ["reduction", "OBSERVATION_MODIFIER", 154, 163], ["cellular energy production", "OBSERVATION", 201, 227]]], ["Broad down-regulation of transcripts encoding metabolic machinery may represent either an antiviral response or viral-mediated disruption of host transcripts.", [["host transcripts", "RNA", 141, 157], ["an antiviral response", "PROBLEM", 87, 108], ["viral-mediated disruption of host transcripts", "PROBLEM", 112, 157], ["metabolic machinery", "OBSERVATION", 46, 65], ["may represent", "UNCERTAINTY", 66, 79], ["antiviral response", "OBSERVATION", 90, 108], ["viral", "OBSERVATION_MODIFIER", 112, 117], ["host transcripts", "OBSERVATION", 141, 157]]], ["We also performed a statistical enrichment test against the Biological Processes Gene Ontology (GO) [24,25].", [["a statistical enrichment test", "TEST", 18, 47]]], ["The most enriched processes (S1C\u2013S1E Fig) are related to either immune responses or translation.", [["S1C", "GENE_OR_GENE_PRODUCT", 29, 32], ["S1C", "PROTEIN", 29, 32], ["most enriched", "OBSERVATION_MODIFIER", 4, 17]]], ["In addition to up-regulation of innate antiviral transcripts (Fig 1B, S1D Fig), we also found a consistent down-regulation of transcripts encoding ribosomal proteins (S1E Fig).ISGs are differentially expressed as a function of viral load ::: ResultsThe SARS-CoV-2 receptor ACE2 is an interferon-regulated gene and is up-regulated in response to SARS-CoV-2 infection [8].", [["ribosomal", "ANATOMY", 147, 156], ["infection", "DISEASE", 356, 365], ["Fig 1B", "GENE_OR_GENE_PRODUCT", 62, 68], ["S1D", "GENE_OR_GENE_PRODUCT", 70, 73], ["ribosomal proteins", "GENE_OR_GENE_PRODUCT", 147, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 253, 263], ["ACE2", "GENE_OR_GENE_PRODUCT", 273, 277], ["SARS-CoV-2", "ORGANISM", 345, 355], ["innate antiviral transcripts", "PROTEIN", 32, 60], ["ribosomal proteins", "PROTEIN", 147, 165], ["S1E Fig", "PROTEIN", 167, 174], ["ISGs", "PROTEIN", 176, 180], ["SARS-CoV-2 receptor", "PROTEIN", 253, 272], ["ACE2", "PROTEIN", 273, 277], ["interferon-regulated gene", "DNA", 284, 309], ["SARS-CoV", "SPECIES", 253, 261], ["SARS-CoV-2", "SPECIES", 345, 355], ["innate antiviral transcripts", "TREATMENT", 32, 60], ["transcripts encoding ribosomal proteins", "PROBLEM", 126, 165], ["The SARS", "TEST", 249, 257], ["CoV", "TEST", 258, 261], ["receptor ACE2", "TREATMENT", 264, 277], ["an interferon-regulated gene", "TREATMENT", 281, 309], ["SARS", "PROBLEM", 345, 349], ["CoV-2 infection", "PROBLEM", 350, 365], ["viral load", "OBSERVATION", 227, 237]]], ["We examined the relationship between viral load\u2014defined by the cycle threshold (Ct) of the SARS-CoV-2 nucleocapsid gene region 1 (N1) target during diagnostic PCR\u2014and ACE2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 91, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["SARS-CoV-2 nucleocapsid gene region 1 (N1) target", "DNA", 91, 140], ["ACE2", "PROTEIN", 167, 171], ["SARS-CoV", "SPECIES", 91, 99], ["viral load", "TEST", 37, 47], ["Ct", "TEST", 80, 82], ["the SARS", "TEST", 87, 95], ["CoV", "TEST", 96, 99]]], ["We found that ACE2 expression was associated with increased viral load: median counts of negative, low viral load (N1 Ct > 24), medium viral load (N1 Ct 24\u201319), and high viral load (N1 Ct < 19) were 0, 1.93, 3.45, and 7.82, respectively (p = 7.46 \u00d7 10\u221213, by Kruskal-Wallis one-way ANOVA; Fig 2A).", [["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["ACE2", "PROTEIN", 14, 18], ["ACE2 expression", "PROBLEM", 14, 29], ["increased viral load", "PROBLEM", 50, 70], ["median counts", "TEST", 72, 85], ["low viral load", "PROBLEM", 99, 113], ["N1 Ct", "TEST", 115, 120], ["medium viral load", "TEST", 128, 145], ["N1 Ct", "TEST", 147, 152], ["high viral load", "PROBLEM", 165, 180], ["N1 Ct", "TEST", 182, 187], ["p", "TEST", 238, 239], ["Kruskal", "TEST", 259, 266], ["Wallis", "TEST", 267, 273], ["ANOVA", "TEST", 282, 287], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["viral load", "OBSERVATION", 60, 70], ["low viral", "OBSERVATION_MODIFIER", 99, 108], ["high", "OBSERVATION_MODIFIER", 165, 169], ["viral load", "OBSERVATION", 170, 180]]], ["A similar trend was found for other interferon-induced genes, a subset of which is shown in Fig 2A, including those significantly up-regulated in SARS-CoV-2 infection (CXCL9, OASL, and MX1), negative regulators of inflammation (CD274/PD-L1 and USP18), and monocyte chemoattractant protein-1 (CCL2) [26].", [["infection", "DISEASE", 157, 166], ["inflammation", "DISEASE", 214, 226], ["interferon", "GENE_OR_GENE_PRODUCT", 36, 46], ["Fig 2A", "GENE_OR_GENE_PRODUCT", 92, 98], ["SARS-CoV-2", "ORGANISM", 146, 156], ["CXCL9", "GENE_OR_GENE_PRODUCT", 168, 173], ["OASL", "GENE_OR_GENE_PRODUCT", 175, 179], ["MX1", "GENE_OR_GENE_PRODUCT", 185, 188], ["CD274", "GENE_OR_GENE_PRODUCT", 228, 233], ["PD-L1", "GENE_OR_GENE_PRODUCT", 234, 239], ["USP18", "GENE_OR_GENE_PRODUCT", 244, 249], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 256, 290], ["CCL2", "GENE_OR_GENE_PRODUCT", 292, 296], ["interferon", "PROTEIN", 36, 46], ["CXCL9", "PROTEIN", 168, 173], ["OASL", "PROTEIN", 175, 179], ["MX1", "PROTEIN", 185, 188], ["CD274", "PROTEIN", 228, 233], ["PD", "PROTEIN", 234, 236], ["L1", "PROTEIN", 237, 239], ["USP18", "PROTEIN", 244, 249], ["monocyte chemoattractant protein-1", "PROTEIN", 256, 290], ["CCL2", "PROTEIN", 292, 296], ["SARS-CoV-2", "SPECIES", 146, 156], ["SARS", "PROBLEM", 146, 150], ["CoV", "TEST", 151, 154], ["2 infection", "PROBLEM", 155, 166], ["CXCL9", "TEST", 168, 173], ["OASL", "TEST", 175, 179], ["inflammation", "PROBLEM", 214, 226], ["CD274", "TEST", 228, 233], ["PD", "TEST", 234, 236], ["USP18", "TEST", 244, 249], ["monocyte chemoattractant protein-", "TEST", 256, 289], ["inflammation", "OBSERVATION", 214, 226], ["monocyte", "ANATOMY", 256, 264]]], ["Conversely, the protease required for viral entry, TMPRSS2, was reduced upon viral infection but was not modulated by viral dose, nor were ribosomal proteins (RPL4, RPS6).ISGs are differentially expressed as a function of viral load ::: ResultsWe next specifically examined gene expression differences between high (N1 Ct < 19, n = 108) relative to low (N1 Ct > 24, n = 99) viral load samples.", [["ribosomal", "ANATOMY", 139, 148], ["samples", "ANATOMY", 385, 392], ["viral infection", "DISEASE", 77, 92], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 51, 58], ["RPL4", "GENE_OR_GENE_PRODUCT", 159, 163], ["RPS6", "GENE_OR_GENE_PRODUCT", 165, 169], ["protease", "PROTEIN", 16, 24], ["TMPRSS2", "PROTEIN", 51, 58], ["ribosomal proteins", "PROTEIN", 139, 157], ["RPL4", "PROTEIN", 159, 163], ["RPS6", "PROTEIN", 165, 169], ["ISGs", "PROTEIN", 171, 175], ["the protease", "TREATMENT", 12, 24], ["viral entry", "PROBLEM", 38, 49], ["TMPRSS2", "PROBLEM", 51, 58], ["viral infection", "PROBLEM", 77, 92], ["ribosomal proteins", "TEST", 139, 157], ["gene expression differences", "PROBLEM", 274, 301], ["N1 Ct", "TEST", 316, 321], ["N1 Ct", "TEST", 354, 359], ["viral load samples", "TEST", 374, 392], ["viral infection", "OBSERVATION", 77, 92], ["viral load", "OBSERVATION", 222, 232]]], ["Fig 2B highlights the 15 most up-regulated and 15 most down-regulated of the 363 total DE genes (adjusted p < 0.1, S2 Table).", [["363 total DE genes", "DNA", 77, 95]]], ["While genes up-regulated in high viral load samples were dominated by proinflammatory and/or interferon-induced factors such as CXCL9/10, IDO1, and CD80, genes with higher expression in low viral load samples included chemokines for neutrophils (CXCL8, S100A9), and B cell\u2013specific transcripts (FCRL2, IGHG1, IGHM, IGLL5, IGHG2, CD22).", [["samples", "ANATOMY", 44, 51], ["samples", "ANATOMY", 201, 208], ["neutrophils", "ANATOMY", 233, 244], ["interferon", "GENE_OR_GENE_PRODUCT", 93, 103], ["CXCL9", "GENE_OR_GENE_PRODUCT", 128, 133], ["10", "GENE_OR_GENE_PRODUCT", 134, 136], ["IDO1", "GENE_OR_GENE_PRODUCT", 138, 142], ["CD80", "GENE_OR_GENE_PRODUCT", 148, 152], ["neutrophils", "CELL", 233, 244], ["CXCL8", "GENE_OR_GENE_PRODUCT", 246, 251], ["S100A9", "GENE_OR_GENE_PRODUCT", 253, 259], ["B cell\u2013specific", "GENE_OR_GENE_PRODUCT", 266, 281], ["FCRL2", "GENE_OR_GENE_PRODUCT", 295, 300], ["IGHG1", "GENE_OR_GENE_PRODUCT", 302, 307], ["IGHM", "GENE_OR_GENE_PRODUCT", 309, 313], ["IGLL5", "GENE_OR_GENE_PRODUCT", 315, 320], ["IGHG2", "GENE_OR_GENE_PRODUCT", 322, 327], ["CD22", "GENE_OR_GENE_PRODUCT", 329, 333], ["interferon", "PROTEIN", 93, 103], ["CXCL9", "PROTEIN", 128, 133], ["IDO1", "PROTEIN", 138, 142], ["CD80", "PROTEIN", 148, 152], ["chemokines", "PROTEIN", 218, 228], ["neutrophils", "CELL_TYPE", 233, 244], ["CXCL8", "PROTEIN", 246, 251], ["S100A9", "PROTEIN", 253, 259], ["B cell\u2013specific transcripts", "RNA", 266, 293], ["FCRL2", "PROTEIN", 295, 300], ["IGHG1", "PROTEIN", 302, 307], ["IGHM", "PROTEIN", 309, 313], ["IGLL5", "PROTEIN", 315, 320], ["IGHG2", "PROTEIN", 322, 327], ["CD22", "PROTEIN", 329, 333], ["high viral load samples", "PROBLEM", 28, 51], ["interferon", "TREATMENT", 93, 103], ["CXCL9", "TEST", 128, 133], ["IDO1", "TEST", 138, 142], ["CD80", "TEST", 148, 152], ["higher expression in low viral load samples", "PROBLEM", 165, 208], ["neutrophils", "TEST", 233, 244], ["CXCL8", "TEST", 246, 251], ["S100A9", "TEST", 253, 259], ["B cell\u2013specific transcripts", "PROBLEM", 266, 293], ["FCRL2", "TEST", 295, 300], ["IGHG1", "TEST", 302, 307], ["IGHM", "TEST", 309, 313], ["IGLL5", "TEST", 315, 320], ["viral load", "OBSERVATION", 33, 43]]], ["Because this suggested differences in immune infiltration as a result of viral load, we performed in silico cell sorting of immune cells using CIBERSORTx [27] and found a higher proportion of transcripts associated with na\u00efve B and T cells, neutrophils, and M2-polarized macrophages in low viral load samples (3.5-, 2.2-, 1.6-, and 1.8-fold increased, respectively), while high viral load samples contained a larger proportion of M1 macrophages, activated NK cells, and activated dendritic cells (DCs) (2.5-, 1.6-, and 1.6-fold up-regulated, respectively; Fig 2C).", [["cell", "ANATOMY", 108, 112], ["immune cells", "ANATOMY", 124, 136], ["na\u00efve B", "ANATOMY", 220, 227], ["T cells", "ANATOMY", 232, 239], ["neutrophils", "ANATOMY", 241, 252], ["macrophages", "ANATOMY", 271, 282], ["samples", "ANATOMY", 301, 308], ["samples", "ANATOMY", 389, 396], ["M1 macrophages", "ANATOMY", 430, 444], ["NK cells", "ANATOMY", 456, 464], ["dendritic cells", "ANATOMY", 480, 495], ["DCs", "ANATOMY", 497, 500], ["cell", "CELL", 108, 112], ["immune cells", "CELL", 124, 136], ["B", "CELL", 226, 227], ["T cells", "CELL", 232, 239], ["neutrophils", "CELL", 241, 252], ["M2", "GENE_OR_GENE_PRODUCT", 258, 260], ["macrophages", "CELL", 271, 282], ["M1 macrophages", "CELL", 430, 444], ["NK cells", "CELL", 456, 464], ["dendritic cells", "CELL", 480, 495], ["DCs", "CELL", 497, 500], ["immune cells", "CELL_TYPE", 124, 136], ["na\u00efve B and T cells", "CELL_TYPE", 220, 239], ["neutrophils", "CELL_TYPE", 241, 252], ["M2-polarized macrophages", "CELL_TYPE", 258, 282], ["M1 macrophages", "CELL_TYPE", 430, 444], ["activated NK cells", "CELL_TYPE", 446, 464], ["activated dendritic cells", "CELL_TYPE", 470, 495], ["DCs", "CELL_TYPE", 497, 500], ["immune infiltration", "PROBLEM", 38, 57], ["viral load", "PROBLEM", 73, 83], ["na\u00efve B and T cells", "PROBLEM", 220, 239], ["neutrophils", "TEST", 241, 252], ["M2", "TEST", 258, 260], ["low viral load samples", "PROBLEM", 286, 308], ["high viral load samples", "PROBLEM", 373, 396], ["M1 macrophages", "PROBLEM", 430, 444], ["activated NK cells", "PROBLEM", 446, 464], ["activated dendritic cells", "PROBLEM", 470, 495], ["DCs", "TEST", 497, 500], ["immune infiltration", "OBSERVATION", 38, 57], ["viral load", "OBSERVATION", 73, 83], ["M2", "ANATOMY", 258, 260], ["polarized macrophages", "OBSERVATION", 261, 282], ["low", "OBSERVATION_MODIFIER", 286, 289], ["viral load", "OBSERVATION", 290, 300], ["larger", "OBSERVATION_MODIFIER", 409, 415], ["M1 macrophages", "OBSERVATION", 430, 444], ["activated NK cells", "OBSERVATION", 446, 464], ["dendritic cells", "OBSERVATION", 480, 495]]], ["Levels of transcripts encoding B cell proteins and neutrophil chemokines varied by viral load (Fig 2D).Human airway epithelial cells recapitulate the cell-intrinsic antiviral response seen in NP swabs ::: ResultsDetection of differential infiltration of antigen-presenting cells and lymphocytes to the nasopharynx in high versus low viral load samples highlights the role that immune cells play in the host response to SARS-CoV-2.", [["B cell", "ANATOMY", 31, 37], ["neutrophil", "ANATOMY", 51, 61], ["airway epithelial cells", "ANATOMY", 109, 132], ["cell", "ANATOMY", 150, 154], ["antigen-presenting cells", "ANATOMY", 254, 278], ["lymphocytes", "ANATOMY", 283, 294], ["nasopharynx", "ANATOMY", 302, 313], ["samples", "ANATOMY", 344, 351], ["immune cells", "ANATOMY", 377, 389], ["SARS", "DISEASE", 419, 423], ["B cell proteins", "GENE_OR_GENE_PRODUCT", 31, 46], ["neutrophil", "CELL", 51, 61], ["Human", "ORGANISM", 103, 108], ["airway epithelial cells", "CELL", 109, 132], ["cell", "CELL", 150, 154], ["antigen", "GENE_OR_GENE_PRODUCT", 254, 261], ["cells", "CELL", 273, 278], ["lymphocytes", "CELL", 283, 294], ["nasopharynx", "ORGAN", 302, 313], ["immune cells", "CELL", 377, 389], ["SARS-CoV-2", "ORGANISM", 419, 429], ["B cell proteins", "PROTEIN", 31, 46], ["neutrophil chemokines", "PROTEIN", 51, 72], ["Human airway epithelial cells", "CELL_TYPE", 103, 132], ["antigen-presenting cells", "CELL_TYPE", 254, 278], ["lymphocytes", "CELL_TYPE", 283, 294], ["immune cells", "CELL_TYPE", 377, 389], ["Human", "SPECIES", 103, 108], ["Human", "SPECIES", 103, 108], ["SARS-CoV", "SPECIES", 419, 427], ["Levels", "TEST", 0, 6], ["transcripts encoding B cell proteins", "TEST", 10, 46], ["neutrophil chemokines", "TEST", 51, 72], ["viral load", "TEST", 83, 93], ["Human airway epithelial cells", "TEST", 103, 132], ["intrinsic antiviral response", "PROBLEM", 155, 183], ["differential infiltration of antigen", "PROBLEM", 225, 261], ["presenting cells", "PROBLEM", 262, 278], ["lymphocytes to the nasopharynx", "PROBLEM", 283, 313], ["low viral load samples", "PROBLEM", 329, 351], ["immune cells", "PROBLEM", 377, 389], ["CoV", "TEST", 424, 427], ["cell", "OBSERVATION", 33, 37], ["airway", "ANATOMY", 109, 115], ["epithelial cells", "OBSERVATION", 116, 132], ["cell", "OBSERVATION", 150, 154], ["antiviral response", "OBSERVATION", 165, 183], ["differential", "OBSERVATION_MODIFIER", 225, 237], ["infiltration", "OBSERVATION", 238, 250], ["nasopharynx", "ANATOMY", 302, 313], ["high", "OBSERVATION_MODIFIER", 317, 321], ["viral load", "OBSERVATION", 333, 343], ["immune cells", "OBSERVATION", 377, 389]]], ["To understand whether in vivo infection could be adequately modeled in vitro, we examined gene expression differences in male human airway epithelial (HAE) cells 3 and 7 days post infection with SARS-CoV-2 and compared the DE genes at day 7 to those from SARS-CoV-2 positive versus negative (Fig 1) and high versus low viral load SARS-CoV-2-positive samples (Fig 2).", [["airway epithelial (HAE) cells", "ANATOMY", 132, 161], ["samples", "ANATOMY", 350, 357], ["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 180, 189], ["human", "ORGANISM", 126, 131], ["airway epithelial (HAE) cells", "CELL", 132, 161], ["SARS-CoV-2", "ORGANISM", 255, 265], ["CoV-2", "GENE_OR_GENE_PRODUCT", 335, 340], ["male human airway epithelial (HAE) cells", "CELL_TYPE", 121, 161], ["DE genes", "DNA", 223, 231], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["SARS-CoV", "SPECIES", 195, 203], ["SARS-CoV", "SPECIES", 255, 263], ["SARS-CoV", "SPECIES", 330, 338], ["vivo infection", "PROBLEM", 25, 39], ["infection", "PROBLEM", 180, 189], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["SARS", "TEST", 255, 259], ["CoV", "TEST", 260, 263], ["Fig", "TEST", 292, 295], ["high versus low viral load SARS", "PROBLEM", 303, 334], ["CoV", "TEST", 335, 338], ["infection", "OBSERVATION", 30, 39], ["airway epithelial", "ANATOMY", 132, 149], ["infection", "OBSERVATION", 180, 189]]], ["Although HAE are tracheal/bronchial epithelial cells and thus reside lower in the respiratory tract than the nasopharynx, we nevertheless found a consensus set of 19 up-regulated genes that define cell-intrinsic host antiviral responses to SARS-CoV-2 infection (Fig 3A; p = 4.81 \u00d7 10\u221269).", [["tracheal", "ANATOMY", 17, 25], ["bronchial epithelial cells", "ANATOMY", 26, 52], ["respiratory tract", "ANATOMY", 82, 99], ["nasopharynx", "ANATOMY", 109, 120], ["cell", "ANATOMY", 197, 201], ["HAE", "DISEASE", 9, 12], ["SARS-CoV-2 infection", "DISEASE", 240, 260], ["bronchial epithelial cells", "CELL", 26, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["nasopharynx", "ORGAN", 109, 120], ["cell", "CELL", 197, 201], ["SARS-CoV-2", "ORGANISM", 240, 250], ["tracheal/bronchial epithelial cells", "CELL_TYPE", 17, 52], ["19 up-regulated genes", "DNA", 163, 184], ["SARS-CoV-2", "SPECIES", 240, 250], ["HAE", "PROBLEM", 9, 12], ["tracheal/bronchial epithelial cells", "PROBLEM", 17, 52], ["SARS", "TEST", 240, 244], ["CoV", "TEST", 245, 248], ["2 infection", "PROBLEM", 249, 260], ["p", "TEST", 270, 271], ["tracheal", "ANATOMY", 17, 25], ["bronchial", "ANATOMY", 26, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["lower", "OBSERVATION_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 82, 99], ["nasopharynx", "ANATOMY", 109, 120], ["host antiviral", "OBSERVATION", 212, 226]]], ["When this consensus set was tested for statistical enrichment in the DisGeNET [28] of disease ontologies, we found a high degree of overlap with influenza signature genes (Fig 3B), including a number of interferon-induced genes that mediate the acute antiviral response in the respiratory tract (Fig 3C).", [["respiratory tract", "ANATOMY", 277, 294], ["interferon", "GENE_OR_GENE_PRODUCT", 203, 213], ["respiratory tract", "ORGANISM_SUBDIVISION", 277, 294], ["influenza signature genes", "DNA", 145, 170], ["interferon-induced genes", "DNA", 203, 227], ["disease ontologies", "PROBLEM", 86, 104], ["influenza signature genes", "PROBLEM", 145, 170], ["interferon", "TREATMENT", 203, 213], ["the acute antiviral response in the respiratory tract", "PROBLEM", 241, 294], ["high degree", "OBSERVATION_MODIFIER", 117, 128], ["influenza", "OBSERVATION", 145, 154], ["acute", "OBSERVATION_MODIFIER", 245, 250], ["antiviral response", "OBSERVATION", 251, 269], ["respiratory tract", "ANATOMY", 277, 294]]], ["Notably, in the HAE cells, there was no sign of induction of an interferon response at 3 days post infection in spite of a 10-fold higher infectious dose of virus used and virus making up 0.3% of reads.", [["HAE cells", "ANATOMY", 16, 25], ["HAE", "DISEASE", 16, 19], ["infection", "DISEASE", 99, 108], ["HAE cells", "CELL", 16, 25], ["HAE cells", "CELL_LINE", 16, 25], ["interferon", "PROTEIN", 64, 74], ["an interferon response", "PROBLEM", 61, 83], ["infection", "PROBLEM", 99, 108], ["a 10-fold higher infectious dose of virus", "TREATMENT", 121, 162], ["virus", "PROBLEM", 172, 177], ["no sign of", "UNCERTAINTY", 37, 47], ["interferon", "OBSERVATION", 64, 74], ["infection", "OBSERVATION", 99, 108]]], ["At 7 days post infection, SARS-CoV-2 constituted 5.3% of reads.Longitudinal analysis of patient-matched samples shows reduced viral load and increased wound healing and humoral immune responses over time ::: ResultsInfection time course may account for the observed differences in immune-related genes in high versus low viral load samples: Patients receiving repeat SARS-CoV-2 testing have a reduced viral load over time [13,29,30].", [["samples", "ANATOMY", 104, 111], ["wound", "ANATOMY", 151, 156], ["infection", "DISEASE", 15, 24], ["SARS", "DISEASE", 26, 30], ["patient", "ORGANISM", 88, 95], ["wound", "PATHOLOGICAL_FORMATION", 151, 156], ["Patients", "ORGANISM", 341, 349], ["patient", "SPECIES", 88, 95], ["Patients", "SPECIES", 341, 349], ["SARS-CoV", "SPECIES", 26, 34], ["infection", "PROBLEM", 15, 24], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["Longitudinal analysis", "TEST", 63, 84], ["matched samples", "TEST", 96, 111], ["reduced viral load", "PROBLEM", 118, 136], ["increased wound healing", "PROBLEM", 141, 164], ["immune-related genes in high versus low viral load samples", "PROBLEM", 281, 339], ["repeat SARS", "TEST", 360, 371], ["CoV-2 testing", "TEST", 372, 385], ["a reduced viral load", "PROBLEM", 391, 411], ["infection", "OBSERVATION", 15, 24], ["reduced", "OBSERVATION_MODIFIER", 118, 125], ["viral load", "OBSERVATION", 126, 136], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["wound healing", "OBSERVATION", 151, 164], ["humoral immune", "OBSERVATION", 169, 183]]], ["Although we do not have the ability to tie our data from our large set of positive samples back to the onset of symptoms, we have seen gene expression changes in a small set (n = 3) of matched longitudinal samples with a mean elapsed time of 6.3 days between collections and a mean increase in Ct value of 5.29, representing a 39-fold reduction in viral load (Fig 4A).", [["samples", "ANATOMY", 206, 213], ["symptoms", "PROBLEM", 112, 120], ["gene expression changes", "PROBLEM", 135, 158], ["collections", "PROBLEM", 259, 270], ["Ct value", "TEST", 294, 302], ["a 39-fold reduction", "TREATMENT", 325, 344], ["small", "OBSERVATION_MODIFIER", 164, 169], ["mean", "OBSERVATION_MODIFIER", 277, 281], ["increase", "OBSERVATION_MODIFIER", 282, 290], ["39-fold", "OBSERVATION_MODIFIER", 327, 334], ["reduction", "OBSERVATION_MODIFIER", 335, 344], ["viral load", "OBSERVATION", 348, 358]]], ["Notably, in the second sample collected, we saw increases in genes such as C1QA, -B, and -C and HLA-DQB1 that drive humoral immune responses and those involved in wound healing (APOE, CD36, RHOC), as well as reductions in negative regulators of each process (i.e., TREM1, TFPI).", [["wound", "ANATOMY", 163, 168], ["C1QA", "GENE_OR_GENE_PRODUCT", 75, 79], ["-B", "GENE_OR_GENE_PRODUCT", 81, 83], ["-C", "GENE_OR_GENE_PRODUCT", 89, 91], ["HLA-DQB1", "GENE_OR_GENE_PRODUCT", 96, 104], ["wound", "PATHOLOGICAL_FORMATION", 163, 168], ["CD36", "GENE_OR_GENE_PRODUCT", 184, 188], ["RHOC", "GENE_OR_GENE_PRODUCT", 190, 194], ["TREM1", "GENE_OR_GENE_PRODUCT", 265, 270], ["TFPI", "GENE_OR_GENE_PRODUCT", 272, 276], ["C1QA", "DNA", 75, 79], ["HLA", "DNA", 96, 99], ["DQB1", "DNA", 100, 104], ["APOE", "PROTEIN", 178, 182], ["CD36", "PROTEIN", 184, 188], ["RHOC", "PROTEIN", 190, 194], ["TREM1", "PROTEIN", 265, 270], ["TFPI", "PROTEIN", 272, 276], ["C1QA", "TEST", 75, 79], ["DQB1", "TREATMENT", 100, 104], ["wound healing", "PROBLEM", 163, 176]]], ["We also tested the 19 SARS-CoV-2 signature genes (Fig 3A) and found reductions in most at the second collection timepoint, although only RSAD2, IFIT2, and HERC5 decreases were statistically significant with 3 samples.", [["RSAD2", "GENE_OR_GENE_PRODUCT", 137, 142], ["IFIT2", "GENE_OR_GENE_PRODUCT", 144, 149], ["HERC5", "GENE_OR_GENE_PRODUCT", 155, 160], ["SARS-CoV-2 signature genes", "DNA", 22, 48], ["RSAD2", "DNA", 137, 142], ["IFIT2", "DNA", 144, 149], ["HERC5", "DNA", 155, 160], ["CoV", "TEST", 27, 30], ["IFIT2", "TEST", 144, 149], ["HERC5 decreases", "PROBLEM", 155, 170], ["reductions", "OBSERVATION_MODIFIER", 68, 78]]], ["We also saw a recovery in the expression of ribosomal proteins over time (Fig 4C).", [["ribosomal", "ANATOMY", 44, 53], ["ribosomal", "CELLULAR_COMPONENT", 44, 53], ["ribosomal proteins", "PROTEIN", 44, 62], ["ribosomal proteins", "PROBLEM", 44, 62]]], ["Analysis of data from additional patients with inclusion of more extensive clinical data is currently under investigation in our group.Factors affecting T-cell trafficking are reduced in older adults infected with SARS-CoV-2 ::: ResultsClinically, COVID-19 cases tend to be more severe for older adults and males [1].", [["T-cell", "ANATOMY", 153, 159], ["SARS", "DISEASE", 214, 218], ["patients", "ORGANISM", 33, 41], ["T-cell", "CELL", 153, 159], ["SARS-CoV-2", "ORGANISM", 214, 224], ["patients", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 214, 222], ["CoV", "TEST", 219, 222], ["COVID", "TEST", 248, 253], ["reduced", "OBSERVATION_MODIFIER", 176, 183]]], ["No significant difference in N1 Ct was observed based on age or sex (Fig 5A).", [["significant difference", "PROBLEM", 3, 25], ["N1 Ct", "TEST", 29, 34], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25]]], ["To understand the differences in host response to SARS-CoV-2 infection, we tested the interaction between infection and age (greater than 60), controlling for non\u2013infection-related age differences with SARS-CoV-2-negative samples.", [["samples", "ANATOMY", 222, 229], ["SARS-CoV-2 infection", "DISEASE", 50, 70], ["infection", "DISEASE", 106, 115], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 202, 212], ["CoV-2", "SPECIES", 55, 60], ["SARS-CoV-2", "SPECIES", 50, 60], ["SARS-CoV", "SPECIES", 202, 210], ["SARS", "PROBLEM", 50, 54], ["CoV-2 infection", "PROBLEM", 55, 70], ["infection", "PROBLEM", 106, 115], ["non\u2013infection", "PROBLEM", 159, 172], ["SARS", "TEST", 202, 206], ["CoV", "TEST", 207, 210], ["infection", "OBSERVATION", 61, 70]]], ["We found only 2 genes altered as a result of the interaction between age and SARS-CoV-2 infection: a 30-fold reduction in production of CXCL11 (Fig 5B), an interferon-induced chemokine for NK and CD8+ T cells, and a 17-fold reduction in polycomb group factor 6 (PCGF6) (S2A Fig), a polycomb repressor complex protein known to play a role in repression of dendritic cell activation [31].", [["NK", "ANATOMY", 189, 191], ["CD8+ T cells", "ANATOMY", 196, 208], ["dendritic cell", "ANATOMY", 355, 369], ["infection", "DISEASE", 88, 97], ["SARS-CoV-2", "ORGANISM", 77, 87], ["CXCL11", "GENE_OR_GENE_PRODUCT", 136, 142], ["Fig 5B", "GENE_OR_GENE_PRODUCT", 144, 150], ["interferon", "GENE_OR_GENE_PRODUCT", 156, 166], ["NK", "CELL", 189, 191], ["CD8", "GENE_OR_GENE_PRODUCT", 196, 199], ["polycomb group factor 6", "GENE_OR_GENE_PRODUCT", 237, 260], ["PCGF6", "GENE_OR_GENE_PRODUCT", 262, 267], ["S2A", "GENE_OR_GENE_PRODUCT", 270, 273], ["dendritic cell", "CELL", 355, 369], ["CXCL11", "PROTEIN", 136, 142], ["interferon", "PROTEIN", 156, 166], ["chemokine", "PROTEIN", 175, 184], ["NK and CD8+ T cells", "CELL_TYPE", 189, 208], ["polycomb group factor 6", "PROTEIN", 237, 260], ["PCGF6", "PROTEIN", 262, 267], ["S2A", "PROTEIN", 270, 273], ["polycomb repressor complex protein", "PROTEIN", 282, 316], ["SARS-CoV", "SPECIES", 77, 85], ["SARS", "PROBLEM", 77, 81], ["CoV-2 infection", "PROBLEM", 82, 97], ["a 30-fold reduction", "TREATMENT", 99, 118], ["CXCL11", "TEST", 136, 142], ["an interferon", "TREATMENT", 153, 166], ["NK", "TEST", 189, 191], ["CD8", "TEST", 196, 199], ["T cells", "PROBLEM", 201, 208], ["a 17-fold reduction", "TREATMENT", 214, 233], ["polycomb group factor", "TEST", 237, 258], ["a polycomb repressor complex protein", "TREATMENT", 280, 316], ["dendritic cell activation", "PROBLEM", 355, 380], ["dendritic cell activation", "OBSERVATION", 355, 380]]], ["Although we did not find additional genes altered specifically as a result of age in SARS-CoV-2 infection, we did find that CXCL9 and CXCL10 are not induced as strongly in SARS-CoV-2-positive patients aged 60 or older.", [["SARS-CoV-2 infection", "DISEASE", 85, 105], ["SARS-CoV-2", "ORGANISM", 85, 95], ["CXCL9", "GENE_OR_GENE_PRODUCT", 124, 129], ["CXCL10", "GENE_OR_GENE_PRODUCT", 134, 140], ["SARS-CoV-2", "ORGANISM", 172, 182], ["patients", "ORGANISM", 192, 200], ["CXCL9", "PROTEIN", 124, 129], ["CXCL10", "PROTEIN", 134, 140], ["patients", "SPECIES", 192, 200], ["SARS-CoV-2", "SPECIES", 85, 95], ["SARS-CoV", "SPECIES", 172, 180], ["SARS", "PROBLEM", 85, 89], ["CoV-2 infection", "PROBLEM", 90, 105], ["CXCL9", "TEST", 124, 129], ["CXCL10", "TEST", 134, 140], ["SARS", "TEST", 172, 176], ["CoV", "TEST", 177, 180]]], ["We also found reduced expression of the receptor for CXCL9/10/11 (CXCR3), the apoptosis-inducing factor GZMB secreted by NK and T cells, and the effector T-cell marker (CD8A).", [["NK", "ANATOMY", 121, 123], ["T cells", "ANATOMY", 128, 135], ["T-cell", "ANATOMY", 154, 160], ["CXCL9", "GENE_OR_GENE_PRODUCT", 53, 58], ["10/11", "GENE_OR_GENE_PRODUCT", 59, 64], ["CXCR3", "GENE_OR_GENE_PRODUCT", 66, 71], ["GZMB", "GENE_OR_GENE_PRODUCT", 104, 108], ["NK", "CELL", 121, 123], ["T cells", "CELL", 128, 135], ["T-cell marker", "GENE_OR_GENE_PRODUCT", 154, 167], ["CD8A", "GENE_OR_GENE_PRODUCT", 169, 173], ["CXCL9", "PROTEIN", 53, 58], ["10/11", "PROTEIN", 59, 64], ["CXCR3", "PROTEIN", 66, 71], ["apoptosis-inducing factor", "PROTEIN", 78, 103], ["GZMB", "PROTEIN", 104, 108], ["NK and T cells", "CELL_TYPE", 121, 135], ["effector T-cell marker", "PROTEIN", 145, 167], ["CD8A", "PROTEIN", 169, 173], ["CXCL9", "TEST", 53, 58], ["CXCR3", "TEST", 66, 71], ["the apoptosis", "TEST", 74, 87], ["factor GZMB", "TEST", 97, 108], ["reduced", "OBSERVATION_MODIFIER", 14, 21]]], ["These data suggest that age-related T-cell and NK cell dysfunction [32,33] may play a role in SARS-CoV-2 pathogenesis in older individuals.Males and females have differences in immune responses to SARS-CoV-2 ::: ResultsWe performed a similar analysis to evaluate sex differences in SARS-CoV-2 infection and found a total of 19 genes for which the differences in expression based on sex could be attributed to SARS-CoV-2 infection.", [["T-cell", "ANATOMY", 36, 42], ["NK cell", "ANATOMY", 47, 54], ["SARS", "DISEASE", 197, 201], ["SARS-CoV-2 infection", "DISEASE", 282, 302], ["infection", "DISEASE", 420, 429], ["T-cell", "CELL", 36, 42], ["NK cell", "CELL", 47, 54], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV-2", "ORGANISM", 282, 292], ["SARS-CoV-2", "ORGANISM", 409, 419], ["SARS-CoV", "SPECIES", 94, 102], ["SARS-CoV-2", "SPECIES", 282, 292], ["SARS-CoV-2", "SPECIES", 409, 419], ["These data", "TEST", 0, 10], ["T-cell", "PROBLEM", 36, 42], ["NK cell dysfunction", "PROBLEM", 47, 66], ["SARS", "PROBLEM", 94, 98], ["CoV", "PROBLEM", 99, 102], ["a similar analysis", "TEST", 232, 250], ["SARS", "PROBLEM", 282, 286], ["CoV", "PROBLEM", 287, 290], ["2 infection", "PROBLEM", 291, 302], ["SARS", "PROBLEM", 409, 413], ["CoV", "PROBLEM", 414, 417], ["2 infection", "PROBLEM", 418, 429], ["NK cell dysfunction", "OBSERVATION", 47, 66], ["infection", "OBSERVATION", 293, 302], ["infection", "OBSERVATION", 420, 429]]], ["S2B Fig highlights the top 10 nonredundant enriched GO categories, most of which are related to immune function.", [["S2B", "GENE_OR_GENE_PRODUCT", 0, 3], ["top", "OBSERVATION_MODIFIER", 23, 26], ["immune function", "OBSERVATION", 96, 111]]], ["In men, we found down-regulation of B cell\u2013specific transcripts (IGHG1 and MSA4A/CD20), down-regulation of the NK cell\u2013activating receptor SLAMF6, and an up-regulation of several inhibitors of NF\u03baB signaling (NDRG1, ARRB2, CD300A, and NFKBID) (Fig 5D).", [["NK", "ANATOMY", 111, 113], ["men", "ORGANISM", 3, 6], ["B", "GENE_OR_GENE_PRODUCT", 36, 37], ["IGHG1", "GENE_OR_GENE_PRODUCT", 65, 70], ["MSA4A", "GENE_OR_GENE_PRODUCT", 75, 80], ["CD20", "GENE_OR_GENE_PRODUCT", 81, 85], ["SLAMF6", "GENE_OR_GENE_PRODUCT", 139, 145], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 193, 197], ["NDRG1", "GENE_OR_GENE_PRODUCT", 209, 214], ["ARRB2", "GENE_OR_GENE_PRODUCT", 216, 221], ["CD300A", "GENE_OR_GENE_PRODUCT", 223, 229], ["NFKBID", "GENE_OR_GENE_PRODUCT", 235, 241], ["B cell\u2013specific transcripts", "PROTEIN", 36, 63], ["IGHG1", "PROTEIN", 65, 70], ["MSA4A", "PROTEIN", 75, 80], ["CD20", "PROTEIN", 81, 85], ["NK cell\u2013activating receptor", "PROTEIN", 111, 138], ["SLAMF6", "PROTEIN", 139, 145], ["NF\u03baB", "PROTEIN", 193, 197], ["NDRG1", "PROTEIN", 209, 214], ["ARRB2", "PROTEIN", 216, 221], ["CD300A", "PROTEIN", 223, 229], ["NFKBID", "PROTEIN", 235, 241], ["men", "SPECIES", 3, 6], ["B cell\u2013specific transcripts", "PROBLEM", 36, 63], ["IGHG1", "TEST", 65, 70], ["MSA4A", "TEST", 75, 80], ["the NK cell\u2013activating receptor SLAMF6", "TREATMENT", 107, 145], ["several inhibitors", "TREATMENT", 171, 189], ["NF", "TEST", 193, 195], ["NDRG1", "TEST", 209, 214], ["ARRB2", "TEST", 216, 221], ["CD300A", "TEST", 223, 229], ["NK", "ANATOMY", 111, 113]]], ["The down-regulation of B cell\u2013specific markers suggests differences in lymphocyte composition and/or trafficking in males.", [["lymphocyte", "ANATOMY", 71, 81], ["B", "GENE_OR_GENE_PRODUCT", 23, 24], ["lymphocyte", "CELL", 71, 81], ["B cell\u2013specific markers", "PROTEIN", 23, 46], ["B cell\u2013specific markers", "TEST", 23, 46], ["lymphocyte composition", "TEST", 71, 93], ["lymphocyte composition", "OBSERVATION", 71, 93]]], ["Furthermore, the reduction in NK cell\u2013activating receptors and up-regulation of negative regulators of immune effector function\u2014and resultant throttling of effector function\u2014is consistent with a more severe manifestation of COVID-19 in males.DiscussionOne of the hallmarks of COVID-19 is a dysregulated antiviral immune response.", [["NK", "ANATOMY", 30, 32], ["COVID-19", "CHEMICAL", 276, 284], ["COVID-19", "CHEMICAL", 276, 284], ["NK cell\u2013activating receptors", "GENE_OR_GENE_PRODUCT", 30, 58], ["COVID-19", "GENE_OR_GENE_PRODUCT", 276, 284], ["NK cell\u2013activating receptors", "PROTEIN", 30, 58], ["the reduction", "TREATMENT", 13, 26], ["NK cell\u2013activating receptors", "TREATMENT", 30, 58], ["immune effector", "PROBLEM", 103, 118], ["resultant throttling of effector function\u2014is", "PROBLEM", 132, 176], ["COVID", "TEST", 224, 229], ["COVID", "TEST", 276, 281], ["a dysregulated antiviral immune response", "TREATMENT", 288, 328], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["NK cell\u2013activating", "OBSERVATION", 30, 48]]], ["Studies of SARS-CoV, which also employs ACE2/TMPRSS2-mediated entry, have demonstrated that infection does not always result in production of interferons in macrophages and dendritic cell [34], and significantly delayed expression of type II or III interferon in lung cells [10].", [["macrophages", "ANATOMY", 157, 168], ["dendritic cell", "ANATOMY", 173, 187], ["lung cells", "ANATOMY", 263, 273], ["SARS", "DISEASE", 11, 15], ["infection", "DISEASE", 92, 101], ["SARS-CoV", "ORGANISM", 11, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 45, 52], ["interferons", "GENE_OR_GENE_PRODUCT", 142, 153], ["macrophages", "CELL", 157, 168], ["dendritic cell [34]", "CELL", 173, 192], ["type II or III interferon", "GENE_OR_GENE_PRODUCT", 234, 259], ["lung cells", "CELL", 263, 273], ["ACE2", "PROTEIN", 40, 44], ["TMPRSS2", "PROTEIN", 45, 52], ["interferons", "PROTEIN", 142, 153], ["macrophages", "CELL_TYPE", 157, 168], ["dendritic cell", "CELL_TYPE", 173, 187], ["type II or III interferon", "PROTEIN", 234, 259], ["lung cells", "CELL_TYPE", 263, 273], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "PROBLEM", 11, 15], ["CoV", "PROBLEM", 16, 19], ["ACE2", "TEST", 40, 44], ["infection", "PROBLEM", 92, 101], ["interferons in macrophages", "PROBLEM", 142, 168], ["dendritic cell", "PROBLEM", 173, 187], ["type II or III interferon in lung cells", "PROBLEM", 234, 273], ["infection", "OBSERVATION", 92, 101], ["interferons", "OBSERVATION", 142, 153], ["dendritic cell", "OBSERVATION", 173, 187], ["lung", "ANATOMY", 263, 267]]], ["Moreover, infection of BALB/c mice with SARS-CoV did not result in detectable interferon beta (IFN\u03b2) until 24 hours, at which point viral titers had nearly reached a peak; lung damage resulting from the subsequent massive infiltration of inflammatory macrophages could be abrogated by pre-treatment with type I interferons [11].", [["lung", "ANATOMY", 172, 176], ["inflammatory macrophages", "ANATOMY", 238, 262], ["infection", "DISEASE", 10, 19], ["SARS", "DISEASE", 40, 44], ["lung damage", "DISEASE", 172, 183], ["BALB/c mice", "ORGANISM", 23, 34], ["SARS-CoV", "ORGANISM", 40, 48], ["interferon beta", "GENE_OR_GENE_PRODUCT", 78, 93], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 95, 99], ["lung", "ORGAN", 172, 176], ["macrophages", "CELL", 251, 262], ["type I interferons", "GENE_OR_GENE_PRODUCT", 304, 322], ["interferon beta", "PROTEIN", 78, 93], ["IFN\u03b2", "PROTEIN", 95, 99], ["inflammatory macrophages", "CELL_TYPE", 238, 262], ["type I interferons", "PROTEIN", 304, 322], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["SARS-CoV", "SPECIES", 40, 48], ["infection of BALB/c mice", "PROBLEM", 10, 34], ["SARS", "PROBLEM", 40, 44], ["CoV", "PROBLEM", 45, 48], ["detectable interferon beta (IFN\u03b2", "TREATMENT", 67, 99], ["viral titers", "TEST", 132, 144], ["lung damage", "PROBLEM", 172, 183], ["the subsequent massive infiltration", "PROBLEM", 199, 234], ["inflammatory macrophages", "PROBLEM", 238, 262], ["type I interferons", "TREATMENT", 304, 322], ["infection", "OBSERVATION", 10, 19], ["lung", "ANATOMY", 172, 176], ["damage", "OBSERVATION", 177, 183], ["massive", "OBSERVATION_MODIFIER", 214, 221], ["infiltration", "OBSERVATION", 222, 234], ["inflammatory macrophages", "OBSERVATION", 238, 262]]], ["Similar viral kinetics have been observed in SARS-CoV-2-infected patients [13,14] and ferrets [12].", [["SARS-CoV-2-infected", "DISEASE", 45, 64], ["SARS-CoV-2", "ORGANISM", 45, 55], ["patients", "ORGANISM", 65, 73], ["ferrets", "ORGANISM", 86, 93], ["CoV-2", "SPECIES", 50, 55], ["patients", "SPECIES", 65, 73], ["ferrets", "SPECIES", 86, 93], ["SARS-CoV-2", "SPECIES", 45, 55], ["Similar viral kinetics", "PROBLEM", 0, 22], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["viral kinetics", "OBSERVATION", 8, 22]]], ["Collectively, these results support a common mechanism by which SARS-CoV and SARS-CoV-2 suppress intracellular viral detection and subsequent interferon induction long enough for viral replication to occur.DiscussionOur transcriptomic analysis of NP swabs, which were collected primarily after the onset of symptoms, reveals the robust induction of an interferon response by SARS-CoV-2 infection, similar to that observed by Butler and colleagues [20] and consistent with genes regulated by other coronaviruses [35,36].", [["intracellular", "ANATOMY", 97, 110], ["NP swabs", "ANATOMY", 247, 255], ["SARS", "DISEASE", 64, 68], ["infection", "DISEASE", 386, 395], ["SARS-CoV", "ORGANISM", 64, 72], ["SARS-CoV-2", "ORGANISM", 77, 87], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 110], ["interferon", "GENE_OR_GENE_PRODUCT", 142, 152], ["NP swabs", "MULTI-TISSUE_STRUCTURE", 247, 255], ["SARS-CoV-2", "ORGANISM", 375, 385], ["coronaviruses", "ORGANISM", 497, 510], ["interferon", "PROTEIN", 142, 152], ["interferon", "PROTEIN", 352, 362], ["SARS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 77, 85], ["SARS-CoV-2", "SPECIES", 375, 385], ["SARS", "PROBLEM", 77, 81], ["CoV", "TEST", 82, 85], ["intracellular viral detection", "TREATMENT", 97, 126], ["subsequent interferon induction", "TREATMENT", 131, 162], ["viral replication", "TREATMENT", 179, 196], ["NP swabs", "TEST", 247, 255], ["symptoms", "PROBLEM", 307, 315], ["an interferon response", "TREATMENT", 349, 371], ["SARS", "PROBLEM", 375, 379], ["CoV-2 infection", "PROBLEM", 380, 395], ["infection", "OBSERVATION", 386, 395], ["consistent with", "UNCERTAINTY", 456, 471]]], ["The highest levels of individual interferon-responsive genes were seen in samples with the highest viral load.", [["samples", "ANATOMY", 74, 81], ["interferon", "GENE_OR_GENE_PRODUCT", 33, 43], ["samples", "CANCER", 74, 81], ["interferon-responsive genes", "DNA", 33, 60], ["individual interferon-responsive genes", "PROBLEM", 22, 60], ["the highest viral load", "PROBLEM", 87, 109], ["interferon", "OBSERVATION", 33, 43], ["responsive genes", "OBSERVATION", 44, 60], ["viral load", "OBSERVATION", 99, 109]]], ["Furthermore, although the in silico cell sorting algorithm we employed has not been specifically validated in NP samples, it detected an enrichment of transcripts associated with inflammatory macrophages and activated DCs and NK cells, 3 primary sources of type I and II interferons, in high viral load samples.", [["cell", "ANATOMY", 36, 40], ["NP samples", "ANATOMY", 110, 120], ["inflammatory macrophages", "ANATOMY", 179, 203], ["DCs", "ANATOMY", 218, 221], ["NK cells", "ANATOMY", 226, 234], ["samples", "ANATOMY", 303, 310], ["cell", "CELL", 36, 40], ["NP samples", "CANCER", 110, 120], ["macrophages", "CELL", 192, 203], ["DCs", "CELL", 218, 221], ["NK cells", "CELL", 226, 234], ["type I and II interferons", "GENE_OR_GENE_PRODUCT", 257, 282], ["inflammatory macrophages", "CELL_TYPE", 179, 203], ["DCs", "CELL_TYPE", 218, 221], ["NK cells", "CELL_TYPE", 226, 234], ["type I and II interferons", "PROTEIN", 257, 282], ["inflammatory macrophages", "PROBLEM", 179, 203], ["activated DCs and NK cells", "PROBLEM", 208, 234], ["type I and II interferons", "PROBLEM", 257, 282], ["high viral load samples", "PROBLEM", 287, 310], ["inflammatory macrophages", "OBSERVATION", 179, 203], ["NK cells", "OBSERVATION", 226, 234], ["high", "OBSERVATION_MODIFIER", 287, 291], ["viral load", "OBSERVATION", 292, 302]]], ["When repeat swabs were taken from patients with an average 6.3-day time period between sampling, the interferon response had waned, as had viral load, while transcripts associated with an anti-inflammatory, wound-healing response had increased.", [["swabs", "ANATOMY", 12, 17], ["wound", "ANATOMY", 207, 212], ["patients", "ORGANISM", 34, 42], ["wound", "PATHOLOGICAL_FORMATION", 207, 212], ["interferon", "PROTEIN", 101, 111], ["patients", "SPECIES", 34, 42], ["repeat swabs", "TEST", 5, 17], ["viral load", "PROBLEM", 139, 149], ["an anti-inflammatory", "TREATMENT", 185, 205], ["wound", "PROBLEM", 207, 212], ["anti-inflammatory", "OBSERVATION_MODIFIER", 188, 205], ["wound", "ANATOMY", 207, 212], ["healing", "OBSERVATION_MODIFIER", 213, 220], ["increased", "OBSERVATION_MODIFIER", 234, 243]]], ["Notably, in contrast to the robust expression of type I interferon-regulated transcripts in HAE 7 days after infection with SARS-CoV-2, there was limited evidence of induction of an antiviral response after only 3 days, consistent with a SARS-CoV-like functional repression of intrinsic antiviral immunity and interferon signaling.", [["HAE", "DISEASE", 92, 95], ["infection", "DISEASE", 109, 118], ["type I interferon", "GENE_OR_GENE_PRODUCT", 49, 66], ["SARS-CoV-2", "ORGANISM", 124, 134], ["interferon", "GENE_OR_GENE_PRODUCT", 310, 320], ["type I interferon-regulated transcripts", "PROTEIN", 49, 88], ["interferon", "PROTEIN", 310, 320], ["SARS-CoV", "SPECIES", 124, 132], ["SARS-CoV", "SPECIES", 238, 246], ["type I interferon", "TREATMENT", 49, 66], ["infection", "PROBLEM", 109, 118], ["SARS", "PROBLEM", 124, 128], ["CoV", "TEST", 129, 132], ["an antiviral response", "TREATMENT", 179, 200], ["a SARS", "PROBLEM", 236, 242], ["CoV", "PROBLEM", 243, 246], ["intrinsic antiviral immunity", "TREATMENT", 277, 305], ["interferon signaling", "PROBLEM", 310, 330], ["consistent with", "UNCERTAINTY", 220, 235], ["antiviral immunity", "OBSERVATION", 287, 305]]], ["Clearly, high temporal-resolution transcriptional data from both in vitro culture systems and patient-matched longitudinal samples, as well as clinical data for patients, are necessary to understand the early events in viral pathogenesis and immune-mediated resolution of infection, respectively.DiscussionCOVID-19 patients frequently develop interleukin-6 (IL-6)-driven cytokine release syndrome (CRS), and elevated serum IL-6 correlates with respiratory failure and poor clinical outcomes [37].", [["samples", "ANATOMY", 123, 130], ["serum", "ANATOMY", 417, 422], ["respiratory", "ANATOMY", 444, 455], ["infection", "DISEASE", 272, 281], ["CRS", "DISEASE", 398, 401], ["respiratory failure", "DISEASE", 444, 463], ["patient", "ORGANISM", 94, 101], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 315, 323], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 343, 356], ["IL-6", "GENE_OR_GENE_PRODUCT", 358, 362], ["serum", "ORGANISM_SUBSTANCE", 417, 422], ["IL-6", "GENE_OR_GENE_PRODUCT", 423, 427], ["cytokine", "PROTEIN", 371, 379], ["serum IL-6", "PROTEIN", 417, 427], ["patient", "SPECIES", 94, 101], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 315, 323], ["high temporal-resolution transcriptional data", "PROBLEM", 9, 54], ["vitro culture systems", "TEST", 68, 89], ["viral pathogenesis", "PROBLEM", 219, 237], ["infection", "PROBLEM", 272, 281], ["DiscussionCOVID", "TEST", 296, 311], ["interleukin", "TEST", 343, 354], ["IL", "TEST", 358, 360], ["cytokine release syndrome", "PROBLEM", 371, 396], ["CRS", "TEST", 398, 401], ["elevated serum IL", "PROBLEM", 408, 425], ["respiratory failure", "PROBLEM", 444, 463], ["poor clinical outcomes", "PROBLEM", 468, 490], ["infection", "OBSERVATION", 272, 281], ["respiratory failure", "OBSERVATION", 444, 463]]], ["Treatment with the IL-6 receptor blocking antibody tocilizumab has effectively treated COVID-19 symptoms in some patients [38].", [["tocilizumab", "CHEMICAL", 51, 62], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 19, 32], ["patients", "ORGANISM", 113, 121], ["IL-6 receptor", "PROTEIN", 19, 32], ["patients", "SPECIES", 113, 121], ["the IL-6 receptor blocking antibody tocilizumab", "TREATMENT", 15, 62], ["COVID", "TEST", 87, 92], ["symptoms", "PROBLEM", 96, 104]]], ["We did not see a significant difference in expression of IL-6, nor of other CRS-associated factors such as TNF or VEGF, when we analyzed SARS-CoV-2 positive samples relative to negative, nor in high versus low viral load SARS-CoV-2-positive samples.", [["samples", "ANATOMY", 157, 164], ["samples", "ANATOMY", 241, 248], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["TNF", "GENE_OR_GENE_PRODUCT", 107, 110], ["VEGF", "GENE_OR_GENE_PRODUCT", 114, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 137, 147], ["CoV-2", "GENE_OR_GENE_PRODUCT", 226, 231], ["IL-6", "PROTEIN", 57, 61], ["CRS-associated factors", "PROTEIN", 76, 98], ["TNF", "PROTEIN", 107, 110], ["VEGF", "PROTEIN", 114, 118], ["IL", "TEST", 57, 59], ["other CRS", "PROBLEM", 70, 79], ["TNF", "PROBLEM", 107, 110], ["VEGF", "PROBLEM", 114, 118], ["SARS", "TEST", 137, 141], ["CoV", "TEST", 142, 145], ["2 positive samples", "PROBLEM", 146, 164], ["low viral load SARS", "PROBLEM", 206, 225], ["CoV", "TEST", 226, 229], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION", 29, 39]]], ["This could be attributed to the nasopharynx not being a particularly sensitive anatomic location to probe markers of systemic inflammation compared to serum or lower respiratory sites; additional studies will be necessary to ascertain how SARS-CoV-2-induced DE of transcripts in the nasopharynx relates to inflammation and pathology in affected organ systems such the lungs, intestinal tract, and circulatory system.", [["nasopharynx", "ANATOMY", 32, 43], ["serum", "ANATOMY", 151, 156], ["respiratory sites", "ANATOMY", 166, 183], ["nasopharynx", "ANATOMY", 283, 294], ["organ systems", "ANATOMY", 345, 358], ["lungs", "ANATOMY", 368, 373], ["intestinal tract", "ANATOMY", 375, 391], ["circulatory system", "ANATOMY", 397, 415], ["inflammation", "DISEASE", 126, 138], ["SARS", "DISEASE", 239, 243], ["inflammation", "DISEASE", 306, 318], ["nasopharynx", "ORGAN", 32, 43], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["SARS-CoV-2", "ORGANISM", 239, 249], ["nasopharynx", "ORGAN", 283, 294], ["organ", "ORGAN", 345, 350], ["lungs", "ORGAN", 368, 373], ["intestinal tract", "MULTI-TISSUE_STRUCTURE", 375, 391], ["circulatory system", "ANATOMICAL_SYSTEM", 397, 415], ["the nasopharynx", "PROBLEM", 28, 43], ["systemic inflammation", "PROBLEM", 117, 138], ["serum or lower respiratory sites", "PROBLEM", 151, 183], ["additional studies", "TEST", 185, 203], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["transcripts in the nasopharynx", "PROBLEM", 264, 294], ["inflammation", "PROBLEM", 306, 318], ["pathology in affected organ systems such the lungs, intestinal tract, and circulatory system", "PROBLEM", 323, 415], ["nasopharynx", "ANATOMY", 32, 43], ["systemic", "OBSERVATION_MODIFIER", 117, 125], ["inflammation", "OBSERVATION", 126, 138], ["respiratory sites", "OBSERVATION", 166, 183], ["transcripts", "OBSERVATION", 264, 275], ["nasopharynx", "ANATOMY", 283, 294], ["inflammation", "OBSERVATION", 306, 318], ["pathology", "OBSERVATION", 323, 332], ["lungs", "ANATOMY", 368, 373], ["intestinal tract", "ANATOMY", 375, 391], ["circulatory system", "ANATOMY", 397, 415]]], ["Notably, the dissection of interferon responses in the lower respiratory tract will be important in light of recent findings that type III interferons in particular can disrupt healing and barrier function of lung epithelial cells following viral infection [39,40], a possible counterindication to the proposed use of type III interferon as treatment for COVID-19.", [["lower respiratory tract", "ANATOMY", 55, 78], ["barrier", "ANATOMY", 189, 196], ["lung epithelial cells", "ANATOMY", 209, 230], ["viral infection", "DISEASE", 241, 256], ["type III interferon", "CHEMICAL", 318, 337], ["interferon", "GENE_OR_GENE_PRODUCT", 27, 37], ["lower", "ORGANISM_SUBDIVISION", 55, 60], ["respiratory tract", "ORGANISM_SUBDIVISION", 61, 78], ["type III interferons", "GENE_OR_GENE_PRODUCT", 130, 150], ["lung epithelial cells", "CELL", 209, 230], ["type III interferon", "GENE_OR_GENE_PRODUCT", 318, 337], ["interferon", "PROTEIN", 27, 37], ["type III interferons", "PROTEIN", 130, 150], ["lung epithelial cells", "CELL_TYPE", 209, 230], ["type III interferon", "PROTEIN", 318, 337], ["the dissection of interferon responses", "TREATMENT", 9, 47], ["the lower respiratory tract", "PROBLEM", 51, 78], ["type III interferons", "TREATMENT", 130, 150], ["lung epithelial cells", "PROBLEM", 209, 230], ["viral infection", "PROBLEM", 241, 256], ["type III interferon", "TREATMENT", 318, 337], ["COVID", "TEST", 355, 360], ["dissection", "OBSERVATION", 13, 23], ["interferon", "OBSERVATION", 27, 37], ["lower", "ANATOMY_MODIFIER", 55, 60], ["respiratory tract", "ANATOMY", 61, 78], ["healing", "OBSERVATION_MODIFIER", 177, 184], ["lung", "ANATOMY", 209, 213], ["epithelial cells", "OBSERVATION", 214, 230]]], ["Finally, our choice to use a large number of samples at relatively low sequencing depth likely reduced our sensitivity to detect differences in low-abundance and short-lived transcripts like cytokines, including interferons.DiscussionOne of the more striking patterns we observed is the marked down-regulation of transcription of ribosomal proteins upon SARS-CoV-2 infection (Fig 1B) and the recovery of expression during disease progression (Fig 4C).", [["samples", "ANATOMY", 45, 52], ["ribosomal", "ANATOMY", 330, 339], ["infection", "DISEASE", 365, 374], ["samples", "CANCER", 45, 52], ["interferons", "GENE_OR_GENE_PRODUCT", 212, 223], ["ribosomal", "CELLULAR_COMPONENT", 330, 339], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 354, 364], ["cytokines", "PROTEIN", 191, 200], ["interferons", "PROTEIN", 212, 223], ["ribosomal proteins", "PROTEIN", 330, 348], ["interferons", "TREATMENT", 212, 223], ["ribosomal proteins", "PROBLEM", 330, 348], ["SARS", "PROBLEM", 354, 358], ["CoV", "TEST", 359, 362], ["2 infection", "PROBLEM", 363, 374], ["expression during disease progression", "PROBLEM", 404, 441]]], ["Global inhibition of host transcription is a strategy employed by many viruses via diverse mechanisms such as disrupting transcriptional pre-initiation complex assembly [41,42] or cleavage of TATA-binding protein [43].", [["TATA-binding protein [43]", "GENE_OR_GENE_PRODUCT", 192, 217], ["transcriptional pre-initiation complex", "PROTEIN", 121, 159], ["TATA-binding protein", "PROTEIN", 192, 212], ["Global inhibition of host transcription", "PROBLEM", 0, 39], ["many viruses via diverse mechanisms", "PROBLEM", 66, 101], ["host transcription", "OBSERVATION", 21, 39], ["viruses", "OBSERVATION", 71, 78]]], ["Middle East respiratory syndrome-coronavirus (MERS-CoV) and SARS-CoV nsp1 both cause decay of host mRNA [44,45]; in MERS-CoV, host mRNA degradation results from an endonucleolytic function of nsp1 itself [46].", [["Middle East respiratory syndrome-coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome-coronavirus", "ORGANISM", 0, 44], ["MERS-CoV", "ORGANISM", 46, 54], ["SARS-CoV nsp1", "ORGANISM", 60, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 116, 124], ["nsp1", "GENE_OR_GENE_PRODUCT", 192, 196], ["SARS-CoV nsp1", "DNA", 60, 73], ["host mRNA", "RNA", 94, 103], ["nsp1", "PROTEIN", 192, 196], ["-coronavirus", "SPECIES", 32, 44], ["Middle East respiratory syndrome-coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 116, 124], ["Middle East respiratory syndrome", "PROBLEM", 0, 32], ["coronavirus", "PROBLEM", 33, 44], ["SARS", "PROBLEM", 60, 64], ["CoV nsp1", "PROBLEM", 65, 73], ["host mRNA", "TEST", 94, 103], ["host mRNA degradation", "PROBLEM", 126, 147], ["respiratory syndrome", "OBSERVATION", 12, 32]]], ["Nsp1 from SARS-CoV and SARS-CoV-2 share 84% amino acid identity, therefore it is likely that SARS-CoV-2 nsp1 can also function directly or indirectly to promote host RNA degradation.", [["amino acid", "CHEMICAL", 44, 54], ["amino acid", "CHEMICAL", 44, 54], ["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "ORGANISM", 10, 18], ["SARS-CoV-2", "ORGANISM", 23, 33], ["amino acid", "AMINO_ACID", 44, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 93, 103], ["nsp1", "GENE_OR_GENE_PRODUCT", 104, 108], ["Nsp1", "PROTEIN", 0, 4], ["nsp1", "PROTEIN", 104, 108], ["SARS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 23, 31], ["Nsp1", "TEST", 0, 4], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["amino acid identity", "TEST", 44, 63], ["SARS", "PROBLEM", 93, 97], ["CoV", "PROBLEM", 98, 101], ["nsp1", "PROBLEM", 104, 108], ["SARS", "OBSERVATION", 10, 14], ["host RNA", "OBSERVATION", 161, 169]]], ["Global down-regulation of host transcription may also be driven in part by SARS-CoV-2 ORF6 protein (which binds to the mRNA export factor RAE1 and nuclear pore protein Nup98 in a similar manner as the vesicular stomatitis virus [VSV] M protein) [47] or the ORF7a protein (which binds to proteins involved in ribosomal assembly and nuclear export) [47].DiscussionFinally, understanding age- and sex-related differences in responses to SARS-CoV-2 infection is of critical importance as approximately 90% of SARS-CoV-2 deaths in Washington State have been seen in individuals over age 60.", [["ribosomal", "ANATOMY", 308, 317], ["nuclear", "ANATOMY", 331, 338], ["SARS", "DISEASE", 434, 438], ["infection", "DISEASE", 445, 454], ["SARS", "DISEASE", 505, 509], ["deaths", "DISEASE", 516, 522], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["ORF6", "GENE_OR_GENE_PRODUCT", 86, 90], ["RAE1", "GENE_OR_GENE_PRODUCT", 138, 142], ["nuclear pore protein Nup98", "GENE_OR_GENE_PRODUCT", 147, 173], ["vesicular stomatitis virus", "ORGANISM", 201, 227], ["VSV] M protein) [47]", "GENE_OR_GENE_PRODUCT", 229, 249], ["ORF7a", "GENE_OR_GENE_PRODUCT", 257, 262], ["ribosomal", "CELLULAR_COMPONENT", 308, 317], ["nuclear", "CELLULAR_COMPONENT", 331, 338], ["SARS-CoV-2", "ORGANISM", 434, 444], ["SARS-CoV-2", "ORGANISM", 505, 515], ["SARS-CoV-2 ORF6 protein", "PROTEIN", 75, 98], ["mRNA export factor", "PROTEIN", 119, 137], ["RAE1", "PROTEIN", 138, 142], ["nuclear pore protein Nup98", "PROTEIN", 147, 173], ["vesicular stomatitis virus [VSV] M protein", "PROTEIN", 201, 243], ["ORF7a protein", "PROTEIN", 257, 270], ["CoV-", "SPECIES", 439, 443], ["stomatitis virus", "SPECIES", 211, 227], ["VSV", "SPECIES", 229, 232], ["SARS-CoV", "SPECIES", 434, 442], ["SARS-CoV", "SPECIES", 505, 513], ["host transcription", "TREATMENT", 26, 44], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["the mRNA export factor RAE1", "TEST", 115, 142], ["nuclear pore protein Nup98", "TEST", 147, 173], ["the vesicular stomatitis virus", "PROBLEM", 197, 227], ["VSV] M protein", "TEST", 229, 243], ["the ORF7a protein", "TEST", 253, 270], ["SARS", "PROBLEM", 434, 438], ["2 infection", "PROBLEM", 443, 454], ["SARS", "PROBLEM", 505, 509], ["vesicular stomatitis", "ANATOMY", 201, 221]]], ["Our data show that in individuals over 60, expression of interferon-induced chemokines is reduced, possibly contributing to a reduction in transcripts for cytotoxic T and NK cells.", [["cytotoxic T", "ANATOMY", 155, 166], ["NK cells", "ANATOMY", 171, 179], ["interferon", "GENE_OR_GENE_PRODUCT", 57, 67], ["T", "CELL", 165, 166], ["NK cells", "CELL", 171, 179], ["interferon", "PROTEIN", 57, 67], ["chemokines", "PROTEIN", 76, 86], ["cytotoxic T and NK cells", "CELL_TYPE", 155, 179], ["Our data", "TEST", 0, 8], ["interferon", "TREATMENT", 57, 67], ["a reduction in transcripts", "PROBLEM", 124, 150], ["cytotoxic T and NK cells", "PROBLEM", 155, 179], ["possibly contributing", "UNCERTAINTY", 99, 120], ["NK cells", "OBSERVATION", 171, 179]]], ["Immune dysfunctions in older individuals are well-characterized [2,3,32,33] and likely contribute to poorer COVID-19 outcomes; results from clinical trials of type I and III interferons in severely ill patients are likely to further define the role of interferon signaling in older adults [48\u201350].DiscussionDifferences in immune responses in males and females are due to a variety of factors, including the effects of sex hormones and the X-linked nature of many immune genes [51].", [["Immune dysfunctions", "DISEASE", 0, 19], ["severely ill", "DISEASE", 189, 201], ["type I and III interferons", "GENE_OR_GENE_PRODUCT", 159, 185], ["patients", "ORGANISM", 202, 210], ["interferon", "GENE_OR_GENE_PRODUCT", 252, 262], ["type I and III interferons", "PROTEIN", 159, 185], ["interferon", "PROTEIN", 252, 262], ["immune genes", "DNA", 463, 475], ["patients", "SPECIES", 202, 210], ["Immune dysfunctions in older individuals", "PROBLEM", 0, 40], ["poorer COVID", "TEST", 101, 113], ["type I and III interferons", "TREATMENT", 159, 185], ["interferon signaling", "TREATMENT", 252, 272]]], ["The bias toward expression of B cell transcripts in females in our study is consistent with higher levels of B cells in females regardless of age [52].", [["B cell", "ANATOMY", 30, 36], ["B cells", "ANATOMY", 109, 116], ["B cell", "CELL", 30, 36], ["B cells", "CELL", 109, 116], ["B cell transcripts", "RNA", 30, 48], ["B cells", "CELL_TYPE", 109, 116], ["B cell transcripts", "PROBLEM", 30, 48], ["our study", "TEST", 63, 72], ["B cells", "PROBLEM", 109, 116], ["B cell transcripts", "OBSERVATION", 30, 48], ["consistent with", "UNCERTAINTY", 76, 91]]], ["Females also tend to have increased inflammation in response to viral infections [4].", [["inflammation", "DISEASE", 36, 48], ["viral infections", "DISEASE", 64, 80], ["increased inflammation", "PROBLEM", 26, 48], ["viral infections", "PROBLEM", 64, 80], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["inflammation", "OBSERVATION", 36, 48], ["viral infections", "OBSERVATION", 64, 80]]], ["The observed increased expression of inhibitors of nuclear factor kappa-B (NF-\u03baB) in males with SARS-CoV-2 may represent either inappropriate throttling of the antiviral immune response or an adaptive mechanism to reduce deleterious inflammation, a hallmark of COVID-19 pathogenesis.DiscussionCollectively, we demonstrate induction of an antiviral response characterized by type I and II interferon induction, which wanes with time and is correlated with viral load.", [["SARS", "DISEASE", 96, 100], ["inflammation", "DISEASE", 233, 245], ["nuclear factor kappa-B", "GENE_OR_GENE_PRODUCT", 51, 73], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["SARS-CoV-2", "ORGANISM", 96, 106], ["COVID-19", "CELL", 261, 269], ["type I and II interferon", "GENE_OR_GENE_PRODUCT", 374, 398], ["nuclear factor kappa-B", "PROTEIN", 51, 73], ["NF-\u03baB", "PROTEIN", 75, 80], ["interferon", "PROTEIN", 388, 398], ["SARS-CoV", "SPECIES", 96, 104], ["nuclear factor kappa", "TEST", 51, 71], ["SARS", "PROBLEM", 96, 100], ["the antiviral immune response", "PROBLEM", 156, 185], ["deleterious inflammation", "PROBLEM", 221, 245], ["COVID", "TEST", 261, 266], ["an antiviral response", "TREATMENT", 335, 356], ["type I and II interferon induction", "TREATMENT", 374, 408], ["viral load", "PROBLEM", 455, 465], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["antiviral immune", "OBSERVATION", 160, 176], ["deleterious", "OBSERVATION_MODIFIER", 221, 232], ["inflammation", "OBSERVATION", 233, 245], ["viral load", "OBSERVATION", 455, 465]]], ["We also find evidence of transcriptional repression by SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["transcriptional repression", "PROBLEM", 25, 51], ["find evidence of", "UNCERTAINTY", 8, 24], ["transcriptional repression", "OBSERVATION", 25, 51]]], ["Lastly, we show that differences in immune responses may underlie disparities in outcomes for 2 higher-risk groups, males and the elderly.Ethics statement ::: MethodsSequencing of excess clinical samples was approved by the University of Washington Institutional Review Board (STUDY00000408) with a consent waiver.Sample collection, RNA extraction, and RT-PCR ::: MethodsNP swabs of patients with suspected SARS-CoV-2 infection were collected in 3 mL viral transport medium (VTM).", [["SARS-CoV-2 infection", "DISEASE", 407, 427], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 383, 391], ["CoV-2", "SPECIES", 412, 417], ["SARS-CoV-2", "SPECIES", 407, 417], ["Sample collection", "TEST", 314, 331], ["RNA extraction", "TEST", 333, 347], ["RT-PCR", "TEST", 353, 359], ["MethodsNP swabs", "TEST", 364, 379], ["suspected SARS", "PROBLEM", 397, 411], ["CoV", "PROBLEM", 412, 415], ["2 infection", "PROBLEM", 416, 427]]], ["Total RNA was extracted from 200 or 140 \u03bcL of VTM using either the Roche MagNAPure (Roche, Basel, Switzerland) or Qiagen BioRobot (Qiagen, Hilden, Germany) automated platforms, respectively [53].", [["Total RNA", "TEST", 0, 9]]], ["RT-PCR for the SARS-CoV2 N1 target was performed on the Applied Biosystems 7500 real time PCR instrument [54,55].Library preparation and sequencing ::: MethodsMetagenomic next-generation sequencing (mNGS) was performed as previously described [17,56].", [["SARS-CoV2 N1 target", "DNA", 15, 34], ["RT-PCR", "TEST", 0, 6], ["the SARS", "TEST", 11, 19], ["PCR instrument", "TEST", 90, 104], ["MethodsMetagenomic", "TREATMENT", 152, 170]]], ["Briefly, 18 \u03bcL of extracted RNA was treated with Turbo DNAse (ThermoFisher, Waltham, MA).", [["extracted RNA", "PROBLEM", 18, 31], ["Turbo DNAse", "TREATMENT", 49, 60]]], ["First strand cDNA synthesis was completed using SuperScript IV (ThermoFisher) and random hexamers (Invitrogen, Carlsbad, CA) followed by second strand synthesis by Sequenase version 2.0 (ThermoFisher).", [["SuperScript IV", "DNA", 48, 62], ["ThermoFisher", "PROTEIN", 64, 76], ["First strand cDNA synthesis", "PROBLEM", 0, 27], ["SuperScript IV (ThermoFisher", "TREATMENT", 48, 76], ["random hexamers (Invitrogen", "TREATMENT", 82, 109], ["second strand synthesis", "TREATMENT", 137, 160]]], ["The resulting cDNA was purified using either the DNA Clean & Concentrator kit (Zymo, Irvine, California) or 1.6\u00d7 volumes of AMPure XP beads (Beckman Coulter, Brea, CA).", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["Zymo", "ORGANISM_SUBSTANCE", 79, 83], ["cDNA", "DNA", 14, 18], ["The resulting cDNA", "PROBLEM", 0, 18], ["AMPure XP beads", "TREATMENT", 124, 139]]], ["Library preparation was performed using the Nextera XT Kit (Illumina, San Diego, CA).", [["Library preparation", "TREATMENT", 0, 19]]], ["Libraries were cleaned with 0.7\u00d7 or 0.75\u00d7 volumes of Ampure beads (Beckman Coulter), quantified using either the Qubit dsDNA HS assay (ThermoFisher) or Quant-iT dsDNA HS assay (ThermoFisher), quality checked by Bioanalyzer or TapeStation (Agilent, Santa Clara, CA), pooled, and sequenced on 1 \u00d7 75 bp runs on an Illumina NextSeq or 1 \u00d7 101 bp runs on an Illumina NovaSeq.Pseudoalignment ::: MethodsRaw FASTQ files were adapter and quality trimmed by Trimmomatic version 0.39 [57] using the call \u201cleading 3 trailing 3 slidingwindow:4:15 minlen 20.\u201d", [["Illumina NextSeq", "DNA", 312, 328], ["Illumina NovaSeq", "DNA", 354, 370], ["Libraries", "TREATMENT", 0, 9], ["Ampure beads (Beckman Coulter", "TREATMENT", 53, 82], ["an Illumina NextSeq", "TREATMENT", 309, 328], ["bp runs", "TEST", 340, 347], ["an Illumina NovaSeq", "TREATMENT", 351, 370]]], ["Trimmed reads were pseudoaligned to the Ensembl version 96 human transcriptome using Kallisto version 0.46 [58] assuming an average library size of 300 \u00b1 100 bp.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["an average library size", "TEST", 121, 144], ["bp", "TEST", 158, 160], ["size", "OBSERVATION_MODIFIER", 140, 144]]], ["Only samples with more than 500,000 pseudoaligned reads were used for RNA sequencing analysis.DE ::: MethodsPseudoaligned reads were pre-filtered to remove any genes with average expression of less than one read per sample, then normalized, and DE was calculated with the R package DEseq2 version 1.28.1 [59].", [["samples", "ANATOMY", 5, 12], ["samples", "CANCER", 5, 12], ["RNA sequencing analysis", "TEST", 70, 93]]], ["Correction for batch effects was incorporated into the design formula and modeling performed using the Wald test with outlier replacement.", [["batch effects", "TREATMENT", 15, 28], ["the Wald test", "TEST", 99, 112], ["outlier replacement", "TREATMENT", 118, 137]]], ["Results were deemed significant at a Benjamini-Hochberg adjusted p < 0.1.", [["a Benjamini", "TEST", 35, 46]]], ["Gene expression differences attributable to sex or age were incorporated into the design formula as interaction terms.GSEA ::: MethodsGSEA was performed on normalized counts on GSEA software version 4.0.3 [21,22].", [["GSEA", "DNA", 118, 122], ["Gene expression differences", "PROBLEM", 0, 27], ["GSEA software version", "TEST", 177, 198]]], ["Gene ranking was generated with the Signal2Noise metric and analyzed against the mSigDB Hallmarks version 7.1 gene sets [23].HAE cultures ::: MethodsThe EpiAirway AIR-100 system (MatTek Corporation, Ashland, MA) consists of normal human-derived tracheo/bronchial epithelial cells that have been cultured to form a pseudostratified, highly differentiated mucociliary epithelium closely resembling that of epithelial tissue in vivo.", [["tracheo/bronchial epithelial cells", "ANATOMY", 245, 279], ["mucociliary epithelium", "ANATOMY", 354, 376], ["epithelial tissue", "ANATOMY", 404, 421], ["HAE", "DISEASE", 125, 128], ["human", "ORGANISM", 231, 236], ["tracheo", "CELL", 245, 252], ["bronchial epithelial cells", "CELL", 253, 279], ["mucociliary epithelium", "TISSUE", 354, 376], ["epithelial tissue", "TISSUE", 404, 421], ["Signal2Noise metric", "DNA", 36, 55], ["mSigDB", "DNA", 81, 87], ["HAE cultures", "CELL_LINE", 125, 137], ["normal human-derived tracheo/bronchial epithelial cells", "CELL_TYPE", 224, 279], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 231, 236], ["the Signal2Noise metric", "TREATMENT", 32, 55], ["HAE cultures", "TEST", 125, 137], ["bronchial epithelial cells", "PROBLEM", 253, 279], ["a pseudostratified, highly differentiated mucociliary epithelium", "PROBLEM", 312, 376], ["epithelial tissue in vivo", "PROBLEM", 404, 429], ["normal", "OBSERVATION", 224, 230], ["bronchial", "ANATOMY", 253, 262], ["epithelial cells", "OBSERVATION", 263, 279], ["highly differentiated", "OBSERVATION_MODIFIER", 332, 353], ["mucociliary epithelium", "OBSERVATION", 354, 376], ["epithelial tissue", "OBSERVATION", 404, 421]]], ["Upon receipt from the manufacturer, HAE cultures were transferred to 6-well plates containing 1.0 mL EpiAirway medium per well (basolateral feeding, with the apical surface remaining exposed to air) and acclimated at 37\u00b0C in 5% CO2 for 24 hours prior to experimentation.Viral growth in HAE ::: MethodsHAE cultures were infected by applying 200 \u03bcL of EpiAirway phosphate-buffered saline (MatTeK TEER Buffer) containing 2,000 PFU or 20,000 PFU of infectious clone-derived SARS-CoV-2 expressing a stable mNeonGreen reporter gene (icSARS-CoV-2-mNG) [60] to the apical surface for 90 min at 37\u00b0C. At 90 min, the medium containing the inoculum was removed, the apical surface was washed with 200 \u03bcL of TEER buffer, and cultures were placed at 37\u00b0C. Cultures were fed every other day with 1.0 mL medium via the basolateral side.", [["basolateral", "ANATOMY", 128, 139], ["apical surface", "ANATOMY", 158, 172], ["apical surface", "ANATOMY", 557, 571], ["apical surface", "ANATOMY", 655, 669], ["basolateral", "ANATOMY", 804, 815], ["HAE", "DISEASE", 36, 39], ["CO2", "CHEMICAL", 228, 231], ["HAE", "DISEASE", 286, 289], ["EpiAirway phosphate", "CHEMICAL", 350, 369], ["icSARS-CoV-2-mNG", "CHEMICAL", 527, 543], ["CO2", "CHEMICAL", 228, 231], ["phosphate", "CHEMICAL", 360, 369], ["HAE cultures", "CELL", 36, 48], ["CO2", "SIMPLE_CHEMICAL", 228, 231], ["MethodsHAE cultures", "CELL", 294, 313], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 360, 385], ["clone", "CELL", 456, 461], ["SARS-CoV-2", "CELL", 470, 480], ["mNeonGreen", "GENE_OR_GENE_PRODUCT", 501, 511], ["apical surface", "MULTI-TISSUE_STRUCTURE", 557, 571], ["HAE cultures", "CELL_LINE", 36, 48], ["MethodsHAE cultures", "CELL_LINE", 294, 313], ["mNeonGreen reporter gene", "DNA", 501, 525], ["icSARS", "DNA", 527, 533], ["CoV", "DNA", 534, 537], ["SARS-CoV", "SPECIES", 470, 478], ["HAE cultures", "TEST", 36, 48], ["basolateral feeding", "TREATMENT", 128, 147], ["the apical surface", "TREATMENT", 154, 172], ["5% CO2", "TREATMENT", 225, 231], ["MethodsHAE cultures", "TEST", 294, 313], ["EpiAirway phosphate", "TREATMENT", 350, 369], ["buffered saline (MatTeK TEER Buffer)", "TREATMENT", 370, 406], ["infectious clone", "TEST", 445, 461], ["CoV", "TEST", 475, 478], ["the inoculum", "TREATMENT", 625, 637], ["TEER buffer", "TREATMENT", 696, 707], ["cultures", "TEST", 713, 721], ["Cultures", "TEST", 743, 751], ["apical", "ANATOMY_MODIFIER", 158, 164], ["air", "OBSERVATION", 194, 197], ["growth", "OBSERVATION_MODIFIER", 276, 282], ["apical", "ANATOMY_MODIFIER", 557, 563], ["inoculum", "OBSERVATION", 629, 637], ["apical", "OBSERVATION_MODIFIER", 655, 661], ["surface", "OBSERVATION_MODIFIER", 662, 669], ["basolateral", "ANATOMY_MODIFIER", 804, 815]]], ["Media was removed, and cultures were lysed with TRIzol Reagent (ThermoFisher) at 3 days post infection (20,000 PFU challenge) and at 7 days post infection (2,000 PFU challenge).", [["cultures", "ANATOMY", 23, 31], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 145, 154], ["cultures", "TEST", 23, 31], ["TRIzol Reagent (ThermoFisher", "TREATMENT", 48, 76], ["infection", "PROBLEM", 93, 102], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["Bam files of viral sequence are deposited in the sequence read archive, NCBI Bioproject PRJNA634194.HAE RNA sequencing and analysis ::: MethodsRNA from uninfected and infected HAE was extracted using Direct-zol RNA MicroPrep (Zymo).", [["HAE", "DISEASE", 100, 103], ["HAE", "DISEASE", 176, 179], ["HAE", "CANCER", 176, 179], ["Zymo", "ORGANISM", 226, 230], ["viral sequence", "DNA", 13, 27], ["HAE RNA", "RNA", 100, 107], ["viral sequence", "TEST", 13, 27], ["MethodsRNA", "TREATMENT", 136, 146], ["infected HAE", "PROBLEM", 167, 179], ["Direct-zol RNA MicroPrep", "TREATMENT", 200, 224], ["uninfected", "OBSERVATION", 152, 162], ["infected", "OBSERVATION_MODIFIER", 167, 175]]], ["Libraries were generated using the TruSeq Stranded mRNA kit (Illumina) and 2 \u00d7 100 bp paired-end reads sequenced on a Novaseq.", [["TruSeq Stranded mRNA kit", "RNA", 35, 59], ["Novaseq", "DNA", 118, 125], ["Libraries", "TREATMENT", 0, 9], ["a Novaseq", "TREATMENT", 116, 125]]], ["Pseudoalignment using Kallisto version 0.44 and DE analysis was performed as earlier.Statistics and visualization ::: MethodsAll calculations were performed in R version 4.0.0.", [["Kallisto version", "TEST", 22, 38], ["DE analysis", "TEST", 48, 59], ["Methods", "TREATMENT", 118, 125], ["All calculations", "TEST", 125, 141]]], ["Statistical enrichment tests of GO [24,25] and DisGeNET [28] pathways were performed in the clusterProfiler R package [61].", [["Statistical enrichment tests", "TEST", 0, 28]]], ["Exact test of the intersection of HAE and NP swab consensus genes was performed with the R package SuperExactTest [62].", [["HAE", "DISEASE", 34, 37], ["HAE", "CANCER", 34, 37], ["HAE and NP swab consensus genes", "DNA", 34, 65], ["HAE", "PROBLEM", 34, 37], ["NP swab consensus genes", "TEST", 42, 65]]], ["Images were generated using packages including DOSE [63], ggplot2, pheatmap, and VennDiagram.", [["Images", "TEST", 0, 6], ["VennDiagram", "TREATMENT", 81, 92]]]], "286084dadc535bba794fcbc468398e7f258ccffa": [["Working equids (horses, ponies, donkeys, and mules) remain essential to ensure the livelihood of poor communities around the world.", [["horses", "ORGANISM_SUBDIVISION", 16, 22], ["ponies", "ORGANISM_SUBDIVISION", 24, 30]]], ["In many developed countries, the equine industry has a significant economical weight, with around 7 million horses in Europe alone.", [["equine", "ORGANISM", 33, 39]]], ["The close relationship between humans and equids, and the fact that the athlete horse is the terrestrial mammal that travels the most worldwide after humans, are important elements to consider in the transmission of pathogens and diseases, amongst equids and to other species.", [["humans", "ORGANISM", 31, 37], ["athlete horse", "ORGANISM", 72, 85], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 31, 37], ["horse", "SPECIES", 80, 85], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 150, 156], ["pathogens", "PROBLEM", 216, 225], ["diseases", "PROBLEM", 230, 238]]], ["The potential effect of climate change on vector ecology and vector-borne diseases is also of concern for both human and animal health.", [["vector-borne diseases", "DISEASE", 61, 82], ["human", "ORGANISM", 111, 116], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["climate change", "PROBLEM", 24, 38], ["vector ecology", "TREATMENT", 42, 56], ["borne diseases", "PROBLEM", 68, 82], ["potential", "UNCERTAINTY", 4, 13], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["climate change", "OBSERVATION", 24, 38]]]], "344a0c97f6551f9ab911925fa27306be8bdca934": [["Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure Patrick M. Honore * , Aude Mugisha, Luc Kugener, Sebastien Redant, Rachid Attou, Andrea Gallerani and David De Bels", [["plasma", "ANATOMY", 12, 18], ["septic shock", "DISEASE", 52, 64], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["Therapeutic plasma exchange", "TREATMENT", 0, 27], ["a routine therapy", "TREATMENT", 31, 48], ["septic shock", "PROBLEM", 52, 64], ["an experimental treatment", "TREATMENT", 72, 97], ["septic shock", "OBSERVATION", 52, 64]]]], "PMC7409616": [["We read with great interest the essay by Harrison and Wu [1] on vaccine confidence in the time of COVID-19.", [["COVID", "TEST", 98, 103]]], ["They wondered if the impact of the COVID-19 global health emergency will solve the problem of vaccine refusal that has worried the global public health community for the last several decades.", [["the COVID", "TREATMENT", 31, 40]]], ["Indeed, the concept of \u2018vaccine hesitancy\u2019 has been considered by the World Health Organization (WHO) as \u201cone of the top-ten threats to global health\u201d [2].", [["\u2018vaccine hesitancy", "PROBLEM", 23, 41]]], ["The debate around vaccines has been in the spotlight over the last few years in Europe, both within the scientific community and the general public discourse.", [["vaccines", "TREATMENT", 18, 26]]], ["In this regard, the case of the Italian vaccination debate is particularly worrying given that Italy has been one of the European countries with the highest number of measles cases in the recent past [3].", [["measles", "DISEASE", 167, 174]]], ["This issue led to the introduction of laws prescribing mandatory vaccinations for children to attend school in December 2017, which gave rise to an active debate [3].", [["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]]], "PMC4898363": [["BackgroundSeveral members of the Flavivirus genus are the causative agents of significant diseases in humans, livestock and wildlife.", [["Flavivirus genus", "DISEASE", 33, 49], ["Flavivirus genus", "ORGANISM", 33, 49], ["humans", "ORGANISM", 102, 108], ["humans", "SPECIES", 102, 108], ["humans", "SPECIES", 102, 108], ["the Flavivirus genus", "PROBLEM", 29, 49], ["significant diseases in humans", "PROBLEM", 78, 108], ["Flavivirus genus", "OBSERVATION", 33, 49], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["diseases", "OBSERVATION", 90, 98]]], ["These include dengue virus that affects more than 50 million people worldwide each year, West Nile virus and Japanese encephalitis virus that caused outbreaks in North America and Asia, respectively [1].", [["dengue virus", "DISEASE", 14, 26], ["Japanese encephalitis virus", "DISEASE", 109, 136], ["dengue virus", "ORGANISM", 14, 26], ["people", "ORGANISM", 61, 67], ["West Nile virus", "ORGANISM", 89, 104], ["Japanese encephalitis virus", "ORGANISM", 109, 136], ["people", "SPECIES", 61, 67], ["Nile virus", "SPECIES", 94, 104], ["Japanese encephalitis virus", "SPECIES", 109, 136], ["dengue virus", "SPECIES", 14, 26], ["West Nile virus", "SPECIES", 89, 104], ["Japanese encephalitis virus", "SPECIES", 109, 136], ["dengue virus", "PROBLEM", 14, 26], ["West Nile virus", "PROBLEM", 89, 104], ["Japanese encephalitis virus", "PROBLEM", 109, 136], ["dengue virus", "OBSERVATION", 14, 26]]], ["Zika virus (ZIKV) is an emerging pathogen in the family Flaviviridae that was first isolated in 1947 from a sentinel rhesus monkey placed in the Zika Forest near Lake Victoria in Uganda [2].", [["Zika virus", "ORGANISM", 0, 10], ["ZIKV", "GENE_OR_GENE_PRODUCT", 12, 16], ["Flaviviridae", "ORGANISM", 56, 68], ["rhesus", "ORGANISM", 117, 123], ["monkey", "ORGANISM", 124, 130], ["Zika virus", "SPECIES", 0, 10], ["rhesus monkey", "SPECIES", 117, 130], ["Zika virus", "SPECIES", 0, 10], ["ZIKV", "SPECIES", 12, 16], ["rhesus monkey", "SPECIES", 117, 130], ["Zika virus", "PROBLEM", 0, 10], ["Flaviviridae", "TREATMENT", 56, 68], ["a sentinel rhesus monkey", "TREATMENT", 106, 130]]], ["ZIKV is transmitted by mosquitoes, especially Aedes africanus, but the virus was also isolated from other Aedes species (reviewed in [3]).", [["ZIKV", "CHEMICAL", 0, 4], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Aedes africanus", "ORGANISM", 46, 61], ["Aedes africanus", "SPECIES", 46, 61], ["ZIKV", "SPECIES", 0, 4], ["Aedes africanus", "SPECIES", 46, 61], ["ZIKV", "PROBLEM", 0, 4], ["Aedes africanus", "PROBLEM", 46, 61], ["the virus", "PROBLEM", 67, 76]]], ["ZIKV infections of humans was first described in 1964 [4], causing a febrile illness with dengue fever like symptoms [5].", [["ZIKV infections", "DISEASE", 0, 15], ["febrile illness", "DISEASE", 69, 84], ["dengue fever", "DISEASE", 90, 102], ["humans", "ORGANISM", 19, 25], ["humans", "SPECIES", 19, 25], ["ZIKV", "SPECIES", 0, 4], ["humans", "SPECIES", 19, 25], ["ZIKV infections of humans", "PROBLEM", 0, 25], ["a febrile illness", "PROBLEM", 67, 84], ["dengue fever like symptoms", "PROBLEM", 90, 116]]], ["Sporadic cases were reported in sub-Saharan Africa and Southeast Asia, followed by an outbreak in Micronesia in 2007 and major epidemics that started around 2013 in New Caledonia, the Cook Islands, French Polynesia and Easter Island [6, 7].", [["Sporadic cases", "PROBLEM", 0, 14], ["New", "OBSERVATION_MODIFIER", 165, 168], ["Caledonia", "OBSERVATION", 169, 178], ["French Polynesia", "OBSERVATION", 198, 214]]], ["A rather dramatic increase in the number of ZIKV cases was reported from the Americas starting in 2015, Brazil being the most affected country with around 1 million cases reported at the end of 2015 [8\u201310].", [["ZIKV", "DISEASE", 44, 48], ["ZIKV", "CANCER", 44, 48], ["ZIKV", "SPECIES", 44, 48], ["A rather dramatic increase", "PROBLEM", 0, 26], ["ZIKV cases", "PROBLEM", 44, 54], ["dramatic", "OBSERVATION_MODIFIER", 9, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["number", "OBSERVATION_MODIFIER", 34, 40], ["ZIKV", "OBSERVATION", 44, 48]]], ["Here, also cases of neurological manifestations and the Guillain-Barr\u00e9 syndrome were described.", [["neurological", "ANATOMY", 20, 32], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 56, 79], ["Guillain-Barr\u00e9", "ORGANISM", 56, 70], ["neurological manifestations", "PROBLEM", 20, 47], ["the Guillain-Barr\u00e9 syndrome", "PROBLEM", 52, 79], ["Barr\u00e9 syndrome", "OBSERVATION", 65, 79]]], ["Recent reports indicate a significant increase in the number of microcephaly cases among newborns in northeast Brazil, suggesting that ZIKV infection in pregnancy may trigger fetal malformations [11].", [["fetal", "ANATOMY", 175, 180], ["microcephaly", "DISEASE", 64, 76], ["infection", "DISEASE", 140, 149], ["fetal malformations", "DISEASE", 175, 194], ["fetal malformations", "PATHOLOGICAL_FORMATION", 175, 194], ["ZIKV", "SPECIES", 135, 139], ["a significant increase", "PROBLEM", 24, 46], ["microcephaly cases", "PROBLEM", 64, 82], ["ZIKV infection in pregnancy", "PROBLEM", 135, 162], ["fetal malformations", "PROBLEM", 175, 194], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["microcephaly", "OBSERVATION", 64, 76], ["ZIKV infection", "OBSERVATION", 135, 149]]], ["Neural progenitor cells can be infected by this virus, leading to attenuation of their growth [12].BackgroundGiven the clinical relevance, we performed a detailed analysis of several features of the ZIKV RNA genome, including the nucleotide (nt) composition, also in the context of the structured RNA genome, and the viral codon usage.", [["Neural progenitor cells", "ANATOMY", 0, 23], ["nucleotide", "CHEMICAL", 230, 240], ["nucleotide", "CHEMICAL", 230, 240], ["Neural progenitor cells", "CELL", 0, 23], ["ZIKV", "GENE_OR_GENE_PRODUCT", 199, 203], ["Neural progenitor cells", "CELL_TYPE", 0, 23], ["ZIKV RNA genome", "DNA", 199, 214], ["structured RNA genome", "DNA", 286, 307], ["ZIKV", "SPECIES", 199, 203], ["Neural progenitor cells", "PROBLEM", 0, 23], ["this virus", "PROBLEM", 43, 53], ["a detailed analysis", "TEST", 152, 171], ["the ZIKV RNA genome", "PROBLEM", 195, 214], ["the nucleotide (nt) composition", "PROBLEM", 226, 257], ["the structured RNA genome", "PROBLEM", 282, 307], ["the viral codon usage", "PROBLEM", 313, 334], ["progenitor cells", "OBSERVATION", 7, 23], ["RNA genome", "OBSERVATION", 297, 307], ["viral codon", "OBSERVATION", 317, 328]]], ["This insight can be central to the understanding of factors that govern virus evolution.", [["virus", "OBSERVATION", 72, 77]]], ["Mutation pressure has been shown to be the dominant factor shaping the nucleotide composition and codon usage in mammalian genomes [13\u201315].", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["mammalian genomes", "DNA", 113, 130], ["Mutation pressure", "TEST", 0, 17], ["the nucleotide composition", "TREATMENT", 67, 93], ["codon usage", "TREATMENT", 98, 109], ["dominant", "OBSERVATION_MODIFIER", 43, 51]]], ["The ZIKV genome of almost 11,000 nts encodes a single polyprotein of 3419 amino acids that is cleaved by the viral serine and cellular furin proteases into the functional domains: the Capsid (C), Precursor of membrane (prM), Envelope (E) and 7 non-structural proteins (NS) [2].", [["cellular", "ANATOMY", 126, 134], ["amino acids", "CHEMICAL", 74, 85], ["amino acids", "CHEMICAL", 74, 85], ["serine", "CHEMICAL", 115, 121], ["amino acids", "AMINO_ACID", 74, 85], ["serine", "AMINO_ACID", 115, 121], ["cellular", "CELL", 126, 134], ["Capsid", "GENE_OR_GENE_PRODUCT", 184, 190], ["membrane", "CELLULAR_COMPONENT", 209, 217], ["prM", "GENE_OR_GENE_PRODUCT", 219, 222], ["Envelope (E)", "GENE_OR_GENE_PRODUCT", 225, 237], ["ZIKV genome", "DNA", 4, 15], ["viral serine and cellular furin proteases", "PROTEIN", 109, 150], ["functional domains", "PROTEIN", 160, 178], ["Capsid (C)", "PROTEIN", 184, 194], ["Precursor of membrane", "PROTEIN", 196, 217], ["prM", "PROTEIN", 219, 222], ["Envelope (E) and 7 non-structural proteins", "PROTEIN", 225, 267], ["NS", "PROTEIN", 269, 271], ["ZIKV", "SPECIES", 4, 8], ["The ZIKV genome", "PROBLEM", 0, 15], ["a single polyprotein", "TEST", 45, 65], ["amino acids", "TREATMENT", 74, 85], ["the viral serine", "PROBLEM", 105, 121], ["cellular furin proteases", "TREATMENT", 126, 150], ["ZIKV genome", "OBSERVATION", 4, 15]]], ["We report that the nucleotide composition of the ZIKV virus genome is strongly biased and this bias directly influences the codons used for translation of the viral proteins.ZIKV sequences ::: MethodsViral RNA genome sequences were obtained from GenBank.", [["nucleotide", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 19, 29], ["ZIKV virus", "ORGANISM", 49, 59], ["ZIKV virus genome", "DNA", 49, 66], ["viral proteins", "PROTEIN", 159, 173], ["ZIKV sequences", "DNA", 174, 188], ["MethodsViral RNA genome sequences", "DNA", 193, 226], ["ZIKV virus", "SPECIES", 49, 59], ["ZIKV", "SPECIES", 174, 178], ["the nucleotide composition", "TREATMENT", 15, 41], ["the ZIKV virus genome", "PROBLEM", 45, 66], ["this bias", "PROBLEM", 90, 99], ["the codons", "TREATMENT", 120, 130], ["the viral proteins", "PROBLEM", 155, 173], ["ZIKV sequences", "TEST", 174, 188], ["MethodsViral RNA genome sequences", "TEST", 193, 226], ["viral proteins", "OBSERVATION", 159, 173]]], ["The MR-766 prototype ZIKV strain originates from the index case: a monkey infected in 1947 in Uganda (Genbank entry NC_012532).", [["MR-766", "CHEMICAL", 4, 10], ["ZIKV", "ORGANISM", 21, 25], ["monkey", "ORGANISM", 67, 73], ["MR", "PROTEIN", 4, 6], ["The MR", "TEST", 0, 6], ["prototype ZIKV strain", "PROBLEM", 11, 32]]], ["Other ZIKV isolates used: KU497555 (Brazil), KU509998 (Haiti), KU501215 (Puerto Rico), KU312312 (Suriname), KU647676 (Martinique), KJ776791 (French Polynesia), KU701217 (Guatamala), KU681082 (Philippines) and KF268950 (Central African Republic).", [["KU497555", "CHEMICAL", 26, 34], ["KU509998", "CHEMICAL", 45, 53], ["KJ776791", "CHEMICAL", 131, 139], ["ZIKV", "SPECIES", 6, 10]]], ["The full genome sequences were manually curated into bona fide open reading frames.Maximum Likelihood (ML) phylogenetic analysis ::: MethodsPhylogenetic and molecular evolutionary analyses were conducted with MEGA v6 [16].", [["bona fide open reading frames", "DNA", 53, 82], ["phylogenetic analysis", "TEST", 107, 128]]], ["The open reading frames (ORFs) of the different ZIKV strains were translated into amino acid sequences, which were aligned by means of the MUSCLE tool.", [["amino acid", "CHEMICAL", 82, 92], ["amino acid", "CHEMICAL", 82, 92], ["ZIKV", "GENE_OR_GENE_PRODUCT", 48, 52], ["amino acid", "AMINO_ACID", 82, 92], ["open reading frames", "DNA", 4, 23], ["ORFs", "DNA", 25, 29], ["ZIKV strains", "DNA", 48, 60], ["ZIKV", "SPECIES", 48, 52], ["the different ZIKV strains", "PROBLEM", 34, 60], ["amino acid sequences", "TEST", 82, 102], ["MUSCLE", "ANATOMY", 139, 145]]], ["The JTT + G model for assessing amino acid replacements during ZIKV evolution turned out to be the best fitting model judged by BIC score (Bayesian Information Criterion, 22469.52863) and AICc value (corrected Akaike Information Criterion, 22317.61634).", [["amino acid", "CHEMICAL", 32, 42], ["amino acid", "CHEMICAL", 32, 42], ["amino acid", "AMINO_ACID", 32, 42], ["The JTT + G model", "TREATMENT", 0, 17], ["assessing amino acid replacements", "TREATMENT", 22, 55], ["ZIKV evolution", "PROBLEM", 63, 77]]], ["Non-uniformity of evolutionary rates among sites was modeled by a discrete Gamma distribution (+G = 0.554328239) with 5 rate categories.", [["a discrete Gamma distribution", "PROBLEM", 64, 93], ["discrete", "OBSERVATION_MODIFIER", 66, 74], ["Gamma distribution", "OBSERVATION", 75, 93]]], ["The ML value for model selection was logL = \u221211140.79817.", [["The ML value", "TEST", 0, 12], ["model selection", "TEST", 17, 32], ["logL", "TEST", 37, 41]]], ["All sites were used for phylogenetic analysis.", [["phylogenetic analysis", "TEST", 24, 45]]], ["A bootstrap test (1000 replicates) indicated robustness of the analysis.", [["A bootstrap test", "TEST", 0, 16], ["the analysis", "TEST", 59, 71]]], ["The hypothetical ancestral sequence (MRCA, Most Recent Common Ancestor) was constructed by means of the FastML server with the advanced options activated [17].", [["FastML server", "DNA", 104, 117]]], ["The MLtree was rooted on the MRCA branch to show the evolutionary course of events.RNA structure prediction ::: MethodsRNA secondary structure prediction was performed by the MFold v3.6 algorithm with default settings [18].", [["MLtree", "DNA", 4, 10]]], ["The MFold output file provided the ss-count, a frequency value that indicates whether an individual nucleotide (nt) is unpaired in the collection of folded structures (maximally 50).", [["nucleotide", "CHEMICAL", 100, 110], ["nucleotide", "CHEMICAL", 100, 110], ["MFold", "PROTEIN", 4, 9], ["The MFold output file", "TEST", 0, 21], ["the ss-count", "TEST", 31, 43], ["a frequency value", "TEST", 45, 62], ["an individual nucleotide (nt)", "PROBLEM", 86, 115], ["output", "OBSERVATION_MODIFIER", 10, 16], ["folded", "OBSERVATION", 149, 155]]], ["We scored an unpaired nt (single-stranded, \"ss\") if present in at least half of the RNA structures.", [["unpaired nt", "DNA", 13, 24], ["RNA", "OBSERVATION", 84, 87]]], ["Nts with a lower ss-count were scored double-stranded (\"ds\").", [["Nts", "GENE_OR_GENE_PRODUCT", 0, 3], ["Nts", "PROTEIN", 0, 3], ["ss", "DNA", 17, 19], ["a lower ss-count", "TEST", 9, 25]]], ["Excel was used for ss/ds discrimination and we generated fasta files to determine the nucleotide composition in MEGA v6 [16].", [["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 86, 96], ["ss/ds discrimination", "TREATMENT", 19, 39]]], ["Because the size limit for submission to the MFold server is 9000 nts, the ZIKV RNA genome was partitioned into two fragments with 1000 nts overlap.", [["fragments", "ANATOMY", 116, 125], ["ZIKV", "GENE_OR_GENE_PRODUCT", 75, 79], ["MFold server", "DNA", 45, 57], ["ZIKV RNA genome", "DNA", 75, 90], ["ZIKV", "SPECIES", 75, 79], ["the ZIKV RNA genome", "TREATMENT", 71, 90], ["size", "OBSERVATION_MODIFIER", 12, 16], ["ZIKV", "OBSERVATION", 75, 79], ["RNA genome", "OBSERVATION", 80, 90], ["two", "OBSERVATION_MODIFIER", 112, 115], ["fragments", "OBSERVATION_MODIFIER", 116, 125]]], ["We arithmetically averaged the ss-count data in the overlap before ss/ds discrimination was performed.Skew analysis ::: MethodsBase composition along the complete RNA genome length and the accompanying ss and ds fasta files was analyzed by cumulative skew diagrams using overlapping windows [19, 20].", [["the ss-count data", "TEST", 27, 44], ["ss/ds discrimination", "TEST", 67, 87], ["MethodsBase composition", "TREATMENT", 120, 143], ["the accompanying ss and ds fasta files", "PROBLEM", 185, 223]]], ["Overlapping windows were defined around 1 % of the sequence length with a step size of 20 % of the window size, which generated about 500 data points per analysis irrespective of sequence length.", [["Overlapping windows", "TEST", 0, 19], ["a step size", "TEST", 72, 83], ["sequence length", "TEST", 179, 194], ["windows", "OBSERVATION", 12, 19], ["size", "OBSERVATION_MODIFIER", 79, 83], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["A skew between nts N1 and N2 is defined as (N1 \u2212 N2)/(N1 + N2).", [["N1", "CHEMICAL", 19, 21], ["N2", "CHEMICAL", 26, 28], ["(N1 \u2212 N2)", "CHEMICAL", 43, 52], ["N2", "CHEMICAL", 59, 61], ["N1", "OBSERVATION", 19, 21], ["N2", "OBSERVATION_MODIFIER", 26, 28]]], ["A positive value indicates that N1 exceeds N2.Codon usage ::: MethodsThe single ZIKV reading frame was analyzed using the \u201cNc-plot\u201d, which plots the effective number of codons (ENC-values) versus the GC-content at the 3rd codon position (GC3) [21].", [["N2", "CHEMICAL", 43, 45], ["ZIKV reading frame", "DNA", 80, 98], ["Nc", "DNA", 123, 125], ["ENC", "DNA", 177, 180], ["3rd codon position", "DNA", 218, 236], ["GC3", "DNA", 238, 241], ["A positive value", "TEST", 0, 16], ["Methods", "TREATMENT", 62, 69], ["codons", "TEST", 169, 175], ["ENC", "TEST", 177, 180], ["the GC", "TEST", 196, 202], ["3rd codon", "ANATOMY", 218, 227]]], ["A continuous line indicates ENC values expected (ENCexp) for random codon usage at that particular GC3 value.", [["ENC", "DNA", 28, 31], ["GC3", "DNA", 99, 102], ["A continuous line", "TREATMENT", 0, 17], ["ENC values", "TEST", 28, 38], ["random codon usage", "PROBLEM", 61, 79]]], ["Deviation from this line in the direction of lower ENC-values (observed ENC values, ENCobs) points to the selection of a preferred set of codons as described for highly expressed genes in yeast [22] and Escherichia coli [23].", [["yeast [22]", "ORGANISM", 188, 198], ["Escherichia coli", "ORGANISM", 203, 219], ["ENC", "DNA", 51, 54], ["yeast", "SPECIES", 188, 193], ["Escherichia coli", "SPECIES", 203, 219], ["yeast", "SPECIES", 188, 193], ["Escherichia coli", "SPECIES", 203, 219], ["Deviation", "PROBLEM", 0, 9], ["this line", "TREATMENT", 15, 24], ["lower ENC", "TEST", 45, 54], ["ENC values", "TEST", 72, 82], ["codons", "TREATMENT", 138, 144], ["highly expressed genes in yeast", "PROBLEM", 162, 193], ["Escherichia coli", "PROBLEM", 203, 219], ["lower", "ANATOMY_MODIFIER", 45, 50]]], ["The ratio ENCobs/ENCexp provides an easy measure of this deviation.", [["ENCexp", "PROTEIN", 17, 23], ["The ratio ENCobs", "TEST", 0, 16], ["this deviation", "PROBLEM", 52, 66]]], ["A ratio value of 1 indicates zero codon bias.", [["A ratio value", "TEST", 0, 13], ["zero codon bias", "PROBLEM", 29, 44], ["zero codon bias", "OBSERVATION", 29, 44]]], ["Values close to 1 (0.8 to 1.0) indicate very weak or virtually absent codon bias.", [["Values", "TEST", 0, 6], ["very weak or virtually absent codon bias", "PROBLEM", 40, 80], ["very", "OBSERVATION_MODIFIER", 40, 44], ["weak", "OBSERVATION", 45, 49], ["codon bias", "OBSERVATION", 70, 80]]], ["ENC and GC3 values of sequence data were determined by means of Simmonic 2005 v1.5 software [24].", [["ENC", "DNA", 0, 3], ["GC3", "DNA", 8, 11], ["sequence data", "TEST", 22, 35]]], ["ENC and GC3 values human and Aedes genes were derived from codon usage tables [25].", [["human", "ORGANISM", 19, 24], ["ENC", "DNA", 0, 3], ["GC3", "DNA", 8, 11], ["human and Aedes genes", "DNA", 19, 40], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["All calculations were performed in Excel v14.0.7128.5000.Nucleotide composition of the ZIKV RNA ::: ResultsWe first analyzed the complete RNA genome of the ZIKV MR-766 prototype strain [2], which originates from a sentinel monkey that became infected in Uganda in 1947 (Genbank entry NC_012532).", [["Nucleotide", "CHEMICAL", 57, 67], ["[2]", "CELL", 185, 188], ["monkey", "ORGANISM", 223, 229], ["ZIKV RNA", "RNA", 87, 95], ["RNA genome", "DNA", 138, 148], ["MR", "PROTEIN", 161, 163], ["ZIKV MR-766", "SPECIES", 156, 167], ["All calculations", "TEST", 0, 16], ["Excel v", "TEST", 35, 42], ["the ZIKV MR", "TEST", 152, 163], ["prototype strain", "PROBLEM", 168, 184], ["sentinel monkey", "OBSERVATION", 214, 229], ["infected", "OBSERVATION", 242, 250]]], ["This positive-stranded RNA genome contains a single extended open reading frame (ORF) that encodes the viral polyprotein, which is subsequently processed into the different structural and enzymatic components.", [["positive-stranded RNA genome", "DNA", 5, 33], ["open reading frame", "DNA", 61, 79], ["ORF", "DNA", 81, 84], ["stranded RNA genome", "PROBLEM", 14, 33], ["a single extended open reading frame", "PROBLEM", 43, 79], ["the viral polyprotein", "PROBLEM", 99, 120], ["stranded RNA genome", "OBSERVATION", 14, 33], ["viral polyprotein", "OBSERVATION", 103, 120], ["different", "OBSERVATION_MODIFIER", 163, 172], ["structural", "OBSERVATION_MODIFIER", 173, 183], ["enzymatic", "OBSERVATION_MODIFIER", 188, 197], ["components", "OBSERVATION_MODIFIER", 198, 208]]], ["The ZIKV RNA genome is 10794 nucleotides (nts) long, with a short 5\u2019-untranslated region (UTR) of 106 nts and a 3\u2019-UTR of 428 nts.", [["nucleotides", "CHEMICAL", 29, 40], ["ZIKV", "GENE_OR_GENE_PRODUCT", 4, 8], ["ZIKV RNA genome", "DNA", 4, 19], ["5\u2019-untranslated region", "DNA", 66, 88], ["UTR", "DNA", 90, 93], ["3\u2019-UTR", "DNA", 112, 118], ["ZIKV", "SPECIES", 4, 8], ["a short 5\u2019-untranslated region", "PROBLEM", 58, 88], ["ZIKV", "OBSERVATION", 4, 8], ["RNA genome", "OBSERVATION", 9, 19]]], ["The four possible nucleotides are not used at equal frequencies, the genome composition ranges from 2305 U (21.3 %) to 3139 G (29.1 %).", [["nucleotides", "CHEMICAL", 18, 29], ["nucleotides", "TREATMENT", 18, 29], ["G", "TEST", 124, 125]]], ["Overall, the RNA genome is enriched for purines (G + A, 56.8 %) over pyrimidines (U + C, 43.2 %), yielding a Pu/Py ratio of 1.31.", [["purines", "CHEMICAL", 40, 47], ["pyrimidines", "CHEMICAL", 69, 80], ["U", "CHEMICAL", 82, 83], ["purines", "CHEMICAL", 40, 47], ["pyrimidines", "CHEMICAL", 69, 80], ["U + C", "CHEMICAL", 82, 87], ["purines", "SIMPLE_CHEMICAL", 40, 47], ["G + A", "SIMPLE_CHEMICAL", 49, 54], ["pyrimidines", "SIMPLE_CHEMICAL", 69, 80], ["U + C", "SIMPLE_CHEMICAL", 82, 87], ["Pu/Py", "SIMPLE_CHEMICAL", 109, 114], ["RNA genome", "DNA", 13, 23], ["purines", "TEST", 40, 47], ["G", "TEST", 49, 50], ["A", "TEST", 53, 54], ["pyrimidines", "TEST", 69, 80], ["U", "TEST", 82, 83], ["C", "TEST", 86, 87], ["a Pu/Py ratio", "TEST", 107, 120], ["RNA genome", "OBSERVATION", 13, 23]]], ["We will relate these ZIKV properties to that of other flaviviruses in the discussion.Nucleotide composition of the ZIKV RNA ::: ResultsThese basic characteristics do not deviate significantly for other ZIKV isolates.", [["flaviviruses", "DISEASE", 54, 66], ["Nucleotide", "CHEMICAL", 85, 95], ["ZIKV", "CANCER", 21, 25], ["ZIKV RNA", "RNA", 115, 123], ["ZIKV", "SPECIES", 202, 206], ["these ZIKV properties", "TREATMENT", 15, 36], ["other ZIKV isolates", "PROBLEM", 196, 215]]], ["We analyzed two early isolates (Uganda and Central African Republic) and 8 recent isolates.", [["Central African Republic", "TREATMENT", 43, 67]]], ["ZIKV from the Philippines is ancestral to those constituting the recent epidemic in southern America.", [["ZIKV", "SPECIES", 0, 4], ["ZIKV", "PROBLEM", 0, 4]]], ["The root of the trifurcated tree indicates that a putative most recent common ancestor (MRCA) circulated in Africa approximately 91 years ago, assuming a constant virus evolution rate and an age of 68 years for the prototype Uganda virus.", [["root", "ANATOMY", 4, 8], ["root", "ORGAN", 4, 8], ["Uganda virus", "ORGANISM", 225, 237], ["Uganda virus", "SPECIES", 225, 237], ["a constant virus evolution rate", "PROBLEM", 152, 183], ["the prototype Uganda virus", "PROBLEM", 211, 237], ["root", "ANATOMY_MODIFIER", 4, 8]]], ["The typical nucleotide composition and purine preference are common features among the ancient and more recent taxa of this ZIKV collection.", [["nucleotide", "CHEMICAL", 12, 22], ["purine", "CHEMICAL", 39, 45], ["nucleotide", "CHEMICAL", 12, 22], ["purine", "CHEMICAL", 39, 45], ["purine", "SIMPLE_CHEMICAL", 39, 45], ["ZIKV", "CANCER", 124, 128], ["ZIKV", "SPECIES", 124, 128], ["The typical nucleotide composition", "TREATMENT", 0, 34], ["common features", "PROBLEM", 61, 76], ["this ZIKV collection", "PROBLEM", 119, 139]]], ["For instance, the recently isolated Natal RGN strain isolated from a Brazilian child with microcephaly [11] contains 21.4 % U and 29.2 % G, with a preference for purines of 56.6 %.", [["microcephaly", "DISEASE", 90, 102], ["purines", "CHEMICAL", 162, 169], ["purines", "CHEMICAL", 162, 169], ["RGN", "GENE_OR_GENE_PRODUCT", 42, 45], ["child", "SPECIES", 79, 84], ["the recently isolated Natal RGN strain", "PROBLEM", 14, 52], ["microcephaly", "PROBLEM", 90, 102], ["purines", "TEST", 162, 169]]], ["We conclude that these nt characteristics are constant properties among ZIKV variants, at least those circulating in the last century.Nucleotide composition of the ZIKV RNA ::: ResultsThis nt bias is likely to influence the codon usage in the single ORF that encodes the ZIKV polyprotein, but in fact the same nt trends are apparent for segments of the RNA genome that are not translated into protein: the short 5\u2019-untranslated region (5\u2019UTR) and 3\u2019UTR of the ZIKV genome (Table 1).", [["Nucleotide", "CHEMICAL", 134, 144], ["ZIKV", "GENE_OR_GENE_PRODUCT", 72, 76], ["ZIKV", "GENE_OR_GENE_PRODUCT", 271, 275], ["ZIKV RNA", "RNA", 164, 172], ["ORF", "DNA", 250, 253], ["ZIKV polyprotein", "RNA", 271, 287], ["RNA genome", "DNA", 353, 363], ["short 5\u2019-untranslated region", "DNA", 406, 434], ["5\u2019UTR", "DNA", 436, 441], ["3\u2019UTR", "DNA", 447, 452], ["ZIKV genome", "DNA", 460, 471], ["these nt characteristics", "PROBLEM", 17, 41], ["ZIKV variants", "PROBLEM", 72, 85], ["the codon usage", "PROBLEM", 220, 235], ["the single ORF", "PROBLEM", 239, 253], ["the ZIKV polyprotein", "PROBLEM", 267, 287], ["the RNA genome", "PROBLEM", 349, 363], ["ZIKV polyprotein", "OBSERVATION", 271, 287], ["RNA genome", "OBSERVATION", 353, 363], ["ZIKV genome", "OBSERVATION", 460, 471]]], ["These regions are very short, 106 and 428 nts respectively for the MR-766 prototype genome, making a statistically sound analysis of the nt-count precarious, but when combined these domains exhibit exactly the same nt ranking order as the full-length RNA: G (29.0 %) > A (26.6 %) > C (25.1 %) > U (19.3 %).", [["MR-766 prototype genome", "DNA", 67, 90], ["the MR", "TEST", 63, 69], ["a statistically sound analysis", "TEST", 99, 129], ["the nt", "TEST", 133, 139], ["G", "TEST", 256, 257], ["A", "TEST", 269, 270], ["C", "TEST", 282, 283], ["U", "TEST", 295, 296], ["very", "OBSERVATION_MODIFIER", 18, 22], ["short", "OBSERVATION_MODIFIER", 23, 28]]], ["Local fluctuations may occur especially near the 5\u2019 and 3\u2019 termini of the genome due to the presence of essential sequence elements that are involved in viral genome replication.", [["3\u2019 termini", "CELLULAR_COMPONENT", 56, 66], ["genome", "CELLULAR_COMPONENT", 74, 80], ["5\u2019 and 3\u2019 termini", "DNA", 49, 66], ["essential sequence elements", "DNA", 104, 131], ["Local fluctuations", "PROBLEM", 0, 18], ["viral genome replication", "TREATMENT", 153, 177], ["viral genome", "OBSERVATION", 153, 165]]], ["For instance, the U-count of the 5\u2019UTR is elevated, in part due to the presence of four U3 stretches in this 106-nt segment.", [["U", "GENE_OR_GENE_PRODUCT", 18, 19], ["5\u2019UTR", "DNA", 33, 38], ["U3 stretches", "DNA", 88, 100], ["106-nt segment", "DNA", 109, 123], ["the U-count", "TEST", 14, 25], ["UTR", "TEST", 35, 38], ["elevated", "PROBLEM", 42, 50], ["elevated", "OBSERVATION", 42, 50], ["U3 stretches", "OBSERVATION", 88, 100], ["nt segment", "ANATOMY_MODIFIER", 113, 123]]], ["Conservation of these specific molecular signals among different ZIKV strains argues for such a biological role, e.g. the 107-nts 5\u2019UTR of the Natal RGN isolate encodes three U3 and two U4 stretches.", [["ZIKV strains", "ORGANISM", 65, 77], ["RGN", "GENE_OR_GENE_PRODUCT", 149, 152], ["107-nts 5\u2019UTR", "DNA", 122, 135], ["Natal RGN isolate", "DNA", 143, 160], ["U3", "DNA", 175, 177], ["U4 stretches", "DNA", 186, 198], ["different ZIKV strains", "PROBLEM", 55, 77], ["U4 stretches", "OBSERVATION", 186, 198]]], ["In addition, the genome ends may encode specific RNA structures with a replicative function [2].Composition of the structured RNA genome ::: ResultsWe previously reported that the unequal nucleotide composition of a viral RNA genome may become even more biased in unpaired domains of the folded RNA molecule.", [["nucleotide", "CHEMICAL", 188, 198], ["nucleotide", "CHEMICAL", 188, 198], ["genome ends", "DNA", 17, 28], ["RNA genome", "DNA", 126, 136], ["viral RNA genome", "DNA", 216, 232], ["folded RNA molecule", "PROTEIN", 288, 307], ["the unequal nucleotide composition", "PROBLEM", 176, 210], ["a viral RNA genome", "PROBLEM", 214, 232], ["RNA genome", "OBSERVATION", 126, 136], ["viral RNA genome", "OBSERVATION", 216, 232], ["folded RNA molecule", "OBSERVATION", 288, 307]]], ["This initial study was performed for HIV-1 RNA, using both MFold-generated structure prediction and the experimentally probed RNA structure [28, 29].", [["HIV-1", "ORGANISM", 37, 42], ["HIV-1 RNA", "RNA", 37, 46], ["MFold", "PROTEIN", 59, 64], ["HIV-1", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 37, 42], ["This initial study", "TEST", 0, 18], ["HIV", "TEST", 37, 40]]], ["The structure of the ZIKV RNA genome was predicted by MFold.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 21, 25], ["ZIKV RNA genome", "DNA", 21, 36], ["MFold", "PROTEIN", 54, 59], ["ZIKV", "SPECIES", 21, 25], ["the ZIKV RNA genome", "PROBLEM", 17, 36], ["ZIKV RNA genome", "OBSERVATION", 21, 36]]], ["We investigated maximally 50 folded structures to provide each individual nt a frequency value of being unpaired (single-stranded, ss) in this collection of predicted structures.", [["maximally 50 folded structures", "PROBLEM", 16, 46]]], ["We subsequently counted the number of ss and ds (double-stranded, paired) positions (Table 2).", [["ss and ds (double-stranded, paired) positions", "TREATMENT", 38, 83]]], ["Paired positions are in excess over unpaired nucleotides in these folded RNA genomes, with a dsRNA value of 62.0 %.", [["nucleotides", "CHEMICAL", 45, 56], ["folded RNA genomes", "RNA", 66, 84], ["a dsRNA value", "TEST", 91, 104], ["positions", "OBSERVATION_MODIFIER", 7, 16], ["folded RNA genomes", "OBSERVATION", 66, 84]]], ["One major and several minor trends can be recognized.", [["several", "OBSERVATION_MODIFIER", 14, 21], ["minor", "OBSERVATION_MODIFIER", 22, 27]]], ["First and most importantly, we observed a strong A-accumulation for the unpaired ss segments of the ZIKV RNA genome (from 27.7 to 44.7 %), which equally means A-depletion (from 27.7 to 17.2 %) in the paired ds genome domains.", [["unpaired ss segments", "DNA", 72, 92], ["ZIKV RNA genome", "DNA", 100, 115], ["paired ds genome domains", "DNA", 200, 224], ["ZIKV", "SPECIES", 100, 104], ["the ZIKV RNA genome", "PROBLEM", 96, 115], ["ZIKV RNA genome", "OBSERVATION", 100, 115]]], ["In other words, G, U and C increase their prevalence in the paired domains, but lose incidence in the unpaired domains due to the prominent A-pressure.", [["A-pressure", "DISEASE", 140, 150], ["the prominent A-pressure", "PROBLEM", 126, 150], ["prominent", "OBSERVATION_MODIFIER", 130, 139], ["A-pressure", "OBSERVATION", 140, 150]]], ["The unpaired part of ZIKV RNA is particularly A-rich (44.7 %) and C-poor (14.6 %), with a multitude of purines (G + A, 68.3 %).", [["purines", "CHEMICAL", 103, 110], ["purines", "CHEMICAL", 103, 110], ["ZIKV", "GENE_OR_GENE_PRODUCT", 21, 25], ["purines", "SIMPLE_CHEMICAL", 103, 110], ["G + A", "SIMPLE_CHEMICAL", 112, 117], ["ZIKV RNA", "RNA", 21, 29], ["ZIKV", "SPECIES", 21, 25], ["ZIKV RNA", "TEST", 21, 29], ["C", "TEST", 66, 67], ["purines", "TEST", 103, 110], ["G", "TEST", 112, 113], ["ZIKV RNA", "OBSERVATION", 21, 29]]], ["These properties may be relevant for interaction with intracellular sensors of the innate immune systems in humans and Aedes [30\u201332].", [["intracellular", "ANATOMY", 54, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["humans", "ORGANISM", 108, 114], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114]]], ["A more definitive analyses should be performed when the experimentally probed structure of the ZIKV virus RNA genome becomes available.Genome skew analysis ::: ResultsA powerful way to visualize trends in nt usage is a nucleotide skew analysis along the viral genome (Fig. 2).", [["nucleotide", "CHEMICAL", 219, 229], ["nucleotide", "CHEMICAL", 219, 229], ["ZIKV virus", "ORGANISM", 95, 105], ["ZIKV virus RNA genome", "DNA", 95, 116], ["viral genome", "DNA", 254, 266], ["ZIKV virus", "SPECIES", 95, 105], ["A more definitive analyses", "TEST", 0, 26], ["the ZIKV virus RNA genome", "PROBLEM", 91, 116], ["a nucleotide skew analysis", "TEST", 217, 243], ["the viral genome", "PROBLEM", 250, 266], ["viral genome", "OBSERVATION", 254, 266]]], ["Note that GA in skew language does not represent a base pair, but rather a comparison of the number of G with the number of A nts.", [["GA", "CHEMICAL", 10, 12], ["a base pair", "PROBLEM", 49, 60]]], ["The skew lines are generally straight, indicating that the observed trends are steady along the 11 kb genome, without significant positional effects along the viral genome, e.g. in the 5\u2019 and 3\u2019UTRs versus the extended ORF.", [["skew lines", "ANATOMY", 4, 14], ["skew lines", "CELL", 4, 14], ["skew lines", "CELL_LINE", 4, 14], ["11 kb genome", "DNA", 96, 108], ["viral genome", "DNA", 159, 171], ["5\u2019 and 3\u2019UTRs", "DNA", 185, 198], ["ORF", "DNA", 219, 222], ["the 11 kb genome", "PROBLEM", 92, 108], ["significant positional effects", "PROBLEM", 118, 148], ["the viral genome", "PROBLEM", 155, 171], ["the extended ORF", "PROBLEM", 206, 222], ["skew lines", "OBSERVATION", 4, 14], ["without", "UNCERTAINTY", 110, 117], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["positional effects", "OBSERVATION", 130, 148], ["viral genome", "OBSERVATION", 159, 171]]], ["The skew analysis of the complete genome is presented in the left panel (all nts).", [["The skew analysis", "TEST", 0, 17], ["genome", "OBSERVATION", 34, 40], ["left", "ANATOMY_MODIFIER", 61, 65]]], ["This assessment underscores the preference of purines over pyrimidines as any direct Py-Pu comparison is won by the latter, resulting in a declining line for CA, UA, CG and UG.", [["purines", "CHEMICAL", 46, 53], ["pyrimidines", "CHEMICAL", 59, 70], ["Py-Pu", "CHEMICAL", 85, 90], ["UA", "CHEMICAL", 162, 164], ["UG", "CHEMICAL", 173, 175], ["purines", "CHEMICAL", 46, 53], ["pyrimidines", "CHEMICAL", 59, 70], ["Py-Pu", "CHEMICAL", 85, 90], ["purines", "SIMPLE_CHEMICAL", 46, 53], ["pyrimidines", "SIMPLE_CHEMICAL", 59, 70], ["Py-Pu", "SIMPLE_CHEMICAL", 85, 90], ["CA", "GENE_OR_GENE_PRODUCT", 158, 160], ["UA", "SIMPLE_CHEMICAL", 162, 164], ["CG", "SIMPLE_CHEMICAL", 166, 168], ["UG", "SIMPLE_CHEMICAL", 173, 175], ["Pu", "DNA", 88, 90], ["This assessment", "TEST", 0, 15], ["purines over pyrimidines", "TREATMENT", 46, 70], ["CA", "TEST", 158, 160], ["UA", "TEST", 162, 164], ["CG", "TEST", 166, 168]]], ["Only the Pu-Pu (GA) and Py-Py (UC) comparisons showed a lack of favorite nt.Genome skew analysis ::: ResultsWe subsequently analyzed the ds and ss positions separately (Fig. 2, ds in middle panel, ss in right panel).", [["right panel", "ANATOMY", 203, 214], ["Pu-Pu", "CHEMICAL", 9, 14], ["Pu-Pu", "SIMPLE_CHEMICAL", 9, 14], ["Py-Py", "SIMPLE_CHEMICAL", 24, 29], ["UC", "PATHOLOGICAL_FORMATION", 31, 33], ["ds and ss positions", "DNA", 137, 156], ["Py-Py (UC", "TEST", 24, 33], ["right", "ANATOMY_MODIFIER", 203, 208]]], ["The skew lines show more divergence in both the ds and ss segments compared with the all-nt skew analysis.", [["skew lines", "CELL", 4, 14], ["skew lines", "CELL_LINE", 4, 14], ["ds and ss segments", "DNA", 48, 66], ["the all-nt skew analysis", "TEST", 81, 105], ["skew lines", "OBSERVATION", 4, 14], ["more", "OBSERVATION_MODIFIER", 20, 24], ["divergence", "OBSERVATION_MODIFIER", 25, 35]]], ["It is also immediately apparent that the ds and ss positions act as communicating vessels.", [["communicating vessels", "ANATOMY", 68, 89], ["communicating vessels", "MULTI-TISSUE_STRUCTURE", 68, 89], ["ds and ss positions", "DNA", 41, 60], ["vessels", "ANATOMY", 82, 89]]], ["The gain of the A-count in the ss segment (strongly declining lines for GA, UA and especially CA) is mirrored by a loss in the ds compartment (strongly rising line for UA, CA and GA).", [["A-count", "DNA", 16, 23], ["ss segment", "DNA", 31, 41], ["CA", "PROTEIN", 172, 174], ["the A-count", "TEST", 12, 23], ["GA", "PROBLEM", 72, 74], ["UA", "TEST", 76, 78], ["a loss in the ds compartment", "PROBLEM", 113, 141], ["UA", "TEST", 168, 170], ["loss", "OBSERVATION", 115, 119]]], ["G seems the second best option in the ss compartment (declining line for UG and CG).", [["G", "GENE_OR_GENE_PRODUCT", 0, 1]]], ["In fact, these trends do not mimic any of the virus-specific trends that we described previously, e.g. for retroviruses and coronaviruses [20, 33\u201335].Codon analysis ::: ResultsIt is quite usual to perform an autonomous codon analysis, but we purposely first presented the general genome characteristics as these may largely influence the codon usage.", [["retroviruses", "ORGANISM", 107, 119], ["the virus", "PROBLEM", 42, 51], ["retroviruses", "PROBLEM", 107, 119], ["coronaviruses", "PROBLEM", 124, 137], ["Codon analysis", "TEST", 150, 164], ["an autonomous codon analysis", "TEST", 205, 233]]], ["It is immediately clear that ZIKV does not use all codons at equal frequency, but the patterns seem to vary (Table 3).", [["ZIKV", "SPECIES", 29, 33], ["ZIKV", "PROBLEM", 29, 33], ["clear", "OBSERVATION", 18, 23], ["ZIKV", "OBSERVATION", 29, 33]]], ["Among the 4-codon groups (Ala, Gly, Pro, Thr and Val), but also the 4-codon set within the 6-codon groups (Leu, Arg and Ser), two quite opposite patterns can be recognized.", [["Ala", "CHEMICAL", 26, 29], ["Gly", "CHEMICAL", 31, 34], ["Pro", "CHEMICAL", 36, 39], ["Thr", "CHEMICAL", 41, 44], ["Val", "CHEMICAL", 49, 52], ["Leu", "CHEMICAL", 107, 110], ["Arg", "CHEMICAL", 112, 115], ["Ser", "CHEMICAL", 120, 123], ["Ala", "AMINO_ACID", 26, 29], ["Gly", "AMINO_ACID", 31, 34], ["Thr", "AMINO_ACID", 41, 44], ["Val", "AMINO_ACID", 49, 52], ["Leu", "AMINO_ACID", 107, 110], ["Arg", "AMINO_ACID", 112, 115], ["Ser", "AMINO_ACID", 120, 123], ["Ala, Gly, Pro, Thr and Val)", "TREATMENT", 26, 53]]], ["Either the A-ending codons prevail (Pro, Ser, Thr), or the G-ending codons win (Leu, Val).", [["Pro", "CHEMICAL", 36, 39], ["Ser", "CHEMICAL", 41, 44], ["Thr", "CHEMICAL", 46, 49], ["Leu", "CHEMICAL", 80, 83], ["Val", "CHEMICAL", 85, 88], ["Ser", "AMINO_ACID", 41, 44], ["Thr", "AMINO_ACID", 46, 49], ["A-ending codons", "DNA", 11, 26]]], ["Some outliers are also apparent: the Gly 4-codon set prefers both A and G, the Ala 4-codon set prefers C with A as second best, and the 4-codon set within the 6-codon group Arg has C as the best option, but with G as the second best.", [["Gly", "CHEMICAL", 37, 40], ["Ala", "CHEMICAL", 79, 82], ["Arg", "CHEMICAL", 173, 176], ["Arg", "AMINO_ACID", 173, 176], ["Gly 4-codon set", "DNA", 37, 52], ["6-codon group", "DNA", 159, 172], ["the Ala 4-codon set", "TREATMENT", 75, 94]]], ["The opposing A/G trend is even more remarkable.", [["The opposing A/G trend", "TEST", 0, 22]]], ["Inspection of the codons provides a possible explanation for this restriction as the suppressed codons encode a CpG motif (marked in bold and by underlining in Table 3).", [["CpG", "CHEMICAL", 112, 115], ["CpG motif", "DNA", 112, 121], ["the codons", "TREATMENT", 14, 24], ["this restriction", "TREATMENT", 61, 77], ["the suppressed codons", "TREATMENT", 81, 102], ["a CpG motif", "TREATMENT", 110, 121]]], ["The CpG motif is a methylation signal in DNA, but is also recognized by host innate immune sensors as a pathogen signature [36], and is discriminated against in many RNA viruses, including poliovirus and the Flaviviridae [37, 38].", [["CpG", "CHEMICAL", 4, 7], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["CpG motif", "DNA", 4, 13], ["The CpG motif", "TREATMENT", 0, 13], ["a methylation signal in DNA", "PROBLEM", 17, 44], ["a pathogen signature", "TEST", 102, 122], ["many RNA viruses", "PROBLEM", 161, 177], ["poliovirus", "PROBLEM", 189, 199], ["RNA viruses", "OBSERVATION", 166, 177]]], ["For ZIKV RNA, a striking GpC/CpG ratio of 2.17 was scored (analysis not shown).", [["CpG", "CHEMICAL", 29, 32], ["GpC", "GENE_OR_GENE_PRODUCT", 25, 28], ["ZIKV RNA", "RNA", 4, 12], ["GpC", "PROTEIN", 25, 28], ["ZIKV", "SPECIES", 4, 8], ["ZIKV RNA", "PROBLEM", 4, 12], ["a striking GpC/CpG ratio", "TEST", 14, 38]]], ["In other words, it seems that G wins unless a CpG motif is created.Codon analysis ::: ResultsA second dinucleotide motif that is discriminated against is UpA with an ApU/UpA ratio of 1.86.", [["dinucleotide", "CHEMICAL", 102, 114], ["CpG", "CHEMICAL", 46, 49], ["dinucleotide", "CHEMICAL", 102, 114], ["UpA", "GENE_OR_GENE_PRODUCT", 154, 157], ["CpG motif", "DNA", 46, 55], ["ResultsA second dinucleotide motif", "DNA", 86, 120], ["UpA", "PROTEIN", 154, 157], ["ApU", "PROTEIN", 166, 169], ["a CpG motif", "TREATMENT", 44, 55], ["Codon analysis", "TEST", 67, 81], ["ResultsA second dinucleotide motif", "TEST", 86, 120], ["an ApU/UpA ratio", "TEST", 163, 179]]], ["This explains most cases where A-ending codons are losing (marked in bold and by underling in Table 3), e.g. within the Leu 6-codon set it clarifies the choices made for both the 2-codon and 4-codon sets.", [["Leu", "CHEMICAL", 120, 123], ["A-ending codons", "DNA", 31, 46], ["Leu 6", "PROTEIN", 120, 125], ["2-codon and 4-codon sets", "DNA", 179, 203], ["A-ending codons", "PROBLEM", 31, 46]]], ["The complete dinucleotide analysis (not shown) indicates that the all purine (GpA/ApG) and all pyrimidine (CpU/UpC) choices are unbiased compared to the four purine/pyrimidine combinations (results not shown).", [["purine", "CHEMICAL", 70, 76], ["pyrimidine", "CHEMICAL", 95, 105], ["purine", "CHEMICAL", 158, 164], ["pyrimidine", "CHEMICAL", 165, 175], ["dinucleotide", "CHEMICAL", 13, 25], ["purine", "CHEMICAL", 70, 76], ["GpA", "CHEMICAL", 78, 81], ["ApG", "CHEMICAL", 82, 85], ["pyrimidine", "CHEMICAL", 95, 105], ["CpU", "CHEMICAL", 107, 110], ["UpC", "CHEMICAL", 111, 114], ["purine", "CHEMICAL", 158, 164], ["pyrimidine", "CHEMICAL", 165, 175], ["purine", "SIMPLE_CHEMICAL", 70, 76], ["pyrimidine", "SIMPLE_CHEMICAL", 95, 105], ["purine", "SIMPLE_CHEMICAL", 158, 164], ["pyrimidine", "SIMPLE_CHEMICAL", 165, 175], ["The complete dinucleotide analysis", "TEST", 0, 34], ["the all purine (GpA/ApG)", "TREATMENT", 62, 86], ["all pyrimidine (CpU/UpC) choices", "TREATMENT", 91, 123], ["the four purine/pyrimidine combinations", "TREATMENT", 149, 188]]], ["Both CpG and UpA discrimination have been reported for other flaviviruses [39, 40], but surprisingly little attention was given to the purine/pyrimidine composition as the potential unifying signature.Codon analysis ::: ResultsOverall, the purines G or A seem to dominate the codon choices made, and U/C choices seem relatively balanced.", [["purine", "CHEMICAL", 135, 141], ["pyrimidine", "CHEMICAL", 142, 152], ["purines", "CHEMICAL", 240, 247], ["CpG", "CHEMICAL", 5, 8], ["purine", "CHEMICAL", 135, 141], ["pyrimidine", "CHEMICAL", 142, 152], ["purines", "CHEMICAL", 240, 247], ["purine", "SIMPLE_CHEMICAL", 135, 141], ["pyrimidine", "SIMPLE_CHEMICAL", 142, 152], ["purines G", "GENE_OR_GENE_PRODUCT", 240, 249], ["U/C", "GENE_OR_GENE_PRODUCT", 300, 303], ["UpA", "DNA", 13, 16], ["UpA discrimination", "TEST", 13, 31], ["other flaviviruses", "PROBLEM", 55, 73], ["the purine/pyrimidine composition", "TREATMENT", 131, 164], ["Codon analysis", "TEST", 201, 215], ["U/C choices", "TREATMENT", 300, 311]]], ["The G-bias is also apparent in the 2-codon groups (G/A column in Table 3), where G wins over A in 3 of 5 case, with a draw for the Gln group and a unique A-win for the 2-codon set within the outlier Arg 6-codon group.", [["Gln", "CHEMICAL", 131, 134], ["Gln", "CHEMICAL", 131, 134], ["Arg", "CHEMICAL", 199, 202], ["Gln", "AMINO_ACID", 131, 134], ["Gln group", "PROTEIN", 131, 140], ["Arg 6-codon group", "PROTEIN", 199, 216], ["the Gln group", "TREATMENT", 127, 140]]], ["Only modest effects were scored for the U/C choice in the 2-codon groups, but C wins in 4 out of 7 cases with two draws, consistent with the overall nt count.", [["the U/C choice", "TREATMENT", 36, 50], ["the overall nt count", "TEST", 137, 157], ["modest", "OBSERVATION_MODIFIER", 5, 11], ["consistent with", "UNCERTAINTY", 121, 136]]], ["Thus, codon usage in ZIKV RNA seems to follow the nt compositional trend with regard to the purine/pyrimidine bias that is present across the viral genome.Codon analysis ::: ResultsCodon usage in the single ZIKV ORF was also analyzed by means of an \u201cNc-plot\u201d (Fig. 3), with the effective number of codons (ENC-values) plotted versus the GC-content at the 3rd codon positions (GC3).", [["purine", "CHEMICAL", 92, 98], ["pyrimidine", "CHEMICAL", 99, 109], ["purine", "CHEMICAL", 92, 98], ["pyrimidine", "CHEMICAL", 99, 109], ["ZIKV", "GENE_OR_GENE_PRODUCT", 21, 25], ["purine", "SIMPLE_CHEMICAL", 92, 98], ["pyrimidine", "SIMPLE_CHEMICAL", 99, 109], ["ZIKV RNA", "RNA", 21, 29], ["viral genome", "DNA", 142, 154], ["ZIKV ORF", "DNA", 207, 215], ["ENC", "DNA", 306, 309], ["3rd codon positions", "DNA", 355, 374], ["GC3", "DNA", 376, 379], ["ZIKV", "SPECIES", 21, 25], ["ZIKV", "SPECIES", 207, 211], ["codon usage", "TREATMENT", 6, 17], ["ZIKV RNA", "PROBLEM", 21, 29], ["the purine/pyrimidine bias", "TREATMENT", 88, 114], ["Codon analysis", "TEST", 155, 169], ["an \u201cNc", "TEST", 246, 252], ["codons (ENC-values", "TEST", 298, 316], ["the GC", "TEST", 333, 339], ["pyrimidine bias", "OBSERVATION", 99, 114], ["viral genome", "OBSERVATION", 142, 154]]], ["The continuous grey line indicates the ENC values expected (ENCexp) for random codon usage at a particular GC3 value.", [["ENC", "DNA", 39, 42], ["GC3", "DNA", 107, 110], ["The continuous grey line", "PROBLEM", 0, 24], ["the ENC values", "TEST", 35, 49], ["random codon usage", "PROBLEM", 72, 90], ["grey line", "OBSERVATION", 15, 24]]], ["Deviation from this line in the direction of lower ENC-values (observed ENC values, ENCobs) points to the selection of a preferred set of codons.", [["ENC", "DNA", 51, 54], ["Deviation", "PROBLEM", 0, 9], ["this line", "TREATMENT", 15, 24], ["lower ENC", "TEST", 45, 54], ["ENC values", "TEST", 72, 82], ["lower", "ANATOMY_MODIFIER", 45, 50]]], ["The ratio ENCobs/ENCexp provides an easy measure for the extent of deviation: the value of 1 (ENCobs = ENCexp) indicates the absence of any codon bias, values below 0.8 may suggest weak codon bias, and even lower values can advocate stronger codon bias.", [["ENCobs", "PROTEIN", 10, 16], ["ENCexp", "PROTEIN", 17, 23], ["The ratio ENCobs", "TEST", 0, 16], ["the value", "TEST", 78, 87], ["ENCobs", "TEST", 94, 100], ["any codon bias", "PROBLEM", 136, 150], ["weak codon bias", "PROBLEM", 181, 196], ["deviation", "OBSERVATION", 67, 76], ["weak codon", "OBSERVATION", 181, 191]]], ["We included two early and several recent ZIKV isolates, but all cluster in a very tiny area of the Nc-plot, confirming their very close genetic relationship.", [["Nc", "DNA", 99, 101], ["ZIKV", "SPECIES", 41, 45]]], ["Most importantly, the ENCobs/ENCexp ratio of all ZIKV isolates is above 0.88, which is close to the unbiased value.", [["ENCobs", "GENE_OR_GENE_PRODUCT", 22, 28], ["ENCexp", "GENE_OR_GENE_PRODUCT", 29, 35], ["ENCobs", "DNA", 22, 28], ["ENCexp", "PROTEIN", 29, 35], ["ZIKV", "SPECIES", 49, 53], ["the ENCobs/ENCexp ratio", "TEST", 18, 41], ["all ZIKV isolates", "PROBLEM", 45, 62], ["all", "OBSERVATION_MODIFIER", 45, 48], ["ZIKV", "OBSERVATION", 49, 53]]], ["We also plotted ENC/GC3 values derived from average codon usage in a set of human and mosquito mRNAs (Homo and Aedes in Fig. 3).", [["human", "ORGANISM", 76, 81], ["ENC", "DNA", 16, 19], ["GC3", "DNA", 20, 23], ["human and mosquito mRNAs", "RNA", 76, 100], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["ENC/GC3 values", "TREATMENT", 16, 30]]], ["ZIKV and human ENC/GC3 values are very similar.", [["human", "ORGANISM", 9, 14], ["ENC", "DNA", 15, 18], ["GC3", "DNA", 19, 22], ["human", "SPECIES", 9, 14], ["ZIKV", "SPECIES", 0, 4], ["human", "SPECIES", 9, 14], ["ZIKV", "PROBLEM", 0, 4], ["human ENC/GC3 values", "TEST", 9, 29]]], ["The mean GC3 value for Aedes genes is somewhat higher (0.63) compared with the values for ZKIV and human genes (0.53).", [["ZKIV", "GENE_OR_GENE_PRODUCT", 90, 94], ["human", "ORGANISM", 99, 104], ["GC3", "DNA", 9, 12], ["Aedes genes", "DNA", 23, 34], ["ZKIV", "DNA", 90, 94], ["human genes", "DNA", 99, 110], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["The mean GC3 value", "TEST", 0, 18], ["Aedes genes", "TEST", 23, 34], ["somewhat", "OBSERVATION_MODIFIER", 38, 46], ["higher", "OBSERVATION_MODIFIER", 47, 53]]], ["Between virus and hosts we did not observe different codon preferences, which are related to codon bias by translational control and indicated by low ENCobs/ENCexp values.", [["ENCobs", "GENE_OR_GENE_PRODUCT", 150, 156], ["ENCexp", "GENE_OR_GENE_PRODUCT", 157, 163], ["ENCobs", "PROTEIN", 150, 156], ["ENCexp", "PROTEIN", 157, 163], ["virus", "PROBLEM", 8, 13], ["codon bias", "PROBLEM", 93, 103], ["translational control", "TREATMENT", 107, 128], ["low ENCobs/ENCexp values", "PROBLEM", 146, 170]]], ["Overall, this analysis suggests that the virus-specific codon usage trends reflect the biased nt composition of these viral RNA genomes.DiscussionThis survey of the ZIKV RNA genome indicates a preference for purines over pyrimidines that is enhanced in the unpaired domains of the viral RNA and that influences the codons used for translation of the viral proteins.", [["purines", "CHEMICAL", 208, 215], ["pyrimidines", "CHEMICAL", 221, 232], ["purines", "CHEMICAL", 208, 215], ["pyrimidines", "CHEMICAL", 221, 232], ["purines", "SIMPLE_CHEMICAL", 208, 215], ["pyrimidines", "SIMPLE_CHEMICAL", 221, 232], ["viral RNA genomes", "DNA", 118, 135], ["ZIKV RNA genome", "DNA", 165, 180], ["viral RNA", "RNA", 281, 290], ["viral proteins", "PROTEIN", 350, 364], ["this analysis", "TEST", 9, 22], ["the virus", "PROBLEM", 37, 46], ["these viral RNA genomes", "PROBLEM", 112, 135], ["the ZIKV RNA genome", "PROBLEM", 161, 180], ["purines over pyrimidines", "TREATMENT", 208, 232], ["the viral RNA", "PROBLEM", 277, 290], ["the codons", "TREATMENT", 311, 321], ["the viral proteins", "PROBLEM", 346, 364], ["viral RNA genomes", "OBSERVATION", 118, 135], ["viral RNA", "OBSERVATION", 281, 290], ["viral proteins", "OBSERVATION", 350, 364]]], ["No significant differences were found among the highly related ZIKV strains concerning these basic properties, ranging from the prototype Uganda strain isolated in 1947 to recent south American isolates.", [["ZIKV", "SPECIES", 63, 67], ["significant differences", "PROBLEM", 3, 26], ["the highly related ZIKV strains", "PROBLEM", 44, 75], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26]]], ["The strong correlation between nucleotide composition and codon usage bias suggests that mutation pressure in ZIKV is an important determinant of the codon bias observed.", [["nucleotide", "CHEMICAL", 31, 41], ["nucleotide", "CHEMICAL", 31, 41], ["nucleotide composition", "TREATMENT", 31, 53], ["codon usage bias", "TREATMENT", 58, 74], ["mutation pressure in ZIKV", "PROBLEM", 89, 114], ["pressure", "OBSERVATION_MODIFIER", 98, 106]]], ["This finding is consistent with previous findings for other viruses, which demonstrate a wide variation in codon usage that usually correlates with the viral RNA-specific nucleotide composition [41].", [["nucleotide", "CHEMICAL", 171, 181], ["nucleotide", "CHEMICAL", 171, 181], ["viral RNA", "RNA", 152, 161], ["other viruses", "PROBLEM", 54, 67], ["a wide variation in codon usage", "PROBLEM", 87, 118], ["the viral RNA", "PROBLEM", 148, 161], ["consistent with", "UNCERTAINTY", 16, 31], ["viruses", "OBSERVATION", 60, 67], ["wide", "OBSERVATION_MODIFIER", 89, 93], ["variation", "OBSERVATION_MODIFIER", 94, 103], ["codon usage", "OBSERVATION", 107, 118]]], ["The ZIKV nt characteristics are quite distinctive from those of other viruses and may thus help to comprehend virus evolution and to provide an additional tool for virus classification purposes or the development of diagnostic reagents for improved surveillance of this class of emerging pathogens.", [["The ZIKV nt characteristics", "PROBLEM", 0, 27], ["other viruses", "PROBLEM", 64, 77], ["virus classification purposes", "TEST", 164, 193], ["diagnostic reagents", "TEST", 216, 235], ["emerging pathogens", "PROBLEM", 279, 297], ["ZIKV", "OBSERVATION", 4, 8], ["viruses", "OBSERVATION", 70, 77], ["pathogens", "OBSERVATION", 288, 297]]], ["A quick comparison of ZIKV to other members of the family Flaviviridae, including the major pathogens dengue virus [42], yellow fever virus, Japanese encephalitis virus, West Nile virus [43] and hepatitis C virus, indicated a similar purine-preference for the mosquito-borne and tick-borne flaviviruses and the pestivirus genus, but not for the hepacivirus group (results not shown).", [["dengue", "DISEASE", 102, 108], ["yellow fever", "DISEASE", 121, 133], ["Japanese encephalitis", "DISEASE", 141, 162], ["hepatitis C virus", "DISEASE", 195, 212], ["purine", "CHEMICAL", 234, 240], ["purine", "CHEMICAL", 234, 240], ["ZIKV", "GENE_OR_GENE_PRODUCT", 22, 26], ["Flaviviridae", "ORGANISM", 58, 70], ["major pathogens", "ORGANISM", 86, 101], ["dengue virus [42", "ORGANISM", 102, 118], ["yellow fever virus", "ORGANISM", 121, 139], ["Japanese encephalitis virus", "ORGANISM", 141, 168], ["West Nile virus [43]", "ORGANISM", 170, 190], ["hepatitis C virus", "ORGANISM", 195, 212], ["purine", "SIMPLE_CHEMICAL", 234, 240], ["dengue virus", "SPECIES", 102, 114], ["yellow fever virus", "SPECIES", 121, 139], ["Japanese encephalitis virus", "SPECIES", 141, 168], ["West Nile virus", "SPECIES", 170, 185], ["hepatitis C virus", "SPECIES", 195, 212], ["ZIKV", "SPECIES", 22, 26], ["dengue virus", "SPECIES", 102, 114], ["yellow fever virus", "SPECIES", 121, 139], ["Japanese encephalitis virus", "SPECIES", 141, 168], ["West Nile virus", "SPECIES", 170, 185], ["hepatitis C virus", "SPECIES", 195, 212], ["tick-borne flaviviruses", "SPECIES", 279, 302], ["Flaviviridae", "TREATMENT", 58, 70], ["the major pathogens dengue virus", "PROBLEM", 82, 114], ["yellow fever virus", "PROBLEM", 121, 139], ["Japanese encephalitis virus", "PROBLEM", 141, 168], ["West Nile virus", "PROBLEM", 170, 185], ["hepatitis C virus", "PROBLEM", 195, 212], ["tick-borne flaviviruses", "PROBLEM", 279, 302], ["the pestivirus genus", "PROBLEM", 307, 327]]], ["Intriguingly, these purine-loving viruses seem to favor either A or G, similar to the \u201ccommunicating\u201d pyrimidine vessels described for coronaviruses [35].", [["vessels", "ANATOMY", 113, 120], ["purine", "CHEMICAL", 20, 26], ["pyrimidine", "CHEMICAL", 102, 112], ["purine", "CHEMICAL", 20, 26], ["pyrimidine", "CHEMICAL", 102, 112], ["purine", "SIMPLE_CHEMICAL", 20, 26], ["vessels", "MULTI-TISSUE_STRUCTURE", 113, 120], ["loving viruses", "PROBLEM", 27, 41], ["A or G", "PROBLEM", 63, 69], ["the \u201ccommunicating\u201d pyrimidine vessels", "TREATMENT", 82, 120], ["coronaviruses", "PROBLEM", 135, 148], ["vessels", "ANATOMY", 113, 120]]], ["Although quite extensive codon analyses have been conducted for flaviviruses [42\u201350], as far as we know the typical purine/pyrimidine pattern has not yet been described previously.DiscussionWe previously presented two possible causes for the presence of viral RNA genomes with a biased nt-composition [51].", [["purine", "CHEMICAL", 116, 122], ["pyrimidine", "CHEMICAL", 123, 133], ["purine", "CHEMICAL", 116, 122], ["pyrimidine", "CHEMICAL", 123, 133], ["purine", "SIMPLE_CHEMICAL", 116, 122], ["pyrimidine", "SIMPLE_CHEMICAL", 123, 133], ["viral RNA genomes", "DNA", 254, 271], ["quite extensive codon analyses", "PROBLEM", 9, 39], ["flaviviruses", "PROBLEM", 64, 76], ["the typical purine/pyrimidine pattern", "PROBLEM", 104, 141], ["viral RNA genomes", "PROBLEM", 254, 271], ["viral RNA genomes", "OBSERVATION", 254, 271]]], ["One frequently entertained possibility is that this is due \u2013 over evolutionary times - to mutational bias of the viral polymerase [52].", [["viral polymerase", "PROTEIN", 113, 129], ["the viral polymerase", "TEST", 109, 129]]], ["Alternatively, we suggested a specific genome composition may be selected for a specific function, e.g. to facilitate RNA packaging in the virion particle or to prevent recognition by innate immune sensors in the infected cell.", [["cell", "ANATOMY", 222, 226], ["cell", "CELL", 222, 226], ["infected cell", "CELL_TYPE", 213, 226], ["RNA packaging", "TREATMENT", 118, 131], ["the virion particle", "TREATMENT", 135, 154], ["the infected cell", "PROBLEM", 209, 226], ["infected cell", "OBSERVATION", 213, 226]]], ["For HIV-1, there are recent indications to support both functional scenario\u2019s [30, 53].", [["HIV-1", "ORGANISM", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["HIV", "PROBLEM", 4, 7]]], ["For ZIKV, one cannot formally exclude that functions are executed by the viral minus-RNA strand, the critical replication intermediate that in terms of nt-composition is the mirror image of the viral plus-strand RNA genome.", [["viral minus-RNA strand", "RNA", 73, 95], ["viral plus-strand RNA genome", "DNA", 194, 222], ["ZIKV", "SPECIES", 4, 8], ["ZIKV", "PROBLEM", 4, 8], ["strand RNA genome", "PROBLEM", 205, 222], ["strand RNA genome", "OBSERVATION", 205, 222]]], ["In addition, the double-stranded RNA replication intermediate and its nt-composition and structure may be screened by several innate immune sensors in the human, monkey and Aedes hosts.DiscussionWe previously reported that virus-specific compositional signatures are commonly enhanced in the unpaired domains of a structured RNA genome.", [["human", "ORGANISM", 155, 160], ["monkey", "ORGANISM", 162, 168], ["Aedes hosts", "ORGANISM", 173, 184], ["unpaired domains", "DNA", 292, 308], ["structured RNA genome", "DNA", 314, 335], ["human", "SPECIES", 155, 160], ["monkey", "SPECIES", 162, 168], ["human", "SPECIES", 155, 160], ["the double-stranded RNA replication", "TREATMENT", 13, 48], ["virus", "PROBLEM", 223, 228], ["virus", "OBSERVATION", 223, 228], ["RNA genome", "OBSERVATION", 325, 335]]], ["This is true for HIV-1, with an average A-count of 36.2 % that increases to 47.5 % in the unpaired genome segments, and also for other retroviruses with a distinct nt bias [28, 34].", [["HIV-1", "ORGANISM", 17, 22], ["retroviruses", "ORGANISM", 135, 147], ["unpaired genome segments", "DNA", 90, 114], ["HIV-1", "SPECIES", 17, 22], ["HIV-1", "SPECIES", 17, 22], ["HIV", "PROBLEM", 17, 20], ["an average A-count", "TEST", 29, 47], ["other retroviruses", "PROBLEM", 129, 147], ["a distinct nt bias", "TEST", 153, 171], ["genome segments", "ANATOMY", 99, 114]]], ["We recently analyzed coronaviruses and reported some common characteristics (high U, low C count), but also species-specific signatures that differentiate the pathogenic MERS/SARS strains from other coronaviruses [35].", [["SARS", "DISEASE", 175, 179], ["coronaviruses", "ORGANISM", 21, 34], ["MERS/SARS strains", "ORGANISM", 170, 187], ["coronaviruses", "PROBLEM", 21, 34], ["high U, low C count)", "PROBLEM", 77, 97], ["the pathogenic MERS", "PROBLEM", 155, 174], ["SARS strains", "PROBLEM", 175, 187], ["other coronaviruses", "PROBLEM", 193, 212]]], ["Again, nucleotide biases were boosted in the unpaired domains of the viral RNA genome.", [["nucleotide", "CHEMICAL", 7, 17], ["nucleotide", "CHEMICAL", 7, 17], ["unpaired domains", "DNA", 45, 61], ["viral RNA genome", "DNA", 69, 85], ["nucleotide biases", "PROBLEM", 7, 24], ["viral RNA genome", "OBSERVATION", 69, 85]]], ["The concentration of nt-bias in certain genome domains may have been selected for a certain function.DiscussionMany reports dwell on the exotic codon usage employed by viruses.", [["genome domains", "DNA", 40, 54], ["nt-bias", "TREATMENT", 21, 28], ["the exotic codon usage", "TREATMENT", 133, 155], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["For instance, a recent report documented codon usage adaptation in pandemic ZIKV virus strains [54].", [["ZIKV virus", "ORGANISM", 76, 86], ["pandemic ZIKV virus", "SPECIES", 67, 86], ["pandemic ZIKV virus", "SPECIES", 67, 86], ["codon usage adaptation", "TREATMENT", 41, 63], ["pandemic ZIKV virus strains", "PROBLEM", 67, 94]]], ["However, a sobering finding is that this bias usually coincides with a bias in nt-composition of the viral RNA genome, and therefore does not represent translational selection of certain codons and/or the matching tRNA species.", [["viral RNA genome", "RNA", 101, 117], ["this bias", "PROBLEM", 36, 45], ["a bias in nt", "PROBLEM", 69, 81], ["the viral RNA genome", "PROBLEM", 97, 117], ["certain codons", "PROBLEM", 179, 193], ["the matching tRNA species", "PROBLEM", 201, 226], ["viral RNA genome", "OBSERVATION", 101, 117], ["does not represent", "UNCERTAINTY", 133, 151], ["tRNA species", "OBSERVATION", 214, 226]]], ["This also seems true for ZIKV, which preferentially uses A- or G-rich codons, but this seems to be a direct consequence of having a purine-rich RNA genome (56.8 %).", [["purine", "CHEMICAL", 132, 138], ["purine", "CHEMICAL", 132, 138], ["ZIKV", "GENE_OR_GENE_PRODUCT", 25, 29], ["purine-rich RNA genome", "DNA", 132, 154], ["ZIKV", "SPECIES", 25, 29], ["ZIKV", "PROBLEM", 25, 29], ["ZIKV", "OBSERVATION", 25, 29]]], ["HIV is the only virus in this collection that combines A-accumulation with weak translational selection by means of codon bias.", [["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["the only virus", "PROBLEM", 7, 21], ["codon bias", "PROBLEM", 116, 126], ["virus", "OBSERVATION", 16, 21], ["weak", "OBSERVATION_MODIFIER", 75, 79]]], ["Previously, we have even documented a tendency in HIV proteins for selection of amino acids encoded by A-rich codons [55].", [["amino acids", "CHEMICAL", 80, 91], ["amino acids", "CHEMICAL", 80, 91], ["HIV", "ORGANISM", 50, 53], ["amino acids", "AMINO_ACID", 80, 91], ["HIV proteins", "PROTEIN", 50, 62], ["HIV", "SPECIES", 50, 53], ["a tendency in HIV proteins", "PROBLEM", 36, 62], ["amino acids", "TREATMENT", 80, 91]]], ["Codon usage can become an important aspect when it comes to optimization of protein production, e.g. in the context of ZIKV vaccine development where efficient viral gene expression may be required to generate immunity [56].", [["ZIKV", "ORGANISM", 119, 123], ["ZIKV", "SPECIES", 119, 123], ["Codon usage", "TREATMENT", 0, 11], ["protein production", "PROBLEM", 76, 94], ["ZIKV vaccine", "TREATMENT", 119, 131]]], ["Given the biased codon usage of this virus, it is important to change towards synonymous codons that are more favored in the relevant production platform, e.g. human cell lines.", [["cell lines", "ANATOMY", 166, 176], ["human", "ORGANISM", 160, 165], ["cell lines", "CELL", 166, 176], ["human cell lines", "CELL_LINE", 160, 176], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["this virus", "PROBLEM", 32, 42], ["synonymous codons", "TREATMENT", 78, 95], ["human cell lines", "TREATMENT", 160, 176], ["biased codon", "OBSERVATION", 10, 22], ["synonymous codons", "OBSERVATION", 78, 95], ["cell lines", "OBSERVATION", 166, 176]]]], "f683a47bca0a7039fb484e8c21750cb2c7e56937": [["IntroductionCountries around the world have had to implement measures to reduce the spread of COVID-19 in order to stop their health services from becoming overwhelmed and to save life.", [["IntroductionCountries", "TREATMENT", 0, 21], ["COVID", "TEST", 94, 99]]], ["In the UK, protocols have been put in place to protect staff and patients, often drawing upon the experience of countries already affected.IntroductionOrthopaedic teams have played a vital role in both inpatient and outpatient settings, often outside their area of expertise.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["protocols", "TREATMENT", 11, 20]]], ["Following British Orthopaedic Association (BOA) guidance [1] , elective surgery was halted, clinics were cut and only necessary trauma theatres have continued.", [["trauma", "DISEASE", 128, 134], ["elective surgery", "TREATMENT", 63, 79], ["trauma theatres", "TREATMENT", 128, 143]]], ["Patients are increasingly treated as day case admissions and non-operative management initiated where possible.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["non-operative management", "TREATMENT", 61, 85]]], ["In many hospitals and within our own trust, wards have merged to facilitate the creation of COVID-19 and non-COVID-19 areas with separate teams allocated to each to reduce cross infection between staff members and patients.", [["infection", "DISEASE", 178, 187], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["COVID", "TEST", 92, 97], ["non-COVID", "TREATMENT", 105, 114], ["cross infection", "PROBLEM", 172, 187], ["infection", "OBSERVATION", 178, 187]]], ["Early patient discharge has allowed an increase in available bed space and reallocation of clinical staff to enable capacity and ensure patient safety standards across the whole hospital.IntroductionAs a society, social distancing and travel restrictions have reduced emergency department admissions to an all time low [2] .", [["patient", "ORGANISM", 6, 13], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 6, 13], ["patient", "SPECIES", 136, 143], ["available bed space", "TREATMENT", 51, 70]]], ["Patients presenting with trauma have significantly reduced in volume, but hip fractures in the elderly are still being seen generally at an unchanged rate.IntroductionIn our own institution, patients admitted via the Emergency Department (ED) are swabbed on arrival and held in a single room on a neutral ward before transfer to a green zone or red zone ward dependent on their swab result.", [["hip", "ANATOMY", 74, 77], ["trauma", "DISEASE", 25, 31], ["fractures", "DISEASE", 78, 87], ["Patients", "ORGANISM", 0, 8], ["hip", "ORGANISM_SUBDIVISION", 74, 77], ["patients", "ORGANISM", 191, 199], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 191, 199], ["trauma", "PROBLEM", 25, 31], ["significantly reduced in volume", "PROBLEM", 37, 68], ["hip fractures", "PROBLEM", 74, 87], ["their swab", "TEST", 372, 382], ["significantly", "OBSERVATION_MODIFIER", 37, 50], ["reduced", "OBSERVATION_MODIFIER", 51, 58], ["volume", "OBSERVATION_MODIFIER", 62, 68], ["hip", "ANATOMY", 74, 77], ["fractures", "OBSERVATION", 78, 87], ["unchanged", "OBSERVATION", 140, 149]]], ["Interval testing of patients with routine re-testing on day 5 of an in-patient stay has also been supported.", [["patients", "ORGANISM", 20, 28], ["patient", "ORGANISM", 71, 78], ["patients", "SPECIES", 20, 28], ["patient", "SPECIES", 71, 78], ["Interval testing", "TEST", 0, 16]]], ["Personal Protective Equipment (PPE) and measures to reduce cross-infection of patients in wards have been implemented consistently.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Personal Protective Equipment (PPE)", "TREATMENT", 0, 35], ["measures", "TREATMENT", 40, 48]]], ["Despite this, we have had outbreaks of COVID-19 infections in green zone wards, most notably in our elderly hip fracture patients who tested negative on admission but then became COVID positive in the days after surgery.The COVID-19 effectEarly observations and a departmental audit of hip fracture patients admitted during March and April of this year (surgically stabilised) demonstrated a trend to higher 30-day mortality in patients who subsequently tested COVID positive after surgery compared to those who did not.", [["hip", "ANATOMY", 108, 111], ["hip", "ANATOMY", 286, 289], ["infections", "DISEASE", 48, 58], ["fracture", "DISEASE", 112, 120], ["fracture", "DISEASE", 290, 298], ["hip", "ORGANISM_SUBDIVISION", 108, 111], ["patients", "ORGANISM", 121, 129], ["hip", "ORGANISM_SUBDIVISION", 286, 289], ["patients", "ORGANISM", 299, 307], ["patients", "ORGANISM", 428, 436], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 299, 307], ["patients", "SPECIES", 428, 436], ["COVID", "TREATMENT", 39, 44], ["our elderly hip fracture", "PROBLEM", 96, 120], ["COVID positive", "PROBLEM", 179, 193], ["surgery", "TREATMENT", 212, 219], ["The COVID", "TEST", 220, 229], ["hip fracture", "PROBLEM", 286, 298], ["surgery", "TREATMENT", 482, 489], ["hip", "ANATOMY", 108, 111], ["fracture", "OBSERVATION", 112, 120], ["hip", "ANATOMY", 286, 289], ["fracture", "OBSERVATION", 290, 298]]], ["Further research into this patient cohort is required to both confirm this trend and research the likely aetiology.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["likely", "UNCERTAINTY", 98, 104]]], ["Concluding that COVID-19 is a main determinant of increased mortality may seem obvious, but other factors should also be considered.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 16, 24], ["COVID-19", "DNA", 16, 24], ["COVID", "TEST", 16, 21], ["increased mortality", "PROBLEM", 50, 69], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["mortality", "OBSERVATION", 60, 69]]], ["Early surgical intervention can improve outcome in patients optimised for surgery.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Early surgical intervention", "TREATMENT", 0, 27], ["surgery", "TREATMENT", 74, 81]]], ["Conversely, prolonged operative time can increase the risk of complications [4] .", [["complications", "PROBLEM", 62, 75]]], ["During the coronavirus pandemic, surgical teams operating on COVID-19 positive patients were subject to stringent personal protective equipment (PPE) protocols in theatre.", [["coronavirus pandemic", "DISEASE", 11, 31], ["patients", "ORGANISM", 79, 87], ["coronavirus", "SPECIES", 11, 22], ["patients", "SPECIES", 79, 87], ["COVID", "TEST", 61, 66]]], ["An increase in the overall operative time has occurred and the result that this has had on common patient outcome measurements such as 30-day mortality and surgical site infection rates remains uncertain.The COVID-19 effectIn the U.K. the use of the best practice tariff in hip fracture patients has significantly reduced 30-day mortality [5] .", [["site", "ANATOMY", 165, 169], ["hip", "ANATOMY", 274, 277], ["infection", "DISEASE", 170, 179], ["fracture", "DISEASE", 278, 286], ["patient", "ORGANISM", 98, 105], ["hip", "ORGANISM_SUBDIVISION", 274, 277], ["patients", "ORGANISM", 287, 295], ["patient", "SPECIES", 98, 105], ["patients", "SPECIES", 287, 295], ["surgical site infection rates", "PROBLEM", 156, 185], ["The COVID", "TEST", 204, 213], ["the best practice tariff", "TREATMENT", 246, 270], ["hip fracture", "PROBLEM", 274, 286], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["overall", "OBSERVATION_MODIFIER", 19, 26], ["operative", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 170, 179], ["hip", "ANATOMY", 274, 277], ["fracture", "OBSERVATION", 278, 286]]], ["This includes having an early orthogeriatric review, receiving surgery on the day of, or the day following admission, a specialist falls assessment and a multidisciplinary approach to rehabilitation [5] .", [["surgery", "TREATMENT", 63, 70], ["a specialist falls assessment", "TEST", 118, 147]]], ["As these services are usually located and focused on the hip fracture unit, they are less accessible to the relocated COVID-19 positive patients.", [["hip", "ANATOMY", 57, 60], ["fracture", "DISEASE", 61, 69], ["hip", "ORGANISM_SUBDIVISION", 57, 60], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["hip", "ANATOMY", 57, 60], ["fracture", "OBSERVATION", 61, 69]]], ["The likely reduced specialist input and reduced surgical specialty review may effect outcome and logistically reviewing and optimising care of these remote patients from the hospital green zone has proved challenging.How have patients become positive during admission and how can this be minimised/prevented?Given the likely increased mortality associated with COVID-19, it is essential that we ensure vulnerable patient groups such as hip fractures continue to receive optimal care regardless of infection status.", [["hip", "ANATOMY", 436, 439], ["hip fractures", "DISEASE", 436, 449], ["infection", "DISEASE", 497, 506], ["COVID-19", "CHEMICAL", 361, 369], ["patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 226, 234], ["patient", "ORGANISM", 413, 420], ["hip", "ORGANISM_SUBDIVISION", 436, 439], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 226, 234], ["patient", "SPECIES", 413, 420], ["positive", "PROBLEM", 242, 250], ["increased mortality", "PROBLEM", 325, 344], ["COVID", "TEST", 361, 366], ["hip fractures", "PROBLEM", 436, 449], ["optimal care", "TREATMENT", 470, 482], ["infection status", "PROBLEM", 497, 513], ["likely", "UNCERTAINTY", 4, 10], ["reduced", "OBSERVATION_MODIFIER", 11, 18], ["positive", "OBSERVATION", 242, 250], ["likely", "UNCERTAINTY", 318, 324], ["increased", "OBSERVATION_MODIFIER", 325, 334], ["mortality", "OBSERVATION", 335, 344], ["hip", "ANATOMY", 436, 439], ["fractures", "OBSERVATION", 440, 449], ["infection", "OBSERVATION", 497, 506]]], ["Identifying the route and cause of acquired infection can also help understand the ways in which this can be prevented.How have patients become positive during admission and how can this be minimised/prevented?It can be concluded that patients who present to hospital with a hip fracture and have an initial positive COVID-19 test contracted the virus prior to admission.", [["hip", "ANATOMY", 275, 278], ["infection", "DISEASE", 44, 53], ["fracture", "DISEASE", 279, 287], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 235, 243], ["hip", "ORGANISM_SUBDIVISION", 275, 278], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 235, 243], ["acquired infection", "PROBLEM", 35, 53], ["positive", "PROBLEM", 144, 152], ["a hip fracture", "PROBLEM", 273, 287], ["an initial positive COVID", "PROBLEM", 297, 322], ["the virus", "PROBLEM", 342, 351], ["infection", "OBSERVATION", 44, 53], ["positive", "OBSERVATION", 144, 152], ["hip", "ANATOMY", 275, 278], ["fracture", "OBSERVATION", 279, 287]]], ["These patients are transferred to the COVID-19 ward and their entire in-patient journey occurs within the COVID positive red zone of the hospital.", [["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 72, 79], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 72, 79]]], ["The route of infection in patients who initially had a negative swab, but later went on to become positive is less clear.", [["swab", "ANATOMY", 64, 68], ["infection", "DISEASE", 13, 22], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["infection", "PROBLEM", 13, 22], ["a negative swab", "PROBLEM", 53, 68], ["infection", "OBSERVATION", 13, 22], ["positive", "OBSERVATION", 98, 106], ["less", "OBSERVATION_MODIFIER", 110, 114], ["clear", "OBSERVATION", 115, 120]]], ["A false negative sample on admission; an infected patient who is in the incubation period or a patient contracting the virus whilst awaiting the result of the first swab would all allow patients with the disease to be transferred to the green zone wards, risking cross infection to patients and staff.How have patients become positive during admission and how can this be minimised/prevented?Isolation of these patients on admission and two negative swabs prior to transfer helps prevent this route of transmission.", [["sample", "ANATOMY", 17, 23], ["infection", "DISEASE", 269, 278], ["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 95, 102], ["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 282, 290], ["patients", "ORGANISM", 310, 318], ["patients", "ORGANISM", 411, 419], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 95, 102], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 282, 290], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 411, 419], ["a patient contracting the virus", "PROBLEM", 93, 124], ["the first swab", "PROBLEM", 155, 169], ["the disease", "PROBLEM", 200, 211], ["risking cross infection", "PROBLEM", 255, 278], ["positive", "PROBLEM", 326, 334], ["false", "OBSERVATION_MODIFIER", 2, 7], ["negative", "OBSERVATION", 8, 16], ["infected", "OBSERVATION", 41, 49], ["infection", "OBSERVATION", 269, 278], ["positive", "OBSERVATION", 326, 334]]], ["However, the value of the second swab depends on the sensitivity of the COVID-19 test used.", [["the second swab", "TEST", 22, 37], ["the COVID", "TEST", 68, 77]]], ["In our own institution, we initially performed two swabs but eventually moved to a single swab as we found the second swab added very little extra information.", [["swab", "ANATOMY", 90, 94], ["two swabs", "TREATMENT", 47, 56], ["a single swab", "TEST", 81, 94], ["the second swab", "PROBLEM", 107, 122]]], ["However, if using a test with lower sensitivity then a second test would likely be more useful.How have patients become positive during admission and how can this be minimised/prevented?Research from Japan demonstrated that a large proportion of infected individuals could be carriers of the virus whilst being entirely asymptomatic [6] .", [["patients", "ORGANISM", 104, 112], ["individuals", "ORGANISM", 255, 266], ["patients", "SPECIES", 104, 112], ["a test", "TEST", 18, 24], ["a second test", "TEST", 53, 66], ["positive", "PROBLEM", 120, 128], ["infected individuals", "PROBLEM", 246, 266], ["the virus", "PROBLEM", 288, 297], ["positive", "OBSERVATION", 120, 128], ["large", "OBSERVATION_MODIFIER", 226, 231], ["infected", "OBSERVATION", 246, 254]]], ["This likely means that patients and staff on our wards are at risk of cross infection and is something that must be considered across all organisations.", [["infection", "DISEASE", 76, 85], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["cross infection", "PROBLEM", 70, 85], ["infection", "OBSERVATION", 76, 85]]], ["This also has issues for informed consent as elective services are re-started and we try and resume normality in the admission and surgical management of injured patients, especially frail/elderly fragility fractures.", [["fragility fractures", "DISEASE", 197, 216], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["elective services", "TREATMENT", 45, 62], ["surgical management", "TREATMENT", 131, 150], ["elderly fragility fractures", "PROBLEM", 189, 216], ["fractures", "OBSERVATION", 207, 216]]], ["Protocols are in place to limit the transmission of infection in this way with appropriate use of PPE.", [["infection", "DISEASE", 52, 61], ["PPE", "GENE_OR_GENE_PRODUCT", 98, 101], ["Protocols", "TREATMENT", 0, 9], ["infection", "PROBLEM", 52, 61], ["PPE", "TREATMENT", 98, 101], ["infection", "OBSERVATION", 52, 61]]], ["All patients now have interval testing with further swabs after theatre, regardless of whether they are symptomatic or not.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["interval testing", "TEST", 22, 38], ["further swabs", "TREATMENT", 44, 57], ["symptomatic", "PROBLEM", 104, 115]]], ["If they are found to be positive they are transferred to COVID-19 ward and continue their in-patient journey in that zone of the hospital.ConclusionWhilst the initial peak and plateau in COVID-19 cases may have passed, attempting to get back to normal or a 'new normal' will take time and many of the clinical adaptations that have been implemented will need to remain in order to protect both patients and staff.", [["patient", "ORGANISM", 93, 100], ["patients", "ORGANISM", 394, 402], ["patient", "SPECIES", 93, 100], ["patients", "SPECIES", 394, 402], ["the initial peak", "TEST", 155, 171], ["plateau in COVID", "TEST", 176, 192]]], ["As social restrictions are eased there is likely to be an increase in the volume of trauma coming through our emergency department.", [["trauma", "DISEASE", 84, 90], ["trauma", "PROBLEM", 84, 90], ["likely to be", "UNCERTAINTY", 42, 54], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["Given that COVID-19 protocols will remain in place, this will put considerable additional pressure on orthopaedic departments.", [["COVID", "TEST", 11, 16]]], ["When we are planning our services in the coming weeks and months it is essential to determine how we will manage the increase in trauma whilst adhering to the stringent COVID-19 protocols.", [["trauma", "DISEASE", 129, 135], ["trauma", "PROBLEM", 129, 135], ["the stringent COVID", "TREATMENT", 155, 174], ["increase", "OBSERVATION_MODIFIER", 117, 125]]], ["We need to remain aware of the likely increased mortality for patients who become COVID positive during hospital admissions and take all precautions necessary to reduce patient and staff exposure and increase the specificity and sensitivity of testing procedures.", [["patients", "ORGANISM", 62, 70], ["patient", "ORGANISM", 169, 176], ["patients", "SPECIES", 62, 70], ["patient", "SPECIES", 169, 176], ["COVID positive", "PROBLEM", 82, 96], ["all precautions", "TREATMENT", 133, 148], ["testing procedures", "TEST", 244, 262]]], ["This issue is not going away anytime soon and it is imperative that our optimal way forward delivers specialist multidisciplinary team input and care to any outlying patients.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174]]]], "PMC2756586": [["IntroductionEach day the human respiratory tract comes into contact with billions of airborne particles, including viruses, microbes and allergens [1].", [["respiratory tract", "ANATOMY", 31, 48], ["human", "ORGANISM", 25, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 31, 48], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["the human respiratory tract", "TREATMENT", 21, 48], ["airborne particles", "TREATMENT", 85, 103], ["respiratory tract", "ANATOMY", 31, 48]]], ["Particle size and the local airway host immune response determine which inhaled viruses and particles will adhere to epithelial surfaces and persist in the airways [1], [2].", [["Particle", "ANATOMY", 0, 8], ["airway", "ANATOMY", 28, 34], ["epithelial surfaces", "ANATOMY", 117, 136], ["airways", "ANATOMY", 156, 163], ["airway", "MULTI-TISSUE_STRUCTURE", 28, 34], ["epithelial surfaces", "TISSUE", 117, 136], ["airways", "MULTI-TISSUE_STRUCTURE", 156, 163], ["inhaled viruses", "TREATMENT", 72, 87], ["size", "OBSERVATION_MODIFIER", 9, 13], ["local airway", "OBSERVATION", 22, 34], ["host immune", "OBSERVATION", 35, 46], ["epithelial", "ANATOMY_MODIFIER", 117, 127], ["surfaces", "OBSERVATION_MODIFIER", 128, 136], ["airways", "ANATOMY", 156, 163]]], ["The lungs and lower respiratory tract have generally been considered sterile in the absence of respiratory disease although very little is known about the microbiota of the upper and lower airways of non-diseased individuals.", [["lungs", "ANATOMY", 4, 9], ["lower respiratory tract", "ANATOMY", 14, 37], ["respiratory", "ANATOMY", 95, 106], ["upper", "ANATOMY", 173, 178], ["lower airways", "ANATOMY", 183, 196], ["respiratory disease", "DISEASE", 95, 114], ["lungs", "ORGAN", 4, 9], ["lower respiratory", "ORGANISM_SUBDIVISION", 14, 31], ["tract", "ORGANISM_SUBDIVISION", 32, 37], ["upper", "ORGANISM_SUBDIVISION", 173, 178], ["lower airways", "ORGANISM_SUBDIVISION", 183, 196], ["respiratory disease", "PROBLEM", 95, 114], ["non-diseased individuals", "PROBLEM", 200, 224], ["lungs", "ANATOMY", 4, 9], ["lower", "ANATOMY_MODIFIER", 14, 19], ["respiratory tract", "ANATOMY", 20, 37], ["respiratory disease", "OBSERVATION", 95, 114], ["upper", "ANATOMY_MODIFIER", 173, 178], ["lower", "ANATOMY_MODIFIER", 183, 188], ["airways", "ANATOMY", 189, 196], ["non-diseased individuals", "OBSERVATION", 200, 224]]], ["Microbes and viruses, including phage, have been implicated in chronic pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (CF) [3]\u2013[8].", [["pulmonary", "ANATOMY", 71, 80], ["pulmonary", "ANATOMY", 119, 128], ["chronic pulmonary diseases", "DISEASE", 63, 89], ["chronic obstructive pulmonary disease", "DISEASE", 99, 136], ["COPD", "DISEASE", 138, 142], ["asthma", "DISEASE", 145, 151], ["cystic fibrosis", "DISEASE", 157, 172], ["CF", "DISEASE", 174, 176], ["pulmonary", "ORGAN", 71, 80], ["pulmonary", "ORGAN", 119, 128], ["viruses", "PROBLEM", 13, 20], ["chronic pulmonary diseases", "PROBLEM", 63, 89], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 99, 143], ["asthma", "PROBLEM", 145, 151], ["cystic fibrosis", "PROBLEM", 157, 172], ["viruses", "OBSERVATION", 13, 20], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["pulmonary", "ANATOMY", 71, 80], ["diseases", "OBSERVATION", 81, 89], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["obstructive", "OBSERVATION_MODIFIER", 107, 118], ["pulmonary", "ANATOMY", 119, 128], ["disease", "OBSERVATION", 129, 136], ["COPD", "OBSERVATION", 138, 142], ["asthma", "OBSERVATION", 145, 151], ["cystic", "OBSERVATION_MODIFIER", 157, 163], ["fibrosis", "OBSERVATION", 164, 172]]], ["However, most of this work has been performed using standard microbial cultures and PCR-based studies, which provide an incomplete picture of the airway microbiota and little opportunity for viral discovery compared to metagenomic techniques.IntroductionMetagenomics is a powerful tool for viral and microbial community characterization since nucleic acids are isolated directly from environmental samples and sequenced, requiring no culturing, cloning, or a priori knowledge of what viruses may be present.", [["airway", "ANATOMY", 146, 152], ["samples", "ANATOMY", 398, 405], ["nucleic acids", "CHEMICAL", 343, 356], ["airway microbiota", "MULTI-TISSUE_STRUCTURE", 146, 163], ["nucleic acids", "SIMPLE_CHEMICAL", 343, 356], ["standard microbial cultures", "TEST", 52, 79], ["PCR", "TEST", 84, 87], ["based studies", "TEST", 88, 101], ["an incomplete picture of the airway microbiota", "PROBLEM", 117, 163], ["viral discovery", "PROBLEM", 191, 206], ["metagenomic techniques", "TEST", 219, 241], ["viral and microbial community characterization", "TEST", 290, 336], ["nucleic acids", "TEST", 343, 356], ["culturing", "TEST", 434, 443], ["airway", "ANATOMY", 146, 152]]], ["Viruses are the most numerous and diverse biological entities on Earth, and metagenomics has been used extensively to describe viral communities in marine ecosystems [9]\u2013[12].", [["Viruses", "PROBLEM", 0, 7], ["most numerous", "OBSERVATION_MODIFIER", 16, 29], ["diverse", "OBSERVATION_MODIFIER", 34, 41], ["biological entities", "OBSERVATION", 42, 61]]], ["The first metagenomic studies of the human microbiome were of viruses in blood, feces, and the lungs, and went far to describe previously unexplored viral communities [13]\u2013[17].", [["blood", "ANATOMY", 73, 78], ["feces", "ANATOMY", 80, 85], ["lungs", "ANATOMY", 95, 100], ["human", "ORGANISM", 37, 42], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["feces", "ORGANISM_SUBSTANCE", 80, 85], ["lungs", "ORGAN", 95, 100], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["The first metagenomic studies", "TEST", 0, 29], ["viruses in blood, feces, and the lungs", "PROBLEM", 62, 100], ["viruses", "OBSERVATION", 62, 69], ["lungs", "ANATOMY", 95, 100]]], ["Recent metagenomic studies of the human microbiome have largely focused on microbial populations, predominantly in the gut and the surface of the skin [18]\u2013[21].IntroductionCystic fibrosis is an autosomal recessive genetic disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator protein (CFTR), a gated ion channel [22], [23].", [["gut", "ANATOMY", 119, 122], ["surface", "ANATOMY", 131, 138], ["skin", "ANATOMY", 146, 150], ["fibrosis", "DISEASE", 180, 188], ["autosomal recessive genetic disease", "DISEASE", 195, 230], ["fibrosis", "DISEASE", 266, 274], ["human", "ORGANISM", 34, 39], ["microbial populations", "CELL", 75, 96], ["gut", "ORGANISM_SUBDIVISION", 119, 122], ["surface", "CELLULAR_COMPONENT", 131, 138], ["skin", "ORGAN", 146, 150], ["cystic fibrosis transmembrane conductance regulator protein", "GENE_OR_GENE_PRODUCT", 259, 318], ["CFTR", "GENE_OR_GENE_PRODUCT", 320, 324], ["cystic fibrosis transmembrane conductance regulator protein", "PROTEIN", 259, 318], ["CFTR", "PROTEIN", 320, 324], ["gated ion channel", "PROTEIN", 329, 346], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["Recent metagenomic studies", "TEST", 0, 26], ["IntroductionCystic fibrosis", "PROBLEM", 161, 188], ["an autosomal recessive genetic disease", "PROBLEM", 192, 230], ["a mutation in the cystic fibrosis", "PROBLEM", 241, 274], ["a gated ion channel", "TEST", 327, 346], ["microbial populations", "OBSERVATION", 75, 96], ["predominantly", "OBSERVATION_MODIFIER", 98, 111], ["gut", "ANATOMY", 119, 122], ["surface", "ANATOMY_MODIFIER", 131, 138], ["skin", "ANATOMY", 146, 150], ["fibrosis", "OBSERVATION", 180, 188], ["autosomal", "OBSERVATION_MODIFIER", 195, 204], ["recessive", "OBSERVATION_MODIFIER", 205, 214], ["genetic disease", "OBSERVATION", 215, 230], ["cystic", "OBSERVATION_MODIFIER", 259, 265], ["fibrosis", "OBSERVATION", 266, 274]]], ["CF affects paranasal sinuses as well as the lower respiratory, hepatobiliary, pancreatic and lower gastro-intestinal tracts [23].", [["paranasal sinuses", "ANATOMY", 11, 28], ["lower respiratory", "ANATOMY", 44, 61], ["hepatobiliary", "ANATOMY", 63, 76], ["pancreatic", "ANATOMY", 78, 88], ["lower gastro-intestinal tracts", "ANATOMY", 93, 123], ["CF", "MULTI-TISSUE_STRUCTURE", 0, 2], ["paranasal sinuses", "MULTI-TISSUE_STRUCTURE", 11, 28], ["hepatobiliary", "ORGAN", 63, 76], ["pancreatic", "CANCER", 78, 88], ["intestinal", "ANATOMICAL_SYSTEM", 106, 116], ["CF affects paranasal sinuses", "PROBLEM", 0, 28], ["the lower respiratory, hepatobiliary, pancreatic and lower gastro-intestinal tracts", "PROBLEM", 40, 123], ["paranasal sinuses", "ANATOMY", 11, 28], ["lower", "ANATOMY_MODIFIER", 44, 49], ["respiratory", "ANATOMY", 50, 61], ["hepatobiliary", "ANATOMY", 63, 76], ["pancreatic", "ANATOMY", 78, 88], ["lower", "ANATOMY_MODIFIER", 93, 98], ["gastro", "ANATOMY", 99, 105], ["intestinal tracts", "ANATOMY", 106, 123]]], ["The current median age of survival for individuals with CF is approximately 38 years.", [["CF", "DISEASE", 56, 58]]], ["Over 80% of CF mortalities are attributable to respiratory failure from chronic bacterial infections of the lungs, most commonly caused by Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia[4], [24].", [["respiratory", "ANATOMY", 47, 58], ["lungs", "ANATOMY", 108, 113], ["CF", "DISEASE", 12, 14], ["respiratory failure", "DISEASE", 47, 66], ["bacterial infections of the lungs", "DISEASE", 80, 113], ["Pseudomonas aeruginosa", "DISEASE", 139, 161], ["Staphylococcus aureus", "DISEASE", 163, 184], ["Burkholderia cepacia", "DISEASE", 190, 210], ["lungs", "ORGAN", 108, 113], ["Pseudomonas aeruginosa", "ORGANISM", 139, 161], ["Staphylococcus aureus", "ORGANISM", 163, 184], ["Pseudomonas aeruginosa", "SPECIES", 139, 161], ["Staphylococcus aureus", "SPECIES", 163, 184], ["Burkholderia cepacia", "SPECIES", 190, 210], ["Pseudomonas aeruginosa", "SPECIES", 139, 161], ["Staphylococcus aureus", "SPECIES", 163, 184], ["Burkholderia cepacia", "SPECIES", 190, 210], ["CF mortalities", "PROBLEM", 12, 26], ["respiratory failure", "PROBLEM", 47, 66], ["chronic bacterial infections of the lungs", "PROBLEM", 72, 113], ["Pseudomonas aeruginosa", "PROBLEM", 139, 161], ["Staphylococcus aureus", "PROBLEM", 163, 184], ["Burkholderia cepacia", "PROBLEM", 190, 210], ["respiratory failure", "OBSERVATION", 47, 66], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["bacterial", "OBSERVATION_MODIFIER", 80, 89], ["infections", "OBSERVATION", 90, 100], ["lungs", "ANATOMY", 108, 113], ["Pseudomonas aeruginosa", "OBSERVATION", 139, 161], ["Staphylococcus aureus", "OBSERVATION", 163, 184]]], ["Individuals with CF have impaired mucociliary clearance (MCC) which results in airway mucus plugging [2][25][2].", [["mucociliary", "ANATOMY", 34, 45], ["airway mucus", "ANATOMY", 79, 91], ["CF", "DISEASE", 17, 19], ["impaired mucociliary clearance", "DISEASE", 25, 55], ["mucociliary", "ORGAN", 34, 45], ["airway mucus", "MULTI-TISSUE_STRUCTURE", 79, 91], ["impaired mucociliary clearance", "PROBLEM", 25, 55], ["airway mucus plugging", "PROBLEM", 79, 100], ["airway", "ANATOMY", 79, 85], ["mucus plugging", "OBSERVATION", 86, 100]]], ["This creates hypoxic microenvironments, forcing invasive microbial species to adapt [2].", [["hypoxic microenvironments", "PROBLEM", 13, 38], ["hypoxic microenvironments", "OBSERVATION", 13, 38]]], ["This unique airway environment is believed to increase viral replication and susceptibility to viral infections in individuals with CF [8], [22].", [["airway", "ANATOMY", 12, 18], ["viral infections", "DISEASE", 95, 111], ["CF", "DISEASE", 132, 134], ["airway", "MULTI-TISSUE_STRUCTURE", 12, 18], ["viral replication", "PROBLEM", 55, 72], ["viral infections", "PROBLEM", 95, 111], ["CF", "TEST", 132, 134], ["airway", "ANATOMY", 12, 18], ["viral", "OBSERVATION_MODIFIER", 95, 100], ["infections", "OBSERVATION", 101, 111]]], ["Expectorated sputum provides a sample of airway secretions from the proximal airways.", [["sputum", "ANATOMY", 13, 19], ["airway secretions", "ANATOMY", 41, 58], ["proximal airways", "ANATOMY", 68, 84], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 41, 58], ["airways", "MULTI-TISSUE_STRUCTURE", 77, 84], ["Expectorated sputum", "TEST", 0, 19], ["sputum", "OBSERVATION", 13, 19], ["airway", "ANATOMY", 41, 47], ["secretions", "OBSERVATION", 48, 58], ["proximal", "ANATOMY_MODIFIER", 68, 76], ["airways", "ANATOMY", 77, 84]]], ["Sputum also contains material from the entire respiratory tract including airway mucus, cellular debris, DNA, and degraded proteins as well as microbes, their associated phage, and eukaryotic viruses [26], [27].IntroductionHere we report the first metagenomic study of airway DNA viral communities using sputum samples from both cystic fibrosis and Non-cystic fibrosis (Non-CF) individuals, including the spouse of an individual with CF and an individual with mild asthma.", [["respiratory tract", "ANATOMY", 46, 63], ["airway mucus", "ANATOMY", 74, 86], ["cellular debris", "ANATOMY", 88, 103], ["airway", "ANATOMY", 269, 275], ["sputum samples", "ANATOMY", 304, 318], ["cystic", "ANATOMY", 329, 335], ["cystic fibrosis", "DISEASE", 329, 344], ["Non-cystic fibrosis", "DISEASE", 349, 368], ["CF", "DISEASE", 434, 436], ["asthma", "DISEASE", 465, 471], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["respiratory tract", "ORGANISM_SUBDIVISION", 46, 63], ["airway mucus", "TISSUE", 74, 86], ["cellular debris", "CELLULAR_COMPONENT", 88, 103], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["airway", "MULTI-TISSUE_STRUCTURE", 269, 275], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["degraded proteins", "PROTEIN", 114, 131], ["Sputum", "TEST", 0, 6], ["airway mucus", "PROBLEM", 74, 86], ["cellular debris", "PROBLEM", 88, 103], ["DNA", "PROBLEM", 105, 108], ["degraded proteins", "PROBLEM", 114, 131], ["eukaryotic viruses", "PROBLEM", 181, 199], ["airway DNA viral communities", "PROBLEM", 269, 297], ["sputum samples", "TEST", 304, 318], ["both cystic fibrosis", "PROBLEM", 324, 344], ["Non-cystic fibrosis", "PROBLEM", 349, 368], ["mild asthma", "PROBLEM", 460, 471], ["respiratory tract", "ANATOMY", 46, 63], ["airway", "ANATOMY", 74, 80], ["mucus", "OBSERVATION", 81, 86], ["cellular debris", "OBSERVATION", 88, 103], ["eukaryotic viruses", "OBSERVATION", 181, 199], ["airway", "ANATOMY", 269, 275], ["cystic", "OBSERVATION_MODIFIER", 329, 335], ["fibrosis", "OBSERVATION", 336, 344], ["Non-cystic", "OBSERVATION_MODIFIER", 349, 359], ["fibrosis", "OBSERVATION", 360, 368], ["mild", "OBSERVATION_MODIFIER", 460, 464], ["asthma", "OBSERVATION", 465, 471]]], ["Viral communities from Non-CF volunteers were characterized and compared to viromes of individuals with cystic fibrosis to determine if there is a core respiratory tract virome in non-diseased individuals.", [["communities", "ANATOMY", 6, 17], ["cystic", "ANATOMY", 104, 110], ["respiratory tract", "ANATOMY", 152, 169], ["cystic fibrosis", "DISEASE", 104, 119], ["respiratory tract virome", "DISEASE", 152, 176], ["volunteers", "ORGANISM", 30, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 152, 169], ["cystic fibrosis", "PROBLEM", 104, 119], ["a core respiratory tract virome in non-diseased individuals", "PROBLEM", 145, 204], ["cystic", "OBSERVATION_MODIFIER", 104, 110], ["fibrosis", "OBSERVATION", 111, 119], ["respiratory tract", "ANATOMY", 152, 169], ["non-diseased individuals", "OBSERVATION", 180, 204]]], ["Metabolic profiles inferred from metagenomic sequences were distinctly different between Non-CF and CF viromes.", [["Non-CF", "CANCER", 89, 95], ["Metabolic profiles", "TEST", 0, 18], ["metagenomic sequences", "TEST", 33, 54]]], ["Our results indicate that regardless of the presence or absence of shared taxa, a core set of metabolic functions defines the non-diseased and diseased respiratory tract DNA viromes.Phage taxonomy reflects airway pathology ::: Results and DiscussionIn all metagenomes, the majority of sequences (>90%) were unknown when compared to the non-redundant database using BLASTn (Table S1), which is comparable to the percentage of unknown sequences in other environmental viromes [9], [12], [28].", [["respiratory tract", "ANATOMY", 152, 169], ["airway", "ANATOMY", 206, 212], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["airway", "PATHOLOGICAL_FORMATION", 206, 212], ["the non-diseased and diseased respiratory tract DNA viromes", "PROBLEM", 122, 181], ["Phage taxonomy", "TEST", 182, 196], ["metabolic functions", "OBSERVATION", 94, 113], ["non-diseased", "OBSERVATION_MODIFIER", 126, 138], ["diseased", "OBSERVATION_MODIFIER", 143, 151], ["respiratory tract", "OBSERVATION", 152, 169], ["DNA viromes", "OBSERVATION", 170, 181], ["airway", "ANATOMY", 206, 212], ["pathology", "OBSERVATION", 213, 222]]], ["CF viromes had more tBLASTx similarities to phage genomes overall than Non-CF viromes, and were similar to a wider range of phage (Figure 1, Table S2).", [["tBLASTx", "GENE_OR_GENE_PRODUCT", 20, 27], ["tBLASTx", "PROTEIN", 20, 27], ["phage genomes", "DNA", 44, 57], ["CF viromes", "TEST", 0, 10], ["Non-CF viromes", "TEST", 71, 85], ["more tBLASTx", "OBSERVATION_MODIFIER", 15, 27]]], ["The tBLASTx analysis identified a core set of 19 phage genomes which had similarities to sequences in all metagenomes (Table S3).", [["tBLASTx", "DNA", 4, 11], ["19 phage genomes", "DNA", 46, 62], ["The tBLASTx analysis", "TEST", 0, 20], ["a core set of 19 phage genomes", "PROBLEM", 32, 62]]], ["This suggests a core set of phage characteristic of the human respiratory tract, and an additional core group in CF individuals.", [["respiratory tract", "ANATOMY", 62, 79], ["human", "ORGANISM", 56, 61], ["respiratory tract", "ORGANISM_SUBDIVISION", 62, 79], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["the human respiratory tract", "PROBLEM", 52, 79], ["phage", "OBSERVATION", 28, 33], ["respiratory tract", "ANATOMY", 62, 79]]], ["A few phage genomes appeared to dominated the Non-CF2, Non-CF3, and Non-CF5 viromes when tBLASTx similarities to phage genomes were plotted against the Phage Proteomic Tree (Figure 1).", [["Non-CF2", "GENE_OR_GENE_PRODUCT", 46, 53], ["Non-CF3", "GENE_OR_GENE_PRODUCT", 55, 62], ["Non-CF5", "GENE_OR_GENE_PRODUCT", 68, 75], ["phage genomes", "DNA", 6, 19], ["Non-CF2, Non-CF3, and Non-CF5 viromes", "DNA", 46, 83], ["tBLASTx", "PROTEIN", 89, 96], ["phage genomes", "DNA", 113, 126], ["A few phage genomes", "PROBLEM", 0, 19], ["the Non-CF2", "TEST", 42, 53], ["Non-CF3", "TEST", 55, 62], ["Non-CF5 viromes", "PROBLEM", 68, 83], ["tBLASTx similarities to phage genomes", "PROBLEM", 89, 126], ["few", "OBSERVATION_MODIFIER", 2, 5], ["phage genomes", "OBSERVATION", 6, 19]]], ["Over 90% of tBLASTx hits to phage in Non-CF2 were to Streptococcus phage Cp-1, and 80% of tBLASTx similaritites in Non-CF3 were attributable to two phage, Haemophilus influenza phage HP-1 and Brucella melitensis 16 M BrucI prophage.", [["tBLASTx", "GENE_OR_GENE_PRODUCT", 12, 19], ["Streptococcus phage", "ORGANISM", 53, 72], ["Cp-1", "GENE_OR_GENE_PRODUCT", 73, 77], ["tBLASTx", "GENE_OR_GENE_PRODUCT", 90, 97], ["Non-CF3", "CANCER", 115, 122], ["Haemophilus influenza phage HP-1", "ORGANISM", 155, 187], ["Brucella melitensis", "ORGANISM", 192, 211], ["tBLASTx hits", "DNA", 12, 24], ["Non-CF2", "DNA", 37, 44], ["tBLASTx similaritites", "DNA", 90, 111], ["Non-CF3", "DNA", 115, 122], ["BrucI prophage", "DNA", 217, 231], ["Streptococcus", "SPECIES", 53, 66], ["Haemophilus influenza phage", "SPECIES", 155, 182], ["Brucella melitensis", "SPECIES", 192, 211], ["Haemophilus influenza phage HP-1", "SPECIES", 155, 187], ["Brucella melitensis", "SPECIES", 192, 211], ["tBLASTx hits to phage", "PROBLEM", 12, 33], ["Non-CF2", "TEST", 37, 44], ["Streptococcus phage Cp", "TEST", 53, 75], ["tBLASTx similaritites in Non-CF3", "PROBLEM", 90, 122], ["Haemophilus influenza phage HP", "TEST", 155, 185], ["Brucella melitensis", "PROBLEM", 192, 211], ["BrucI prophage", "TREATMENT", 217, 231]]], ["The large relative abundance of these phage may reflect their prevalence in inhaled air, since environmental air has been shown to contain diverse bacterial communities [29].Phage taxonomy reflects airway pathology ::: Results and DiscussionThe phage profiles of Non-CF1Asthma and Non-CF4Spouse were more similar to those of CF individuals than to other Non-CF individuals.", [["airway", "ANATOMY", 198, 204], ["airway", "PATHOLOGICAL_FORMATION", 198, 204], ["Non-CF1Asthma", "GENE_OR_GENE_PRODUCT", 263, 276], ["Non-CF4Spouse", "GENE_OR_GENE_PRODUCT", 281, 294], ["Non-CF1Asthma", "PROTEIN", 263, 276], ["these phage", "TREATMENT", 32, 43], ["inhaled air", "PROBLEM", 76, 87], ["environmental air", "PROBLEM", 95, 112], ["diverse bacterial communities", "PROBLEM", 139, 168], ["Phage taxonomy", "TEST", 174, 188], ["large", "OBSERVATION_MODIFIER", 4, 9], ["relative", "OBSERVATION_MODIFIER", 10, 18], ["abundance", "OBSERVATION_MODIFIER", 19, 28], ["inhaled air", "OBSERVATION", 76, 87], ["diverse", "OBSERVATION_MODIFIER", 139, 146], ["bacterial", "OBSERVATION_MODIFIER", 147, 156], ["airway", "ANATOMY", 198, 204], ["pathology", "OBSERVATION", 205, 214]]], ["Non-CF1Asthma and Non-CF4Spouse had values for the first and second principal components which were nearly identical to those of the CF metagenomes.", [["Non-CF1Asthma", "GENE_OR_GENE_PRODUCT", 0, 13], ["Non-CF1Asthma", "PROTEIN", 0, 13], ["Non-CF4Spouse", "PROTEIN", 18, 31]]], ["The other Non-CF metagenomes had more random distribution of phage genotypes and did not appear to cluster on the PCA graph.", [["Non-CF metagenomes", "DNA", 10, 28], ["The other Non-CF metagenomes", "PROBLEM", 0, 28], ["phage genotypes", "PROBLEM", 61, 76]]], ["More specifically, Non-CF2, NonCF3, and Non-CF5 all had positive values for the first principal component (0.40, 0.42, and 0.27 respectively) while all other metagenomes had negative values.", [["Non-CF2", "GENE_OR_GENE_PRODUCT", 19, 26], ["NonCF3", "GENE_OR_GENE_PRODUCT", 28, 34], ["Non-CF5", "GENE_OR_GENE_PRODUCT", 40, 47], ["Non-CF2", "PROTEIN", 19, 26], ["NonCF3", "PROTEIN", 28, 34], ["Non-CF5", "PROTEIN", 40, 47], ["Non-CF2", "TEST", 19, 26], ["NonCF3", "TEST", 28, 34], ["Non-CF5", "TEST", 40, 47], ["positive", "OBSERVATION", 56, 64], ["negative", "OBSERVATION", 174, 182]]], ["This was driven by a large positive loading of the first principal component by the Streptococcus phage Cp-1, which segregated Non-CF2, and negative loadings on the set of phage genomes shared by Non-CF1Asthma, Non-CF4Spouse and the CF metagenomes.", [["Cp-1", "GENE_OR_GENE_PRODUCT", 104, 108], ["Non-CF2", "GENE_OR_GENE_PRODUCT", 127, 134], ["Non-CF1Asthma", "GENE_OR_GENE_PRODUCT", 196, 209], ["Streptococcus phage Cp-1", "DNA", 84, 108], ["Non-CF2", "DNA", 127, 134], ["phage genomes", "DNA", 172, 185], ["Non-CF1Asthma, Non-CF4Spouse and the CF metagenomes", "DNA", 196, 247], ["the Streptococcus phage Cp", "TEST", 80, 106], ["large", "OBSERVATION_MODIFIER", 21, 26], ["positive loading", "OBSERVATION_MODIFIER", 27, 43], ["Streptococcus phage", "OBSERVATION", 84, 103]]], ["Additionally, the second principal component was positively loaded by the Brucella melitensis 16 M phi Bruc1 prophage genome which was nearly absent in Non-CF2, giving a negative value of the second principal component for Non-CF2.Phage taxonomy reflects airway pathology ::: Results and DiscussionThese results indicate that the sputum phage community in Non-CF individuals appears to represent a random, transient sampling of the exterior environment.", [["airway", "ANATOMY", 255, 261], ["Brucella melitensis", "ORGANISM", 74, 93], ["airway", "PATHOLOGICAL_FORMATION", 255, 261], ["Bruc1 prophage genome", "DNA", 103, 124], ["Non-CF2", "CELL_LINE", 152, 159], ["Non-CF2", "PROTEIN", 223, 230], ["Brucella melitensis", "SPECIES", 74, 93], ["Brucella melitensis", "SPECIES", 74, 93], ["the Brucella melitensis", "PROBLEM", 70, 93], ["phi Bruc1 prophage genome", "TREATMENT", 99, 124], ["Phage taxonomy", "TEST", 231, 245], ["the sputum phage", "PROBLEM", 326, 342], ["Brucella melitensis", "OBSERVATION", 74, 93], ["negative", "OBSERVATION", 170, 178], ["airway", "ANATOMY", 255, 261], ["pathology", "OBSERVATION", 262, 271], ["appears to represent", "UNCERTAINTY", 375, 395]]], ["In CF individuals, phage communities are driven by airway pathology, and correspond to a shared internal respiratory environment.", [["airway", "ANATOMY", 51, 57], ["respiratory", "ANATOMY", 105, 116], ["airway", "MULTI-TISSUE_STRUCTURE", 51, 57], ["a shared internal respiratory environment", "PROBLEM", 87, 128], ["airway", "ANATOMY", 51, 57], ["pathology", "OBSERVATION", 58, 67], ["respiratory environment", "OBSERVATION", 105, 128]]], ["The phage community in the Non-CF4Spouse virome reflects a continuous sampling of CF-associated phage via a shared external environment.", [["community", "ANATOMY", 10, 19], ["a continuous sampling of CF", "TREATMENT", 57, 84], ["phage", "OBSERVATION_MODIFIER", 4, 9], ["community", "OBSERVATION_MODIFIER", 10, 19]]], ["Common phage taxonomy in CF individuals and Non-CF1Asthma occurs because of shared respiratory pathology (i.e., similar internal environments).", [["respiratory", "ANATOMY", 83, 94], ["shared respiratory pathology", "PROBLEM", 76, 104], ["respiratory", "ANATOMY", 83, 94], ["pathology", "OBSERVATION", 95, 104]]], ["Both CF and asthma are conditions marked by impaired mucociliary clearance (MCC) [2], [25], [30].", [["mucociliary", "ANATOMY", 53, 64], ["CF", "DISEASE", 5, 7], ["asthma", "DISEASE", 12, 18], ["mucociliary", "ORGAN", 53, 64], ["asthma", "PROBLEM", 12, 18], ["impaired mucociliary clearance", "PROBLEM", 44, 74], ["CF", "OBSERVATION", 5, 7], ["asthma", "OBSERVATION", 12, 18], ["marked", "OBSERVATION_MODIFIER", 34, 40], ["impaired", "OBSERVATION_MODIFIER", 44, 52], ["mucociliary clearance", "OBSERVATION", 53, 74]]], ["MCC is slowed in asthma, leading to increased retention of microbes and hence their phage [30].", [["MCC", "DISEASE", 0, 3], ["asthma", "DISEASE", 17, 23], ["MCC", "CANCER", 0, 3], ["MCC", "PROBLEM", 0, 3], ["asthma", "PROBLEM", 17, 23], ["increased retention of microbes", "PROBLEM", 36, 67], ["slowed", "OBSERVATION_MODIFIER", 7, 13], ["asthma", "OBSERVATION", 17, 23], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["retention", "OBSERVATION_MODIFIER", 46, 55]]], ["In CF, mucus is extremely viscous and stagnant, forming obstructive plugs, and creating hypoxic microenvironments that serve as scaffolds for bacterial biofilm formation [2], [25].", [["mucus", "ANATOMY", 7, 12], ["biofilm", "ANATOMY", 152, 159], ["mucus", "ORGANISM_SUBSTANCE", 7, 12], ["[25]", "SIMPLE_CHEMICAL", 175, 179], ["extremely viscous", "PROBLEM", 16, 33], ["forming obstructive plugs", "PROBLEM", 48, 73], ["creating hypoxic microenvironments", "PROBLEM", 79, 113], ["bacterial biofilm formation", "PROBLEM", 142, 169], ["mucus", "OBSERVATION", 7, 12], ["extremely", "OBSERVATION_MODIFIER", 16, 25], ["viscous", "OBSERVATION_MODIFIER", 26, 33], ["stagnant", "OBSERVATION_MODIFIER", 38, 46], ["obstructive", "OBSERVATION_MODIFIER", 56, 67], ["plugs", "OBSERVATION", 68, 73], ["hypoxic microenvironments", "OBSERVATION", 88, 113]]], ["Therefore, in both asthma and CF, phage communities are derived from microbes which persist in the airways for longer periods of time than in healthy individuals.Inferred host ranges for respiratory tract phage ::: Results and DiscussionThe putative microbial host range of respiratory tract phage reflected a few dominant but distinct phage in Non-CF2, Non-CF3, and Non-CF5 (Figure 3).Host ranges of Non-CF1Asthma and Non-CF4Spouse were highly similar to those of the CF phage communities, but were under-represented in Streptococcus and Staphylococcus phage.", [["communities", "ANATOMY", 40, 51], ["airways", "ANATOMY", 99, 106], ["communities", "ANATOMY", 478, 489], ["asthma", "DISEASE", 19, 25], ["CF", "DISEASE", 30, 32], ["airways", "MULTI-TISSUE_STRUCTURE", 99, 106], ["Non-CF1Asthma", "GENE_OR_GENE_PRODUCT", 401, 414], ["Non-CF4Spouse", "GENE_OR_GENE_PRODUCT", 419, 432], ["Staphylococcus phage", "ORGANISM", 539, 559], ["Non-CF1Asthma", "PROTEIN", 401, 414], ["Staphylococcus phage", "SPECIES", 539, 559], ["both asthma and CF", "PROBLEM", 14, 32], ["respiratory tract phage", "PROBLEM", 274, 297], ["Streptococcus", "PROBLEM", 521, 534], ["Staphylococcus phage", "PROBLEM", 539, 559], ["both", "OBSERVATION_MODIFIER", 14, 18], ["asthma", "OBSERVATION", 19, 25], ["airways", "ANATOMY", 99, 106], ["host ranges", "OBSERVATION", 171, 182], ["respiratory tract", "ANATOMY", 274, 291], ["few", "OBSERVATION_MODIFIER", 310, 313], ["dominant", "OBSERVATION", 314, 322], ["distinct", "OBSERVATION_MODIFIER", 327, 335], ["phage", "OBSERVATION", 336, 341], ["ranges", "OBSERVATION_MODIFIER", 391, 397], ["Staphylococcus phage", "OBSERVATION", 539, 559]]], ["The higher abundance of Staphylococcus phage in CF is consistent with the increased induction of Staphylococcus prophage by antibiotics in CF individuals, as shown by previous studies [31].", [["Staphylococcus phage", "ORGANISM", 24, 44], ["CF", "PATHOLOGICAL_FORMATION", 48, 50], ["Staphylococcus phage", "SPECIES", 24, 44], ["Staphylococcus phage in CF", "PROBLEM", 24, 50], ["Staphylococcus prophage", "TREATMENT", 97, 120], ["antibiotics", "TREATMENT", 124, 135], ["previous studies", "TEST", 167, 183], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["abundance", "OBSERVATION_MODIFIER", 11, 20], ["Staphylococcus phage", "OBSERVATION", 24, 44], ["consistent with", "UNCERTAINTY", 54, 69], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["Staphylococcus prophage", "OBSERVATION", 97, 120]]], ["P. aeruginosa was cultured from the sputum of all CF participants, yet Pseudomonas phage were not abundant in the metagenomes.", [["sputum", "ANATOMY", 36, 42], ["P. aeruginosa", "ORGANISM", 0, 13], ["P. aeruginosa", "SPECIES", 0, 13], ["participants", "SPECIES", 53, 65], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa", "PROBLEM", 0, 13], ["the sputum", "TEST", 32, 42], ["Pseudomonas phage", "PROBLEM", 71, 88]]], ["Pseudomonas phage may be of novel types not closely related to those in the database, making them undetectable by tBLASTx.", [["Pseudomonas phage", "ORGANISM", 0, 17], ["tBLASTx", "PROTEIN", 114, 121], ["Pseudomonas phage", "PROBLEM", 0, 17], ["novel types", "PROBLEM", 28, 39]]], ["Even if known phage are present, infections of Pseudomonas in CF may be unsuccessful, since phage may not be able to penetrate the biofilm to access susceptible microbial hosts [32].", [["biofilm", "ANATOMY", 131, 138], ["infections", "DISEASE", 33, 43], ["known phage", "PROBLEM", 8, 19], ["Pseudomonas in CF", "PROBLEM", 47, 64], ["phage", "TREATMENT", 92, 97], ["Pseudomonas", "OBSERVATION", 47, 58]]], ["Alternatively, P. aeruginosa may not be as abundant in the CF airway as indicated by culturing, an idea supported by 16S rDNA and Terminal Restriction Fragment Polymorphism (T-RFLP) analysis of bacteria in CF sputum and bronchoalveolar lavage fluid [33]\u2013[35].", [["CF airway", "ANATOMY", 59, 68], ["CF sputum", "ANATOMY", 206, 215], ["bronchoalveolar lavage fluid", "ANATOMY", 220, 248], ["P. aeruginosa", "ORGANISM", 15, 28], ["CF airway", "MULTI-TISSUE_STRUCTURE", 59, 68], ["rDNA", "CELLULAR_COMPONENT", 121, 125], ["CF sputum", "ORGANISM_SUBSTANCE", 206, 215], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 220, 242], ["16S rDNA", "DNA", 117, 125], ["P. aeruginosa", "SPECIES", 15, 28], ["P. aeruginosa", "SPECIES", 15, 28], ["P. aeruginosa", "PROBLEM", 15, 28], ["culturing", "TEST", 85, 94], ["Terminal Restriction Fragment Polymorphism", "PROBLEM", 130, 172], ["bacteria in CF sputum", "TEST", 194, 215], ["bronchoalveolar lavage fluid", "TEST", 220, 248], ["airway", "ANATOMY", 62, 68], ["Terminal", "OBSERVATION_MODIFIER", 130, 138], ["Restriction", "OBSERVATION_MODIFIER", 139, 150], ["Fragment", "OBSERVATION_MODIFIER", 151, 159], ["bronchoalveolar lavage", "OBSERVATION", 220, 242]]], ["T-RFLP uses fluorescently labeled 5\u2032 PCR primers coupled with restriction digests to allow for rapid profiling of unknown microbial communities, providing a less biased picture of microbial diversity than culture-based studies [35].Diversity of respiratory tract viruses ::: Results and DiscussionThere were approximately 175 unique species of DNA viruses in respiratory tract viral communities (Table 1).", [["communities", "ANATOMY", 132, 143], ["respiratory tract", "ANATOMY", 245, 262], ["respiratory tract viruses", "DISEASE", 245, 270], ["respiratory tract", "ORGANISM_SUBDIVISION", 245, 262], ["DNA", "CELLULAR_COMPONENT", 344, 347], ["RFLP", "DNA", 2, 6], ["PCR primers", "DNA", 37, 48], ["PCR primers", "TEST", 37, 48], ["restriction digests", "TREATMENT", 62, 81], ["culture", "TEST", 205, 212], ["DNA viruses", "PROBLEM", 344, 355], ["respiratory tract", "ANATOMY", 245, 262], ["respiratory tract", "ANATOMY", 359, 376]]], ["There were no significant differences in the estimated number of species between CF and Non-CF viromes.", [["significant differences", "PROBLEM", 14, 37], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Diversity estimates were based on sequence assemblies and PHACCs, so all metagenomic sequences were used, not just those with BLAST similarities to viral databases [36].", [["PHACCs", "DNA", 58, 64], ["metagenomic sequences", "DNA", 73, 94], ["Diversity estimates", "TEST", 0, 19], ["sequence assemblies", "TEST", 34, 53], ["PHACCs", "TEST", 58, 64], ["all metagenomic sequences", "TEST", 69, 94], ["viral databases", "TEST", 148, 163]]], ["The estimated number of DNA viral species has been reported to be as low as 1440 in hot springs, and as high as 129,000 in the open ocean [9], [37].", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["DNA viral species", "PROBLEM", 24, 41], ["number", "OBSERVATION_MODIFIER", 14, 20], ["DNA viral species", "OBSERVATION", 24, 41]]], ["In comparison with other environmental viromes, the respiratory tract viromes had low species richness.", [["respiratory tract", "ANATOMY", 52, 69], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["the respiratory tract viromes", "PROBLEM", 48, 77], ["low species richness", "PROBLEM", 82, 102], ["respiratory tract", "ANATOMY", 52, 69], ["low species", "OBSERVATION", 82, 93]]], ["Similarly, Rogers et al. [34] found low diversity of Bacteria in CF sputum using T-RFLP analysis.", [["CF sputum", "ANATOMY", 65, 74], ["Bacteria", "CELL", 53, 61], ["low diversity of Bacteria in CF sputum", "PROBLEM", 36, 74], ["T-RFLP analysis", "TEST", 81, 96], ["low diversity", "OBSERVATION_MODIFIER", 36, 49], ["Bacteria", "OBSERVATION_MODIFIER", 53, 61]]], ["Low species richness probably results from physical and biological barriers to microbial and viral persistence, including both MCC as well as innate and adaptive immunity [2], [38].", [["MCC", "CANCER", 127, 130], ["Low species richness", "PROBLEM", 0, 20], ["viral persistence", "PROBLEM", 93, 110]]], ["Richness may be further depressed in CF individuals because of antibiotic therapies and the metabolic adaptations required for microbial and viral survival in the unique microenvironment of the CF airway [26], [27].Diversity of respiratory tract viruses ::: Results and DiscussionCross-BLASTn analysis showed that CF viromes shared more sequences with each other than Non-CF viromes.", [["CF airway", "ANATOMY", 194, 203], ["respiratory tract", "ANATOMY", 228, 245], ["Richness", "DISEASE", 0, 8], ["depressed", "DISEASE", 24, 33], ["respiratory tract viruses", "DISEASE", 228, 253], ["respiratory tract", "ORGANISM_SUBDIVISION", 228, 245], ["CF viromes", "DNA", 314, 324], ["Non-CF viromes", "DNA", 368, 382], ["further depressed in CF individuals", "PROBLEM", 16, 51], ["antibiotic therapies", "TREATMENT", 63, 83], ["microbial and viral survival", "TREATMENT", 127, 155], ["BLASTn analysis", "TEST", 286, 301], ["CF viromes", "PROBLEM", 314, 324], ["Non-CF viromes", "PROBLEM", 368, 382], ["airway", "ANATOMY", 197, 203], ["respiratory tract", "ANATOMY", 228, 245]]], ["Sequences from each metagenome were compared pairwise to all other metagenomes using BLASTn to identify shared sequences as explained in Methods[39].", [["Sequences from each metagenome", "TEST", 0, 30]]], ["The majority of the common CF sequences were not found in any Non-CF metagneomes.", [["common CF sequences", "DNA", 20, 39], ["the common CF sequences", "TEST", 16, 39]]], ["Sequential BLAST analysis identified 31,413 sequences common to all CF viromes, and 12,824 of these did not appear in any of the Non-CF viromes.", [["Non-CF viromes", "DNA", 129, 143], ["Sequential BLAST analysis", "TEST", 0, 25], ["all CF viromes", "TEST", 64, 78], ["Non-CF", "OBSERVATION", 129, 135]]], ["Non-CF viromes shared 11,995 sequences, and 330 could not be found in any CF virome.", [["11,995 sequences", "DNA", 22, 38], ["Non-CF viromes", "TEST", 0, 14]]], ["Both the larger group of shared and unique sequences in CF metagenomes suggests that CF viral communities are more similar than Non-CF communities.Taxonomy of eukaryotic viruses ::: Results and DiscussionEukaryotic DNA viral communities in CF individuals were dominated by a few viral genomes which were highly variable in their abundances.", [["DNA", "CELLULAR_COMPONENT", 215, 218], ["viral genomes", "DNA", 279, 292], ["unique sequences in CF metagenomes", "TEST", 36, 70], ["CF viral communities", "PROBLEM", 85, 105], ["Eukaryotic DNA viral communities in CF individuals", "PROBLEM", 204, 254], ["a few viral genomes", "PROBLEM", 273, 292], ["larger", "OBSERVATION_MODIFIER", 9, 15], ["eukaryotic viruses", "OBSERVATION", 159, 177], ["few", "OBSERVATION_MODIFIER", 275, 278], ["viral genomes", "OBSERVATION", 279, 292]]], ["Non-CF individuals shared numerous eukaryotic viruses with more even abundances, suggestive of a core virome (Figure 4A).", [["Non-CF individuals", "PROBLEM", 0, 18], ["numerous eukaryotic viruses", "PROBLEM", 26, 53], ["numerous", "OBSERVATION_MODIFIER", 26, 34], ["eukaryotic viruses", "OBSERVATION", 35, 53], ["suggestive of", "UNCERTAINTY", 81, 94], ["core", "OBSERVATION_MODIFIER", 97, 101], ["virome", "OBSERVATION", 102, 108]]], ["All CF metagenomes had similarities (>1%) to Reticuloendotheliosis virus (Figure S1) and other retro-transcribing viruses (Figure 4B).", [["Reticuloendotheliosis virus", "ORGANISM", 45, 72], ["Reticuloendotheliosis virus", "SPECIES", 45, 72], ["All CF metagenomes", "TEST", 0, 18], ["Reticuloendotheliosis virus", "PROBLEM", 45, 72], ["other retro-transcribing viruses", "PROBLEM", 89, 121], ["Reticuloendotheliosis virus", "OBSERVATION", 45, 72]]], ["We confirmed bioinformatically that similarities to retroviruses were not actually similarities to the human genome, therefore, we assume that retroviruses must have been present in the metagenomes as DNA intermediates. indicating that retroviruses may establish persistent infections in the airways, and could be useful therapeutic vectors for CF as previously suggested [40].", [["airways", "ANATOMY", 292, 299], ["infections", "DISEASE", 274, 284], ["CF", "DISEASE", 345, 347], ["retroviruses", "ORGANISM", 52, 64], ["human", "ORGANISM", 103, 108], ["retroviruses", "ORGANISM", 143, 155], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["retroviruses", "ORGANISM", 236, 248], ["airways", "MULTI-TISSUE_STRUCTURE", 292, 299], ["human genome", "DNA", 103, 115], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["retroviruses", "PROBLEM", 236, 248], ["persistent infections in the airways", "PROBLEM", 263, 299], ["therapeutic vectors", "TREATMENT", 321, 340], ["CF", "PROBLEM", 345, 347], ["human genome", "OBSERVATION", 103, 115], ["retroviruses", "OBSERVATION", 143, 155], ["retroviruses", "OBSERVATION", 236, 248], ["persistent", "OBSERVATION_MODIFIER", 263, 273], ["infections", "OBSERVATION", 274, 284], ["airways", "ANATOMY", 292, 299]]], ["CF viromes also shared several human herpesviruses (HHV) including Epstein-Barr virus (HHV-4), HHV-6B, and HHV-8P.", [["human", "ORGANISM", 31, 36], ["HHV", "GENE_OR_GENE_PRODUCT", 52, 55], ["Epstein-Barr virus", "ORGANISM", 67, 85], ["HHV-4", "ORGANISM", 87, 92], ["HHV-6B", "ORGANISM", 95, 101], ["HHV-8P.", "ORGANISM", 107, 114], ["human", "SPECIES", 31, 36], ["Barr virus", "SPECIES", 75, 85], ["human herpesviruses", "SPECIES", 31, 50], ["HHV", "SPECIES", 52, 55], ["Epstein-Barr virus", "SPECIES", 67, 85], ["HHV-6B", "SPECIES", 95, 101], ["HHV-8P.", "SPECIES", 107, 114], ["several human herpesviruses", "PROBLEM", 23, 50], ["HHV", "PROBLEM", 52, 55], ["Epstein-Barr virus", "PROBLEM", 67, 85], ["HHV", "TEST", 87, 90], ["HHV", "TEST", 95, 98], ["HHV", "PROBLEM", 107, 110], ["several", "OBSERVATION_MODIFIER", 23, 30], ["human herpesviruses", "OBSERVATION_MODIFIER", 31, 50], ["Barr virus", "OBSERVATION", 75, 85]]], ["Infection with Epstein-Barr virus in adolescent CF patients has been linked to exacerbations and poor clinical outcomes, and has also been observed in adults [41].Taxonomy of eukaryotic viruses ::: Results and DiscussionCF2 and CF4 had many similarities to Geminiviruses and Nanoviruses, single-stranded DNA viruses of plants (Figure 4B).", [["Epstein-Barr virus", "DISEASE", 15, 33], ["CF", "DISEASE", 48, 50], ["Epstein-Barr virus", "ORGANISM", 15, 33], ["patients", "ORGANISM", 51, 59], ["CF4", "GENE_OR_GENE_PRODUCT", 228, 231], ["DNA", "CELLULAR_COMPONENT", 304, 307], ["CF4", "DNA", 228, 231], ["patients", "SPECIES", 51, 59], ["Epstein-Barr virus", "SPECIES", 15, 33], ["Infection", "PROBLEM", 0, 9], ["Epstein-Barr virus", "PROBLEM", 15, 33], ["exacerbations", "PROBLEM", 79, 92], ["Geminiviruses", "TREATMENT", 257, 270], ["Nanoviruses", "TREATMENT", 275, 286], ["Barr virus", "OBSERVATION", 23, 33], ["eukaryotic viruses", "OBSERVATION", 175, 193], ["Geminiviruses", "OBSERVATION", 257, 270]]], ["However, these similarities were concentrated at one location in the genome, the coding sequence for the replication initiator (Rep) protein.", [["Rep", "GENE_OR_GENE_PRODUCT", 128, 131], ["replication initiator (Rep) protein", "PROTEIN", 105, 140], ["the replication initiator (Rep) protein", "TREATMENT", 101, 140], ["concentrated", "OBSERVATION_MODIFIER", 33, 45]]], ["Specifically, they were localized to the WalkerA and WalkerB motifs of Rep which correspond to an ATP-binding domain in the translated protein [42].", [["ATP", "CHEMICAL", 98, 101], ["ATP", "CHEMICAL", 98, 101], ["WalkerA", "GENE_OR_GENE_PRODUCT", 41, 48], ["Rep", "GENE_OR_GENE_PRODUCT", 71, 74], ["ATP", "SIMPLE_CHEMICAL", 98, 101], ["WalkerA and WalkerB motifs", "DNA", 41, 67], ["Rep", "PROTEIN", 71, 74], ["ATP-binding domain", "PROTEIN", 98, 116], ["an ATP-binding domain", "PROBLEM", 95, 116]]], ["ATP-binding motifs are common to Rep proteins from a variety of viruses, including Geminiviruses, Nanoviruses, Circoviruses, Parvoviruses, and phage [42].", [["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["Rep", "GENE_OR_GENE_PRODUCT", 33, 36], ["Geminiviruses", "GENE_OR_GENE_PRODUCT", 83, 96], ["Circoviruses", "GENE_OR_GENE_PRODUCT", 111, 123], ["ATP-binding motifs", "PROTEIN", 0, 18], ["Rep proteins", "PROTEIN", 33, 45], ["ATP-binding motifs", "PROBLEM", 0, 18], ["Rep proteins", "PROBLEM", 33, 45], ["a variety of viruses", "PROBLEM", 51, 71], ["Geminiviruses", "TREATMENT", 83, 96], ["Nanoviruses", "TREATMENT", 98, 109], ["Circoviruses", "TREATMENT", 111, 123], ["Parvoviruses", "PROBLEM", 125, 137], ["viruses", "OBSERVATION", 64, 71]]], ["Therefore, tBLASTx similarities to specific Rep motifs indicate the presence of a virus, but not specifically a Gemini- or Nanovirus.Taxonomy of eukaryotic viruses ::: Results and DiscussionNon-CF viromes had similarities to fewer unique viral genomes, that is, there were fewer genomes with tBLASTx hits only in one virome (Table S4).", [["Rep", "GENE_OR_GENE_PRODUCT", 44, 47], ["Gemini", "GENE_OR_GENE_PRODUCT", 112, 118], ["tBLASTx", "PROTEIN", 11, 18], ["Rep motifs", "DNA", 44, 54], ["viral genomes", "DNA", 238, 251], ["tBLASTx hits", "DNA", 292, 304], ["tBLASTx", "TREATMENT", 11, 18], ["a virus", "PROBLEM", 80, 87], ["Nanovirus", "PROBLEM", 123, 132], ["fewer unique viral genomes", "PROBLEM", 225, 251], ["tBLASTx hits", "PROBLEM", 292, 304], ["virus", "OBSERVATION", 82, 87], ["eukaryotic viruses", "OBSERVATION", 145, 163], ["viral genomes", "OBSERVATION", 238, 251]]], ["Non-CF3 had significant similarities to a Geminivirus, but all hits were to the WalkerA and Walker B motifs of the Rep protein.", [["Non-CF3", "GENE_OR_GENE_PRODUCT", 0, 7], ["Walker B", "GENE_OR_GENE_PRODUCT", 92, 100], ["Rep", "GENE_OR_GENE_PRODUCT", 115, 118], ["Non-CF3", "PROTEIN", 0, 7], ["WalkerA and Walker B motifs", "DNA", 80, 107], ["Rep protein", "PROTEIN", 115, 126], ["a Geminivirus", "PROBLEM", 40, 53], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["Geminivirus", "OBSERVATION", 42, 53]]], ["Human papillomavirus Type 34 comprised over 5% of tBLASTx hits in both Non-CF2 and Non-CF5, and Non-CF2 also had many similarities to Human papillomavirus type 71.", [["Human papillomavirus type", "DISEASE", 134, 159], ["Human papillomavirus Type 34", "ORGANISM", 0, 28], ["tBLASTx", "GENE_OR_GENE_PRODUCT", 50, 57], ["Non-CF2", "GENE_OR_GENE_PRODUCT", 71, 78], ["Non-CF5", "GENE_OR_GENE_PRODUCT", 83, 90], ["Non-CF2", "GENE_OR_GENE_PRODUCT", 96, 103], ["Human papillomavirus type 71", "ORGANISM", 134, 162], ["tBLASTx hits", "DNA", 50, 62], ["Non-CF2", "DNA", 71, 78], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 134, 139], ["Human papillomavirus Type 34", "SPECIES", 0, 28], ["Human papillomavirus type 71", "SPECIES", 134, 162], ["tBLASTx hits", "PROBLEM", 50, 62], ["Human papillomavirus type", "TEST", 134, 159]]], ["Human papillomaviruses have been been detected previously in the respiratory tract and are commonly found in tumors in the lungs and the oropharynx [43]\u2013[45].Taxonomy of eukaryotic viruses ::: Results and DiscussionThe majority of viral species found in Non-CF viromes were from a core set of 20 viral genomes, which were shared by all metagenomes (Table S5; Figure S2).", [["respiratory tract", "ANATOMY", 65, 82], ["tumors", "ANATOMY", 109, 115], ["lungs", "ANATOMY", 123, 128], ["oropharynx", "ANATOMY", 137, 147], ["Human papillomaviruses", "DISEASE", 0, 22], ["tumors", "DISEASE", 109, 115], ["Human", "ORGANISM", 0, 5], ["papillomaviruses", "ORGANISM", 6, 22], ["respiratory tract", "ORGAN", 65, 82], ["tumors", "CANCER", 109, 115], ["lungs", "ORGAN", 123, 128], ["oropharynx", "ORGAN", 137, 147], ["Non-CF viromes", "CANCER", 254, 268], ["viral genomes", "DNA", 296, 309], ["Human", "SPECIES", 0, 5], ["Human papillomaviruses", "SPECIES", 0, 22], ["Human papillomaviruses", "PROBLEM", 0, 22], ["viral species", "PROBLEM", 231, 244], ["Non-CF viromes", "PROBLEM", 254, 268], ["20 viral genomes", "PROBLEM", 293, 309], ["papillomaviruses", "OBSERVATION", 6, 22], ["respiratory tract", "ANATOMY", 65, 82], ["tumors", "OBSERVATION", 109, 115], ["lungs", "ANATOMY", 123, 128], ["oropharynx", "ANATOMY", 137, 147], ["eukaryotic viruses", "OBSERVATION", 170, 188], ["viral species", "OBSERVATION", 231, 244], ["viral genomes", "OBSERVATION", 296, 309]]], ["These included a mammalian adenovirus (Bovine adenovirus A), eight mammalian herpesviruses, and three poxviruses.", [["mammalian herpesviruses", "DISEASE", 67, 90], ["adenovirus", "ORGANISM", 27, 37], ["Bovine adenovirus A", "ORGANISM", 39, 58], ["Bovine", "SPECIES", 39, 45], ["Bovine adenovirus A", "SPECIES", 39, 58], ["a mammalian adenovirus (Bovine adenovirus A", "TREATMENT", 15, 58], ["eight mammalian herpesviruses", "PROBLEM", 61, 90], ["mammalian adenovirus", "OBSERVATION", 17, 37], ["mammalian herpesviruses", "OBSERVATION", 67, 90]]], ["Adenoviruses and herpesviruses have been detected in the airways of both CF and Non-CF individuals, and tBLASTx similarities to non-human viruses represent related undiscovered human variants [8].", [["airways", "ANATOMY", 57, 64], ["herpesviruses", "ORGANISM", 17, 30], ["airways", "MULTI-TISSUE_STRUCTURE", 57, 64], ["tBLASTx", "GENE_OR_GENE_PRODUCT", 104, 111], ["non-human viruses", "ORGANISM", 128, 145], ["human", "ORGANISM", 177, 182], ["human", "SPECIES", 177, 182], ["non-human viruses", "SPECIES", 128, 145], ["human", "SPECIES", 177, 182], ["Adenoviruses", "PROBLEM", 0, 12], ["herpesviruses", "PROBLEM", 17, 30], ["Non-CF individuals", "PROBLEM", 80, 98], ["tBLASTx similarities to non-human viruses", "PROBLEM", 104, 145], ["undiscovered human variants", "PROBLEM", 164, 191], ["airways", "ANATOMY", 57, 64], ["both", "ANATOMY_MODIFIER", 68, 72], ["CF", "ANATOMY", 73, 75], ["Non-CF", "OBSERVATION", 80, 86], ["human variants", "OBSERVATION", 177, 191]]], ["Several other viruses, such as algal and insect viruses, were shared among all metagenomes, but similarities to these viruses were largely concentrated in one area of the genome.", [["insect viruses", "ORGANISM", 41, 55], ["Several other viruses", "PROBLEM", 0, 21], ["algal and insect viruses", "PROBLEM", 31, 55], ["these viruses", "PROBLEM", 112, 125], ["viruses", "OBSERVATION", 14, 21], ["viruses", "OBSERVATION", 118, 125], ["concentrated", "OBSERVATION_MODIFIER", 139, 151], ["genome", "OBSERVATION", 171, 177]]], ["Since metagenomics allows direct sequencing of environmental DNA, metagenomic techniques often isolate novel viruses and microbes.", [["DNA", "CELLULAR_COMPONENT", 61, 64], ["environmental DNA", "TREATMENT", 47, 64], ["metagenomic techniques", "TREATMENT", 66, 88]]], ["The hallmark of a novel viral genotype is a large concentration of sequences in one discrete region of a previously sequenced genome.", [["genome", "CELLULAR_COMPONENT", 126, 132], ["a novel viral genotype", "PROBLEM", 16, 38], ["a previously sequenced genome", "PROBLEM", 103, 132], ["hallmark", "OBSERVATION_MODIFIER", 4, 12], ["viral genotype", "OBSERVATION", 24, 38], ["large", "OBSERVATION_MODIFIER", 44, 49], ["one discrete", "OBSERVATION_MODIFIER", 80, 92], ["sequenced genome", "OBSERVATION", 116, 132]]], ["Therefore, these results suggest the presence of a novel virus common to all individuals which cannot be identified using database similarities, analogous to viruses detected in human blood [15].Taxonomy of eukaryotic viruses ::: Results and DiscussionDifferences in eukaryotic DNA viral communities in CF versus Non-CF individuals were confirmed by PCA (Figure 5).", [["blood", "ANATOMY", 184, 189], ["human", "ORGANISM", 178, 183], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["DNA", "CELLULAR_COMPONENT", 278, 281], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["a novel virus", "PROBLEM", 49, 62], ["Non-CF individuals", "PROBLEM", 313, 331], ["eukaryotic viruses", "OBSERVATION", 207, 225]]], ["Non-CF viromes all had nearly identical values for the first and second principal components, resulting in a tight cluster on the graph.", [["Non-CF viromes", "TEST", 0, 14], ["a tight cluster on the graph", "PROBLEM", 107, 135], ["tight", "OBSERVATION_MODIFIER", 109, 114], ["cluster", "OBSERVATION_MODIFIER", 115, 122]]], ["This was largely driven by the general absence of ssDNA and Retro-transcribing viruses from Non-CF viromes (Figure 4A).", [["ssDNA", "CELLULAR_COMPONENT", 50, 55], ["ssDNA", "PROBLEM", 50, 55]]], ["Principal components for CF viromes were more variable, reflecting the tendency for CF viromes to have a small number (between one and four) of highly abundant viral species.", [["CF viromes", "PROBLEM", 25, 35], ["CF viromes", "PROBLEM", 84, 94], ["highly abundant viral species", "PROBLEM", 144, 173], ["small", "OBSERVATION_MODIFIER", 105, 110], ["abundant", "OBSERVATION_MODIFIER", 151, 159], ["viral species", "OBSERVATION", 160, 173]]], ["Specifically, the outlying behavior of CF2 was driven by a high positive loading of the second principal component by the Geminivirus Sugarcane streak Egypt virus.", [["CF2", "CHEMICAL", 39, 42], ["CF2", "GENE_OR_GENE_PRODUCT", 39, 42], ["Geminivirus", "ORGANISM", 122, 133], ["Sugarcane streak Egypt virus", "ORGANISM", 134, 162], ["Egypt virus", "SPECIES", 151, 162], ["the outlying behavior of CF2", "PROBLEM", 14, 42], ["a high positive loading of the second principal component", "PROBLEM", 57, 114], ["the Geminivirus Sugarcane streak Egypt virus", "PROBLEM", 118, 162], ["Geminivirus", "OBSERVATION", 122, 133]]], ["CF4 did not cluster with other metagenomes due to a high negative loading of the first principal component by Reticuloendotheliosis virus.Taxonomy of eukaryotic viruses ::: Results and DiscussionIn Non-CF individuals, eukaryotic viral communities likely represent transient infections rapidly cleared by immune cells or viral particles being removed from the airway via MCC.", [["communities", "ANATOMY", 235, 246], ["immune cells", "ANATOMY", 304, 316], ["airway", "ANATOMY", 359, 365], ["MCC", "ANATOMY", 370, 373], ["infections", "DISEASE", 274, 284], ["CF4", "GENE_OR_GENE_PRODUCT", 0, 3], ["Reticuloendotheliosis virus", "ORGANISM", 110, 137], ["immune cells", "CELL", 304, 316], ["airway", "MULTI-TISSUE_STRUCTURE", 359, 365], ["MCC", "CANCER", 370, 373], ["CF4", "DNA", 0, 3], ["immune cells", "CELL_TYPE", 304, 316], ["Reticuloendotheliosis virus", "SPECIES", 110, 137], ["other metagenomes", "PROBLEM", 25, 42], ["Reticuloendotheliosis virus", "PROBLEM", 110, 137], ["eukaryotic viral communities", "PROBLEM", 218, 246], ["transient infections", "PROBLEM", 264, 284], ["immune cells", "PROBLEM", 304, 316], ["viral particles", "PROBLEM", 320, 335], ["Reticuloendotheliosis virus", "OBSERVATION", 110, 137], ["eukaryotic viruses", "OBSERVATION", 150, 168], ["viral communities", "OBSERVATION", 229, 246], ["transient", "OBSERVATION_MODIFIER", 264, 273], ["infections", "OBSERVATION", 274, 284], ["viral particles", "OBSERVATION", 320, 335], ["airway", "ANATOMY", 359, 365]]], ["In CF individuals, communities probably correspond to more persistent infections.", [["communities", "ANATOMY", 19, 30], ["infections", "DISEASE", 70, 80], ["more persistent infections", "PROBLEM", 54, 80], ["probably correspond to", "UNCERTAINTY", 31, 53], ["more", "OBSERVATION_MODIFIER", 54, 58], ["persistent", "OBSERVATION_MODIFIER", 59, 69], ["infections", "OBSERVATION", 70, 80]]], ["Viral replication is increased in the CF airway and synergism between persistent bacteria and incipient eukaryotic viruses pre-disposes CF individuals to acquiring viral infections [8].", [["CF airway", "ANATOMY", 38, 47], ["viral infections", "DISEASE", 164, 180], ["Viral", "ORGANISM", 0, 5], ["CF airway", "MULTI-TISSUE_STRUCTURE", 38, 47], ["Viral replication", "PROBLEM", 0, 17], ["synergism", "PROBLEM", 52, 61], ["persistent bacteria", "PROBLEM", 70, 89], ["incipient eukaryotic viruses", "PROBLEM", 94, 122], ["CF individuals", "PROBLEM", 136, 150], ["acquiring viral infections", "PROBLEM", 154, 180], ["replication", "OBSERVATION", 6, 17], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["airway", "ANATOMY", 41, 47], ["persistent", "OBSERVATION_MODIFIER", 70, 80], ["bacteria", "OBSERVATION", 81, 89], ["incipient", "OBSERVATION_MODIFIER", 94, 103], ["eukaryotic viruses", "OBSERVATION", 104, 122]]], ["This is in contrast to asthma, where the sequelae of viral infections are often severe in the lower respiratory tract, yet individuals are no more likely to acquire such infections [3].", [["lower respiratory tract", "ANATOMY", 94, 117], ["asthma", "DISEASE", 23, 29], ["viral infections", "DISEASE", 53, 69], ["infections", "DISEASE", 170, 180], ["lower", "ORGANISM_SUBDIVISION", 94, 99], ["respiratory tract", "ORGANISM_SUBDIVISION", 100, 117], ["individuals", "ORGANISM", 123, 134], ["asthma", "PROBLEM", 23, 29], ["viral infections", "PROBLEM", 53, 69], ["severe in the lower respiratory tract", "PROBLEM", 80, 117], ["such infections", "PROBLEM", 165, 180], ["asthma", "OBSERVATION", 23, 29], ["sequelae", "OBSERVATION_MODIFIER", 41, 49], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infections", "OBSERVATION", 59, 69], ["lower", "ANATOMY_MODIFIER", 94, 99], ["respiratory tract", "ANATOMY", 100, 117], ["no more likely", "UNCERTAINTY", 139, 153]]], ["It is difficult to distinguish clinical symptoms of viral infections from the typical respiratory distress associated with CF, so it is possible that CF individuals in this study could have had extant viral infections [8].Metabolic profiles of respiratory tract viruses ::: Results and DiscussionNon-CF individuals shared a common viral metabolic profile which was distinctly different from that of CF individuals (Figure 6).", [["respiratory", "ANATOMY", 86, 97], ["respiratory tract", "ANATOMY", 244, 261], ["viral infections", "DISEASE", 52, 68], ["respiratory distress", "DISEASE", 86, 106], ["CF", "DISEASE", 123, 125], ["viral infections", "DISEASE", 201, 217], ["respiratory tract viruses", "DISEASE", 244, 269], ["respiratory tract", "ORGANISM_SUBDIVISION", 244, 261], ["clinical symptoms", "PROBLEM", 31, 48], ["viral infections", "PROBLEM", 52, 68], ["the typical respiratory distress", "PROBLEM", 74, 106], ["CF", "PROBLEM", 123, 125], ["CF individuals", "PROBLEM", 150, 164], ["this study", "TEST", 168, 178], ["extant viral infections", "PROBLEM", 194, 217], ["respiratory tract viruses", "PROBLEM", 244, 269], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infections", "OBSERVATION", 58, 68], ["typical", "OBSERVATION_MODIFIER", 78, 85], ["respiratory distress", "OBSERVATION", 86, 106], ["viral", "OBSERVATION_MODIFIER", 201, 206], ["infections", "OBSERVATION", 207, 217], ["respiratory tract", "ANATOMY", 244, 261]]], ["Functional annotations were assigned to metagenomic sequences by tBLASTx comparison to the non-redundant SEED database at the highest subsystem level, which consists of 25 classifications (Figure 7A).", [["metagenomic sequences", "DNA", 40, 61], ["metagenomic sequences", "TEST", 40, 61]]], ["The percentage of known sequences (i.e., sequences with significant similarity to the database) was much higher than reported in the literature for other viral metagenomes (Figure S3) [28].Metabolic profiles of respiratory tract viruses ::: Results and DiscussionMetabolic functions encoded by viruses are determined by the environment, and functional genes carried by phage largely mirror those of their hosts [28].", [["respiratory tract", "ANATOMY", 211, 228], ["respiratory tract viruses", "DISEASE", 211, 236], ["respiratory tract", "ORGANISM_SUBDIVISION", 211, 228], ["functional genes", "DNA", 341, 357], ["the database", "TEST", 82, 94], ["other viral metagenomes", "PROBLEM", 148, 171], ["respiratory tract viruses", "PROBLEM", 211, 236], ["respiratory tract", "ANATOMY", 211, 228]]], ["The CF airway has distinct regions characterized by hypoxia and low pH, and airway secretions are enriched in amino acids, DNA, phospholipids and other cellular debris [4], [26].", [["CF airway", "ANATOMY", 4, 13], ["airway secretions", "ANATOMY", 76, 93], ["cellular", "ANATOMY", 152, 160], ["hypoxia", "DISEASE", 52, 59], ["amino acids", "CHEMICAL", 110, 121], ["amino acids", "CHEMICAL", 110, 121], ["CF airway", "MULTI-TISSUE_STRUCTURE", 4, 13], ["airway secretions", "ORGANISM_SUBSTANCE", 76, 93], ["amino acids", "AMINO_ACID", 110, 121], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["phospholipids", "SIMPLE_CHEMICAL", 128, 141], ["cellular", "CELL", 152, 160], ["hypoxia", "PROBLEM", 52, 59], ["low pH", "PROBLEM", 64, 70], ["airway secretions", "PROBLEM", 76, 93], ["amino acids", "TEST", 110, 121], ["DNA", "TEST", 123, 126], ["phospholipids", "TEST", 128, 141], ["other cellular debris", "PROBLEM", 146, 167], ["airway", "ANATOMY", 7, 13], ["distinct", "OBSERVATION_MODIFIER", 18, 26], ["hypoxia", "OBSERVATION", 52, 59], ["low pH", "OBSERVATION", 64, 70], ["airway", "ANATOMY", 76, 82], ["secretions", "OBSERVATION", 83, 93], ["debris", "OBSERVATION", 161, 167]]], ["The specific adaptations required for survival in this environment are reflected by the metabolic profiles of CF viromes.Metabolic profiles of respiratory tract viruses ::: Results and DiscussionNon-CF1Asthma and Non-CF4Spouse shared phage taxonomy with CF viromes, but did not share metabolic profiles because they have a Non-CF airway environment.", [["respiratory tract", "ANATOMY", 143, 160], ["airway", "ANATOMY", 330, 336], ["respiratory tract viruses", "DISEASE", 143, 168], ["respiratory tract", "ORGANISM_SUBDIVISION", 143, 160], ["airway", "MULTI-TISSUE_STRUCTURE", 330, 336], ["survival", "TREATMENT", 38, 46], ["CF viromes", "PROBLEM", 110, 120], ["respiratory tract viruses", "PROBLEM", 143, 168], ["CF viromes", "TEST", 254, 264], ["respiratory tract", "ANATOMY", 143, 160], ["airway", "ANATOMY", 330, 336]]], ["These results are similar to findings in the human gut, where microbiomes were determined to share a set of core metabolic genes even when different microbial taxa were present, and aberrant physiological states (i.e., obesity) lead to definitive changes in the metabolic consortium [21].", [["gut", "ANATOMY", 51, 54], ["obesity", "DISEASE", 219, 226], ["human", "ORGANISM", 45, 50], ["gut", "ORGANISM_SUBDIVISION", 51, 54], ["core metabolic genes", "DNA", 108, 128], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["different microbial taxa", "PROBLEM", 139, 163], ["aberrant physiological states", "PROBLEM", 182, 211], ["obesity", "PROBLEM", 219, 226], ["definitive changes", "PROBLEM", 236, 254], ["human gut", "ANATOMY", 45, 54], ["metabolic genes", "OBSERVATION", 113, 128], ["metabolic consortium", "OBSERVATION", 262, 282]]], ["As indicated by CF5, there may be more than one disease state which defines metabolism in CF, reflecting differences in pathology, disease development and/or treatment regimes.Metabolic profiles of respiratory tract viruses ::: Results and DiscussionAll of the CF metagenomes (including CF5) were over-represented in functions related to the metabolism of aromatic compounds (Figure 7A).", [["respiratory tract", "ANATOMY", 198, 215], ["respiratory tract viruses", "DISEASE", 198, 223], ["respiratory tract", "ORGANISM_SUBDIVISION", 198, 215], ["aromatic compounds", "SIMPLE_CHEMICAL", 356, 374], ["CF5", "DNA", 287, 290], ["one disease state", "PROBLEM", 44, 61], ["metabolism in CF", "PROBLEM", 76, 92], ["disease development", "PROBLEM", 131, 150], ["treatment regimes", "TREATMENT", 158, 175], ["respiratory tract viruses", "PROBLEM", 198, 223], ["the CF metagenomes", "TEST", 257, 275], ["CF5", "TEST", 287, 290], ["may be", "UNCERTAINTY", 27, 33], ["disease", "OBSERVATION", 48, 55], ["metabolism", "OBSERVATION_MODIFIER", 76, 86], ["CF", "OBSERVATION", 90, 92], ["respiratory tract", "ANATOMY", 198, 215], ["aromatic compounds", "OBSERVATION", 356, 374]]], ["At the second hierarchical subsystem level, CF1-4 were over-represented in anaerobic degradation of aromatics, while CF5 had more genes related to peripheral catabolism pathways, most of which were aerobic (Figure 7B).", [["aromatics", "CHEMICAL", 100, 109], ["CF5", "CHEMICAL", 117, 120], ["aromatics", "CHEMICAL", 100, 109], ["CF1-4", "GENE_OR_GENE_PRODUCT", 44, 49], ["aromatics", "SIMPLE_CHEMICAL", 100, 109], ["CF5", "SIMPLE_CHEMICAL", 117, 120], ["CF1-4", "DNA", 44, 49], ["CF5", "PROTEIN", 117, 120], ["CF1", "TEST", 44, 47], ["anaerobic degradation of aromatics", "PROBLEM", 75, 109], ["peripheral catabolism pathways", "PROBLEM", 147, 177], ["anaerobic degradation", "OBSERVATION", 75, 96], ["peripheral", "ANATOMY_MODIFIER", 147, 157], ["catabolism pathways", "OBSERVATION", 158, 177]]], ["Non-CF metagenomes were enriched for metabolism of central intermediates via aerobic mechanisms.", [["Non-CF metagenomes", "PROBLEM", 0, 18], ["central intermediates via aerobic mechanisms", "PROBLEM", 51, 95], ["aerobic mechanisms", "OBSERVATION", 77, 95]]], ["CF sputum is derived from hypoxic microenvironments which require persistent microbes to acquire anaerobic adaptations [26].", [["CF sputum", "ANATOMY", 0, 9], ["CF sputum", "TEST", 0, 9], ["hypoxic microenvironments", "PROBLEM", 26, 51], ["persistent microbes", "PROBLEM", 66, 85], ["hypoxic microenvironments", "OBSERVATION", 26, 51]]], ["Aromatic amino acids have been implicated both as preferred carbon sources and also regulators of quinolone signaling and biofilm formation for Pseudomonas aeruginosa in CF sputum [26], [27].Metabolic profiles of respiratory tract viruses ::: Results and DiscussionThe presence of anaerobic aromatic catabolism genes in phage may represent lateral gene transfer with well-adapted hosts [46].", [["biofilm", "ANATOMY", 122, 129], ["respiratory tract", "ANATOMY", 213, 230], ["amino acids", "CHEMICAL", 9, 20], ["quinolone", "CHEMICAL", 98, 107], ["respiratory tract viruses", "DISEASE", 213, 238], ["Aromatic amino acids", "CHEMICAL", 0, 20], ["carbon", "CHEMICAL", 60, 66], ["quinolone", "CHEMICAL", 98, 107], ["Aromatic", "SIMPLE_CHEMICAL", 0, 8], ["amino acids", "AMINO_ACID", 9, 20], ["quinolone", "SIMPLE_CHEMICAL", 98, 107], ["biofilm", "SIMPLE_CHEMICAL", 122, 129], ["Pseudomonas aeruginosa", "ORGANISM", 144, 166], ["respiratory tract", "ORGANISM_SUBDIVISION", 213, 230], ["anaerobic aromatic catabolism genes", "DNA", 281, 316], ["Pseudomonas aeruginosa", "SPECIES", 144, 166], ["Pseudomonas aeruginosa", "SPECIES", 144, 166], ["Aromatic amino acids", "TREATMENT", 0, 20], ["carbon sources", "TREATMENT", 60, 74], ["quinolone signaling", "TREATMENT", 98, 117], ["biofilm formation", "TREATMENT", 122, 139], ["Pseudomonas aeruginosa in CF sputum", "PROBLEM", 144, 179], ["respiratory tract viruses", "PROBLEM", 213, 238], ["anaerobic aromatic catabolism genes in phage", "TREATMENT", 281, 325], ["respiratory tract", "ANATOMY", 213, 230]]], ["Alternatively, phage may be degrading aromatics in order to reduce biofilm formation and the exopolysaccharide layer, allowing access to susceptible Bacterial hosts.Metabolic profiles of respiratory tract viruses ::: Results and DiscussionCF5 was dramatically over-represented in phosphorous metabolism and virulence pathways (Figure 7A).", [["biofilm", "ANATOMY", 67, 74], ["respiratory tract", "ANATOMY", 187, 204], ["respiratory tract viruses", "DISEASE", 187, 212], ["phosphorous", "CHEMICAL", 280, 291], ["aromatics", "CHEMICAL", 38, 47], ["phosphorous", "CHEMICAL", 280, 291], ["respiratory tract", "ORGANISM_SUBDIVISION", 187, 204], ["phosphorous", "SIMPLE_CHEMICAL", 280, 291], ["phage", "TREATMENT", 15, 20], ["biofilm formation", "PROBLEM", 67, 84], ["the exopolysaccharide layer", "TREATMENT", 89, 116], ["susceptible Bacterial hosts", "PROBLEM", 137, 164], ["respiratory tract viruses", "PROBLEM", 187, 212], ["respiratory tract", "ANATOMY", 187, 204]]], ["Over 75% of tBLASTx similarities to the phosphorous metabolism subsystem were to the gene encoding Guanosine-5\u2032-triphosphate,3\u2032-diphosphate pyrophosphatase.", [["phosphorous", "CHEMICAL", 40, 51], ["Guanosine-5\u2032-triphosphate", "CHEMICAL", 99, 124], ["3\u2032-diphosphate", "CHEMICAL", 125, 139], ["phosphorous", "CHEMICAL", 40, 51], ["Guanosine-5\u2032-triphosphate", "CHEMICAL", 99, 124], ["3\u2032-diphosphate", "CHEMICAL", 125, 139], ["tBLASTx", "GENE_OR_GENE_PRODUCT", 12, 19], ["phosphorous", "SIMPLE_CHEMICAL", 40, 51], ["Guanosine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 99, 124], ["3\u2032-diphosphate pyrophosphatase", "SIMPLE_CHEMICAL", 125, 155], ["Guanosine-5\u2032-triphosphate,3\u2032-diphosphate pyrophosphatase", "PROTEIN", 99, 155], ["tBLASTx", "TREATMENT", 12, 19], ["the phosphorous metabolism subsystem", "PROBLEM", 36, 72], ["Guanosine", "TEST", 99, 108], ["triphosphate", "TREATMENT", 112, 124], ["diphosphate pyrophosphatase", "TREATMENT", 128, 155]]], ["This enzyme catalyzes the removal of a phosphate group from guanosine pentaphosphate (pppGpp) to generate guanosine tetraphosphate (ppGpp) [47].", [["phosphate", "CHEMICAL", 39, 48], ["guanosine pentaphosphate", "CHEMICAL", 60, 84], ["pppGpp", "CHEMICAL", 86, 92], ["guanosine tetraphosphate", "CHEMICAL", 106, 130], ["ppGpp", "CHEMICAL", 132, 137], ["phosphate", "CHEMICAL", 39, 48], ["guanosine pentaphosphate", "CHEMICAL", 60, 84], ["pppGpp", "CHEMICAL", 86, 92], ["guanosine tetraphosphate", "CHEMICAL", 106, 130], ["ppGpp", "CHEMICAL", 132, 137], ["phosphate", "SIMPLE_CHEMICAL", 39, 48], ["guanosine pentaphosphate", "SIMPLE_CHEMICAL", 60, 84], ["pppGpp", "SIMPLE_CHEMICAL", 86, 92], ["guanosine tetraphosphate", "SIMPLE_CHEMICAL", 106, 130], ["ppGpp", "SIMPLE_CHEMICAL", 132, 137], ["This enzyme", "TEST", 0, 11], ["the removal", "TREATMENT", 22, 33], ["a phosphate group", "TREATMENT", 37, 54], ["guanosine pentaphosphate (pppGpp", "TREATMENT", 60, 92], ["guanosine tetraphosphate", "TREATMENT", 106, 130]]], ["Both pppGpp and ppGpp are part of the canonical bacterial stringent response which is enacted to slow growth rates during nutrient stress [48].", [["pppGpp", "GENE_OR_GENE_PRODUCT", 5, 11], ["ppGpp", "GENE_OR_GENE_PRODUCT", 16, 21], ["pppGpp", "PROTEIN", 5, 11], ["ppGpp", "PROTEIN", 16, 21], ["the canonical bacterial stringent response", "PROBLEM", 34, 76], ["slow growth rates", "PROBLEM", 97, 114], ["ppGpp", "OBSERVATION", 16, 21], ["bacterial stringent", "OBSERVATION", 48, 67]]], ["They have also been linked to bacterial virulence, antibiotic resistance, biofilm formation, quorum sensing, and phage induction in a variety of bacteria including Pseudomonas aeruginosa[47], [48].", [["biofilm", "ANATOMY", 74, 81], ["Pseudomonas aeruginosa", "ORGANISM", 164, 186], ["Pseudomonas aeruginosa", "SPECIES", 164, 186], ["Pseudomonas aeruginosa", "SPECIES", 164, 186], ["bacterial virulence", "PROBLEM", 30, 49], ["antibiotic resistance", "TREATMENT", 51, 72], ["biofilm formation", "TREATMENT", 74, 91], ["quorum sensing", "TREATMENT", 93, 107], ["phage induction", "TREATMENT", 113, 128], ["bacteria", "PROBLEM", 145, 153], ["Pseudomonas aeruginosa", "PROBLEM", 164, 186]]], ["For many bacteria ppGpp is a more potent effector molecule than pppGpp, suggesting a need for increased levels of Guanosine-5\u2032-triphosphate,3\u2032-diphosphate pyrophosphatase [47], [49].Additional considerations and recommendations for human microbiome studies ::: Results and DiscussionWe used sputum samples as a proxy for the human respiratory tract, much as fecal samples have been used as a proxy for the human gut [18]\u2013[20].", [["sputum samples", "ANATOMY", 291, 305], ["respiratory tract", "ANATOMY", 331, 348], ["fecal samples", "ANATOMY", 358, 371], ["ppGpp", "CHEMICAL", 18, 23], ["Guanosine-5\u2032-triphosphate,3\u2032-diphosphate", "CHEMICAL", 114, 154], ["Guanosine-5\u2032-triphosphate", "CHEMICAL", 114, 139], ["3\u2032-diphosphate", "CHEMICAL", 140, 154], ["ppGpp", "GENE_OR_GENE_PRODUCT", 18, 23], ["pppGpp", "GENE_OR_GENE_PRODUCT", 64, 70], ["Guanosine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 114, 139], ["3\u2032-diphosphate pyrophosphatase", "SIMPLE_CHEMICAL", 140, 170], ["human", "ORGANISM", 232, 237], ["human", "ORGANISM", 325, 330], ["respiratory tract", "ORGANISM_SUBDIVISION", 331, 348], ["fecal samples", "ORGANISM_SUBSTANCE", 358, 371], ["human", "ORGANISM", 406, 411], ["gut", "ORGANISM_SUBDIVISION", 412, 415], ["ppGpp", "PROTEIN", 18, 23], ["effector molecule", "PROTEIN", 41, 58], ["pppGpp", "PROTEIN", 64, 70], ["Guanosine-5\u2032-triphosphate,3\u2032-diphosphate pyrophosphatase", "PROTEIN", 114, 170], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 406, 411], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 406, 411], ["many bacteria ppGpp", "PROBLEM", 4, 23], ["increased levels of Guanosine", "TREATMENT", 94, 123], ["triphosphate", "TREATMENT", 127, 139], ["diphosphate pyrophosphatase", "TEST", 143, 170], ["sputum samples", "TEST", 291, 305], ["the human respiratory tract", "TREATMENT", 321, 348], ["fecal samples", "TEST", 358, 371], ["bacteria ppGpp", "OBSERVATION", 9, 23], ["respiratory tract", "ANATOMY", 331, 348]]], ["Expectorated sputum has been routinely exploited as a rapid, inexpensive, non-invasive method to sample the lung and lower respiratory tract, and sputum samples can achieve sensitivity and accuracy comparable to bronchoalveolar lavage for detection of respiratory infections [50].", [["sputum", "ANATOMY", 13, 19], ["lung", "ANATOMY", 108, 112], ["lower respiratory tract", "ANATOMY", 117, 140], ["sputum samples", "ANATOMY", 146, 160], ["bronchoalveolar lavage", "ANATOMY", 212, 234], ["respiratory", "ANATOMY", 252, 263], ["respiratory infections", "DISEASE", 252, 274], ["lung", "ORGAN", 108, 112], ["lower respiratory", "ORGANISM_SUBDIVISION", 117, 134], ["tract", "ORGANISM_SUBDIVISION", 135, 140], ["lavage", "ORGANISM_SUBSTANCE", 228, 234], ["Expectorated sputum", "PROBLEM", 0, 19], ["a rapid, inexpensive, non-invasive method to sample the lung and lower respiratory tract", "PROBLEM", 52, 140], ["sputum samples", "TEST", 146, 160], ["sensitivity", "TEST", 173, 184], ["accuracy", "TEST", 189, 197], ["bronchoalveolar lavage", "TEST", 212, 234], ["respiratory infections", "PROBLEM", 252, 274], ["lung", "ANATOMY", 108, 112], ["lower", "ANATOMY_MODIFIER", 117, 122], ["respiratory tract", "ANATOMY", 123, 140], ["bronchoalveolar lavage", "OBSERVATION", 212, 234], ["respiratory", "ANATOMY", 252, 263], ["infections", "OBSERVATION", 264, 274]]], ["T-RFLP analysis of bacterial communities demonstrated that sputum is not substantially contaminated by saliva and bacterial flora of the oral cavity [34].", [["communities", "ANATOMY", 29, 40], ["sputum", "ANATOMY", 59, 65], ["oral cavity", "ANATOMY", 137, 148], ["sputum", "ORGANISM_SUBSTANCE", 59, 65], ["saliva", "ORGANISM_SUBSTANCE", 103, 109], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 137, 148], ["T-RFLP analysis", "TEST", 0, 15], ["bacterial communities", "PROBLEM", 19, 40], ["sputum", "TEST", 59, 65], ["bacterial flora of the oral cavity", "PROBLEM", 114, 148], ["bacterial communities", "OBSERVATION", 19, 40], ["sputum", "OBSERVATION", 59, 65], ["bacterial flora", "OBSERVATION", 114, 129], ["oral cavity", "ANATOMY", 137, 148]]], ["However, the degree to which sputum represents the upper and lower respiratory tract is unknown, especially in healthy individuals.", [["sputum", "ANATOMY", 29, 35], ["lower respiratory tract", "ANATOMY", 61, 84], ["upper", "ORGANISM_SUBDIVISION", 51, 56], ["lower", "ORGANISM_SUBDIVISION", 61, 66], ["respiratory tract", "ORGANISM_SUBDIVISION", 67, 84], ["sputum", "TEST", 29, 35], ["the upper and lower respiratory tract", "PROBLEM", 47, 84], ["degree", "OBSERVATION_MODIFIER", 13, 19], ["sputum", "OBSERVATION", 29, 35], ["upper", "ANATOMY_MODIFIER", 51, 56], ["lower", "ANATOMY_MODIFIER", 61, 66], ["respiratory tract", "ANATOMY", 67, 84]]], ["Microbial communities in fecal samples have been shown to differ significantly from those in intestinal mucosal samples, based on 16S rDNA analysis, and similarly, sputum samples may contain different communities than the lung or lower respiratory tract [19].Additional considerations and recommendations for human microbiome studies ::: Results and DiscussionIn this study, human genomic DNA contamination was detected bioinformatically and removed.", [["communities", "ANATOMY", 10, 21], ["fecal samples", "ANATOMY", 25, 38], ["intestinal mucosal samples", "ANATOMY", 93, 119], ["sputum samples", "ANATOMY", 164, 178], ["communities", "ANATOMY", 201, 212], ["lung", "ANATOMY", 222, 226], ["lower respiratory tract", "ANATOMY", 230, 253], ["fecal samples", "ORGANISM_SUBSTANCE", 25, 38], ["intestinal mucosal samples", "TISSUE", 93, 119], ["rDNA", "CELLULAR_COMPONENT", 134, 138], ["lung", "ORGAN", 222, 226], ["human", "ORGANISM", 309, 314], ["human", "ORGANISM", 375, 380], ["DNA", "CELLULAR_COMPONENT", 389, 392], ["16S rDNA", "DNA", 130, 138], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 375, 380], ["Microbial communities in fecal samples", "PROBLEM", 0, 38], ["intestinal mucosal samples", "TEST", 93, 119], ["16S rDNA analysis", "TEST", 130, 147], ["sputum samples", "TEST", 164, 178], ["lower respiratory tract", "PROBLEM", 230, 253], ["this study", "TEST", 363, 373], ["human genomic DNA contamination", "PROBLEM", 375, 406], ["communities", "OBSERVATION_MODIFIER", 10, 21], ["fecal", "ANATOMY", 25, 30], ["intestinal mucosal", "ANATOMY", 93, 111], ["lung", "ANATOMY", 222, 226], ["lower", "ANATOMY_MODIFIER", 230, 235], ["respiratory tract", "ANATOMY", 236, 253]]], ["Previously, we sequenced control viromes from CF sputum which were not DNase I treated.", [["CF sputum", "ANATOMY", 46, 55], ["DNase I", "GENE_OR_GENE_PRODUCT", 71, 78], ["DNase I", "PROTEIN", 71, 78], ["CF sputum", "PROBLEM", 46, 55]]], ["These metagenomes contained over 90% of sequences from human genomic DNA as determined by BLASTn analysis (data not shown).", [["human", "ORGANISM", 55, 60], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["human genomic DNA", "DNA", 55, 72], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["These metagenomes", "TEST", 0, 17], ["human genomic DNA", "PROBLEM", 55, 72], ["BLASTn analysis", "TEST", 90, 105]]], ["This human DNA comes from neutrophils present in the airway, either through the active dissemination of neutrophil extracellular traps (NETs) or by the release of cellular contents during cell death [51].", [["neutrophils", "ANATOMY", 26, 37], ["airway", "ANATOMY", 53, 59], ["neutrophil extracellular", "ANATOMY", 104, 128], ["NETs", "ANATOMY", 136, 140], ["cellular", "ANATOMY", 163, 171], ["cell", "ANATOMY", 188, 192], ["death", "DISEASE", 193, 198], ["human", "ORGANISM", 5, 10], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["neutrophils", "CELL", 26, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 53, 59], ["neutrophil extracellular traps", "GENE_OR_GENE_PRODUCT", 104, 134], ["cellular", "CELL", 163, 171], ["cell", "CELL", 188, 192], ["neutrophils", "CELL_TYPE", 26, 37], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["This human DNA", "PROBLEM", 0, 14], ["neutrophils", "PROBLEM", 26, 37], ["neutrophil extracellular traps", "TREATMENT", 104, 134], ["airway", "ANATOMY", 53, 59], ["active", "OBSERVATION_MODIFIER", 80, 86], ["dissemination", "OBSERVATION_MODIFIER", 87, 100], ["neutrophil extracellular traps", "OBSERVATION", 104, 134], ["cellular contents", "OBSERVATION", 163, 180]]], ["Using the protocol described above, the percent of human DNA detected ranged from 10% to 34% (Table 2).", [["human", "ORGANISM", 51, 56], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["human DNA", "DNA", 51, 60], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["the protocol", "TREATMENT", 6, 18], ["human DNA", "TEST", 51, 60]]], ["This was markedly lower than in the control metagenomes, and was comparable to the percentage of human DNA (24% and 36%) obtained by Allander et al. [16] for viral isolation from pooled nasal aspirate samples.", [["nasal aspirate samples", "ANATOMY", 186, 208], ["human", "ORGANISM", 97, 102], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["nasal aspirate samples", "MULTI-TISSUE_STRUCTURE", 186, 208], ["human DNA", "DNA", 97, 106], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["human DNA", "TEST", 97, 106], ["viral isolation", "TREATMENT", 158, 173], ["pooled nasal aspirate samples", "TEST", 179, 208], ["markedly", "OBSERVATION_MODIFIER", 9, 17], ["lower", "OBSERVATION_MODIFIER", 18, 23], ["nasal", "ANATOMY", 186, 191]]], ["As studies of the human microbiome move away from characterization of microbes using 16S rDNA and towards complete metagenomic analysis of both microbial and viral communities, human genomic DNA contamination becomes unavoidable.Additional considerations and recommendations for human microbiome studies ::: Results and DiscussionAfter all contaminating sequences were removed, there were still at least 130,000 sequences comprising over 30 Mbp in all metagenomes.", [["communities", "ANATOMY", 164, 175], ["human", "ORGANISM", 18, 23], ["rDNA", "CELLULAR_COMPONENT", 89, 93], ["human", "ORGANISM", 177, 182], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["human", "ORGANISM", 279, 284], ["16S rDNA", "DNA", 85, 93], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 279, 284], ["16S rDNA", "TEST", 85, 93], ["complete metagenomic analysis", "TEST", 106, 135], ["human genomic DNA contamination", "PROBLEM", 177, 208], ["viral communities", "OBSERVATION", 158, 175]]], ["To verify the presence of viruses in the metagenomes, we assembled two metagenomes and compared contigs to the non-redudant database using BLASTn.", [["viruses in the metagenomes", "PROBLEM", 26, 52], ["viruses", "OBSERVATION", 26, 33]]], ["There were 23 contigs assembled from Non-CF2 which had BLASTn matches to Streptococcus phage Cp-1 (E-value <10\u22125), with an alignment length greater than 50 bp, and greater than 85% identity (Figure S4).", [["Cp-1", "GENE_OR_GENE_PRODUCT", 93, 97], ["Non-CF2", "DNA", 37, 44], ["Streptococcus phage Cp-1", "DNA", 73, 97], ["Non-CF2", "TEST", 37, 44], ["BLASTn matches", "TEST", 55, 69], ["Streptococcus phage Cp", "TEST", 73, 95], ["E-value", "TEST", 99, 106], ["an alignment length", "TEST", 120, 139], ["bp", "TEST", 156, 158], ["alignment", "OBSERVATION_MODIFIER", 123, 132], ["length", "OBSERVATION_MODIFIER", 133, 139]]], ["The assembly of the CF3 metagenome yielded high coverage and significant BLASTn hits to the genome of H. influenza prophage Mu (Figure S5).Additional considerations and recommendations for human microbiome studies ::: Results and DiscussionHere, we isolated DNA viruses from sputum, including both phage and eukaryotic viruses.", [["sputum", "ANATOMY", 275, 281], ["CF3", "GENE_OR_GENE_PRODUCT", 20, 23], ["H. influenza", "ORGANISM", 102, 114], ["Mu (Figure S5", "GENE_OR_GENE_PRODUCT", 124, 137], ["human", "ORGANISM", 189, 194], ["DNA", "CELLULAR_COMPONENT", 258, 261], ["sputum", "ORGANISM_SUBSTANCE", 275, 281], ["CF3 metagenome", "DNA", 20, 34], ["BLASTn hits", "DNA", 73, 84], ["H. influenza prophage Mu", "DNA", 102, 126], ["H. influenza", "SPECIES", 102, 114], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["the CF3 metagenome", "TEST", 16, 34], ["high coverage", "PROBLEM", 43, 56], ["significant BLASTn hits", "PROBLEM", 61, 84], ["H. influenza prophage", "PROBLEM", 102, 123], ["DNA viruses", "PROBLEM", 258, 269], ["sputum", "TEST", 275, 281], ["eukaryotic viruses", "PROBLEM", 308, 326], ["high coverage", "OBSERVATION", 43, 56], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["BLASTn hits", "OBSERVATION", 73, 84], ["influenza prophage", "OBSERVATION", 105, 123], ["eukaryotic viruses", "OBSERVATION", 308, 326]]], ["The majority of respiratory infections (>75%) have been attributed to RNA viruses such as rhinoviruses, coronaviruses, and paramyxoviruses, so many previous studies have focused on the characterization of RNA viruses in the respiratory tract [38].", [["respiratory", "ANATOMY", 16, 27], ["respiratory tract", "ANATOMY", 224, 241], ["respiratory infections", "DISEASE", 16, 38], ["rhinoviruses, coronaviruses", "DISEASE", 90, 117], ["rhinoviruses", "ORGANISM", 90, 102], ["respiratory infections", "PROBLEM", 16, 38], ["RNA viruses", "PROBLEM", 70, 81], ["rhinoviruses", "PROBLEM", 90, 102], ["coronaviruses", "PROBLEM", 104, 117], ["paramyxoviruses", "PROBLEM", 123, 138], ["many previous studies", "TEST", 143, 164], ["RNA viruses in the respiratory tract", "PROBLEM", 205, 241], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["respiratory", "ANATOMY", 16, 27], ["infections", "OBSERVATION", 28, 38], ["attributed to", "UNCERTAINTY", 56, 69], ["RNA viruses", "OBSERVATION", 70, 81], ["rhinoviruses", "OBSERVATION", 90, 102], ["RNA viruses", "OBSERVATION", 205, 216], ["respiratory tract", "ANATOMY", 224, 241]]], ["CF is predominantly a microbial disease, and phage are known to exert important top-down controls on microbial communities [52].", [["CF", "DISEASE", 0, 2], ["CF", "PROBLEM", 0, 2], ["a microbial disease", "PROBLEM", 20, 39], ["phage", "PROBLEM", 45, 50], ["predominantly", "OBSERVATION_MODIFIER", 6, 19], ["microbial disease", "OBSERVATION", 22, 39]]], ["However, little work has been done to describe phage communities and DNA viruses associated with CF or with the airways in general [4], [38].", [["airways", "ANATOMY", 112, 119], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["airways", "MULTI-TISSUE_STRUCTURE", 112, 119], ["DNA viruses", "PROBLEM", 69, 80], ["CF", "PROBLEM", 97, 99], ["airways", "ANATOMY", 112, 119]]], ["Over 98% of all completely sequenced phage have DNA genomes, therefore to assess phage diversity, taxonomy, and function, it was necessary to isolate viral DNA [53].", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["DNA genomes", "DNA", 48, 59], ["DNA genomes", "PROBLEM", 48, 59], ["taxonomy", "TEST", 98, 106], ["viral DNA", "PROBLEM", 150, 159]]], ["Future studies of the respiratory tract virome should be expanded to include characterization of RNA viral communities.Additional considerations and recommendations for human microbiome studies ::: Results and DiscussionA caveat to this study was the use of Multiple Displacement Amplification (MDA) with phi29 polymerase to amplify viral DNA prior to pyrosequencing.", [["respiratory tract", "ANATOMY", 22, 39], ["respiratory tract", "ORGANISM_SUBDIVISION", 22, 39], ["human", "ORGANISM", 169, 174], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["phi29 polymerase", "PROTEIN", 305, 321], ["viral DNA", "DNA", 333, 342], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["Future studies", "TEST", 0, 14], ["the respiratory tract virome", "PROBLEM", 18, 46], ["RNA viral communities", "PROBLEM", 97, 118], ["this study", "TEST", 232, 242], ["Multiple Displacement Amplification (MDA)", "TREATMENT", 258, 299], ["phi29 polymerase", "TREATMENT", 305, 321], ["viral DNA", "PROBLEM", 333, 342], ["pyrosequencing", "TEST", 352, 366], ["respiratory tract", "ANATOMY", 22, 39]]], ["MDA generally provides an even representation of genomes except at the ends, however, certain genomes (small and circular or large and linear) may be preferentially amplified [54], [55].", [["MDA", "CHEMICAL", 0, 3], ["MDA", "CHEMICAL", 0, 3], ["MDA", "SIMPLE_CHEMICAL", 0, 3], ["certain genomes (small and circular or large and linear)", "PROBLEM", 86, 142], ["genomes", "OBSERVATION", 49, 56], ["small", "OBSERVATION_MODIFIER", 103, 108], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["To avoid random biases introduced by initial reaction conditions, we performed five separate amplifications which were then combined.", [["random biases", "PROBLEM", 9, 22], ["five separate amplifications", "TREATMENT", 79, 107]]], ["All of the metagenomes used here were collected, processed and amplified in an identical manner, so any biases would have been introduced equally in all samples.Conclusions ::: Results and DiscussionMetagenomic analysis of the human respiratory tract DNA virome illustrated that airway viral communities in the diseased and non-diseased states are defined by metabolism and not by taxonomy.", [["samples", "ANATOMY", 153, 160], ["respiratory tract", "ANATOMY", 233, 250], ["airway", "ANATOMY", 279, 285], ["human", "ORGANISM", 227, 232], ["DNA", "CELLULAR_COMPONENT", 251, 254], ["human respiratory tract DNA virome", "DNA", 227, 261], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 227, 232], ["Metagenomic analysis", "TEST", 199, 219], ["the human respiratory tract DNA virome", "PROBLEM", 223, 261], ["airway viral communities in the diseased and non-diseased states", "PROBLEM", 279, 343], ["respiratory tract", "ANATOMY", 233, 250], ["airway", "ANATOMY", 279, 285], ["viral communities", "OBSERVATION", 286, 303], ["diseased", "OBSERVATION", 311, 319]]], ["The non-diseased airway virome contains a set of shared core metabolic functions, which deviate strongly in the face of chronic disease.", [["airway", "ANATOMY", 17, 23], ["chronic disease", "DISEASE", 120, 135], ["airway", "MULTI-TISSUE_STRUCTURE", 17, 23], ["The non-diseased airway virome", "PROBLEM", 0, 30], ["chronic disease", "PROBLEM", 120, 135], ["non-diseased", "OBSERVATION", 4, 16], ["airway virome", "OBSERVATION", 17, 30], ["metabolic functions", "OBSERVATION", 61, 80], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["disease", "OBSERVATION", 128, 135]]], ["These deviations are driven by dramatic environmental changes in the airways, induced by the nature of cystic fibrosis, such as the introduction of hypoxic microenvironments and novel carbon sources [26], [27].", [["airways", "ANATOMY", 69, 76], ["cystic", "ANATOMY", 103, 109], ["fibrosis", "DISEASE", 110, 118], ["carbon", "CHEMICAL", 184, 190], ["airways", "MULTI-TISSUE_STRUCTURE", 69, 76], ["These deviations", "PROBLEM", 0, 16], ["dramatic environmental changes in the airways", "PROBLEM", 31, 76], ["cystic fibrosis", "PROBLEM", 103, 118], ["hypoxic microenvironments", "PROBLEM", 148, 173], ["novel carbon sources", "PROBLEM", 178, 198], ["deviations", "OBSERVATION", 6, 16], ["dramatic", "OBSERVATION_MODIFIER", 31, 39], ["environmental", "OBSERVATION", 40, 53], ["airways", "ANATOMY", 69, 76], ["cystic", "OBSERVATION_MODIFIER", 103, 109], ["fibrosis", "OBSERVATION", 110, 118], ["hypoxic microenvironments", "OBSERVATION", 148, 173]]], ["In cases where phage taxonomy was shared between Non-CF and CF individuals, metabolic functions still remained distinct.", [["Non-CF", "CANCER", 49, 55], ["phage taxonomy", "TEST", 15, 29], ["metabolic functions", "TEST", 76, 95]]], ["The converse was also true, that is, even when Non-CF viromes differed in phage and eukaryotic viral constituents, they maintained typical Non-CF metabolic profiles.", [["Non-CF viromes", "PROBLEM", 47, 61], ["eukaryotic viral constituents", "PROBLEM", 84, 113], ["viral constituents", "OBSERVATION", 95, 113], ["metabolic profiles", "OBSERVATION", 146, 164]]], ["The presence of two alternative metabolic states in CF reflects the heterogenous nature of disease.", [["disease", "PROBLEM", 91, 98], ["metabolic states", "OBSERVATION", 32, 48], ["heterogenous", "OBSERVATION_MODIFIER", 68, 80], ["disease", "OBSERVATION", 91, 98]]], ["Though CF is generally considered to be well-characterized, there is still inherent individual variation.", [["CF", "PROBLEM", 7, 9], ["CF", "OBSERVATION", 7, 9], ["inherent", "OBSERVATION_MODIFIER", 75, 83], ["individual variation", "OBSERVATION", 84, 104]]], ["The need for alternative therapies for CF is increasing, as microbial antibiotic resistance becomes widespread.", [["CF", "DISEASE", 39, 41], ["alternative therapies", "TREATMENT", 13, 34], ["CF", "PROBLEM", 39, 41], ["microbial antibiotic resistance", "TREATMENT", 60, 91], ["increasing", "OBSERVATION_MODIFIER", 45, 55], ["widespread", "OBSERVATION_MODIFIER", 100, 110]]], ["The results of this study suggest that CF therapeutics might be better aimed at changing the environment of the airways rather than targeting dominant taxa.Ethics statement ::: MethodsSubject recruitment and sample collection were approved by the San Diego State University Institutional Review Board (SDSU IRB 2121) and Environmental Health Services (BUA 06-02-062R).", [["airways", "ANATOMY", 112, 119], ["airways", "MULTI-TISSUE_STRUCTURE", 112, 119], ["this study", "TEST", 15, 25], ["CF therapeutics", "PROBLEM", 39, 54], ["airways", "ANATOMY", 112, 119]]], ["Written consent forms were obtained from all study subjects.Study population ::: MethodsThe five individuals with CF who volunteered for this study were patients at the Cystic Fibrosis Foundation accredited Adult cystic fibrosis Clinic at the University of California San Diego Medical Center.", [["Fibrosis", "DISEASE", 176, 184], ["cystic fibrosis", "DISEASE", 213, 228], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Methods", "TREATMENT", 81, 88], ["this study", "TEST", 137, 147], ["the Cystic Fibrosis", "PROBLEM", 165, 184], ["Adult cystic fibrosis", "PROBLEM", 207, 228], ["Cystic", "OBSERVATION_MODIFIER", 169, 175], ["Fibrosis", "OBSERVATION", 176, 184], ["cystic", "OBSERVATION_MODIFIER", 213, 219], ["fibrosis", "OBSERVATION", 220, 228]]], ["Patients were eligible if they could be classified as clinically stable (i.e., in a non-exacerbated state and free from systemic antibiotic therapy for at least thirty days), and had no reportable cold or flu-like symptoms in the previous thirty days.", [["flu-like symptoms", "DISEASE", 205, 222], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["systemic antibiotic therapy", "TREATMENT", 120, 147], ["reportable cold or flu-like symptoms", "PROBLEM", 186, 222], ["no", "UNCERTAINTY", 183, 185]]], ["All volunteers with CF were screened for signs and symptoms of a upper respiratory infection for the thirty days prior to the study.", [["respiratory", "ANATOMY", 71, 82], ["CF", "DISEASE", 20, 22], ["respiratory infection", "DISEASE", 71, 92], ["volunteers", "ORGANISM", 4, 14], ["upper respiratory", "ORGANISM_SUBDIVISION", 65, 82], ["signs", "PROBLEM", 41, 46], ["symptoms", "PROBLEM", 51, 59], ["a upper respiratory infection", "PROBLEM", 63, 92], ["the study", "TEST", 122, 131], ["upper", "ANATOMY_MODIFIER", 65, 70], ["respiratory", "ANATOMY", 71, 82], ["infection", "OBSERVATION", 83, 92]]], ["All CF subjects were required to have a well documented diagnosis with either two known mutations in the cystic fibrosis Transmembrane Regulator (CFTR) or an abnormally high sweat chloride test.", [["fibrosis", "DISEASE", 112, 120], ["sweat chloride", "CHEMICAL", 174, 188], ["chloride", "CHEMICAL", 180, 188], ["CFTR", "GENE_OR_GENE_PRODUCT", 146, 150], ["cystic fibrosis Transmembrane Regulator", "PROTEIN", 105, 144], ["CFTR", "PROTEIN", 146, 150], ["two known mutations", "PROBLEM", 78, 97], ["the cystic fibrosis Transmembrane Regulator", "PROBLEM", 101, 144], ["an abnormally high sweat chloride test", "PROBLEM", 155, 193], ["mutations", "OBSERVATION", 88, 97], ["cystic", "OBSERVATION_MODIFIER", 105, 111], ["fibrosis", "OBSERVATION", 112, 120]]], ["In addition, all CF patients had Pseudomonas aeruginosa present in their sputum, as determined by culturing in the clinic's microbiology lab.", [["sputum", "ANATOMY", 73, 79], ["patients", "ORGANISM", 20, 28], ["Pseudomonas aeruginosa", "ORGANISM", 33, 55], ["sputum", "ORGANISM_SUBSTANCE", 73, 79], ["patients", "SPECIES", 20, 28], ["Pseudomonas aeruginosa", "SPECIES", 33, 55], ["Pseudomonas aeruginosa", "SPECIES", 33, 55], ["Pseudomonas aeruginosa", "PROBLEM", 33, 55]]], ["The five CF individuals randomly selected for the study consisted of two males and three females.", [["the study", "TEST", 46, 55]]], ["The age range was from 20 to 35 years and all patients had severe airway obstruction as assessed by standard spirometry (FEV1<50% of predicted).Study population ::: MethodsFour Non-CF volunteers were recruited from the campus of San Diego State University, and were subject to the same exclusion criteria for upper respiratory infection.", [["airway", "ANATOMY", 66, 72], ["respiratory", "ANATOMY", 315, 326], ["airway obstruction", "DISEASE", 66, 84], ["respiratory infection", "DISEASE", 315, 336], ["patients", "ORGANISM", 46, 54], ["airway obstruction", "PATHOLOGICAL_FORMATION", 66, 84], ["volunteers", "ORGANISM", 184, 194], ["patients", "SPECIES", 46, 54], ["severe airway obstruction", "PROBLEM", 59, 84], ["standard spirometry", "TEST", 100, 119], ["FEV1", "TEST", 121, 125], ["upper respiratory infection", "PROBLEM", 309, 336], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["airway", "ANATOMY", 66, 72], ["obstruction", "OBSERVATION", 73, 84], ["upper", "ANATOMY_MODIFIER", 309, 314], ["respiratory", "ANATOMY", 315, 326], ["infection", "OBSERVATION", 327, 336]]], ["One of these Non-CF individuals had mild asthma controlled by medication.", [["asthma", "DISEASE", 41, 47], ["mild asthma", "PROBLEM", 36, 47], ["medication", "TREATMENT", 62, 72], ["Non-CF", "OBSERVATION", 13, 19], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["asthma", "OBSERVATION", 41, 47]]], ["A final Non-CF volunteer was the spouse of a CF patient and was recruited from the greater San Diego area.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["The five Non-CF individuals consisted of four females and one male, with an age range of 24 to 50 years.Sample collection ::: MethodsSputum samples of approximately 10 ml were obtained from CF patients at the Adult cystic fibrosis Clinic by expectoration into a sterile cup, as directed by clinic staff.", [["samples", "ANATOMY", 140, 147], ["fibrosis", "DISEASE", 222, 230], ["patients", "ORGANISM", 193, 201], ["cystic", "ORGAN", 215, 221], ["patients", "SPECIES", 193, 201], ["MethodsSputum samples", "TEST", 126, 147], ["a sterile cup", "TREATMENT", 260, 273], ["cystic", "OBSERVATION_MODIFIER", 215, 221], ["fibrosis", "OBSERVATION", 222, 230]]], ["Since sputum expectoration is difficult in general for Non-CF individuals, all Non-CF subjects were first required to do an oral rinse with water to prevent excessive salivary contamination and then take five deep breaths to loosen lung secretions.", [["sputum", "ANATOMY", 6, 12], ["oral", "ANATOMY", 124, 128], ["salivary", "ANATOMY", 167, 175], ["lung secretions", "ANATOMY", 232, 247], ["sputum expectoration", "DISEASE", 6, 26], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["salivary", "ORGANISM_SUBSTANCE", 167, 175], ["lung", "ORGAN", 232, 236], ["secretions", "ORGANISM_SUBSTANCE", 237, 247], ["sputum expectoration", "PROBLEM", 6, 26], ["Non-CF individuals", "PROBLEM", 55, 73], ["an oral rinse", "TREATMENT", 121, 134], ["water", "TREATMENT", 140, 145], ["excessive salivary contamination", "PROBLEM", 157, 189], ["loosen lung secretions", "PROBLEM", 225, 247], ["salivary", "ANATOMY", 167, 175], ["contamination", "OBSERVATION", 176, 189], ["lung", "ANATOMY", 232, 236], ["secretions", "OBSERVATION", 237, 247]]], ["Subjects were then instructed to cough deeply into a sterile cup.", [["cup", "ANATOMY", 61, 64], ["Subjects", "ORGANISM", 0, 8], ["cup", "ORGANISM_SUBDIVISION", 61, 64], ["a sterile cup", "TREATMENT", 51, 64]]], ["The deep breathing and coughing procedures were repeated until at least 1 ml of sputum was obtained.Metagenomic library preparation ::: MethodsAll sputum samples were diluted with an equal volume of Suspension Medium (SM) buffer (1 M NaCl, 10 mM MgSO4, 50 mM Tris-HCl pH 7.4).", [["sputum", "ANATOMY", 80, 86], ["sputum samples", "ANATOMY", 147, 161], ["NaCl", "CHEMICAL", 234, 238], ["MgSO4", "CHEMICAL", 246, 251], ["Tris-HCl", "CHEMICAL", 259, 267], ["NaCl", "CHEMICAL", 234, 238], ["MgSO4", "CHEMICAL", 246, 251], ["Tris-HCl", "CHEMICAL", 259, 267], ["sputum", "ORGANISM_SUBSTANCE", 80, 86], ["sputum samples", "ORGANISM_SUBSTANCE", 147, 161], ["The deep breathing", "TREATMENT", 0, 18], ["coughing procedures", "TREATMENT", 23, 42], ["sputum", "TEST", 80, 86], ["Methods", "TREATMENT", 136, 143], ["All sputum samples", "TEST", 143, 161], ["an equal volume of Suspension Medium (SM) buffer", "TREATMENT", 180, 228], ["1 M NaCl", "TREATMENT", 230, 238], ["10 mM MgSO4", "TREATMENT", 240, 251], ["Tris", "TEST", 259, 263], ["HCl pH", "TEST", 264, 270], ["deep", "ANATOMY_MODIFIER", 4, 8], ["breathing", "ANATOMY", 9, 18]]], ["To aid in mucus dissolution, samples were incubated with 10 ml of 6.5 mM dithiothreitol (Acros Organics: Morris Plains, New Jersey) for 30 minutes at 37\u00b0C. The treated sputum was homogenized using a PowerGen 125 mechanical homogenizer (Fisher Scientific: Hampton, New Hampshire) until it was uniform in color and there was no visible particulate debris.", [["mucus", "ANATOMY", 10, 15], ["samples", "ANATOMY", 29, 36], ["sputum", "ANATOMY", 168, 174], ["dithiothreitol", "CHEMICAL", 73, 87], ["dithiothreitol", "CHEMICAL", 73, 87], ["mucus", "ORGANISM_SUBSTANCE", 10, 15], ["dithiothreitol", "SIMPLE_CHEMICAL", 73, 87], ["mucus dissolution", "PROBLEM", 10, 27], ["6.5 mM dithiothreitol (Acros Organics", "TREATMENT", 66, 103], ["The treated sputum", "PROBLEM", 156, 174], ["a PowerGen 125 mechanical homogenizer", "TREATMENT", 197, 234], ["visible particulate debris", "PROBLEM", 326, 352], ["mucus dissolution", "OBSERVATION", 10, 27], ["no visible", "UNCERTAINTY", 323, 333], ["particulate", "OBSERVATION_MODIFIER", 334, 345], ["debris", "OBSERVATION", 346, 352]]], ["Homogenized samples were filtered through a 0.8 micron black polycarbonate filter (GE Water & Process Technologies: Trevose, Pennsylvania) followed by a 0.45 micron MILLEX\u00aeHV filter (Millipore: Carrigtwohill, Colorado) to remove eukaryotic and microbial cells.", [["samples", "ANATOMY", 12, 19], ["cells", "ANATOMY", 254, 259], ["polycarbonate", "CHEMICAL", 61, 74], ["microbial cells", "CELL", 244, 259], ["eukaryotic and microbial cells", "CELL_TYPE", 229, 259], ["Homogenized samples", "TEST", 0, 19], ["a 0.8 micron black polycarbonate filter", "TREATMENT", 42, 81], ["a 0.45 micron MILLEX\u00aeHV filter", "TREATMENT", 151, 181], ["eukaryotic and microbial cells", "TREATMENT", 229, 259], ["microbial cells", "OBSERVATION", 244, 259]]], ["Viruses in the 0.45 micron filtrate were purified and concentrated using a cesium chloride (CsCl) gradient to remove free DNA and any remaining cellular material [56].", [["cellular", "ANATOMY", 144, 152], ["cesium chloride", "CHEMICAL", 75, 90], ["CsCl", "CHEMICAL", 92, 96], ["cesium chloride", "CHEMICAL", 75, 90], ["CsCl", "CHEMICAL", 92, 96], ["cesium chloride", "SIMPLE_CHEMICAL", 75, 90], ["CsCl", "SIMPLE_CHEMICAL", 92, 96], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["cellular", "CELL", 144, 152], ["Viruses", "PROBLEM", 0, 7], ["a cesium chloride (CsCl) gradient", "TREATMENT", 73, 106], ["free DNA", "PROBLEM", 117, 125], ["any remaining cellular material", "PROBLEM", 130, 161], ["free DNA", "OBSERVATION", 117, 125], ["cellular material", "OBSERVATION", 144, 161]]], ["After collection of viral concentrates from the CsCl gradient, the presence of virus-like particles (VLPs) and the absence of microbial contamination were verified by epifluorescence microscopy using SYBR\u00ae Gold (Invitrogen: Eugene, Oregon) as described in [56].", [["CsCl", "CHEMICAL", 48, 52], ["virus-like particles", "GENE_OR_GENE_PRODUCT", 79, 99], ["VLPs", "ORGANISM", 101, 105], ["viral concentrates", "PROBLEM", 20, 38], ["the CsCl gradient", "TREATMENT", 44, 61], ["virus-like particles (VLPs", "PROBLEM", 79, 105], ["microbial contamination", "PROBLEM", 126, 149], ["epifluorescence microscopy", "TEST", 167, 193], ["viral concentrates", "OBSERVATION", 20, 38], ["CsCl gradient", "OBSERVATION", 48, 61], ["virus", "OBSERVATION", 79, 84], ["particles", "OBSERVATION_MODIFIER", 90, 99], ["microbial contamination", "OBSERVATION", 126, 149]]], ["Sputum samples from healthy subjects contained approximately 107 VLPs per ml, while the samples from CF patients contained approximately 109 VLPs per ml.", [["Sputum samples", "ANATOMY", 0, 14], ["samples", "ANATOMY", 88, 95], ["Sputum samples", "CANCER", 0, 14], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["Sputum samples", "TEST", 0, 14], ["the samples", "TEST", 84, 95]]], ["A sample epifluoresence micrograph is shown in Figure S6.", [["A sample epifluoresence micrograph", "TEST", 0, 34], ["Figure S6", "OBSERVATION", 47, 56]]], ["Chloroform was added to the viral concentrates to rupture the membranes of any remaining cells.", [["membranes", "ANATOMY", 62, 71], ["cells", "ANATOMY", 89, 94], ["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "CHEMICAL", 0, 10], ["Chloroform", "SIMPLE_CHEMICAL", 0, 10], ["membranes", "CELLULAR_COMPONENT", 62, 71], ["cells", "CELL", 89, 94], ["Chloroform", "TREATMENT", 0, 10], ["the viral concentrates", "TREATMENT", 24, 46], ["rupture the membranes", "PROBLEM", 50, 71], ["rupture", "OBSERVATION", 50, 57], ["remaining cells", "OBSERVATION", 79, 94]]], ["Following a one hour incubation and centrifugation, choloroform was removed by pipetting.", [["choloroform", "SIMPLE_CHEMICAL", 52, 63], ["centrifugation", "TREATMENT", 36, 50], ["choloroform", "TREATMENT", 52, 63]]], ["To degrade any remaining free DNA prior to viral DNA extraction, samples were treated with 2 units per \u00b5l of Dnase I (Sigma-Aldrich: St. Louis, MO) at 37\u00b0C for 1 hour.", [["samples", "ANATOMY", 65, 72], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 118, 131], ["St. Louis", "ORGANISM", 133, 142], ["any remaining free DNA", "PROBLEM", 11, 33], ["viral DNA extraction", "TREATMENT", 43, 63], ["free DNA", "OBSERVATION", 25, 33]]], ["Viral DNA was isolated using CTAB/phenol:choloroform extractions and amplified using multiple displacement amplification with Phi29 polymerase [56].", [["CTAB/phenol", "CHEMICAL", 29, 40], ["CTAB", "CHEMICAL", 29, 33], ["phenol", "CHEMICAL", 34, 40], ["choloroform", "CHEMICAL", 41, 52], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["phenol", "SIMPLE_CHEMICAL", 34, 40], ["choloroform", "SIMPLE_CHEMICAL", 41, 52], ["Viral DNA", "DNA", 0, 9], ["Phi29 polymerase", "PROTEIN", 126, 142], ["Viral DNA", "PROBLEM", 0, 9], ["CTAB", "TREATMENT", 29, 33], ["choloroform extractions", "TREATMENT", 41, 64], ["multiple displacement amplification with Phi29 polymerase", "TREATMENT", 85, 142]]], ["Viral DNA was sequenced at 454 Life Sciences (Branford, CT) using the GSFLX pyrosequencing platform to produce ten total viral metagenomic libraries.", [["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["Viral DNA", "DNA", 0, 9], ["viral metagenomic libraries", "DNA", 121, 148], ["Viral DNA", "PROBLEM", 0, 9], ["CT", "TEST", 56, 58], ["the GSFLX pyrosequencing platform", "TREATMENT", 66, 99], ["ten total viral metagenomic libraries", "PROBLEM", 111, 148], ["metagenomic libraries", "OBSERVATION", 127, 148]]], ["The ten viral metagenomes are accessible from NCBI (www.ncbi.nlm.gov) under the genome project ID 39545.Initial bioinformatic processing of metagenomes ::: MethodsAll metagenomes were compared to the Human Genome build 36.3 (http://www.ncbi.nlm.mih.gov) using BLASTn to determine how effective the combination of cesium chloride density gradient centrifugation and DNase I treatment was for removing human genomic contamination from the viral preps [39].", [["ID 39545", "CHEMICAL", 95, 103], ["cesium chloride", "CHEMICAL", 313, 328], ["cesium chloride", "CHEMICAL", 313, 328], ["Human", "ORGANISM", 200, 205], ["cesium chloride", "SIMPLE_CHEMICAL", 313, 328], ["DNase I", "GENE_OR_GENE_PRODUCT", 365, 372], ["human", "ORGANISM", 400, 405], ["DNase I", "PROTEIN", 365, 372], ["Human", "SPECIES", 200, 205], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 400, 405], ["The ten viral metagenomes", "PROBLEM", 0, 25], ["Methods", "TREATMENT", 156, 163], ["All metagenomes", "TEST", 163, 178], ["BLASTn", "TREATMENT", 260, 266], ["cesium chloride density gradient centrifugation", "TREATMENT", 313, 360], ["DNase I treatment", "TREATMENT", 365, 382], ["human genomic contamination", "PROBLEM", 400, 427], ["viral metagenomes", "OBSERVATION", 8, 25]]], ["Sequences with 80% identity over 80% of their length to human sequences were considered contaminating human genomic DNA and were removed prior to further bioinformatic analyses.", [["human", "ORGANISM", 56, 61], ["human", "ORGANISM", 102, 107], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["human sequences", "DNA", 56, 71], ["human genomic DNA", "DNA", 102, 119], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 102, 107], ["Sequences", "TEST", 0, 9], ["human sequences", "TEST", 56, 71], ["contaminating human genomic DNA", "PROBLEM", 88, 119], ["further bioinformatic analyses", "TEST", 146, 176]]], ["Characteristics of viromes and the percentage of human genomic sequences detected are provided in Table 2.Initial bioinformatic processing of metagenomes ::: MethodsFollowing removal of human sequences, dinucleotide relative abundance analysis was used as a secondary screen to detect human DNA contamination, which manifests as an overall depression of CG dinucleotides [57], [58].", [["dinucleotide", "CHEMICAL", 203, 215], ["depression", "DISEASE", 340, 350], ["dinucleotide", "CHEMICAL", 203, 215], ["dinucleotides", "CHEMICAL", 357, 370], ["human", "ORGANISM", 49, 54], ["human", "ORGANISM", 186, 191], ["dinucleotide", "SIMPLE_CHEMICAL", 203, 215], ["human", "ORGANISM", 285, 290], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["human genomic sequences", "DNA", 49, 72], ["human sequences", "DNA", 186, 201], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 285, 290], ["viromes", "TEST", 19, 26], ["human genomic sequences", "TEST", 49, 72], ["human sequences", "TEST", 186, 201], ["dinucleotide relative abundance analysis", "TEST", 203, 243], ["a secondary screen", "TEST", 256, 274], ["human DNA contamination", "PROBLEM", 285, 308], ["an overall depression of CG dinucleotides", "PROBLEM", 329, 370], ["viromes", "OBSERVATION", 19, 26]]], ["In all of the decontaminated metagenomes, the relative abundance odds ratios for CG dinucleotides were between 0.83 and 1.09, within the normal range as defined by Karlin, indicating successful removal of human DNA (Table 2) [57], [58].", [["dinucleotides", "CHEMICAL", 84, 97], ["human", "ORGANISM", 205, 210], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 205, 210], ["CG dinucleotides", "TEST", 81, 97], ["successful removal of human DNA", "TREATMENT", 183, 214], ["normal range", "OBSERVATION_MODIFIER", 137, 149], ["successful", "OBSERVATION_MODIFIER", 183, 193], ["removal", "OBSERVATION", 194, 201]]], ["All viromes were AT rich (in comparison to microbial metagenomes) as expected, with GC content between 40\u201343%, just below the average of approximately 45% previously reported for viral metagenomes [58].", [["GC content", "TEST", 84, 94], ["viral metagenomes", "PROBLEM", 179, 196]]], ["The human genomic DNA decontaminated metagenomic libraries were named according to the subject group they were derived from (Non-CF or CF) and were numbered 1 through 5 in each group.", [["human", "ORGANISM", 4, 9], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["human genomic DNA decontaminated metagenomic libraries", "DNA", 4, 58], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human genomic DNA decontaminated metagenomic libraries", "TREATMENT", 0, 58]]], ["Viromes derived from the individual with asthma and the CF spouse were designated as Non-CF1Asthma and Non-CF4Spouse.Diversity estimation ::: MethodsTo estimate viral diversity and community structure within metagenomes, contig spectra were generated using the free software Circonspect (http://sourceforge.net/projects/circonspect/).", [["asthma", "DISEASE", 41, 47], ["asthma", "PROBLEM", 41, 47], ["Methods", "TREATMENT", 142, 149], ["contig spectra", "TEST", 221, 235], ["asthma", "OBSERVATION", 41, 47], ["viral diversity", "OBSERVATION", 161, 176]]], ["Average contig spectra were calculated using assemblies of 10,000 randomly selected sequences with enough repetitions to achieve 2\u00d7 coverage of each metagenome.", [["Average contig spectra", "TEST", 0, 22]]], ["The assembly parameters were 98% minimal match and 35 base pair overlap.", [["pair overlap", "OBSERVATION", 59, 71]]], ["Sequences less than 100 base pairs were discarded and all other sequences were trimmed to 100 base pairs prior to assembly to obtain identical sequence size in the repeated assemblies.", [["100 base pairs", "DNA", 90, 104], ["Sequences", "TEST", 0, 9], ["all other sequences", "TEST", 54, 73], ["size", "OBSERVATION_MODIFIER", 152, 156]]], ["Average contig spectra were used as inputs to Phage Communities from Contig Spectra (PHACCS) tool (http:biome.sdsu.edu/phaccs), which estimates diversity using rank-abun [36].", [["Average contig spectra", "TREATMENT", 0, 22], ["Contig Spectra", "TEST", 69, 83]]], ["Diversity estimates were based on the best-fit model, in this case the logarithmic model.Sequential BLAST analysis ::: MethodsMetagenomic libraries were compared to each other using BLASTn to find shared sequences between all Non-CF viromes and all CF viromes.", [["Diversity estimates", "TEST", 0, 19], ["Sequential BLAST analysis", "TEST", 89, 114], ["MethodsMetagenomic libraries", "TREATMENT", 119, 147], ["BLASTn", "TREATMENT", 182, 188], ["all Non-CF viromes", "TREATMENT", 222, 240]]], ["Common sequences (E-value<10\u22125 and a minimum of 98% similarity over at least 35 base pairs) were identified and then used as a database for BLASTn versus a third metagenome.", [["Common sequences", "TEST", 0, 16], ["E-value", "TEST", 18, 25], ["BLASTn", "PROBLEM", 140, 146]]], ["Sequential BLASTn analysis resulted in two datasets, one containing sequences common to all Non-CF metagenomes and the other with sequences common to CF metagenomes.", [["Non-CF metagenomes", "DNA", 92, 110], ["CF metagenomes", "DNA", 150, 164], ["Sequential BLASTn analysis", "TEST", 0, 26]]], ["The common Non-CF sequences were then compared using BLASTn to all CF metagenomes to determine which sequences were not present in any CF library (i.e., unique to Non-CF individuals).", [["Non-CF sequences", "DNA", 11, 27], ["CF metagenomes", "DNA", 67, 81], ["CF library", "DNA", 135, 145], ["The common Non-CF sequences", "TEST", 0, 27]]], ["This was also performed in reverse, to find unique CF sequences.Comparison to phage and viral genome databases ::: MethodsMetagenomic libraries were compared to two boutique databases, the first containing 510 complete phage genomes (http://phage.sdsu.edu/phage) and the second, 3,074 complete eukaryotic viral genomes (http://www.ncbi.nlm.nih.gov/genomes/VIRUSES/viruses.html) using tBLASTx with an E-value cutoff of 10\u22125[39].", [["CF sequences", "DNA", 51, 63], ["phage and viral genome databases", "DNA", 78, 110], ["510 complete phage genomes", "DNA", 206, 232], ["3,074 complete eukaryotic viral genomes", "DNA", 279, 318], ["http://www.ncbi.nlm.nih.gov/genomes/VIRUSES/viruses.html", "DNA", 320, 376], ["tBLASTx", "DNA", 384, 391], ["unique CF sequences", "TEST", 44, 63], ["MethodsMetagenomic libraries", "TREATMENT", 115, 143], ["tBLASTx", "TEST", 384, 391], ["an E-value cutoff", "TEST", 397, 414], ["viral genomes", "OBSERVATION", 305, 318]]], ["Counts of best tBLASTx similarities to each genome were normalized for genome size by weighting the number of significant similarities by the total number of base pairs in the database divided by the size of the genome in base pairs.", [["tBLASTx", "GENE_OR_GENE_PRODUCT", 15, 22], ["tBLASTx", "DNA", 15, 22], ["base pairs", "RNA", 158, 168], ["genome size", "PROBLEM", 71, 82], ["size", "OBSERVATION_MODIFIER", 78, 82], ["significant", "OBSERVATION_MODIFIER", 110, 121], ["base", "ANATOMY_MODIFIER", 158, 162], ["size", "OBSERVATION_MODIFIER", 200, 204], ["genome", "OBSERVATION", 212, 218], ["base", "ANATOMY_MODIFIER", 222, 226]]], ["Similarity counts were also normalized for the number of sequences per metagenome, to allow direct comparisons between metagenomes.", [["Similarity counts", "TEST", 0, 17]]], ["Normalized best tBLASTx similarities to the phage database were plotted against the Phage Proteomic Tree version 4 (http://phage.sdsu.edu/~rob/PhageTree/v4) using Bio-Metamapper [53], [56].", [["tBLASTx", "DNA", 16, 23], ["the phage database", "TEST", 40, 58]]], ["Similarities to dsDNA, ssDNA, and retro-transcribing eukaryotic viruses were plotted according to NCBI taxonomy (http://www.ncbi.nlm.nih.gov/genome).", [["dsDNA", "CELLULAR_COMPONENT", 16, 21], ["ssDNA", "CELLULAR_COMPONENT", 23, 28], ["dsDNA", "DNA", 16, 21], ["ssDNA", "DNA", 23, 28], ["ssDNA", "PROBLEM", 23, 28], ["retro-transcribing eukaryotic viruses", "PROBLEM", 34, 71], ["dsDNA", "ANATOMY", 16, 21], ["ssDNA", "ANATOMY", 23, 28], ["viruses", "OBSERVATION", 64, 71]]], ["Similarities to RNA viruses were not included because they were artifactual, since only DNA was sequenced in this study.", [["DNA", "CELLULAR_COMPONENT", 88, 91], ["RNA viruses", "PROBLEM", 16, 27], ["DNA", "PROBLEM", 88, 91], ["this study", "TEST", 109, 119], ["RNA viruses", "OBSERVATION", 16, 27]]], ["Significant similarities to RNA viruses comprised less than 1% of all tBLASTx similarities.Assessment of metabolic potential ::: MethodsThe metabolic potential of each virome was assessed by BLASTx (E-value<10\u22125) comparison to the SEED database using the MG-RAST service [59], [60].", [["tBLASTx", "GENE_OR_GENE_PRODUCT", 70, 77], ["Significant similarities to RNA viruses", "PROBLEM", 0, 39], ["Methods", "TREATMENT", 129, 136], ["each virome", "PROBLEM", 163, 174], ["RNA viruses", "OBSERVATION", 28, 39], ["metabolic potential", "OBSERVATION", 105, 124]]], ["MG-RAST assigns sequences to three hierarchical levels of metabolic subsystems, which consist of groups of genes that comprise a metabolic function or pathway [61].", [["MG-RAST", "GENE_OR_GENE_PRODUCT", 0, 7], ["RAST", "PROTEIN", 3, 7], ["MG", "TEST", 0, 2], ["RAST assigns sequences", "TEST", 3, 25], ["metabolic subsystems", "TEST", 58, 78], ["metabolic subsystems", "OBSERVATION", 58, 78]]], ["The non-parametric statisical program XIPE was used to detect significant differences between metabolic profiles of viral metagenomes at a 95% confidence level [62].", [["The non-parametric statisical program XIPE", "TREATMENT", 0, 42], ["viral metagenomes", "PROBLEM", 116, 133]]], ["XIPE identifies the specific subsystems driving the differences between metagenomes, and in which metagenome the function was are over-represented.Complete metagenomic assembly ::: MethodsComplete assembly of the Non-CF2 and CF3 metagenomes was performed using PHRAP as a quality check to confirm sucessful isolation of viral genomes [63].", [["Non-CF2", "GENE_OR_GENE_PRODUCT", 213, 220], ["XIPE", "PROTEIN", 0, 4], ["Non-CF2 and CF3 metagenomes", "DNA", 213, 240], ["PHRAP", "PROTEIN", 261, 266], ["viral genomes", "DNA", 320, 333], ["the Non-CF2 and CF3 metagenomes", "TEST", 209, 240], ["PHRAP", "TREATMENT", 261, 266], ["a quality check", "TEST", 270, 285], ["viral genomes", "PROBLEM", 320, 333], ["viral genomes", "OBSERVATION", 320, 333]]], ["These two metagenomes were assembled because they had high coverage of phage genomes as indicated by tBLASTx.", [["phage genomes", "DNA", 71, 84], ["tBLASTx", "DNA", 101, 108], ["phage genomes", "TREATMENT", 71, 84]]], ["There were 9,508 contigs ranging in size from 40 to 14,982 bp for Non-CF2, and 8,163 contigs from 212 to 7,748 base pairs for CF3.", [["Non-CF2", "DNA", 66, 73], ["CF3", "DNA", 126, 129], ["contigs", "TEST", 17, 24], ["bp", "TEST", 59, 61], ["Non-CF2", "TEST", 66, 73], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["Contigs were compared to the non-redundant nucleotide database maintained at NCBI (http://www.ncbi.nlm.nih.gov) using BLASTn to assign taxonomy.Statistical analyses ::: MethodsAll statistical analyses, with the exception of XIPE, were performed using the software package R (www.r-project.org) [64].", [["nucleotide", "CHEMICAL", 43, 53], ["the non-redundant nucleotide database", "TEST", 25, 62], ["Methods", "TREATMENT", 169, 176], ["All statistical analyses", "TEST", 176, 200]]], ["Principal components analysis (PCA) with the R function prcomp was used to examine overall taxonomic similarities between metagenomes [65].", [["the R function prcomp", "TEST", 41, 62]]], ["Non-metric multidimensional scaling (NM-MDS) with the R function isoMDS was used to determine relationships between metagenomes based on metabolic profiles.", [["Non-metric multidimensional scaling", "PROBLEM", 0, 35]]], ["The analysis was performed with NM-MDS instead of PCA for metabolic potential because all metagenomes had at least one hit to each of the 25 subsystems (i.e., there were no zero values).", [["The analysis", "TEST", 0, 12], ["NM", "TREATMENT", 32, 34], ["PCA", "TREATMENT", 50, 53], ["all metagenomes", "PROBLEM", 86, 101]]], ["Similar to PCA, NM-MDS does not require a priori classification of the data and plotting the MDS coordinates shows natural grouping patterns.", [["MDS", "DISEASE", 93, 96], ["the data", "TEST", 67, 75], ["natural grouping", "OBSERVATION", 115, 131]]], ["Clusters observed in PCA and NM-MDS scatterplots were confirmed statistically using k-means clustering.", [["MDS scatterplots", "TEST", 32, 48], ["PCA", "ANATOMY", 21, 24]]], ["To determine the optimal number of clusters, within-group sums of squares were calculated for partitions involving between 1 and 9 clusters [63], [65].", [["clusters", "OBSERVATION_MODIFIER", 35, 43]]]], "e6770322967f62347b58e916f2d078e03ab67652": [["IntroductionSexual violence, which we use as a comprehensive term inclusive of sexual harassment, coercion, and assault, has long been regarded as a gendered issue.", [["IntroductionSexual violence", "DISEASE", 0, 27], ["sexual harassment", "DISEASE", 79, 96]]], ["Preventing and responding to women's needs regarding sexual violence are important priorities for many women and feminist activists and academics alike.", [["sexual violence", "DISEASE", 53, 68], ["women", "ORGANISM", 29, 34], ["women", "ORGANISM", 103, 108], ["women", "SPECIES", 29, 34], ["women", "SPECIES", 103, 108]]], ["Sexual violence disproportionately affects the lives of women and girls (Rozee & Koss, 2001; Senn, 2015) , and in Canadian statistics, it is estimated that one in three women will experience sexual violence in their lifetime (Statistics Canada, 2006) .", [["Sexual violence", "DISEASE", 0, 15], ["sexual violence", "DISEASE", 191, 206], ["women", "ORGANISM", 56, 61], ["women", "ORGANISM", 169, 174], ["women", "SPECIES", 56, 61], ["girls", "SPECIES", 66, 71], ["women", "SPECIES", 169, 174]]], ["Sexual violence and other forms of violence against women continues to be one of the most prominent issues that impact the lives and wellbeing of women, girls, and marginalized genders throughout the world today.IntroductionThe international COVID-19 pandemic affects women and marginalized communities in ways unique to the impacts of structural inequalities.", [["Sexual violence", "DISEASE", 0, 15], ["violence", "DISEASE", 35, 43], ["women", "ORGANISM", 52, 57], ["women", "ORGANISM", 146, 151], ["women", "ORGANISM", 268, 273], ["women", "SPECIES", 52, 57], ["women", "SPECIES", 146, 151], ["girls", "SPECIES", 153, 158], ["women", "SPECIES", 268, 273]]], ["We do this to discuss the impacts of the COVID-19 pandemic on both the issue of sexual violence and our work as resistance educators at a Canadian university.", [["sexual violence", "DISEASE", 80, 95], ["the COVID", "TEST", 37, 46]]], ["Making the most of the available time granted to us by the unanticipated situation created by the COVID-19 outbreak, we then look towards the future of the EAAA program, both as a feminist project, and as an important intervention that must adapt to meet women's needs during and after pandemic times.", [["women", "ORGANISM", 255, 260], ["women", "SPECIES", 255, 260], ["an important intervention", "TREATMENT", 205, 230]]], ["We include a section exploring the theoretical possibilities that critical disability theory and queer theory present to the EAAA program, which originates in radical feminist theory, and argue that incorporating concepts from these frameworks will complement the goals of the EAAA program and improve inclusivity of queer, trans, and disabled participants.", [["participants", "SPECIES", 344, 356], ["a section", "TREATMENT", 11, 20], ["the EAAA program", "TREATMENT", 273, 289]]], ["Finally, we conclude with a look into the future of impacts of COVID-19 on our work with hopes for continuing sexual assault resistance education programming.EAAA: A Feminist Response to Sexual ViolenceIncreasingly, sexual violence in higher education has become a public concern, with releases of documents like, It's Never Okay: An Action Plan to Stop Sexual Violence and Harassment (Ontario, 2015) and The Summary Report of the Student Voices (CCI Research Inc., 2019) which identify that women are disproportionately exposed to sexual violence in institutions of higher education.", [["sexual violence", "DISEASE", 216, 231], ["sexual violence", "DISEASE", 532, 547], ["women", "ORGANISM", 492, 497], ["women", "SPECIES", 492, 497], ["COVID", "TEST", 63, 68], ["continuing sexual assault resistance education programming", "TREATMENT", 99, 157]]], ["In response to women's increased risk of sexual assault during the post-secondary setting, the Enhanced Assess Acknowledge Act (EAAA) sexual assault resistance education program was developed by Dr. Charlene Senn (2015) based on decades of prior feminist research on women's resistance against male violence.", [["sexual assault", "DISEASE", 41, 55], ["violence", "DISEASE", 299, 307], ["women", "ORGANISM", 15, 20], ["women", "ORGANISM", 267, 272], ["women", "SPECIES", 15, 20], ["women", "SPECIES", 267, 272], ["sexual assault", "PROBLEM", 41, 55], ["sexual assault", "OBSERVATION", 41, 55]]], ["EAAA is a four-unit, 12-hour long program that addresses myths of sexual coercion and assault, educates women about our sexual rights, and teaches women how to defend ourselves against male attackers using effective forceful verbal and physical resistance strategies.EAAA: A Feminist Response to Sexual ViolenceEAAA is the result of many years of feminist research contributions, primarily from the discipline of feminist psychology, as well as women's self-defense teachings of Wen-Do Toronto (see Nurius & Norris, 1996; Ullman, 1997; Rozee & Koss, 2001; and; Senn et al., 2015 , Chard, 2019 .", [["sexual coercion", "DISEASE", 66, 81], ["women", "ORGANISM", 104, 109], ["women", "ORGANISM", 147, 152], ["women", "ORGANISM", 445, 450], ["women", "SPECIES", 104, 109], ["women", "SPECIES", 147, 152], ["women", "SPECIES", 445, 450], ["physical resistance strategies", "TREATMENT", 236, 266]]], ["It is supported by a randomized controlled trial of 899 first-year women attending three different Canadian universities which showed that women who completed the program were found to be 46% less likely to have experienced a completed sexual assault and 63% less likely to have experienced attempted sexual assault one-year post-program .EAAA: A Feminist Response to Sexual ViolenceThe EAAA program is delivered in four units, usually taking place over two days or four evenings.", [["sexual assault", "DISEASE", 236, 250], ["Sexual Violence", "DISEASE", 368, 383], ["women", "ORGANISM", 67, 72], ["women", "ORGANISM", 139, 144], ["women", "SPECIES", 67, 72], ["women", "SPECIES", 139, 144]]], ["The objectives of the first two units, Assess and Acknowledge, include recognizing risk of sexual assault for all women, understanding the differences between assault by a stranger versus an acquaintance, and overcoming emotional barriers related to identifying risk and initiating acts of resistance (Senn, 2015) .", [["sexual assault", "DISEASE", 91, 105], ["women", "ORGANISM", 114, 119], ["women", "SPECIES", 114, 119]]], ["The logic of Assess and Acknowledge being the first units of the program is that with this order, women will be better prepared to actually use the self-defense strategies they learn and practice in the later units.", [["women", "ORGANISM", 98, 103], ["women", "SPECIES", 98, 103], ["the self-defense strategies", "TREATMENT", 144, 171]]], ["As a program for women, EAAA is empowering in that it provides women with tools to respond to situations that arise from no fault of our own:EAAA: A Feminist Response to Sexual ViolenceWe are not advocating a \"just say no\" approach here-according to Koss (1988) , 70% of date rape victim-survivors in their sample said \"no\" and physically resisted, but were raped anyway.", [["women", "ORGANISM", 17, 22], ["women", "ORGANISM", 63, 68], ["women", "SPECIES", 17, 22], ["women", "SPECIES", 63, 68]]], ["The AAA algorithm is a way for women to have a well-rehearsed and realistic plan for using physical force when necessary to escape dangerous situations without spending time anticipating and fearing them (Rozee & Koss, 2001, p.", [["women", "ORGANISM", 31, 36], ["women", "SPECIES", 31, 36], ["AAA", "OBSERVATION", 4, 7]]], ["30) During the third unit, Act, women learn physical and verbal resistance strategies to effectively deter attackers.", [["women", "ORGANISM", 32, 37], ["women", "SPECIES", 32, 37], ["verbal resistance strategies", "TREATMENT", 57, 85]]], ["As part of our training to prepare to teach the Act unit, we, as EAAA facilitators attended annual training with Wen-Do Women's Self-defense, an organization in Toronto, Ontario (Senn, 2015; Chard, 2019) .", [["Women", "SPECIES", 120, 125]]], ["During Act, participants practice strategies such as yelling, making a fist and punching, front and back kicks, elbow strikes, and breaking out of body holds, and think about how they would use these moves in realistic scenarios in which a male acquaintance is becoming increasingly threatening (Senn, 2015, Unit 3: Act; Chard, 2019) .EAAA: A Feminist Response to Sexual ViolenceThe self-defense unit, although only a short part of the 12-hour long program, is based on research about how women experience and respond to violence.", [["body", "ANATOMY", 147, 151], ["Sexual Violence", "DISEASE", 364, 379], ["violence", "DISEASE", 521, 529], ["elbow", "ORGANISM_SUBDIVISION", 112, 117], ["body", "ORGANISM_SUBDIVISION", 147, 151], ["women", "ORGANISM", 489, 494], ["participants", "SPECIES", 12, 24], ["women", "SPECIES", 489, 494], ["practice strategies", "TREATMENT", 25, 44], ["punching, front and back kicks", "PROBLEM", 80, 110], ["elbow strikes", "PROBLEM", 112, 125], ["back", "ANATOMY", 100, 104], ["elbow", "ANATOMY", 112, 117], ["self-defense unit", "OBSERVATION_MODIFIER", 383, 400]]], ["Women are encouraged to identify and work through their own particular barriers to resistance.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["The moves they learn are designed to use large body parts against smaller and more vulnerable body parts on the attacker (eyes, nose, throat, collar bone, testicles, knees, etc.) because this strategy helps resistance efforts to be effective regardless of women's physical strength (Senn, 2015, Unit 3: Act) .", [["body", "ANATOMY", 47, 51], ["body parts", "ANATOMY", 94, 104], ["eyes", "ANATOMY", 122, 126], ["nose", "ANATOMY", 128, 132], ["throat", "ANATOMY", 134, 140], ["bone", "ANATOMY", 149, 153], ["testicles", "ANATOMY", 155, 164], ["knees", "ANATOMY", 166, 171], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["eyes", "ORGANISM_SUBDIVISION", 122, 126], ["nose", "ORGANISM_SUBDIVISION", 128, 132], ["throat", "ORGANISM_SUBDIVISION", 134, 140], ["collar bone", "TISSUE", 142, 153], ["testicles", "ORGAN", 155, 164], ["knees", "ORGANISM_SUBDIVISION", 166, 171], ["women", "ORGANISM", 256, 261], ["women", "SPECIES", 256, 261], ["large body parts", "TREATMENT", 41, 57], ["the attacker (eyes, nose, throat, collar bone, testicles, knees", "PROBLEM", 108, 171], ["eyes", "ANATOMY", 122, 126], ["nose", "ANATOMY", 128, 132], ["throat", "ANATOMY", 134, 140], ["collar bone", "ANATOMY", 142, 153], ["testicles", "ANATOMY", 155, 164], ["knees", "ANATOMY", 166, 171]]], ["The program reinforces the belief that all women are capable of physically defending ourselves, and in the Act unit, participants are given the tools to believe this for themselves (Senn, 2015) .EAAA: A Feminist Response to Sexual ViolenceThe EAAA program can be taught in its original Assess, Acknowledge, Act format first suggested by Rozee and Koss (2001) based on the cognitive ecological model Nurius and Norris (1996) conceptualized.", [["Sexual Violence", "DISEASE", 224, 239], ["women", "ORGANISM", 43, 48], ["women", "SPECIES", 43, 48], ["participants", "SPECIES", 117, 129]]], ["But a fourth unit, Relationships and Sexuality, was added because the feedback Dr. Senn received \"while she was developing [EAAA] reflected the fact that [women] wanted more help dealing with and resisting sexual pressure within their longer-term relationships\" (Senn, 2015, Unit 4: Relationships and Sexuality, p.", [["women", "ORGANISM", 155, 160], ["women", "SPECIES", 155, 160]]], ["This final unit 'enhances' the original AAA conceptual framework for responding to sexual coercion by providing additional activities and discussions related to women's sexual desire, communication, and romantic relationships (Senn, Gee, & Thake, 2011) .EAAA: A Feminist Response to Sexual ViolenceThe Relationships and Sexuality unit has particular focus on expanding women's experiences of sex from normative sex which prioritizes men's pleasure above women's and involves practices which are not protective of women's safety, towards including a range of sexual activities and language maximized for women's pleasure and comfort.", [["sexual desire", "DISEASE", 169, 182], ["Sexual Violence", "DISEASE", 283, 298], ["women", "ORGANISM", 161, 166], ["women", "ORGANISM", 369, 374], ["men", "ORGANISM", 433, 436], ["women", "ORGANISM", 454, 459], ["women", "ORGANISM", 513, 518], ["women", "ORGANISM", 603, 608], ["women", "SPECIES", 161, 166], ["women", "SPECIES", 369, 374], ["men", "SPECIES", 433, 436], ["women", "SPECIES", 454, 459], ["women", "SPECIES", 513, 518], ["women", "SPECIES", 603, 608]]], ["According to the developer's argument for the inclusion of the enhanced sexuality unit, this education \"is critical to women's increased abilities both to seek out sex they do want and to reject and actively resist sex that they do not want\" (Senn, Gee, & Thake, 2011, p.", [["women", "ORGANISM", 119, 124], ["women", "SPECIES", 119, 124], ["increased abilities", "PROBLEM", 127, 146]]], ["The units that comprise the EAAA program result in an educational experience which is empowering and informative for many women, including those who are survivors of prior acts of sexual and other forms of violence.EAAA: A Feminist Response to Sexual ViolenceA successful program requires two facilitators, who work together to advertise and facilitate the EAAA program for women students on our campus.", [["violence", "DISEASE", 206, 214], ["women", "ORGANISM", 122, 127], ["women", "ORGANISM", 374, 379], ["women", "SPECIES", 122, 127], ["women", "SPECIES", 374, 379]]], ["We are responsible for recruiting and communicating with interested participants, setting up and taking down the program, facilitating the program, supporting women during the program, and more.", [["women", "ORGANISM", 159, 164], ["participants", "SPECIES", 68, 80], ["women", "SPECIES", 159, 164]]], ["We aim to provide young women in our campus community with knowledge about how to defend themselves in potentially assaultive situations in order to reduce the risk and level of harm violence poses to women's safety and wellbeing, and to deliver Senn (2015)'s feminist program in a way that is inclusive for as many students as possible.", [["violence", "DISEASE", 183, 191], ["women", "ORGANISM", 24, 29], ["women", "ORGANISM", 201, 206], ["women", "SPECIES", 24, 29], ["women", "SPECIES", 201, 206]]], ["COVID-19, though, has prevented our ability to continue our work.Sexual Violence and COVID-19The issue of sexual violence did not disappear when COVID-19 became a crisis in Canada.", [["sexual violence", "DISEASE", 106, 121], ["COVID", "TEST", 0, 5], ["COVID", "TEST", 85, 90], ["COVID", "TEST", 145, 150], ["a crisis", "PROBLEM", 161, 169]]], ["In fact, the social effects of pandemic times place women at an increased risk of violence, and \"mounting data suggests that domestic abuse is acting like an opportunistic infection, flourishing in the conditions created by the pandemic\" (Taub, 2020, p.", [["violence", "DISEASE", 82, 90], ["domestic abuse", "DISEASE", 125, 139], ["opportunistic infection", "DISEASE", 158, 181], ["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["an opportunistic infection", "PROBLEM", 155, 181], ["opportunistic", "OBSERVATION_MODIFIER", 158, 171], ["infection", "OBSERVATION", 172, 181]]], ["Evidence suggests that family violence increases following large scale disasters, and at times when families are spending increased time together, such as over holidays (Taub, 2020; Bradbury-Jones, 2020) .", [["family violence", "DISEASE", 23, 38]]], ["Public health instructions to stay at home to help reduce the spread of the virus essentially asked women who live in abusive homes to stay in close proximity to an abuser for extended periods of time, and to reduce contacts outside of the home.", [["women", "ORGANISM", 100, 105], ["women", "SPECIES", 100, 105]]], ["Isolation is a risk factor for sexual violence and other forms of violence (Senn, 2015) .", [["sexual violence", "DISEASE", 31, 46], ["violence", "DISEASE", 66, 74]]], ["Chances of bystander intervention are lower when women are isolated, and as women stay at home, they may have an increasingly hard time reaching out to support networks including friends, family members, and crisis lines.", [["women", "ORGANISM", 49, 54], ["women", "ORGANISM", 76, 81], ["crisis lines", "CELL", 208, 220], ["crisis lines", "CELL_LINE", 208, 220], ["women", "SPECIES", 49, 54], ["women", "SPECIES", 76, 81], ["bystander intervention", "TREATMENT", 11, 33], ["crisis lines", "OBSERVATION", 208, 220]]], ["Being laid-off, or being made to work or study from home, lowers women's connections with others and opportunities to leave abusive homes.", [["women", "ORGANISM", 65, 70], ["women", "SPECIES", 65, 70]]], ["A survivor needing urgent health care following physical or sexual violence may experience increased anxiety about seeking services from a hospital because of additional concerns about risk of coronavirus transmission, and may be unable to access other social services to cope with the impacts of sexual and intimate partner violence.", [["physical or sexual violence", "DISEASE", 48, 75], ["anxiety", "DISEASE", 101, 108], ["coronavirus", "DISEASE", 193, 204], ["sexual and intimate partner violence", "DISEASE", 297, 333], ["coronavirus", "ORGANISM", 193, 204], ["urgent health care", "TREATMENT", 19, 37], ["increased anxiety", "PROBLEM", 91, 108], ["coronavirus transmission", "PROBLEM", 193, 217]]], ["Other infrastructural impacts of the pandemic, such as reduced public transportation service and cutbacks to social service agency hours and funding, create further barriers to accessing services.Sexual Violence and COVID-19The EAAA program is one piece of the puzzle that co-exists alongside other prevention efforts.", [["COVID", "TEST", 216, 221], ["The EAAA program", "TREATMENT", 224, 240], ["infrastructural", "OBSERVATION_MODIFIER", 6, 21], ["impacts", "OBSERVATION_MODIFIER", 22, 29]]], ["As a program for women, EAAA does not prevent sexual violence by educating or rehabilitating perpetrators, nor does it provide survivors with essential services, such as shelter and health care, to enhance their immediate safety.", [["sexual violence", "DISEASE", 46, 61], ["women", "ORGANISM", 17, 22], ["women", "SPECIES", 17, 22]]], ["Rather, the role of EAAA, and other sexual assault resistance and self-defense education programs such as Wen-Do, is to provide the women who voluntarily attend with information and tools that helps them to identify and fight back in sexually coercive situations.Sexual Violence and COVID-19As educators who deliver an empirically tested program (Senn et al., 2013; Senn et al., 2015; Senn et al., 2017) , we know that our work is meaningful because there are now dozens of women who are better prepared to identify and respond to danger in future situations using the knowledge and skills they gained from attending EAAA training.", [["women", "ORGANISM", 132, 137], ["women", "ORGANISM", 474, 479], ["women", "SPECIES", 132, 137], ["women", "SPECIES", 474, 479]]], ["Women who attended the EAAA program in a controlled trial reported a significantly lower rate of completed rape than the control group, and EAAA is the only intervention of its kind that is backed by such empirical evidence .", [["EAAA", "CHEMICAL", 140, 144], ["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["Furthermore, a possible secondary outcome of the EAAA program is that women may become more knowledgeable about the reality of sexual violence and more willing to protect and support other women and sexual assault survivors in their lives.Sexual Violence and COVID-19Not only are women at increased risk and may be less likely to access support services during the current pandemic, women cannot access our educational program in this context.", [["sexual violence", "DISEASE", 127, 142], ["women", "ORGANISM", 70, 75], ["women", "ORGANISM", 189, 194], ["women", "ORGANISM", 280, 285], ["women", "ORGANISM", 383, 388], ["women", "SPECIES", 70, 75], ["women", "SPECIES", 189, 194], ["women", "SPECIES", 280, 285], ["women", "SPECIES", 383, 388]]], ["As an in-person program, EAAA relies on having a group of women in a private room for program delivery.", [["women", "ORGANISM", 58, 63], ["women", "SPECIES", 58, 63], ["program delivery", "TREATMENT", 86, 102]]], ["Small groups and pairs are used during program activities which favour participants and facilitators being in close contact with one another.", [["participants", "SPECIES", 71, 83], ["Small groups and pairs", "PROBLEM", 0, 22], ["groups", "OBSERVATION", 6, 12]]], ["The impact of EAAA may be relatively small in scope, but it is a powerful experience for many women, and most importantly, it is a growing program.", [["EAAA", "CHEMICAL", 14, 18], ["women", "ORGANISM", 94, 99], ["women", "SPECIES", 94, 99], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["small", "OBSERVATION", 37, 42]]], ["On our campus over the past year, we noticed an increase in women's interest in the program compared to the previous two academic years.", [["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["This can be attributed to many factors, such as increased promotional efforts on our part, growing awareness about sexual violence resulting from the #metoo movement, and changes within our particular campus culture.", [["sexual violence", "DISEASE", 115, 130], ["the #metoo movement", "PROBLEM", 146, 165]]], ["Not only do we not know when our work can resume, it is becoming increasingly clear that we cannot expect it to continue unaffected by the social infrastructural impacts of the pandemic.Our experiences in-the-moment: Personal Narratives of COVID-19's ImpactWe know that all women are strong and resilient, and will make choices that will best protect the safety of themselves and their families whilst people all around the world are confined to their homes during the COVID-19 pandemic.", [["women", "ORGANISM", 274, 279], ["people", "ORGANISM", 402, 408], ["women", "SPECIES", 274, 279], ["people", "SPECIES", 402, 408], ["COVID", "TREATMENT", 240, 245], ["the COVID", "TEST", 465, 474], ["pandemic", "PROBLEM", 478, 486], ["clear", "OBSERVATION", 78, 83]]], ["Education efforts, for now, are largely put on hold, and frontline services to meet the needs of women and survivors are of utmost importance.", [["women", "ORGANISM", 97, 102], ["women", "SPECIES", 97, 102]]], ["During the current stay-at-home orders and physical distancing measures, it is not possible for many prevention efforts to continue without adapting to digital spaces, a project which takes time, and uncertainty about what physical distancing measures will be in place over the next year further complicates our ability to plan for the future.Our experiences in-the-moment: Personal Narratives of COVID-19's ImpactThis past school year, we facilitated the EAAA program five times.", [["physical distancing measures", "TREATMENT", 43, 71], ["COVID", "TEST", 397, 402]]], ["We were looking forward to facilitating the second day on March 14th to teach the participants the necessary self-defense skills included in the program and to work with each woman in a way which validated their own wants and needs in a romantic and/or sexual relationship.", [["woman", "ORGANISM", 175, 180], ["participants", "SPECIES", 82, 94], ["woman", "SPECIES", 175, 180]]], ["In this section, we turn to our own individual narratives to speak about the impact of COVID-19 on each facilitator personally.Margaret's NarrativeOn Thursday, March 12th we received an email from one of our participants inquiring as to whether we still intended on carrying out the program on Saturday.", [["participants", "SPECIES", 208, 220], ["COVID", "TREATMENT", 87, 92]]], ["At that point, we had no university response to COVID-19, and therefore had no intention of cancelling.", [["COVID", "TEST", 48, 53], ["intention of cancelling", "PROBLEM", 79, 102]]], ["\"I think only if the school cancels classes?\" she proposed, \"if they don't then we don't have to cancel just tell people not to come if they're sick .\"", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120]]], ["That morning in the gym, a usually busy place, I noticed that it was almost empty.", [["empty", "OBSERVATION", 76, 81]]], ["I witnessed a person with a giant bag full of Lysol wipes walking across campus.", [["person", "SPECIES", 14, 20], ["a giant bag", "TREATMENT", 26, 37], ["Lysol wipes walking", "TREATMENT", 46, 65]]], ["We would need to reconsider the way we serve food, the cleanliness of the room we facilitate in, and how selfdefense moves would be taught in a way which would not require ourselves and participants to be in close proximity and, how to teach women self-defense without using consensual physical contact for demonstrations and practices.Margaret's NarrativeAt 10:13 AM on Friday March 13th, 2020, all students received an email which indicated that classes would be cancelled, and that all campus events before April 30th, 2020Margaret's Narrativewere to be postponed.", [["women", "ORGANISM", 242, 247], ["participants", "SPECIES", 186, 198], ["women", "SPECIES", 242, 247]]], ["We received word to cancel, but were concerned about ourselves and our participants.", [["participants", "SPECIES", 71, 83]]], ["We now had the task of ensuring that all participants were aware that the session, less than twenty-four hours away, was now cancelled.", [["participants", "SPECIES", 41, 53]]], ["I took the work cell phone home overnight, to follow-up with any participants who did not respond to our cancellation email by text-message.Margaret's NarrativeAt that time, we really did not know how the situation would unfold.", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["participants", "SPECIES", 65, 77]]], ["Holly suggested that \"if the situation has died down this week, we'll try to at least offer a day for women to finish it (but it may not work well because of exams)\".", [["women", "ORGANISM", 102, 107], ["women", "SPECIES", 102, 107], ["exams", "TEST", 158, 163]]], ["We really wanted to be able to offer women the last two units, because of the evidence-based nature of the program, we knew missing these two sessions would impact the program's efficacy for the group of women .Margaret's NarrativeIn the past at our university, there have been decisions to cancel the second day of the EAAA program due to low enrollment.", [["women", "ORGANISM", 37, 42], ["women", "ORGANISM", 204, 209], ["women", "SPECIES", 37, 42], ["women", "SPECIES", 204, 209], ["the EAAA program", "TREATMENT", 316, 332], ["low enrollment", "PROBLEM", 340, 354]]], ["Attrition is a significant barrier to successful implementation of the program that we know women at many universities offering EAAA struggle with.", [["women", "ORGANISM", 92, 97], ["women", "SPECIES", 92, 97]]], ["One potential risk, that we try to mitigate through skilled facilitation of EAAA's activities and discussions, is that women leave the program acutely aware of their risk of sexual assault, which they may not have been as aware of prior to attending the program.", [["sexual assault", "DISEASE", 174, 188], ["women", "ORGANISM", 119, 124], ["women", "SPECIES", 119, 124]]], ["After completing the Act unit or a Wen-Do course, the hope is that women feel confident in their ability to physically fight off attackers in future situations.", [["women", "ORGANISM", 67, 72], ["women", "SPECIES", 67, 72]]], ["However, when women attend Assess and Acknowledge and not the Act unit, this outcome may not be reached.", [["women", "ORGANISM", 14, 19], ["women", "SPECIES", 14, 19]]], ["As the days crept on, we came to understand that we would not be facilitating the second day of our program to the participants anytime soon.", [["participants", "SPECIES", 115, 127]]], ["While our employers within the university suggested we consider an online format to complete the session, personally we were exhausted from the emotional tolls of the pandemic, our studies, our work, and technically, felt unprepared to teach the content in an empirically supported manner through an online format.", [["our studies", "TEST", 177, 188]]], ["I remember, in January, hearing about a new virus originating in China, but I admittedly felt too far removed from the risk to pay much attention.Holly's NarrativeOn Thursday March 12th, 2020, upon finishing the coffee I had brought to my 8:30AM lecture and deciding I needed a refill to get through the day, I was surprised that the campus Starbucks would not refill my travel cup and gave me a disposable one instead.", [["cup", "ORGANISM_SUBDIVISION", 378, 381], ["a new virus", "PROBLEM", 38, 49]]], ["I heard jokes made in my classes that day about the possibility of this being the last time we would meet in-person for the semester.", [["person", "SPECIES", 109, 115]]], ["In the past when programs have been cancelled or postponed due to low enrollment, we have at least been able to offer women the opportunity to sign up for the next set of dates, usually occurring again within a month or two since we aim to offer two or three programs each semester.", [["women", "ORGANISM", 118, 123], ["women", "SPECIES", 118, 123], ["low enrollment", "PROBLEM", 66, 80]]], ["The rapidly changing situation with COVID-19 did not allow for us to make any predictions or promises about when the second day would next be offered, and we expect the persisting uncertainty of the pandemic to continue affecting our work.", [["COVID-19", "CHEMICAL", 36, 44]]], ["At the time of writing on March 13th, we were optimistic and in our email notifying women of the cancellation, we told them that we \"hope that you will be able to join us for the rest of the program or a full self-defense course at a date to be determined in the near future.", [["women", "ORGANISM", 84, 89], ["women", "SPECIES", 84, 89]]], ["I entered university and began working with the EAAA program while in an abusive relationship, which I left during my second year, and I now find myself graduating in the middle of global pandemic.", [["middle", "ANATOMY_MODIFIER", 171, 177], ["pandemic", "OBSERVATION", 188, 196]]], ["I am glad to be returning to school in September rather than being in a position of graduating and trying to enter the workforce in a full-time position during an international pandemic that has created massive losses in employment and increased the personal risks that frontline service providers encounter in their work.", [["massive", "OBSERVATION_MODIFIER", 203, 210], ["losses", "OBSERVATION", 211, 217]]], ["However, the possibility of using this unexpected time to refresh the program for our new normal during and post-COVID to reach a wider audience makes me optimistic of the future of EAAA.Theoretical Possibilities and Hopes for the Future of EAAAWhile COVID-19 forced us to think about the women who come to our program and what they would miss, it also allowed us to think about the women who we could not reach because of the limited inclusivity of the program, an issue we have constantly discussed and reflected on throughout our time working together.", [["EAAA", "CHEMICAL", 182, 186], ["EAAA", "CANCER", 182, 186], ["women", "ORGANISM", 289, 294], ["women", "ORGANISM", 383, 388], ["women", "SPECIES", 289, 294], ["women", "SPECIES", 383, 388], ["EAAA", "PROBLEM", 182, 186]]], ["As passionate feminists, social work students, researchers, and educators, we are highly critical of ideologies which promote oppression, violence, and marginalization of any group in society.", [["violence", "DISEASE", 138, 146]]], ["Each of our feminism is influenced by multiple sources, and is impacted by our social location and life experiences.Theoretical Possibilities and Hopes for the Future of EAAAFor us, disability theory and queer theory are particular areas of interest.", [["feminism", "OBSERVATION", 12, 20], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["sources", "OBSERVATION", 47, 54], ["impacted", "OBSERVATION_MODIFIER", 63, 71]]], ["We also, however, assert that in order to continue growing and maintain relevance to post-secondary students in the current era and post-COVID, theoretical influences outside of the foundational body of feminist research should be consulted.Theoretical Possibilities and Hopes for the Future of EAAAEAAA was developed under the research of a radical feminist who sought \"to put feminist and social psychological theories into practice; to expand and reinforce young women's knowledge and skills so that they are better able to defend themselves against sexual coercion and assault by known men; and to facilitate broader social change on sexual assault at least on my own campus and city\" (Senn, 2011, p.", [["sexual coercion", "DISEASE", 553, 568], ["sexual assault", "DISEASE", 638, 652], ["women", "ORGANISM", 466, 471], ["men", "ORGANISM", 590, 593], ["women", "SPECIES", 466, 471], ["men", "SPECIES", 590, 593]]], ["Radical feminism, founded on Marxist principles, identifies women as a subordinate class within a patriarchal society.", [["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["Radical feminism", "PROBLEM", 0, 16], ["feminism", "OBSERVATION", 8, 16], ["patriarchal society", "OBSERVATION", 98, 117]]], ["This approach to feminism \"starts from the idea of conflict between the sexes as a fundamental conflict, and oppression against women as a direct implication of patriarchy\" (Vukoi\u010di\u0107, 2017, p.", [["women", "ORGANISM", 128, 133], ["women", "SPECIES", 128, 133]]], ["Wilchins (2004) critiques lesbian/feminism and radical feminism for the tendency to \"adopt [...] a reflexive antagonism toward anything male, and [...] to ground womanhood in the most rudimentary biological determinism\" (p.", [["radical feminism", "OBSERVATION", 47, 63]]], ["As a result, lesbian feminists, particularly within academia, are at times \"automatically hostile toward transgender people\", and historically, \"lesbian/feminist and 'radical feminist' academics\" have used \"transgender men and women as examples of everything from wrong-headedness and false consciousness to artificiality and patriarchy gone wild\" (Wilchins, 2004, p.", [["headedness", "DISEASE", 270, 280], ["false consciousness", "DISEASE", 285, 304], ["artificiality", "DISEASE", 308, 321], ["men", "ORGANISM", 219, 222], ["women", "ORGANISM", 227, 232], ["people", "SPECIES", 117, 123], ["men", "SPECIES", 219, 222], ["women", "SPECIES", 227, 232], ["headedness", "PROBLEM", 270, 280], ["false consciousness", "PROBLEM", 285, 304]]], ["15 , emphasis in original text).Theoretical Possibilities and Hopes for the Future of EAAADue to the focus on a male/female sexual binary, radical feminism appears inadequate for EAAA in the present day.", [["EAAA", "PROBLEM", 179, 183]]], ["Increasingly, young women and feminist spaces are becoming more welcoming to gender identities and expressions outside a rigid and exclusionary definition of womanhood.", [["women", "ORGANISM", 20, 25], ["women", "SPECIES", 20, 25]]], ["We hope that future renditions of the EAAA program will continue to adapt to the ever-changing needs of young women and marginalized folks.", [["women", "ORGANISM", 110, 115], ["women", "SPECIES", 110, 115], ["the EAAA program", "TREATMENT", 34, 50]]], ["In this section, we introduce relevant concepts from queer theory and critical disability theory, present critiques of some aspects of Senn (2015)'s program, and suggest possible ways of increasing accessibility and inclusion of queer, trans, and disabled perspectives.Queer Theory and Critical Disability TheoryThe meaning of queer theory has taken multiple forms over time (Seidman, 1994) .Queer Theory and Critical Disability TheoryThe term 'queer' itself can take on a broad meaning, as that which is external to the dominant normative theoretical lenses, and represents those who fall outside of a typical normative binary (Colebrook, 2009) .", [["dominant", "OBSERVATION_MODIFIER", 521, 529], ["theoretical lenses", "OBSERVATION", 540, 558]]], ["\"Queer is by definition whatever is at odds with the normal, the legitimate, the dominant.", [["normal", "OBSERVATION", 53, 59], ["dominant", "OBSERVATION", 81, 89]]], ["Queer theory has a particular focus on identifying hegemonic power imbalances in which normalization and norms occur, and builds upon feminist theory, sexuality, gay and lesbian studies, and transgender studies (Seidman, 1994) .Queer Theory and Critical Disability TheoryQueer theory questions the very meaning of sex and gender, as \"somewhere in the 18th century, sex as we know it was invented\" (Laquer, 1990 , cited in Wilchins, 2004 ).Queer Theory and Critical Disability TheoryLiljestr\u00f6m (2019) outlines that central focuses in queer theory include the revelation of gender and identity; the conflation between terms with gender, sex, and sexuality, and the impact of this; and using queering methodologies to question sexuality and pleasure.Queer Theory and Critical Disability TheoryWhile there is no single way to understand and approach disability using critical disability theory (CDT), the aim of this theory, is to reinterpret what it means to be disabled, to bring the perspectives of persons with disabilities into reality, and to challenge barriers to universal accessibility (Reaume, 2014) .", [["disability", "DISEASE", 846, 856], ["persons", "ORGANISM", 998, 1005], ["persons", "SPECIES", 998, 1005], ["lesbian studies", "TEST", 170, 185], ["transgender studies", "TEST", 191, 210], ["queering methodologies", "TREATMENT", 689, 711], ["no", "UNCERTAINTY", 805, 807]]], ["CDT analyzes how societal perceptions of disability impacts equity of opportunities for inclusion, increases barriers, and takes away fundamental citizenship rights from disabled peoples (Rioux & Valentine, 2006) .", [["disability", "DISEASE", 41, 51]]], ["CDT advocates for the alteration of conventional perceptions of persons with disabilities as \"pitiable, tragic victims who should adjust to the world around them \", to seeing people with disabilities as equal members of society (Reaume, 2014 (Reaume, , p.", [["disabilities", "DISEASE", 77, 89], ["disabilities", "DISEASE", 187, 199], ["persons", "ORGANISM", 64, 71], ["people", "ORGANISM", 175, 181], ["persons", "SPECIES", 64, 71], ["people", "SPECIES", 175, 181]]], ["1248 (Reaume, -1249 .", [["1248", "CHEMICAL", 0, 4], ["Reaume, -1249", "CHEMICAL", 6, 19]]], ["It challenges binary approaches to disabilities and the 'othering' of disabled persons (Devlin & Pothier, 2006; Vehmas & Watson, 2014) .Queer Theory and Critical Disability TheoryCentral to CDT is understanding how oppression of disabled people is perpetuated in society at large (Goodley, 2013) .", [["disabilities", "DISEASE", 35, 47], ["persons", "ORGANISM", 79, 86], ["people", "ORGANISM", 238, 244], ["persons", "SPECIES", 79, 86], ["people", "SPECIES", 238, 244]]], ["This oppression is called ableism, defined by Hodge (2013) as \"a network of beliefs, processes, and practices that cast disability as a diminished state of being human\" (p.", [["ableism", "DISEASE", 26, 33], ["disability", "DISEASE", 120, 130], ["human", "ORGANISM", 162, 167], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 162, 167]]], ["Ableism is embedded in structures which assume normativity, negatively impacting persons with disabilities, making them invisible in society (Goodley, Liddard, & Runswick-Cole, 2018) .", [["persons", "SPECIES", 81, 88]]], ["Furthermore, expectation of ability, and judgment based on abilities, ingrained and overlooked in society perpetuate ableism, drive disabled persons to the outskirts of society (Goodley et al., 2018; Wolbring, 2008) .Queer Theory and Critical Disability TheoryQueer studies and critical disability studies overlap and contribute to one another in that they both critique ideals of hegemonic normalcy and universal norms that exclude the atypical (Sherry, 2010) .", [["ableism", "DISEASE", 117, 124], ["persons", "SPECIES", 141, 148], ["critical disability studies", "TEST", 278, 305]]], ["The analysis of sexuality conversations surrounding disability and sexuality further have relied on queer theory.", [["disability", "DISEASE", 52, 62]]], ["Loeser, Pini, & Crowley (2018) identify that both disabled and queer persons, and disabled queer persons have historically been viewed as deviant.", [["persons", "ORGANISM", 69, 76], ["persons", "ORGANISM", 97, 104], ["persons", "SPECIES", 69, 76], ["persons", "SPECIES", 97, 104]]], ["Considering this along with critiques of feminism's lack of inclusion of trans experiences, it is therefore not surprising that there are inadequacies within the EAAA program in including queer, disabled, and disabled queer persons.Possibilities for Queer Theory and Critical Disability Theory and EAAAUsing a queer theory lens, we adopt Butler (2004)'s definitions of gender for our analysis:Possibilities for Queer Theory and Critical Disability Theory and EAAAGender is not exactly what one 'is' nor is it precisely what one 'has.'", [["persons", "ORGANISM", 224, 231], ["persons", "SPECIES", 224, 231]]], ["Gender is the apparatus by which the production and normalization of masculine and feminine take place along with the interstitial forms of hormonal, chromosomal, psychic, and performative that gender assumes. (p.", [["chromosomal", "ANATOMY", 150, 161], ["chromosomal", "CELLULAR_COMPONENT", 150, 161], ["masculine and feminine", "TREATMENT", 69, 91], ["the interstitial forms of hormonal, chromosomal, psychic", "PROBLEM", 114, 170], ["interstitial", "ANATOMY_MODIFIER", 118, 130]]], ["42)Possibilities for Queer Theory and Critical Disability Theory and EAAAWe agree with Butler's (2004) identification that gender is not contingent on a binary of 'masculine' and 'feminine' and believe considering gender (as a social concept) triumphs sex (as a biological concept) in facilitating a program made for women (referring to the gender) such as EAAA.", [["women", "ORGANISM", 317, 322], ["women", "SPECIES", 317, 322]]], ["In our critique of the EAAA program, we also \"separate sexuality from gender, so that to have a gender does not presuppose that one engages sexual practice in any particular way, and to engage in a given sexual practice, anal sex, for instance, does not presuppose that one is a given gender \", (Butler, 2004, p.", [["anal", "ANATOMY", 221, 225], ["anal", "ORGANISM_SUBDIVISION", 221, 225]]], ["54) This is imperative for an inclusive perspective on sexuality, to make all women (again, specifically referring to gender) feel safe to take our program and represented in its content.Possibilities for Queer Theory and Critical Disability Theory and EAAABecause queer and trans women/folks are underrepresented in research on sexual assault, statistics referenced in the EAAA program do not include up to date information on sexual violence against these communities.", [["sexual assault", "DISEASE", 329, 343], ["sexual violence", "DISEASE", 428, 443], ["women", "ORGANISM", 78, 83], ["women", "ORGANISM", 281, 286], ["women", "SPECIES", 78, 83], ["women", "SPECIES", 281, 286]]], ["In one activity in the Assess unit, women are asked to name a group of women at higher risk for sexual assault (the suggested answers are women/girls with disabilities, First Nation, Metis and Inuit women, young women, and previously victimized women) and the troubleshooting guidance provided to facilitators for when participants inquire about other racialized, gendered and sexualized social locations references \"some research [that] ... suggests that trans-individuals (trans women and trans men) are at a higher risk of sexual violence than non-trans men, but not than for non-trans women\" (Senn, 1015, Unit 1: Assess, p.", [["sexual assault", "DISEASE", 96, 110], ["sexual violence", "DISEASE", 526, 541], ["women", "ORGANISM", 36, 41], ["women", "ORGANISM", 71, 76], ["women", "ORGANISM", 138, 143], ["women", "ORGANISM", 199, 204], ["women", "ORGANISM", 212, 217], ["women", "ORGANISM", 245, 250], ["women", "ORGANISM", 481, 486], ["men", "ORGANISM", 497, 500], ["men", "ORGANISM", 557, 560], ["women", "ORGANISM", 589, 594], ["women", "SPECIES", 36, 41], ["women", "SPECIES", 71, 76], ["women", "SPECIES", 138, 143], ["girls", "SPECIES", 144, 149], ["women", "SPECIES", 199, 204], ["women", "SPECIES", 212, 217], ["women", "SPECIES", 245, 250], ["participants", "SPECIES", 319, 331], ["women", "SPECIES", 481, 486], ["men", "SPECIES", 497, 500], ["men", "SPECIES", 557, 560], ["women", "SPECIES", 589, 594], ["sexual assault", "PROBLEM", 96, 110], ["one activity", "OBSERVATION_MODIFIER", 3, 15]]], ["Despite lacking concrete statistical evidence, this creates a hierarchy where cis women are at most risk of sexual assault, followed by trans men and women, then finally cis men.", [["sexual assault", "DISEASE", 108, 122], ["women", "ORGANISM", 82, 87], ["men", "ORGANISM", 142, 145], ["women", "ORGANISM", 150, 155], ["men", "ORGANISM", 174, 177], ["women", "SPECIES", 82, 87], ["men", "SPECIES", 142, 145], ["women", "SPECIES", 150, 155], ["men", "SPECIES", 174, 177], ["assault", "OBSERVATION", 115, 122]]], ["In this same activity, Senn (2015) acknowledges that disabled persons are at a higher risk of sexual violence but does not elaborate on disabled women's increased vulnerability being situated within an ableist society.", [["sexual violence", "DISEASE", 94, 109], ["persons", "ORGANISM", 62, 69], ["women", "ORGANISM", 145, 150], ["persons", "SPECIES", 62, 69], ["women", "SPECIES", 145, 150], ["increased vulnerability", "PROBLEM", 153, 176]]], ["By identifying this without providing more insight, visibly disabled women in the room may feel othered, or having heightened awareness of their risk of sexual assault without consol.", [["sexual assault", "DISEASE", 153, 167], ["women", "ORGANISM", 69, 74], ["women", "SPECIES", 69, 74]]], ["This activity is highly beneficial as it highlights the risks that women face, from a lens of intersectionality.", [["women", "ORGANISM", 67, 72], ["women", "SPECIES", 67, 72]]], ["A more inclusive activity, though, should recognize the failure to include statistics on other groups which may be at higher risk.", [["A more inclusive activity", "PROBLEM", 0, 25], ["the failure", "PROBLEM", 52, 63], ["inclusive activity", "OBSERVATION_MODIFIER", 7, 25], ["failure", "OBSERVATION", 56, 63]]], ["Queer experiences can be included by including providing statistics on estimated, likely higher, rates of sexual assault against queer and trans people, or the manual can direct facilitators to inform participants that unfortunately existing surveys fail to capture the full context of queer and trans experiences of sexual assault.", [["sexual assault", "DISEASE", 317, 331], ["people", "SPECIES", 145, 151], ["participants", "SPECIES", 201, 213], ["sexual assault", "PROBLEM", 317, 331]]], ["To ensure that women in this activity who may fall under a group which is at higher risk do not feel ostracized, direct and in-the-moment information should be shared on why these groups may be at higher risk, and how they can decrease their disproportionate risk using the same knowledge and skills present to all EAAA participants.Possibilities for Queer Theory and Critical Disability Theory and EAAAIn the Acknowledge unit, participants are challenged in various activities to put themselves into a fictitious scenario and to respond as to how the woman might be feeling and thinking, and what she could say and do in the situation.", [["women", "ORGANISM", 15, 20], ["woman", "ORGANISM", 552, 557], ["women", "SPECIES", 15, 20], ["participants", "SPECIES", 320, 332], ["participants", "SPECIES", 428, 440], ["woman", "SPECIES", 552, 557]]], ["One such scenario is read out to the women about going to a bar with friends, speaking with a friend's boyfriend, when \"after chatting for about five minutes, you get up to go to the bathroom\", later being pinned against the wall by the friend's boyfriend (Senn, 2015, Unit 2: Acknowledge, p.", [["women", "ORGANISM", 37, 42], ["wall", "TISSUE", 225, 229], ["women", "SPECIES", 37, 42]]], ["This activity makes ableist assumptions by assuming that all participants would have the ability to \"get up\" (Senn, 2015, Unit 2: Acknowledge, p.", [["participants", "SPECIES", 61, 73]]], ["It is important for participants to acknowledge their risk by putting themselves into fictitious scenarios, but the scenarios must be applicable to those who do not fit normative assumptions of gender and ability.Possibilities for Queer Theory and Critical Disability Theory and EAAAIn an exercise intended to demonstrate that sexual assault is not the result of miscommunication (Senn, 2015, Unit 2: Acknowledge, p.", [["sexual assault", "DISEASE", 327, 341], ["participants", "SPECIES", 20, 32]]], ["41) , discussions about the role of alcohol also arise.", [["alcohol", "CHEMICAL", 36, 43], ["alcohol", "CHEMICAL", 36, 43], ["alcohol", "SIMPLE_CHEMICAL", 36, 43]]], ["In the discussion, facilitators are instructed to point out the differences in how men and women metabolize alcohol (Senn, 2015 , Unit 2: Acknowledge, p.", [["alcohol", "CHEMICAL", 108, 115], ["alcohol", "CHEMICAL", 108, 115], ["men", "ORGANISM", 83, 86], ["women", "ORGANISM", 91, 96], ["alcohol", "SIMPLE_CHEMICAL", 108, 115], ["men", "SPECIES", 83, 86], ["women", "SPECIES", 91, 96]]], ["42), a problematic statement when considering trans, intersex, and non-binary bodies.", [["trans, intersex, and non-binary bodies", "PROBLEM", 46, 84], ["non-binary", "ANATOMY", 67, 77], ["bodies", "ANATOMY_MODIFIER", 78, 84]]], ["Alcohol is said to be statistically the most commonly used date rape drug (Senn, 2015) .", [["Alcohol", "CHEMICAL", 0, 7], ["Alcohol", "CHEMICAL", 0, 7]]], ["Consistent with the information provided in the EAAA program on alcohol, other research (Murchison, Boyd, & Pachankis, 2017) argues lesbian, gay, bisexual and queer undergraduates use alcohol in much the same way as their heterosexual cisgender peers and it therefore contributes to sexual assault risk in a similar way.", [["alcohol", "CHEMICAL", 64, 71], ["alcohol", "CHEMICAL", 184, 191], ["alcohol", "CHEMICAL", 64, 71], ["alcohol", "CHEMICAL", 184, 191], ["alcohol", "SIMPLE_CHEMICAL", 64, 71], ["alcohol", "SIMPLE_CHEMICAL", 184, 191]]], ["West, Graham, and Temple (2017) though propose that college students with disabilities may not participate in as many activities surrounding alcohol.", [["disabilities", "DISEASE", 74, 86], ["alcohol", "CHEMICAL", 141, 148], ["alcohol", "CHEMICAL", 141, 148], ["alcohol", "SIMPLE_CHEMICAL", 141, 148]]], ["These students typically do not have access to targeted alcohol and drug prevention programming (West, Graham, & Temple, 2017) .", [["alcohol", "CHEMICAL", 56, 63], ["alcohol", "CHEMICAL", 56, 63]]], ["Regardless of their own relationships to alcohol use, the role of alcohol in the occurrence of sexual assault is important for all EAAA participants to know about because alcohol is present in many sexual assaults.", [["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 66, 73], ["sexual assault", "DISEASE", 95, 109], ["alcohol", "CHEMICAL", 171, 178], ["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 66, 73], ["alcohol", "CHEMICAL", 171, 178], ["alcohol", "SIMPLE_CHEMICAL", 41, 48], ["alcohol", "SIMPLE_CHEMICAL", 66, 73], ["alcohol", "SIMPLE_CHEMICAL", 171, 178], ["participants", "SPECIES", 136, 148]]], ["Here, the program content is applicable to cis women, queer and trans participants, and disabled women as long as it is delivered in a way that does not essentialize sex with gender, and negate to consider women's physical abilities.Possibilities for Queer Theory and Critical Disability Theory and EAAAIn the third unit, Act, women learn physical and verbal resistance strategies to effectively deter attackers from facilitators (Senn, 2015) .", [["women", "ORGANISM", 47, 52], ["women", "ORGANISM", 97, 102], ["women", "ORGANISM", 206, 211], ["women", "ORGANISM", 327, 332], ["women", "SPECIES", 47, 52], ["participants", "SPECIES", 70, 82], ["women", "SPECIES", 97, 102], ["women", "SPECIES", 206, 211], ["women", "SPECIES", 327, 332], ["verbal resistance strategies", "TREATMENT", 352, 380]]], ["Queering this unit requires working to reduce the conflations of being a man with having a penis and being a perpetrator, and of being a woman with having a vagina and being at risk of sexual assault.", [["penis", "ANATOMY", 91, 96], ["vagina", "ANATOMY", 157, 163], ["sexual assault", "DISEASE", 185, 199], ["man", "ORGANISM", 73, 76], ["penis", "ORGAN", 91, 96], ["woman", "ORGANISM", 137, 142], ["vagina", "ORGANISM_SUBDIVISION", 157, 163], ["man", "SPECIES", 73, 76], ["woman", "SPECIES", 137, 142], ["a vagina", "PROBLEM", 155, 163], ["sexual assault", "PROBLEM", 185, 199], ["penis", "ANATOMY", 91, 96], ["vagina", "ANATOMY", 157, 163], ["assault", "OBSERVATION", 192, 199]]], ["In order to create a more inclusive space in Act, each facilitator would also require increased knowledge and training in augmenting the program in facilitating for women of various abilities.", [["women", "ORGANISM", 165, 170], ["women", "SPECIES", 165, 170]]], ["Furthermore, when a woman is unable to complete a strategy, alternative strategies which are equivalent in purpose and effect must be shown as a complement.", [["woman", "ORGANISM", 20, 25], ["woman", "SPECIES", 20, 25], ["a strategy", "TREATMENT", 48, 58], ["alternative strategies", "TREATMENT", 60, 82]]], ["All women have barriers which can make them resistant to using particular self-defense moves against particular vulnerable body parts.", [["body", "ANATOMY", 123, 127], ["women", "ORGANISM", 4, 9], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["women", "SPECIES", 4, 9]]], ["In showing alternatives for women of a variety of abilities, such as those who may be vision-impaired, deaf or hard of hearing, have restricted mobility, all participants will have increased tools to fight off an attacker.Possibilities for Queer Theory and Critical Disability Theory and EAAAWhile the Relationships and Sexuality unit was added to 'enhance' the program by giving women the ability to explore sexual desire, communication, and romance (Senn, Gee, & Thake, 2011) , in a queer and CDT analysis, this unit appears the least inclusive and most normative of the program units.", [["vision-impaired", "DISEASE", 86, 101], ["sexual desire", "DISEASE", 409, 422], ["women", "ORGANISM", 28, 33], ["women", "ORGANISM", 380, 385], ["women", "SPECIES", 28, 33], ["participants", "SPECIES", 158, 170], ["women", "SPECIES", 380, 385], ["hard of hearing", "PROBLEM", 111, 126], ["increased tools", "PROBLEM", 181, 196], ["an attacker", "TREATMENT", 210, 221], ["CDT analysis", "TEST", 495, 507]]], ["The objectives of the unit, however, are rich in connections to queer theory and CDT's interrogation of normalcy, and focus on inclusive pleasure, desire, and sexual freedom.", [["CDT's interrogation", "TEST", 81, 100]]], ["If \"emancipatory sexuality education is protective for women [because] it challenges the male focus presumed in normative heterosexual interactions and scripts that support rape\" (Senn, Gee & Thake, 2011, p.", [["women", "ORGANISM", 55, 60], ["women", "SPECIES", 55, 60]]], ["84; Gavey, 2005) , it therefore also holds potential to be empowering for queer, trans, and disabled participants.Possibilities for Queer Theory and Critical Disability Theory and EAAAFor example, a discussion in the Relationships and Sexuality unit, called Expanding Notions of Having Sex, aims to provide participants with knowledge about what \"having sex\" means, broadening sex from meaning only penetrative penis-in-vagina intercourse, to a variety of potentially pleasurable sexual activities including oral and anal sex and mutual masturbation (Senn, 2015, Unit 4: Relationships & Sexuality, pp. 17-18) .", [["penis", "ANATOMY", 411, 416], ["vagina", "ANATOMY", 420, 426], ["oral", "ANATOMY", 508, 512], ["anal", "ANATOMY", 517, 521], ["penis", "ORGANISM_SUBDIVISION", 411, 416], ["vagina", "ORGANISM_SUBDIVISION", 420, 426], ["oral", "ORGANISM_SUBDIVISION", 508, 512], ["anal", "ORGANISM_SUBDIVISION", 517, 521], ["participants", "SPECIES", 101, 113], ["participants", "SPECIES", 307, 319], ["penetrative penis", "ANATOMY", 399, 416], ["vagina", "ANATOMY", 420, 426], ["anal", "ANATOMY", 517, 521]]], ["In this discussion, women are asked to define \"having sex\" and \"sexual intercourse .\"", [["sexual intercourse", "DISEASE", 64, 82], ["women", "ORGANISM", 20, 25], ["women", "SPECIES", 20, 25]]], ["Next, women are asked to come up with a list of \"consummative interpersonal sexual activities\" in addition to vaginal intercourse.", [["vaginal", "ANATOMY", 110, 117], ["women", "ORGANISM", 6, 11], ["vaginal", "ORGANISM_SUBDIVISION", 110, 117], ["women", "SPECIES", 6, 11], ["vaginal intercourse", "TREATMENT", 110, 129], ["vaginal", "ANATOMY", 110, 117]]], ["This broadening of sex from a narrow heteronormative definition that suppresses women's sexual desire and advances men's perpetration of sexual violence is important because of the insidious ways \"everyday taken-for-granted normative forms of heterosexuality work as a cultural scaffolding for rape\" (Gavey, 2005, p.", [["sexual desire", "DISEASE", 88, 101], ["sexual violence", "DISEASE", 137, 152], ["heterosexuality", "DISEASE", 243, 258], ["women", "ORGANISM", 80, 85], ["men", "ORGANISM", 115, 118], ["women", "SPECIES", 80, 85], ["men", "SPECIES", 115, 118], ["a narrow heteronormative definition", "PROBLEM", 28, 63]]], ["However, ableist and heteronormative assumptions likely cause the activity to fall short of meeting its goals for all participants.Possibilities for Queer Theory and Critical Disability Theory and EAAAThe idea of broadening what sex itself means is in alignment with queer conceptualizations of sex and desire and disrupting heteronormativity.", [["heteronormativity", "DISEASE", 325, 342], ["participants", "SPECIES", 118, 130], ["disrupting heteronormativity", "PROBLEM", 314, 342]]], ["However, while brainstorming sex acts, participants are asked to label people, based on body parts, as male or female, by describing the possible \"consummative interpersonal sexual\" acts they suggest as occurring between female-female, male-male, or male-female pairs (Senn, 2015, Unit 4: Relationships & Sexuality, p.", [["body parts", "ANATOMY", 88, 98], ["people", "ORGANISM", 71, 77], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["participants", "SPECIES", 39, 51], ["people", "SPECIES", 71, 77]]], ["Some limited information on considering trans people in this discussion of sexuality is included in the troubleshooting information for facilitators (Senn, 2015, Unit 4: Relationships & Sexuality, p.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52]]], ["16) , but according to the instructions, trans and non-binary people should only be mentioned if a participant asks.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68]]], ["Further work on specifically including trans people and their partners in this discussion is necessary in order to meet the objective of providing all participants with greater knowledge about their comfort with different words used for sexuality.Possibilities for Queer Theory and Critical Disability Theory and EAAAFrom a CDT lens, not only does this activity make assumptions surrounding what gender does what 'types' of sex, but it is potentially ableist.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["participants", "SPECIES", 151, 163]]], ["While this activity identifies that there are diverse ways in which \"people may experience pleasure and intimacy that is not necessarily genital-centric\" (Loeser, Pini, & Crowley, 2018, p.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["diverse", "OBSERVATION_MODIFIER", 46, 53]]], ["265) it reduces the wider conceptualizations of sex by disability advocates into a category called \"third-norm activities\" (Senn, 2015, Unit 4: Relationships & Sexuality, p.", [["disability", "DISEASE", 55, 65]]], ["This term, which attempts to provide young people with an option beyond sex with a condom or no sex, is a potentially stigmatizing term for disabled folks.", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["disabled folks", "PROBLEM", 140, 154]]], ["Furthermore, the activity gives no facilitator guidance on the inclusion of objects such as sex toys and personal supportive equipment which can enhance a disabled persons sex life.", [["persons", "SPECIES", 164, 171]]], ["Naphtali, MacHattie and Elliot's \"pleasureABLE Sexual Device Manual for Persons with Disabilities\" (2017) identifies that disabled persons can have motor and autonomic dysfunctions, impacting their sexuality, and that sexuality for disabled people must require increased creativity, individual to the persons who are engaging in the action.", [["motor and autonomic dysfunctions", "DISEASE", 148, 180], ["persons", "ORGANISM", 131, 138], ["people", "ORGANISM", 241, 247], ["persons", "ORGANISM", 301, 308], ["Persons", "SPECIES", 72, 79], ["persons", "SPECIES", 131, 138], ["people", "SPECIES", 241, 247], ["persons", "SPECIES", 301, 308], ["Naphtali", "TREATMENT", 0, 8], ["MacHattie", "TREATMENT", 10, 19], ["Elliot", "TREATMENT", 24, 30], ["motor and autonomic dysfunctions", "PROBLEM", 148, 180]]], ["Furthermore, Loeser, Pini, and Crowley, (2018) Breaking the myth that disabled persons are unable to engage in sex is essential for this unit to be inclusive of women with disabilities rather than perpetuating ableist beliefs, and a small reference to a guide such as this can help women and their potential partners of all abilities engage in consensual, safe, and fun sex.", [["persons", "ORGANISM", 79, 86], ["women", "ORGANISM", 161, 166], ["women", "ORGANISM", 282, 287], ["persons", "SPECIES", 79, 86], ["women", "SPECIES", 161, 166], ["women", "SPECIES", 282, 287]]], ["Therefore an expanded notion of sex is needed in order to increase the inclusivity of the program for women of various abilities and for women who are in relationships with disabled persons.Possibilities for Queer Theory and Critical Disability Theory and EAAAAfter the Expanding Notions of Having Sex activity, EAAA participants individually complete a continuum sheet indicating their desire or potential desire to engage in different intimate and sexual activities with someone else.", [["women", "ORGANISM", 102, 107], ["women", "ORGANISM", 137, 142], ["persons", "ORGANISM", 182, 189], ["women", "SPECIES", 102, 107], ["women", "SPECIES", 137, 142], ["persons", "SPECIES", 182, 189], ["participants", "SPECIES", 317, 329], ["a continuum sheet", "TREATMENT", 352, 369]]], ["Activities range from sexual acts (oral, vaginal, and anal sex) to other activities including, giving/receiving a massage, reading erotica, and skinny dipping (Senn, Unit 4: Relationships & Sexuality, .", [["oral", "ANATOMY", 35, 39], ["vaginal", "ANATOMY", 41, 48], ["anal", "ANATOMY", 54, 58], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["vaginal", "ORGANISM_SUBDIVISION", 41, 48], ["anal", "ORGANISM_SUBDIVISION", 54, 58], ["sexual acts", "TREATMENT", 22, 33], ["oral, vaginal, and anal sex", "TREATMENT", 35, 62], ["a massage", "TREATMENT", 112, 121], ["reading erotica", "PROBLEM", 123, 138], ["vaginal", "ANATOMY", 41, 48], ["anal", "ANATOMY", 54, 58]]], ["Making this exercise more inclusive may only require a few relatively small changes, such as to a few instances of gendered language about body parts, including discussions of objects that increase sexual pleasure and access, and adding a few more possible sexual activities, including those that do not require a normative body or normative body movement patterns.", [["body", "ANATOMY", 139, 143], ["body", "ANATOMY", 324, 328], ["body", "ANATOMY", 342, 346], ["body", "ORGANISM_SUBDIVISION", 139, 143], ["body", "ORGANISM_SUBDIVISION", 324, 328], ["body", "ORGANISM_SUBDIVISION", 342, 346]]], ["In this activity, many sexual possibilities are omitted, even though as noted above, one goal of the Relationships and Sexuality unit is broadening participants' conceptualization of what having sex means (Senn, 2015) .", [["participants", "SPECIES", 148, 160]]], ["These activities should account for a wider range of possible sexual acts, particularly those most relevant to queer and disabled sex.Continuing the Program in/after Pandemic TimesAs facilitators of an evidence-based sexual assault resistance education program which can no longer be approached in its traditional form, we now have an opportunity to improve the accessibility and inclusivity of the program to a wider and more diverse audience of women.", [["women", "ORGANISM", 447, 452], ["women", "SPECIES", 447, 452]]], ["With increasing awareness that things will not 'return to normal' as we knew it before the pandemic struck, we are now considering how to get the program content across to participants while maintaining physical and social distancing.", [["participants", "SPECIES", 172, 184]]], ["If we are permitted to continue the program with in-person delivery, we fear that students will not be living on/near campus, hindering their ability to attend the sessions.Continuing the Program in/after Pandemic TimesOne such solution we have investigated includes facilitating EAAA through a webbased approach.", [["EAAA", "SIMPLE_CHEMICAL", 280, 284], ["a webbased approach", "TREATMENT", 293, 312]]], ["The internet is commonly used for university students to gain beneficial sexual information (Boies, 2002) , and web-based approaches have been investigated in their usefulness for an STI and HIV intervention for youth (Shoveller et al., 2012) .", [["HIV", "SPECIES", 191, 194], ["HIV intervention", "TREATMENT", 191, 207]]], ["Furthermore, Mustanski, Greene, Ryan and Whitton's 2015 investigation of Queer Sex Ed through an online format was highly satisfactory for LGBT youth participants who completed the program, and youth increased their knowledge about sexual functioning, HIV and STIs, contraceptives, sexual orientation, and relationships.", [["HIV and STIs", "DISEASE", 252, 264], ["contraceptives", "CHEMICAL", 266, 280], ["participants", "SPECIES", 150, 162], ["HIV", "SPECIES", 252, 255], ["HIV", "SPECIES", 252, 255], ["HIV", "PROBLEM", 252, 255], ["contraceptives", "TREATMENT", 266, 280]]], ["We are hopeful that if we pursue facilitating sexual assault resistance education in an online format that we can increase the capacity and accessibility of our program.Continuing the Program in/after Pandemic TimesUnfortunately, because EAAA has been empirically supported as an in-person program with interactive components that are necessary to its delivery, the program would no longer be evidence-based if hastily moved to a digital platform.", [["EAAA", "CHEMICAL", 238, 242], ["interactive components", "TREATMENT", 303, 325]]], ["We would be unable to do certain activities, and may need to consider privacy and security of participants in a more complex way.", [["participants", "SPECIES", 94, 106]]], ["Women in unstable home environments may be unable to consume the content, and web security will need to be explored.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["Furthermore, online formats have been identified as missing social components that are usually gained in an in-person experience.Continuing the Program in/after Pandemic TimesThis may decrease learning outcomes (Richardson, Maeda, Lv & Caskurlu, 2017; Shoveller et al., 2012) .", [["Lv", "ANATOMY", 231, 233]]], ["We may find ourselves unable to support participants' emotional needs and to create a supportive environment for all women in the program.Continuing the Program in/after Pandemic TimesAnother potential option for facilitation we have explored, if social distancing guidelines permit us to do so, is to offer private group sessions to small, pre-established groups of women.", [["women", "ORGANISM", 117, 122], ["women", "ORGANISM", 367, 372], ["participants", "SPECIES", 40, 52], ["women", "SPECIES", 117, 122], ["women", "SPECIES", 367, 372]]], ["Pre-established groups, such as women's clubs, sports teams, and sororities, can contact us to set up a private session for their group only.", [["women", "ORGANISM", 32, 37], ["women", "SPECIES", 32, 37]]], ["This approach reduces administrative work for us as facilitators, ensures attendance, and promotes strong connections between participants.", [["participants", "SPECIES", 126, 138]]], ["Furthermore, this allows participants to reduce the amount of new in-person contacts they make with others.", [["participants", "SPECIES", 25, 37]]], ["However, this approach may not be the most inclusive, unless we specifically target broad ranging and intersectional groups which include or are made up of diverse women.", [["women", "ORGANISM", 164, 169], ["women", "SPECIES", 164, 169]]], ["Women who are isolated or who do not have preestablished connections, though, will be missed.Continuing the Program in/after Pandemic TimesEven with much of university life being hosted online, and COVID-19 taking a lot of space within people's lives, sexual violence is not gone.", [["sexual violence", "DISEASE", 252, 267], ["Women", "ORGANISM", 0, 5], ["people", "ORGANISM", 236, 242], ["Women", "SPECIES", 0, 5], ["people", "SPECIES", 236, 242]]], ["There remains a need for EAAA or a similar sexual violence prevention education program in the university setting to ensure that women know their risk of assault, and can build their confidence to fight off attackers.ConclusionsIt is becoming increasingly apparent that within this pandemic, social issues which were once prioritized are becoming harder to address.", [["sexual violence", "DISEASE", 43, 58], ["women", "ORGANISM", 129, 134], ["women", "SPECIES", 129, 134], ["EAAA", "TREATMENT", 25, 29]]], ["Much like sexual assault, the COVID-19 pandemic disproportionately affects marginalized communities in ways unique to the impacts of structural inequalities related to gender, sexuality, disability, race, and socioeconomic status.ConclusionsAs feminist students, workers, and sexual assault resistance educators we have been impacted uniquely by this pandemic.", [["sexual assault", "DISEASE", 10, 24], ["disability", "DISEASE", 187, 197], ["assault", "OBSERVATION", 17, 24]]], ["Our ability to support and empower women has become complicated by issues of outreach, access, and the lack of empirical evidence.", [["women", "ORGANISM", 35, 40], ["women", "SPECIES", 35, 40]]], ["Using theoretical positions of critical disability theory and queer theory, we hope that the future of EAAA and other sexual assault resistance education programming can address the issue of inclusivity of queer, trans, and disabled participants.", [["participants", "SPECIES", 233, 245], ["EAAA", "TREATMENT", 103, 107]]]], "PMC7247878": [["IntroductionA deterministic finite automaton (DFA) is said to be a permutation DFA if every input symbol induces a permutation on the state set.", [["a permutation DFA", "TEST", 65, 82]]], ["A language recognized by a permutation DFA is called a permutation language.", [["permutation DFA", "DNA", 27, 42]]], ["The aim of this paper is to study this class in detail, including the operational state complexity.IntroductionThe state complexity of a regular operation is the number of states sufficient and necessary in the worst case for a DFA to accept the language resulting from the operation, considered as a function of the numbers of states in DFAs for operands.", [["a regular operation", "TREATMENT", 135, 154], ["the operation", "TREATMENT", 270, 283]]], ["The state complexity of basic regular operations was given by Maslov [15] and Yu et al. [23].IntroductionIf the operands of an operation belong to some subclass of regular languages, then the complexity of this operation may be significantly smaller than in the general case.", [["basic regular operations", "TREATMENT", 24, 48], ["an operation", "TREATMENT", 124, 136], ["this operation", "TREATMENT", 206, 220], ["significantly", "OBSERVATION_MODIFIER", 228, 241], ["smaller", "OBSERVATION_MODIFIER", 242, 249]]], ["C\u00e2mpeanu et al. [6] considered finite languages, Han and Salomaa [8, 9] investigated prefix-free and suffix-free languages, and Brzozowski et al. [3, 4] examined ideal and closed languages.", [["prefix", "TEST", 85, 91]]], ["We provide alternative proofs to those in [22]; our proofs use automata constructions and properties of permutation DFAs.", [["automata constructions", "TREATMENT", 63, 85], ["permutation DFAs", "TREATMENT", 104, 120]]], ["Moreover, we prove that permutation languages are not closed under power, positive closure, cut, shuffle, cyclic shift, and permutation.", [["permutation languages", "TREATMENT", 24, 45], ["positive closure", "TREATMENT", 74, 90], ["cyclic shift", "TREATMENT", 106, 118], ["closure", "OBSERVATION", 83, 90]]], ["For each considered operation, we obtain tight upper bounds on its state complexity.", [["operation", "TREATMENT", 20, 29], ["operation", "OBSERVATION", 20, 29]]], ["In the case of left and right quotients, we need", [["left", "ANATOMY", 15, 19], ["left", "ANATOMY_MODIFIER", 15, 19], ["right", "ANATOMY_MODIFIER", 24, 29]]]], "f9038609394768c6eb4a8ec24b9e09f8c43a2e9c": [["Our aim is to provide clinicians with an evidence-based guideline illustrating ways departments can both minimize the risk of transmission while managing significantly reduced capacity.", [["significantly reduced capacity", "PROBLEM", 154, 184]]], ["This work was the beginning of a conversation about what is possible and sensible in a time of global crisis.", [["global crisis", "PROBLEM", 95, 108], ["crisis", "OBSERVATION", 102, 108]]]]}